13. 多発性硬化症／視神経脊髄炎 Disease details / Clinical trials / Drug dev / DR info

(-)-trans-delta-9-Tetrahydrocannabinol   
   Bionorica research GmbH
      2007   Phase 3   EUCTR2006-004255-38-DK   Austria;Denmark;Germany;
      2007   -   EUCTR2006-004255-38-DE   Austria;Germany;
      2007   -   EUCTR2006-004255-38-AT   Austria;Germany;
(IM) AVONEX®   
   Trio Medicines Ltd.
      2001   Phase 1   NCT01863069   United Kingdom;
(R) 3-(5-Dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1- methylethyl) benzamide   
   Canbex Therapeutics Ltd
      2015   Phase 2   EUCTR2014-004412-11-GB   United Kingdom;
/0.5ml GA   
   Teva Pharmaceutical Industries Ltd.
      2012   -   EUCTR2011-005550-57-PL   Albania;Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;Estonia;Georgia;Germany;Greece;Hungary;Latvia;Lithuania;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Montenegro;Poland;Romania;Russian Federation;Serbia;Ukraine;United States;
      2012   -   EUCTR2011-005550-57-LV   Albania;Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;Estonia;Georgia;Germany;Greece;Hungary;Latvia;Lithuania;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Montenegro;Poland;Romania;Russian Federation;Serbia;Ukraine;United States;
      2012   -   EUCTR2011-005550-57-GR   Albania;Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Estonia;Georgia;Greece;Latvia;Lithuania;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Montenegro;Poland;Romania;Russian Federation;Serbia;Ukraine;United States;
      2012   -   EUCTR2011-005550-57-EE   Albania;Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;Estonia;Georgia;Germany;Greece;Hungary;Latvia;Lithuania;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Montenegro;Poland;Romania;Russian Federation;Serbia;Ukraine;United States;
      2012   -   EUCTR2011-005550-57-BG   Albania;Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;Estonia;Georgia;Germany;Greece;Hungary;Latvia;Lithuania;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Montenegro;Poland;Romania;Russian Federation;Serbia;Ukraine;United States;
/0.5ml glatiramer acetate   
   Teva Pharmaceutical Industries Ltd.
      2012   -   EUCTR2011-005550-57-PL   Albania;Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;Estonia;Georgia;Germany;Greece;Hungary;Latvia;Lithuania;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Montenegro;Poland;Romania;Russian Federation;Serbia;Ukraine;United States;
      2012   -   EUCTR2011-005550-57-LV   Albania;Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;Estonia;Georgia;Germany;Greece;Hungary;Latvia;Lithuania;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Montenegro;Poland;Romania;Russian Federation;Serbia;Ukraine;United States;
      2012   -   EUCTR2011-005550-57-GR   Albania;Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Estonia;Georgia;Greece;Latvia;Lithuania;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Montenegro;Poland;Romania;Russian Federation;Serbia;Ukraine;United States;
      2012   -   EUCTR2011-005550-57-EE   Albania;Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;Estonia;Georgia;Germany;Greece;Hungary;Latvia;Lithuania;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Montenegro;Poland;Romania;Russian Federation;Serbia;Ukraine;United States;
      2012   -   EUCTR2011-005550-57-BG   Albania;Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;Estonia;Georgia;Germany;Greece;Hungary;Latvia;Lithuania;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Montenegro;Poland;Romania;Russian Federation;Serbia;Ukraine;United States;
0,5 mg Fingolimod   
   Novartis Pharmaceuticals
      2016   Phase 4   NCT02575365   Turkey;
032166011   
   OSPEDALE SAN RAFFAELE
      2018   Phase 4   EUCTR2016-004819-12-IT   Italy;
033283045   
   OSPEDALE SAN RAFFAELE
      2018   Phase 4   EUCTR2016-004819-12-IT   Italy;
034091165   
   OSPEDALE SAN RAFFAELE
      2018   Phase 4   EUCTR2016-004819-12-IT   Italy;
035418060   
   OSPEDALE SAN RAFFAELE
      2018   Phase 4   EUCTR2016-004819-12-IT   Italy;
1 - Andrographis paniculata p/st extract   
   Universidad Austral de Chile
      2012   Phase 1/Phase 2   NCT02280876   Chile;
1-{6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl}-2-pyrrolidinone   
   GlaxoSmithKline Research & Development Ltd
      2013   Phase 2   EUCTR2012-003627-38-GB   Bulgaria;Canada;Czech Republic;Germany;Spain;Sweden;Ukraine;United Kingdom;
      2013   Phase 2   EUCTR2012-003627-38-BG   Bulgaria;Canada;Czech Republic;Germany;Spain;Sweden;Ukraine;United Kingdom;
      2013   -   EUCTR2012-003627-38-SE   Bulgaria;Canada;Czech Republic;Germany;Spain;Sweden;Ukraine;United Kingdom;
      2013   -   EUCTR2012-003627-38-DE   Bulgaria;Canada;Czech Republic;Germany;Spain;Sweden;Ukraine;United Kingdom;
      2013   -   EUCTR2012-003627-38-CZ   Bulgaria;Canada;Czech Republic;Germany;Spain;Sweden;Ukraine;United Kingdom;
10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP)   
   Acorda Therapeutics
      2003   Phase 2   NCT00053417   Canada;United States;
10000IU vitamin D   
   University College Dublin
      2012   Phase 1/Phase 2   NCT01728922   Ireland;
11C-ACETATE   
   department of neurology, Osaka university school of medicine
      2015   -   JPRN-UMIN000018154   Japan;
11C-BMS-986196   
   Bristol-Myers Squibb
      2021   Phase 1   NCT05064436   United Kingdom;United States;
11C-MCI   
   National Institute of Mental Health (NIMH)
      2022   Phase 2   NCT05062083   United States;
11C-PBR28   
   Massachusetts General Hospital
      2020   Phase 4   NCT04230174   -
11C-PIB   
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2009   -   EUCTR2008-004174-40-FR   France;
11C]-PK-11195   
   AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA
      2016   Phase 2   EUCTR2015-001202-34-IT   Italy;
11C]flumazenil   
   VU University medical center Amsterdam
      2017   Phase 4   EUCTR2017-002636-16-NL   Netherlands;
13-PCV Booster   
   Hoffmann-La Roche
      2015   Phase 3   NCT02545868   Canada;United States;
13-valent pneumococcal conjugate vaccine (13-PCV)   
   Novartis Pharmaceuticals
      2018   Phase 3   NCT03650114   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
1393641-34-3   
   GENEURO SA
      2016   Phase 2   EUCTR2015-004059-29-IT   Bulgaria;Croatia;Czech Republic;Estonia;France;Germany;Hungary;Italy;Poland;Russian Federation;Serbia;Spain;Ukraine;
14C]-RPC1063 Solution (0.1 mg/mL) for Oral Administration   
   Celgene International II Sàrl
      2016   Phase 1   EUCTR2016-003073-18-GB   United Kingdom;
18F-DPA-714 and 18F-FDG   
   Assistance Publique - Hôpitaux de Paris
      2012   -   NCT02305264   France;
18F-PM-PBB3   
   Chang Gung Memorial Hospital
      2020   Phase 1/Phase 2   NCT04242056   -
18F]DPA-714   
   VU University Medical Center
      2014   -   EUCTR2014-002547-17-NL   Netherlands;
19 nor vitamin d   
   University of Wisconsin, Madison
      1998   Phase 1   NCT01257958   United States;
2 - Excipients   
   Universidad Austral de Chile
      2012   Phase 1/Phase 2   NCT02280876   Chile;
2 mA Transcranial Direct Current Stimulation   
   University of Iowa
      2020   -   NCT04391023   United States;
2-(2-(2-Amino-9H-purin-9-yl)ethyl)-1,3-propanediol diacetate ester   
   Queen Mary University London
      2019   Phase 2   EUCTR2019-000169-19-GB   United Kingdom;
2-CdA, 2-chloro-2'-deoxy-beta-D-adenosine   
   MERCK SERONO SA
      2011   Phase 3   EUCTR2009-017978-21-IT   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Finland;Georgia;Germany;Greece;India;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Poland;Portugal;Russian Federation;Saudi Arabia;Singapore;Spain;Sweden;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States Minor Outlying Islands;
2-CdA, 2-chloro-2'-deoxy-ß-D-adenosine   
   MERCK SERONO SA
      2011   Phase 3   EUCTR2009-017978-21-IT   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Finland;Georgia;Germany;Greece;India;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Poland;Portugal;Russian Federation;Saudi Arabia;Singapore;Spain;Sweden;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States Minor Outlying Islands;
2-CdA, 2-chloro-2?-deoxy-beta-D-adenosine   
   Merck Serono S.A. - Geneva
      2011   Phase 3   EUCTR2009-017978-21-ES   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
2-CdA, 2-chloro-2?-deoxy-ß-D-adenosine   
   Merck Serono S.A. - Geneva
      2011   Phase 3   EUCTR2009-017978-21-ES   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
2-CdA, 2-chloro-2’-deoxy-beta-D-adenosine   
   Merck Serono S.A. - Geneva
      2012   Phase 3   EUCTR2009-017978-21-PT   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2012   Phase 3   EUCTR2009-017978-21-PL   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2012   Phase 3   EUCTR2009-017978-21-GR   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-017978-21-SE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-017978-21-LV   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-017978-21-GB   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-017978-21-FI   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-017978-21-EE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-017978-21-DK   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-017978-21-BG   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-017978-21-BE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-017978-21-AT   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2011   -   EUCTR2009-017978-21-LT   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2011   -   EUCTR2009-017978-21-CZ   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2010   Phase 3   EUCTR2009-017978-21-DE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
2-CdA, 2-chloro-2’-deoxy-ß-D-adenosine   
   Merck Serono S.A. - Geneva
      2012   Phase 3   EUCTR2009-017978-21-PT   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2012   Phase 3   EUCTR2009-017978-21-PL   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2012   Phase 3   EUCTR2009-017978-21-GR   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-017978-21-SE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-017978-21-LV   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-017978-21-GB   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-017978-21-FI   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-017978-21-EE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-017978-21-DK   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-017978-21-BG   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-017978-21-BE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-017978-21-AT   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2011   -   EUCTR2009-017978-21-LT   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2011   -   EUCTR2009-017978-21-CZ   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2010   Phase 3   EUCTR2009-017978-21-DE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
2-chloro-2'-deoxy-beta-D-adenosine (2-CdA)   
   Merck Serono S.A. - Geneva
      2009   Phase 3   EUCTR2008-003706-33-GB   Argentina;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Lebanon;Macedonia, the former Yugoslav Republic of;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
2-chloro-2'-deoxy-ß-D-adenosine (2-CdA)   
   Merck Serono S.A. - Geneva
      2009   Phase 3   EUCTR2008-003706-33-GB   Argentina;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Lebanon;Macedonia, the former Yugoslav Republic of;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
2-chloro-2'-deoxyadenosine (2-CdA)   
   MERCK KGAA
      2018   Phase 4   EUCTR2017-002631-42-IT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Norway;Poland;Spain;Sweden;Switzerland;United Kingdom;
   Merck KGaA
      2018   Phase 4   EUCTR2017-002632-17-SK   Australia;Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Greece;Hungary;Italy;Lithuania;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2018   Phase 4   EUCTR2017-002632-17-SE   Australia;Austria;Belgium;Czech Republic;Denmark;Finland;France;Greece;Hungary;Italy;Lithuania;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2018   Phase 4   EUCTR2017-002632-17-PT   Australia;Austria;Belgium;Czech Republic;Denmark;Finland;France;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;Switzerland;United Kingdom;
      2018   Phase 4   EUCTR2017-002632-17-NL   Australia;Austria;Belgium;Czech Republic;Denmark;Finland;France;Greece;Hungary;Italy;Lithuania;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2018   Phase 4   EUCTR2017-002632-17-LT   Australia;Austria;Belgium;Czech Republic;Denmark;Finland;France;Greece;Hungary;Italy;Lithuania;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2018   Phase 4   EUCTR2017-002632-17-HU   Australia;Austria;Belgium;Czech Republic;Denmark;Finland;France;Greece;Hungary;Ireland;Israel;Italy;Lithuania;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;Switzerland;United Kingdom;
      2018   Phase 4   EUCTR2017-002632-17-GR   Australia;Austria;Belgium;Czech Republic;Denmark;Finland;France;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;Switzerland;United Kingdom;
      2018   Phase 4   EUCTR2017-002632-17-GB   Austria;Belgium;Czech Republic;Denmark;Finland;France;Greece;Hungary;Italy;Lithuania;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2018   Phase 4   EUCTR2017-002632-17-FR   Australia;Austria;Belgium;Czech Republic;Denmark;Finland;France;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;Switzerland;United Kingdom;
      2018   Phase 4   EUCTR2017-002632-17-FI   Australia;Austria;Belgium;Czech Republic;Denmark;Finland;France;Greece;Hungary;Italy;Lithuania;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2018   Phase 4   EUCTR2017-002632-17-ES   Australia;Austria;Belgium;Czech Republic;Denmark;Finland;France;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;Switzerland;United Kingdom;
      2018   Phase 4   EUCTR2017-002632-17-DK   Australia;Austria;Belgium;Czech Republic;Denmark;Finland;France;Greece;Hungary;Italy;Lithuania;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2018   Phase 4   EUCTR2017-002632-17-CZ   Australia;Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Greece;Hungary;Italy;Lithuania;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2018   Phase 4   EUCTR2017-002632-17-BE   Australia;Austria;Belgium;Czech Republic;Denmark;Finland;France;Greece;Hungary;Italy;Lithuania;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2018   Phase 4   EUCTR2017-002632-17-AT   Australia;Austria;Belgium;Czech Republic;Denmark;Finland;France;Greece;Hungary;Italy;Lithuania;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2-chloro-2'-deoxyadenosine, 2CdA   
   Merck Serono International S.A.
      2006   -   EUCTR2004-005148-28-LT   Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;United Kingdom;
      2005   -   EUCTR2004-005148-28-FI   Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;United Kingdom;
      2005   -   EUCTR2004-005148-28-EE   Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;United Kingdom;
      2005   -   EUCTR2004-005148-28-DK   Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;United Kingdom;
      2005   -   EUCTR2004-005148-28-CZ   Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;United Kingdom;
      2005   -   EUCTR2004-005148-28-BE   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;United Kingdom;
   Merck Serono International, a branch of Laboratoires Serono S.A.
      2005   Phase 3   EUCTR2004-005148-28-GB   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;Slovakia;United Kingdom;
   Merck Serono International, a branch of Laboratories Serono S.A.
      2005   -   EUCTR2004-005148-28-DE   Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;United Kingdom;
   Serono International S.A.
      2006   Phase 3   EUCTR2004-005148-28-SK   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;Slovakia;United Kingdom;
      2006   -   EUCTR2004-005148-28-LV   Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;United Kingdom;
      2005   -   EUCTR2004-005148-28-AT   Austria;Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;United Kingdom;
2-chloro-2?-deoxy-beta-D-adenosine   
   Merck Serono International
      2009   -   EUCTR2008-003706-33-ES   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Greece;Italy;Norway;Portugal;Spain;Sweden;United Kingdom;
2-chloro-2?-deoxy-ß-D-adenosine   
   Merck Serono International
      2009   -   EUCTR2008-003706-33-ES   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Greece;Italy;Norway;Portugal;Spain;Sweden;United Kingdom;
2-chloro-2’-deoxy-beta-D-adenosine   
   Merck Serono International
      2010   -   EUCTR2008-003706-33-GR   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Greece;Italy;Norway;Portugal;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2008-003706-33-FR   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Greece;Italy;Norway;Portugal;Spain;Sweden;United Kingdom;
   Merck Serono S.A. - Geneva
      2009   -   EUCTR2008-003706-33-NO   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Greece;Italy;Norway;Portugal;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-003706-33-AT   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Greece;Italy;Norway;Portugal;Spain;Sweden;United Kingdom;
2-chloro-2’-deoxy-beta-D-adenosine (2-CdA)   
   Merck Serono S.A. - Geneva
      2009   Phase 3   EUCTR2008-003706-33-BE   Argentina;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Lebanon;Macedonia, the former Yugoslav Republic of;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2009   -   EUCTR2008-003706-33-SE   Argentina;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Lebanon;Macedonia, the former Yugoslav Republic of;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2009   -   EUCTR2008-003706-33-DE   Argentina;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Lebanon;Macedonia, the former Yugoslav Republic of;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2009   -   EUCTR2008-003706-33-CZ   Argentina;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Lebanon;Macedonia, the former Yugoslav Republic of;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2009   -   EUCTR2008-003706-33-BG   Argentina;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Lebanon;Macedonia, the former Yugoslav Republic of;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2008   -   EUCTR2008-003706-33-FI   Argentina;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Lebanon;Macedonia, the former Yugoslav Republic of;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2008   -   EUCTR2008-003706-33-EE   Argentina;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Lebanon;Macedonia, the former Yugoslav Republic of;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
   Merck Serono SA - Geneva
      2009   -   EUCTR2008-003706-33-PT   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Greece;Italy;Norway;Portugal;Spain;Sweden;United Kingdom;
2-chloro-2’-deoxy-ß-D-adenosine   
   Merck Serono International
      2010   -   EUCTR2008-003706-33-GR   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Greece;Italy;Norway;Portugal;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2008-003706-33-FR   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Greece;Italy;Norway;Portugal;Spain;Sweden;United Kingdom;
   Merck Serono S.A. - Geneva
      2009   -   EUCTR2008-003706-33-NO   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Greece;Italy;Norway;Portugal;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-003706-33-AT   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Greece;Italy;Norway;Portugal;Spain;Sweden;United Kingdom;
2-chloro-2’-deoxy-ß-D-adenosine (2-CdA)   
   Merck Serono S.A. - Geneva
      2009   Phase 3   EUCTR2008-003706-33-BE   Argentina;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Lebanon;Macedonia, the former Yugoslav Republic of;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2009   -   EUCTR2008-003706-33-SE   Argentina;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Lebanon;Macedonia, the former Yugoslav Republic of;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2009   -   EUCTR2008-003706-33-DE   Argentina;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Lebanon;Macedonia, the former Yugoslav Republic of;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2009   -   EUCTR2008-003706-33-CZ   Argentina;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Lebanon;Macedonia, the former Yugoslav Republic of;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2009   -   EUCTR2008-003706-33-BG   Argentina;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Lebanon;Macedonia, the former Yugoslav Republic of;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2008   -   EUCTR2008-003706-33-FI   Argentina;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Lebanon;Macedonia, the former Yugoslav Republic of;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2008   -   EUCTR2008-003706-33-EE   Argentina;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Lebanon;Macedonia, the former Yugoslav Republic of;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
   Merck Serono SA - Geneva
      2009   -   EUCTR2008-003706-33-PT   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Greece;Italy;Norway;Portugal;Spain;Sweden;United Kingdom;
2-chloro-2’-deoxyadenosine (2-CdA)   
   Merck KGaA
      2018   Phase 4   EUCTR2017-002631-42-SE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Norway;Poland;Spain;Sweden;Switzerland;United Kingdom;
      2018   Phase 4   EUCTR2017-002631-42-HU   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Norway;Spain;Sweden;Switzerland;United Kingdom;
      2018   Phase 4   EUCTR2017-002631-42-GB   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Norway;Poland;Spain;Sweden;Switzerland;United Kingdom;
      2018   Phase 4   EUCTR2017-002631-42-FR   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Norway;Spain;Sweden;Switzerland;United Kingdom;
      2018   Phase 4   EUCTR2017-002631-42-FI   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Norway;Spain;Sweden;Switzerland;United Kingdom;
      2018   Phase 4   EUCTR2017-002631-42-CZ   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Norway;Spain;Sweden;Switzerland;United Kingdom;
      2018   Phase 4   EUCTR2017-002631-42-BE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Norway;Poland;Spain;Sweden;Switzerland;United Kingdom;
      2018   Phase 4   EUCTR2017-002631-42-AT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Norway;Poland;Spain;Sweden;Switzerland;United Kingdom;
   Merck Serono International S.A.
      2008   -   EUCTR2007-000381-20-NL   Austria;Bulgaria;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
      2008   -   EUCTR2007-000381-20-GR   Austria;Bulgaria;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
      2007   Phase 3   EUCTR2007-000381-20-FR   Austria;Belgium;Bulgaria;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Italy;Latvia;Lithuania;Netherlands;Portugal;United Kingdom;
   Merck Serono S.A. - Geneva
      2008   Phase 3   EUCTR2007-000381-20-GB   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Italy;Latvia;Lebanon;Lithuania;Morocco;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2008   Phase 3   EUCTR2007-000381-20-BE   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Italy;Latvia;Lebanon;Lithuania;Morocco;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2008   -   EUCTR2007-000381-20-PT   Austria;Bulgaria;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
      2008   -   EUCTR2007-000381-20-LV   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Italy;Latvia;Lebanon;Lithuania;Morocco;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2008   -   EUCTR2007-000381-20-LT   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Italy;Latvia;Lebanon;Lithuania;Morocco;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2008   -   EUCTR2007-000381-20-EE   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Italy;Latvia;Lebanon;Lithuania;Morocco;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2008   -   EUCTR2007-000381-20-DK   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Italy;Latvia;Lebanon;Lithuania;Morocco;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2008   -   EUCTR2007-000381-20-DE   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Italy;Latvia;Lebanon;Lithuania;Morocco;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2008   -   EUCTR2007-000381-20-CZ   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Italy;Latvia;Lebanon;Lithuania;Morocco;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2008   -   EUCTR2007-000381-20-BG   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Italy;Latvia;Lebanon;Lithuania;Morocco;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2007   -   EUCTR2007-000381-20-FI   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Italy;Latvia;Lebanon;Lithuania;Morocco;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2007   -   EUCTR2007-000381-20-AT   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Italy;Latvia;Lebanon;Lithuania;Morocco;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Switzerland;Turkey;Ukraine;United Kingdom;United States;
200106 or EMD 28162   
   Merck Serono
      2011   -   EUCTR2010-020328-23-LV   Austria;Belgium;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;Netherlands;Norway;Portugal;Switzerland;
      2011   -   EUCTR2010-020328-23-LT   Austria;Belgium;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;Netherlands;Norway;Portugal;Switzerland;
      2010   Phase 2   EUCTR2010-020328-23-DK   Austria;Belgium;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;Netherlands;Norway;Portugal;Switzerland;
      2010   -   EUCTR2010-020328-23-FI   Austria;Belgium;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;Netherlands;Norway;Portugal;Switzerland;
   Merck Serono SA - Geneva, an affiliate of Merck KGaA
      2012   Phase 2   EUCTR2010-020328-23-PT   Austria;Belgium;Denmark;Estonia;Finland;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Portugal;Switzerland;
      2011   -   EUCTR2010-020328-23-AT   Austria;Belgium;Denmark;Estonia;Finland;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Portugal;Switzerland;
23-PPV   
   Hoffmann-La Roche
      2015   Phase 3   NCT02545868   Canada;United States;
23-valent pneumococcal polysaccharide vaccine   
   Biogen
      2015   Phase 2   NCT02097849   United States;
23-valent pneumococcal polysaccharide vaccine (23-PPV)   
   Novartis Pharmaceuticals
      2018   Phase 3   NCT03650114   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
25OH-Vitamin D   
   Charité - Universitätsmedizin Berlin
      2011   Phase 2   EUCTR2011-002785-20-DE   Germany;
2B3-201   
   BBB-Therapeutics B.V.
      2013   Phase 1   NCT02048358   Netherlands;
3,4-diaminopyridine   
   Assistance Publique - Hôpitaux de Paris
      2005   Phase 3   NCT00190268   France;
   University of Aarhus
      2006   Phase 2   NCT00342381   Denmark;
4 mA Transcranial Direct Current Stimulation   
   University of Iowa
      2020   -   NCT04391023   United States;
5000IU vitamin D   
   University College Dublin
      2012   Phase 1/Phase 2   NCT01728922   Ireland;
52069.00.01   
   Philipps-Universität Marburg
      2010   -   EUCTR2009-011088-35-DE   Germany;
9060X   
   Allergan
      2008   -   EUCTR2006-006299-39-NL   France;Netherlands;
      2008   -   EUCTR2006-006299-39-FR   France;Netherlands;
   Allergan Ltd.
      2013   -   EUCTR2012-000957-30-PT   Belgium;Canada;Czech Republic;France;Poland;Portugal;Russian Federation;United Kingdom;United States;
      2013   -   EUCTR2012-000957-30-GB   Belgium;Canada;Czech Republic;France;Poland;Portugal;Russian Federation;United Kingdom;United States;
      2012   -   EUCTR2012-000957-30-CZ   Belgium;Canada;Czech Republic;France;Poland;Portugal;Russian Federation;United Kingdom;United States;
      2012   -   EUCTR2012-000957-30-BE   Belgium;Canada;Czech Republic;France;Poland;Portugal;Russian Federation;United Kingdom;United States;
A4I Antagonist   
   Hoffmann-La Roche
      2007   Phase 2   NCT00104143   Bulgaria;Canada;Czech Republic;Finland;Germany;Poland;Russian Federation;Slovakia;Spain;United Kingdom;United States;
AB1010   
   AB Science
      2022   Phase 3   EUCTR2021-000639-30-ES   Bulgaria;Canada;Finland;France;Germany;Greece;Hungary;Israel;Italy;Poland;Portugal;Russian Federation;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-003735-32-SK   Argentina;Belgium;Brazil;Bulgaria;Canada;Colombia;Germany;Greece;Italy;Mexico;Slovakia;Spain;Switzerland;United Kingdom;
      2015   Phase 3   EUCTR2012-003735-32-GR   Argentina;Belgium;Brazil;Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;Mexico;Slovakia;Spain;United Kingdom;
      2015   Phase 3   EUCTR2010-021219-17-BG   Argentina;Bosnia and Herzegovina;Brazil;Bulgaria;France;Germany;Greece;Hungary;Italy;Mexico;Morocco;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Tunisia;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2010-021219-17-GR   Bulgaria;Germany;Greece;Poland;Slovakia;Spain;Turkey;
      2013   -   EUCTR2010-021219-17-PL   Czech Republic;France;Germany;Greece;Poland;Romania;Slovakia;Spain;
      2012   Phase 3   EUCTR2010-021219-17-SK   Argentina;Bosnia and Herzegovina;Brazil;Bulgaria;France;Germany;Greece;Hungary;Italy;Mexico;Morocco;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Tunisia;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-021219-17-ES   Bulgaria;Czech Republic;France;Germany;Greece;Poland;Romania;Slovakia;Spain;United States;
      2011   Phase 3   EUCTR2010-021219-17-DE   Argentina;Bosnia and Herzegovina;Brazil;Bulgaria;France;Germany;Greece;Hungary;Italy;Mexico;Morocco;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Tunisia;Ukraine;United Kingdom;United States;
ABR-215062   
   TEVA
      2005   -   EUCTR2004-003943-28-IT   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
   Teva Pharmaceutical Industries Ldt
      2005   Phase 2   EUCTR2005-004334-41-IT   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
ABR-215062 sodium salt   
   Teva Pharmaceutical Industries Ltd
      2010   Phase 3   EUCTR2009-015815-42-SK   Bulgaria;Czech Republic;Estonia;Germany;Italy;Lithuania;Poland;Slovakia;Spain;
      2010   Phase 3   EUCTR2009-015815-42-PL   Bulgaria;Czech Republic;Estonia;Georgia;Germany;Israel;Italy;Lithuania;Macedonia, the former Yugoslav Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;United States;
      2010   Phase 3   EUCTR2009-015815-42-LT   Bulgaria;Czech Republic;Estonia;Georgia;Germany;Israel;Italy;Lithuania;Macedonia, the former Yugoslav Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;United States;
      2010   Phase 3   EUCTR2009-015815-42-EE   Bulgaria;Czech Republic;Estonia;Georgia;Germany;Israel;Italy;Lithuania;Macedonia, the former Yugoslav Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;United States;
      2010   Phase 3   EUCTR2009-015815-42-CZ   Bulgaria;Czech Republic;Estonia;Georgia;Germany;Israel;Italy;Lithuania;Macedonia, the former Yugoslav Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;United States;
      2010   Phase 3   EUCTR2009-015815-42-BG   Bulgaria;Czech Republic;Estonia;Georgia;Germany;Israel;Italy;Lithuania;Macedonia, the former Yugoslav Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;United States;
      2010   Phase 3   EUCTR2009-012989-30-SE   Austria;Bulgaria;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2009-012989-30-FR   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
      2010   Phase 3   EUCTR2009-012989-30-BG   Austria;Bulgaria;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2009-012989-30-AT   Austria;Bulgaria;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2009   Phase 3   EUCTR2009-012989-30-NL   Austria;Bulgaria;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2009   Phase 3   EUCTR2009-012989-30-LT   Austria;Bulgaria;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2009   Phase 3   EUCTR2009-012989-30-HU   Austria;Bulgaria;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2009   Phase 3   EUCTR2009-012989-30-GB   Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2009   Phase 3   EUCTR2009-012989-30-ES   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2009-012989-30-EE   Austria;Bulgaria;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2009   Phase 3   EUCTR2009-012989-30-CZ   Austria;Bulgaria;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2009   -   EUCTR2009-011234-99-DE   Germany;
      2008   -   EUCTR2007-003226-19-PT   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-003226-19-LT   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-003226-19-BG   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2007   Phase 3   EUCTR2007-003226-19-FR   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2007   Phase 3   EUCTR2007-003226-19-ES   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-003226-19-SE   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-003226-19-NL   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-003226-19-LV   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-003226-19-HU   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-003226-19-GB   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-003226-19-EE   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-003226-19-DE   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-003226-19-CZ   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-003226-19-AT   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2006   Phase 2   EUCTR2005-004334-41-GB   Czech Republic;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Spain;United Kingdom;
      2006   Phase 2   EUCTR2005-004334-41-ES   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
      2006   Phase 2   EUCTR2005-004334-41-DE   Czech Republic;Germany;Hungary;Israel;Italy;Russian Federation;Spain;United Kingdom;
      2006   Phase 2   EUCTR2005-004334-41-CZ   Czech Republic;Germany;Hungary;Israel;Italy;Russian Federation;Spain;United Kingdom;
      2005   Phase 2   EUCTR2005-004334-41-HU   Czech Republic;Germany;Hungary;Israel;Italy;Russian Federation;Spain;United Kingdom;
      2005   Phase 2   EUCTR2004-003943-28-GB   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
      2005   Phase 2   EUCTR2004-003943-28-ES   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-003943-28-HU   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-003943-28-DE   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-003943-28-CZ   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
ABT-555   
   AbbVie
      2016   Phase 1   NCT02601885   United States;
      2015   Phase 1   NCT02606630   United Kingdom;
ABT-874/Human monoclonal antibody against IL-12   
   AbbVie (prior sponsor, Abbott)
      2004   Phase 2   NCT00086671   Canada;Germany;Netherlands;United Kingdom;United States;
ABX-1431 HCl   
   Abide Therapeutics
      2017   Phase 1   NCT03138421   United Kingdom;
ACT-1   
   Actelion Pharmaceuticals Ltd
      2015   Phase 3   EUCTR2012-000540-10-LV   Argentina;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-000540-10-LT   Argentina;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-000540-10-GR   Argentina;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-000540-10-FR   Argentina;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-000540-10-FI   Argentina;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-000540-10-CZ   Argentina;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
ACT-128800   
   ACTELION Pharmaceuticals Ltd
      2010   Phase 2   EUCTR2009-011470-15-PL   Austria;Bulgaria;Canada;Czech Republic;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2010   Phase 2   EUCTR2009-011470-15-NL   Austria;Bulgaria;Canada;Czech Republic;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2010   Phase 2   EUCTR2009-011470-15-HU   Australia;Austria;Bulgaria;Canada;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2010   Phase 2   EUCTR2009-011470-15-GB   Austria;Bulgaria;Canada;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2010   Phase 2   EUCTR2009-011470-15-FI   Austria;Bulgaria;Canada;Czech Republic;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2010   Phase 2   EUCTR2009-011470-15-DE   Austria;Bulgaria;Canada;Czech Republic;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2010   Phase 2   EUCTR2009-011470-15-CZ   Austria;Bulgaria;Canada;Czech Republic;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2010   Phase 2   EUCTR2009-011470-15-BG   Austria;Bulgaria;Canada;Czech Republic;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2010   Phase 2   EUCTR2009-011470-15-AT   Austria;Bulgaria;Canada;Czech Republic;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2009-011470-15-ES   Austria;Bulgaria;Czech Republic;Finland;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;
   ACTELION Pharmaceuticals Ltd.
      2010   Phase 2   EUCTR2009-011470-15-SE   Austria;Bulgaria;Canada;Czech Republic;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
   Actelion Pharmaceuticals Ltd
      2015   Phase 3   EUCTR2012-000540-10-SE   Argentina;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-000540-10-PT   Argentina;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-000540-10-PL   Argentina;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-000540-10-LV   Argentina;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-000540-10-LT   Argentina;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-000540-10-HU   Argentina;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-000540-10-HR   Argentina;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-000540-10-GR   Argentina;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-000540-10-FR   Argentina;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-000540-10-FI   Argentina;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-000540-10-ES   Argentina;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-000540-10-DE   Argentina;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-000540-10-CZ   Argentina;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2010   Phase 2   EUCTR2008-006786-92-FR   Austria;Belgium;Bulgaria;Czech Republic;Finland;France;Hungary;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-011470-15-IT   Austria;Bulgaria;Czech Republic;Finland;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2009   Phase 2   EUCTR2008-006786-92-ES   Austria;Belgium;Bulgaria;Czech Republic;Finland;France;Hungary;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2009   Phase 2   EUCTR2008-006786-92-CZ   Austria;Belgium;Bulgaria;Czech Republic;Finland;France;Hungary;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2009   Phase 2   EUCTR2008-006786-92-BE   Austria;Belgium;Bulgaria;Czech Republic;Finland;France;Hungary;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-006786-92-SE   Austria;Bulgaria;Czech Republic;Finland;France;Hungary;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-006786-92-PL   Austria;Bulgaria;Czech Republic;Finland;France;Hungary;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-006786-92-NL   Austria;Bulgaria;Czech Republic;Finland;France;Hungary;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-006786-92-HU   Austria;Bulgaria;Czech Republic;Finland;France;Hungary;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-006786-92-GB   Austria;Bulgaria;Czech Republic;Finland;France;Hungary;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-006786-92-FI   Austria;Bulgaria;Czech Republic;Finland;France;Hungary;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-006786-92-BG   Austria;Bulgaria;Czech Republic;Finland;France;Hungary;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-006786-92-AT   Austria;Bulgaria;Czech Republic;Finland;France;Hungary;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;
   Actelion Pharmaceuticals Ltd.
      2019   Phase 3   EUCTR2012-000541-12-HR   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Mexico;Poland;Portugal;Russian Federation;Spain;Switzerland;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-004719-10-PT   Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-004719-10-LV   Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-004719-10-HU   Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-004719-10-HR   Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-004719-10-GR   Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-004719-10-GB   Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-004719-10-FI   Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-004719-10-CZ   Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-004719-10-BG   Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2012-000541-12-BE   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Poland;Portugal;Spain;United States;
      2017   Phase 3   EUCTR2016-004719-10-SE   Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-004719-10-PL   Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-004719-10-LT   Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-004719-10-ES   Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2012-000541-12-PL   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Poland;Portugal;Spain;United States;
      2017   Phase 3   EUCTR2012-000541-12-FR   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Poland;Portugal;Spain;United States;
      2017   Phase 3   EUCTR2012-000541-12-FI   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Poland;Portugal;Spain;United States;
      2017   Phase 3   EUCTR2012-000541-12-BG   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Poland;Portugal;Spain;United States;
      2016   Phase 3   EUCTR2012-000541-12-PT   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Poland;Portugal;Spain;United States;
      2016   Phase 3   EUCTR2012-000541-12-HU   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Poland;Portugal;Spain;United States;
      2016   Phase 3   EUCTR2012-000541-12-GR   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Poland;Portugal;Spain;United States;
      2016   Phase 3   EUCTR2012-000541-12-ES   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Poland;Portugal;Spain;United States;
      2016   Phase 3   EUCTR2012-000541-12-DK   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Poland;Portugal;Spain;United States;
      2016   Phase 3   EUCTR2012-000541-12-DE   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Poland;Portugal;Spain;United States;
      2016   Phase 3   EUCTR2012-000541-12-CZ   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Poland;Portugal;Spain;United States;
      2016   Phase 3   EUCTR2012-000541-12-AT   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Poland;Portugal;Spain;United States;
      2009   -   EUCTR2008-006786-92-IT   Austria;Bulgaria;Czech Republic;Finland;France;Hungary;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;
ACT-128800 Dose 1   
   Actelion
      2009   Phase 2   NCT01006265   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
ACT-128800 Dose 2   
   Actelion
      2009   Phase 2   NCT01006265   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
ACT-128800 Dose 3   
   Actelion
      2009   Phase 2   NCT01006265   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
ACTH   
   Neurologique Foundation, Inc.
      2009   Phase 2/Phase 3   NCT00947895   United States;
   Providence Health & Services
      2015   Phase 3   NCT02315872   United States;
   University of Minnesota
      2013   Phase 2   NCT01950234   United States;
   University of Southern California
      2009   Phase 1   NCT01049451   United States;
ACTHAR Gel (ACTH)   
   University of Colorado, Denver
      2013   Phase 4   NCT01838174   United States;
ACTOS (Pioglitazone)   
   University of Illinois at Chicago
      2003   Phase 1   NCT00242177   United States;
ADS-5102   
   Adamas Pharmaceuticals, Inc.
      2015   Phase 2   NCT02471222   United States;
ADS-5102,   
   Adamas Pharmaceuticals, Inc.
      2018   Phase 3   NCT03567057   Canada;United States;
      2018   Phase 3   NCT03436199   Canada;United States;
AERT, (R)-Baclofen   
   Osmotica Pharmaceutical US LLC
      2018   Phase 3   EUCTR2017-004101-40-PL   Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Moldova, Republic of;Poland;Russian Federation;Serbia;Ukraine;United States;
      2018   Phase 3   EUCTR2017-004101-40-HR   Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Moldova, Republic of;Poland;Russian Federation;Serbia;Ukraine;United States;
      2018   Phase 3   EUCTR2017-004101-40-BG   Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Moldova, Republic of;Poland;Russian Federation;Serbia;Ukraine;United States;
      2018   Phase 3   EUCTR2017-004100-22-PL   Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Moldova, Republic of;Poland;Russian Federation;Serbia;Ukraine;United States;
      2018   Phase 3   EUCTR2017-004100-22-HR   Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Moldova, Republic of;Poland;Russian Federation;Serbia;Ukraine;United States;
      2018   Phase 3   EUCTR2017-004100-22-BG   Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Moldova, Republic of;Poland;Russian Federation;Serbia;Ukraine;United States;
AGEE cream   
   University of Nebraska
      2010   Phase 4   NCT00988988   United States;
AHSC   
   University Medical Centre Hamburg-Eppendorf
      2020   Phase 2   EUCTR2016-001166-29-DE   Germany;
AIMSPRO   
   Daval International Limited
      2008   Phase 2   EUCTR2006-006872-39-GB   United Kingdom;
AIN   
   NOVARTIS FARMA
      2013   -   EUCTR2012-004019-29-IT   Argentina;Canada;Colombia;Finland;Germany;Italy;Japan;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United States;
AIN457   
   NOVARTIS FARMA
      2013   -   EUCTR2012-004019-29-IT   Argentina;Canada;Colombia;Finland;Germany;Italy;Japan;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United States;
   Novartis Farmacéutica, S.A.
      2013   -   EUCTR2012-004019-29-ES   Argentina;Belgium;Canada;Colombia;Czech Republic;Finland;France;Germany;Italy;Japan;Poland;Portugal;Romania;Russian Federation;Spain;Sweden;Switzerland;Turkey;United States;
   Novartis Pharma AG
      2013   Phase 2   EUCTR2012-004019-29-CZ   Argentina;Belgium;Canada;Colombia;Czech Republic;Finland;France;Germany;Italy;Japan;Poland;Portugal;Romania;Russian Federation;Spain;Sweden;Switzerland;Turkey;United States;
      2013   Phase 2   EUCTR2012-004019-29-BE   Argentina;Belgium;Canada;Colombia;Czech Republic;Finland;France;Germany;Italy;Japan;Poland;Portugal;Romania;Russian Federation;Spain;Sweden;Switzerland;Turkey;United States;
      2013   -   EUCTR2012-004019-29-SE   Argentina;Belgium;Canada;Colombia;Czech Republic;Finland;France;Germany;Italy;Japan;Poland;Portugal;Romania;Russian Federation;Spain;Sweden;Switzerland;Turkey;United States;
      2013   -   EUCTR2012-004019-29-PT   Argentina;Belgium;Canada;Colombia;Czech Republic;Finland;France;Germany;Italy;Japan;Poland;Portugal;Romania;Russian Federation;Spain;Sweden;Switzerland;Turkey;United States;
      2013   -   EUCTR2012-004019-29-PL   Argentina;Belgium;Canada;Colombia;Czech Republic;Finland;France;Germany;Italy;Japan;Poland;Portugal;Romania;Russian Federation;Spain;Sweden;Switzerland;Turkey;United States;
      2013   -   EUCTR2012-004019-29-FI   Argentina;Belgium;Canada;Colombia;Czech Republic;Finland;France;Germany;Italy;Japan;Poland;Portugal;Romania;Russian Federation;Spain;Sweden;Switzerland;Turkey;United States;
      2013   -   EUCTR2012-004019-29-DE   Argentina;Belgium;Canada;Colombia;Czech Republic;Finland;France;Germany;Italy;Japan;Poland;Portugal;Romania;Russian Federation;Spain;Sweden;Switzerland;Turkey;United States;
   Novartis Pharma K.K.
      2013   Phase 2   JPRN-JapicCTI-132178   -
   Novartis Pharma Services AG
      2012   -   EUCTR2011-001629-25-CZ   Czech Republic;Russian Federation;Ukraine;
      2009   Phase 2   EUCTR2009-011626-34-SE   Czech Republic;Sweden;
      2009   -   EUCTR2009-011626-34-CZ   Czech Republic;Russian Federation;Serbia;Sweden;Ukraine;
   Novartis Pharmaceuticals
      2013   Phase 2   NCT01874340   Belgium;Canada;Czech Republic;Finland;France;Germany;Italy;Japan;Poland;Romania;Russian Federation;Spain;Sweden;Switzerland;Turkey;United States;
      2012   Phase 2   NCT01433250   Czech Republic;Russian Federation;Ukraine;
      2009   Phase 2   NCT01051817   Czech Republic;Russian Federation;Serbia;Sweden;Ukraine;
ALKS 8700   
   Biogen
      2017   Phase 3   NCT03093324   Germany;Poland;United States;
      2015   Phase 3   NCT02634307   Belgium;Bulgaria;Canada;Germany;Poland;Russian Federation;Serbia;Spain;Ukraine;United States;
ALKS 8700 Delayed Release (DR)   
   Alkermes, Inc.
      2019   Phase 3   EUCTR2017-001294-16-DE   Germany;Poland;United States;
      2017   Phase 3   EUCTR2017-001294-16-PL   Germany;Poland;United States;
ALKS 8700 Delayed Release (DR) Capsule   
   Alkermes, Inc.
      2016   Phase 3   EUCTR2015-005160-41-PL   Belgium;Bulgaria;Canada;Germany;Poland;Russian Federation;Serbia;Spain;Ukraine;United States;
      2016   Phase 3   EUCTR2015-005160-41-ES   Belgium;Bulgaria;Canada;Germany;Poland;Russian Federation;Serbia;Spain;Ukraine;United States;
      2016   Phase 3   EUCTR2015-005160-41-BG   Belgium;Bulgaria;Canada;Germany;Poland;Russian Federation;Serbia;Spain;Ukraine;United States;
      2016   Phase 3   EUCTR2015-005160-41-BE   Belgium;Bulgaria;Canada;Germany;Poland;Russian Federation;Serbia;Spain;Ukraine;United States;
   Biogen Idec Research Limited
      2016   Phase 3   EUCTR2015-005160-41-DE   Belgium;Bulgaria;Canada;Germany;Poland;Russian Federation;Serbia;Spain;Ukraine;United States;
ALTRI FARMACI DEL SISTEMA NERVOSO   
   GLAXO SMITHKLINE
      2004   -   EUCTR2004-000374-31-IT   Italy;
ALXN1210   
   ALEXION PHARMACEUTICALS INCORPORATED
      2020   Phase 3   EUCTR2019-003352-37-IT   Australia;Austria;Canada;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
   Alexion Pharmaceuticals, Inc.
      2020   Phase 3   EUCTR2019-003352-37-PL   Australia;Austria;Canada;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-003352-37-NL   Australia;Austria;Canada;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-003352-37-ES   Australia;Austria;Canada;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-003352-37-DK   Australia;Austria;Canada;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-003352-37-DE   Australia;Austria;Canada;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-003352-37-AT   Australia;Austria;Canada;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
AMILORIDE HYDROCHLORIDE, 2 H2O   
   Universitätsklinik für Neurologie, Medizinische Universität Wien
      2013   -   EUCTR2012-005113-39-AT   Austria;
AN100226   
   Biogen Idec Limited
      2011   -   EUCTR2010-024000-10-ES   Belgium;Germany;Italy;Spain;
      2011   -   EUCTR2010-024000-10-DE   Belgium;Germany;Italy;Spain;
      2011   -   EUCTR2010-024000-10-BE   Belgium;Germany;Italy;Spain;
   Biogen Idec Ltd.
      2004   -   EUCTR2004-000047-18-SE   Sweden;
AN100226, BG00002   
   Biogen Idec Limited
      2012   Phase 3   EUCTR2010-021978-11-IE   Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Ireland;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2012   -   EUCTR2010-021978-11-BE   Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Ireland;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-021978-11-GB   Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Ireland;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-021978-11-ES   Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Ireland;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-021978-11-DK   Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Ireland;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-021978-11-CZ   Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Ireland;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2010-021978-11-SE   Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Ireland;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2010-021978-11-PL   Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Ireland;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2010-021978-11-FI   Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Ireland;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2010-021978-11-DE   Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Iraq;Ireland;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
   Biogen Idec Research Limited
      2019   Phase 3   EUCTR2018-002145-11-NL   Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;New Zealand;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002145-11-FR   Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002145-11-ES   Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;New Zealand;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002145-11-DE   Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;New Zealand;Spain;United Kingdom;United States;
      2015   Phase 4   EUCTR2013-004622-29-DK   Australia;Czech Republic;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
      2015   Phase 4   EUCTR2013-004622-29-DE   Australia;Czech Republic;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
      2015   -   EUCTR2013-005586-39-DE   Germany;Italy;United States;
      2014   Phase 4   EUCTR2013-004622-29-SE   Australia;Czech Republic;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
      2014   Phase 4   EUCTR2013-004622-29-GB   Australia;Czech Republic;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
      2014   Phase 4   EUCTR2013-004622-29-ES   Australia;Canada;Czech Republic;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
      2014   Phase 4   EUCTR2013-004622-29-CZ   Australia;Czech Republic;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
      2014   -   EUCTR2013-004622-29-IT   Australia;Canada;Czech Republic;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-005082-13-IT   Italy;
ANK-700   
   Anokion SA
      2020   Phase 1   NCT04602390   United States;
ARICEPT   
   OSPEDALE S. RAFFAELE
      2008   -   EUCTR2008-001940-38-IT   Italy;
ARN-6039   
   Arrien Pharmaceuticals
      2016   Phase 1   NCT03237832   -
ARZERRA - 100 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONE(VETRO) - 5 ML(20MG/ML) 3 FLACONI   
   NOVARTIS PHARMA SERVICES AG
      2017   Phase 3   EUCTR2015-005419-33-IT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Egypt;Finland;France;Germany;Hungary;India;Italy;Latvia;Lebanon;Lithuania;Mexico;Peru;Portugal;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Arab Emirates;United Kingdom;United States;
ARZERRA - 1000 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) - 50 ML (20 MG/ML) 1 FLACONCINO + 2 KIT DI PROLUNGA   
   NOVARTIS PHARMA SERVICES AG
      2017   Phase 3   EUCTR2015-005418-31-IT   Argentina;Australia;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
ASA   
   Biogen Idec Research Limited
      2014   -   EUCTR2013-001895-40-IE   Ireland;United Kingdom;
ASB-683699   
   GLAXO SMITHKLINE
      2004   -   EUCTR2004-000374-31-IT   Italy;
ATA188   
   Atara Biotherapeutics
      2017   Phase 1/Phase 2   NCT03283826   Australia;United States;
ATG   
   Baylor College of Medicine
      1999   Phase 2   NCT00040482   United States;
ATL1102   
   Antisense Therapeutics Ltd.
      2007   Phase 2   EUCTR2006-004736-79-SK   Czech Republic;Slovakia;
      2007   -   EUCTR2006-004736-79-CZ   Czech Republic;
ATX-MS-1467   
   Apitope Technology (Bristol) Ltd.
      2010   Phase 1   NCT01097668   Russian Federation;United Kingdom;
   Merck KGaA
      2014   Phase 2   NCT01973491   Germany;
      2013   Phase 2   EUCTR2013-002916-28-LV   Latvia;Russian Federation;
AUBAGIO - 14 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BISTER (ALU/ALU) PERFORATO MONODOSE - 10 X 1 COMPRESSA   
   NOVARTIS PHARMA SERVICES AG
      2017   Phase 3   EUCTR2015-005419-33-IT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Egypt;Finland;France;Germany;Hungary;India;Italy;Latvia;Lebanon;Lithuania;Mexico;Peru;Portugal;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Arab Emirates;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005418-31-IT   Argentina;Australia;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
AUBAGIO - 14 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (ALU/ALU) - 28 COMPRESSE   
   UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI
      2016   Phase 4   EUCTR2016-001515-20-IT   Italy;
AUTOLOGOUS T-LYMPHOCYTES   
   ImCyse S.A
      2014   Phase 1;Phase 2   EUCTR2014-001081-99-BE   Belgium;
AV605   
   Avigen Inc
      2007   Phase 2   EUCTR2007-001031-63-CZ   Czech Republic;Germany;
      2007   -   EUCTR2007-001031-63-DE   Germany;
AVONEX - 30 MCG (6 MILIONI UI) POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 4 FLACONI CON DISPOSITIVO BIOSET + 4 SIRINGHE PRERIEMPITE USO INTRAMUSCOLARE   
   OSPEDALE SAN RAFFAELE
      2018   Phase 4   EUCTR2016-004819-12-IT   Italy;
AVONEX 30 microgramos/0,5 ml (Interferón Beta - 1a) Solución inyectable   
   Biogen Idec Ltd
      2010   Phase 3   EUCTR2009-012500-11-ES   Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Slovenia;Spain;Sweden;United Kingdom;
AVONEX 30 µg/0,5 ml solution for injection   
   Università degli Studi Aldo Moro
      2019   Phase 3   EUCTR2017-005129-18-IT   Italy;
AVONEX IM 4SIR 30MCG/0,5ML 4AG   
   Universita di Firenze
      2006   -   EUCTR2006-004937-13-IT   Italy;
AVONEX*IM 4SIR 30MCG/0,5ML+4AG   
   TEVA ITALIA srl
      2008   -   EUCTR2007-005450-23-IT   Bulgaria;Czech Republic;Estonia;Germany;Italy;Lithuania;Spain;
AVONEX®   
   BIOGEN IDEC RESEARCH LIMITED
      2019   Phase 3   EUCTR2018-003008-38-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
   Biogen Idec Research Limited
      2020   Phase 3   EUCTR2018-003008-38-DE   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-003008-38-SK   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-003008-38-PT   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-003008-38-HU   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-003008-38-HR   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-003008-38-GR   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-003008-38-ES   Argentina;Belgium;Brazil;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;
      2019   Phase 3   EUCTR2018-003008-38-CZ   Argentina;Belgium;Brazil;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;
      2019   Phase 3   EUCTR2018-003008-38-BG   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-003008-38-BE   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      -   Phase 3   EUCTR2018-003008-38-FR   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
AVP-923   
   Avanir Pharmaceuticals
      2011   Phase 2   NCT01324232   Argentina;Czech Republic;Czechia;Germany;Poland;Spain;United Kingdom;United States;
      2002   Phase 3   NCT00050232   United States;
   Avanir Pharmaceuticals, Inc.
      2012   Phase 2   EUCTR2011-002178-22-GB   Argentina;Bulgaria;Czech Republic;Germany;Poland;Spain;United Kingdom;United States;
      2012   -   EUCTR2011-002178-22-PL   Argentina;Bulgaria;Czech Republic;Germany;Poland;Spain;United Kingdom;United States;
      2012   -   EUCTR2011-002178-22-CZ   Argentina;Bulgaria;Czech Republic;Germany;Poland;Spain;United Kingdom;United States;
      2011   Phase 2   EUCTR2011-002178-22-ES   Argentina;Bulgaria;Czech Republic;Poland;Spain;United Kingdom;United States;
AZATIOPRINA HEX. 50CPR 50MG BL   
   Universita di Firenze
      2006   -   EUCTR2006-004937-13-IT   Italy;
Abatacept   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2010   Phase 2   NCT01116427   Canada;United States;
Abobotulinumtoxin A   
   Neurology Center of New England P.C.
      2018   Phase 3   NCT03585569   United States;
Acetaminophen Tab   
   Columbia University
      2019   Phase 1/Phase 2   NCT03824938   United States;
Acetazolamide   
   The University of Texas Health Science Center, Houston
      2016   Phase 2   NCT02466074   United States;
Acetylsalicylic acid   
   Biogen
      2014   Phase 4   NCT02090413   Ireland;United Kingdom;
Acetylsalicylic acid at 1st visit,   
   Columbia University
      2017   Early Phase 1   NCT03051646   United States;
Aciclovir   
   Genzyme, a Sanofi Company
      2014   Phase 4   NCT02205489   Belgium;France;Netherlands;Spain;
Aclasta 5 mg Infusionslösung   
   Novartis Pharma GmbH
      2010   -   EUCTR2009-011888-37-DE   Germany;
Aclasta 5mg solution for infusion   
   North Bristol Trust
      2009   -   EUCTR2008-005304-93-GB   United Kingdom;
Acthar   
   OhioHealth
      2014   -   NCT02258217   United States;
Acthar Gel   
   Aaron Miller
      2013   -   NCT01900093   United States;
   Tanner Foundation for Multiple Sclerosis
      2013   -   NCT01906684   United States;
Active Comparator receiving Extavia®   
   Charite University, Berlin, Germany
      2013   Phase 2/Phase 3   NCT01647880   Germany;
Active Control   
   Biogen
      2014   Phase 1   NCT02201849   United States;
Acyclovir   
   Genzyme, a Sanofi Company
      2017   Phase 3   NCT03368664   Austria;Belgium;Bulgaria;Czechia;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;
      2015   Phase 1   NCT02583594   Spain;
      2014   Phase 1   NCT02282826   Germany;
   Sanofi
      2016   Phase 1   NCT02977533   Germany;
Ad26.COV2.S   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States;
Adderall XR   
   London Health Sciences Centre
      2012   Phase 2/Phase 3   NCT01667484   Canada;
   Sarah Morrow
      2016   Phase 2/Phase 3   NCT02676739   Canada;
Adrenocorticotropic hormone (ACTH) gel (H.P. Acthar®)   
   Weill Medical College of Cornell University
      2016   Phase 4   NCT02446886   United States;
Albumin (Human) , United States Pharmacopeia (USP)   
   Grifols Therapeutics Inc.
      2002   Phase 2   NCT00220779   Austria;Canada;Czech Republic;Germany;Greece;Hungary;Israel;Poland;Slovakia;Sweden;United Kingdom;United States;
Albuterol   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2001   -   NCT00039988   United States;
Alcohol Wipes vs. No Alcohol Wipes   
   Teva Neuroscience, Inc.
      2004   Phase 4   NCT00220922   United States;
Alemtuzumab   
   Cambridge University Hospitals NHS Foundation Trust
      2012   Phase 1/Phase 2   NCT01712945   United Kingdom;
   Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
      2012   Phase 2   EUCTR2011-005606-30-GB   United Kingdom;
   Central Texas Neurology Consultants
      2011   Phase 3   NCT01333358   -
   GENZYME CORPORATION
      2017   Phase 3   EUCTR2016-003100-30-IT   Austria;Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;
   Genzyme Corporation
      2017   Phase 3   EUCTR2016-003100-30-PT   Austria;Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2017   Phase 3   EUCTR2016-003100-30-NO   Austria;Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2017   Phase 3   EUCTR2016-003100-30-NL   Austria;Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2017   Phase 3   EUCTR2016-003100-30-GR   Austria;Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2017   Phase 3   EUCTR2016-003100-30-GB   Austria;Belgium;Bulgaria;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;
      2017   Phase 3   EUCTR2016-003100-30-ES   Austria;Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2017   Phase 3   EUCTR2016-003100-30-DE   Austria;Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2017   Phase 3   EUCTR2016-003100-30-BE   Austria;Belgium;Bulgaria;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;
      2017   Phase 3   EUCTR2016-003100-30-AT   Austria;Belgium;Bulgaria;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;
      2015   Phase 3;Phase 4   EUCTR2013-003884-71-NL   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2015   Phase 3;Phase 4   EUCTR2013-003884-71-DK   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2009-010788-18-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2015   -   EUCTR2013-003884-71-BE   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;France;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;
      2014   Phase 4   EUCTR2014-000092-62-NL   Belgium;France;Netherlands;Spain;Switzerland;
      2014   Phase 4   EUCTR2014-000092-62-FR   Belgium;France;Netherlands;Spain;Switzerland;
      2014   Phase 4   EUCTR2014-000092-62-ES   Belgium;France;Netherlands;Spain;Switzerland;
      2014   Phase 4   EUCTR2014-000092-62-BE   Belgium;France;Netherlands;Spain;Switzerland;
      2014   Phase 3;Phase 4   EUCTR2013-003884-71-IT   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;France;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;
      2014   Phase 3;Phase 4   EUCTR2013-003884-71-HR   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2013-003884-71-DE   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2013-003884-71-CZ   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2014   -   EUCTR2013-003884-71-ES   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;France;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;
      2011   Phase 3   EUCTR2009-010788-18-IT   Austria;Belgium;Czech Republic;Denmark;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2010   Phase 3   EUCTR2009-010788-18-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2009-010788-18-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2009-010788-18-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2009-010788-18-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2009-010788-18-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2009   Phase 3   EUCTR2009-010788-18-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2009   Phase 3   EUCTR2009-010788-18-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2009   -   EUCTR2009-010788-18-DK   Argentina;Australia;Austria;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2008   Phase 3   EUCTR2007-001162-32-FR   Austria;Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2008   Phase 3   EUCTR2007-001162-32-ES   Austria;Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2008   Phase 3   EUCTR2007-001162-32-CZ   Austria;Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2008   Phase 3   EUCTR2007-001162-32-BE   Austria;Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2008   Phase 3   EUCTR2007-001161-14-FR   Czech Republic;France;Germany;Poland;Sweden;United Kingdom;
      2008   -   EUCTR2007-001162-32-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;France;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2008   -   EUCTR2007-001162-32-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;France;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2008   -   EUCTR2007-001162-32-NL   Austria;Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-001162-32-IT   Austria;Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-001162-32-DK   Argentina;Australia;Austria;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;France;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2008   -   EUCTR2007-001162-32-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;France;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2008   -   EUCTR2007-001162-32-AT   Austria;Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-001161-14-SE   Argentina;Australia;Brazil;Croatia;Czech Republic;France;Germany;Mexico;Poland;Russian Federation;Serbia;Sweden;Ukraine;United Kingdom;
      2008   -   EUCTR2007-001161-14-PL   Argentina;Australia;Brazil;Croatia;Czech Republic;France;Germany;Mexico;Poland;Russian Federation;Serbia;Sweden;Ukraine;United Kingdom;
      2008   -   EUCTR2007-001161-14-DE   Argentina;Australia;Brazil;Croatia;Czech Republic;France;Germany;Mexico;Poland;Russian Federation;Serbia;Sweden;Ukraine;United Kingdom;
      2008   -   EUCTR2007-001161-14-CZ   Argentina;Australia;Brazil;Croatia;Czech Republic;France;Germany;Mexico;Poland;Russian Federation;Serbia;Sweden;Ukraine;United Kingdom;
      2007   Phase 3   EUCTR2007-001162-32-GB   Austria;Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-001161-14-GB   Czech Republic;France;Germany;Poland;Sweden;United Kingdom;
      -   Phase 3   EUCTR2016-003100-30-PL   Austria;Belgium;Bulgaria;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;
      -   Phase 3   EUCTR2016-003100-30-Outside-EU/EEA   Austria;Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      -   Phase 3   EUCTR2016-003100-30-FR   Austria;Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      -   Phase 3   EUCTR2016-003100-30-BG   Austria;Belgium;Bulgaria;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;
   Genzyme, a Sanofi Company
      2009   Phase 3   NCT00930553   Argentina;Australia;Austria;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2007   Phase 3   NCT00548405   Argentina;Australia;Austria;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;France;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2007   Phase 3   NCT00530348   Argentina;Australia;Brazil;Canada;Croatia;Czech Republic;Former Serbia and Montenegro;France;Germany;Mexico;Poland;Russian Federation;Serbia;Sweden;Ukraine;United Kingdom;United States;
      2002   Phase 2   NCT00050778   Croatia;Poland;Russian Federation;United Kingdom;United States;
   Glostrup University Hospital, Copenhagen
      2017   -   NCT03193086   Denmark;
   Hadassah Medical Organization
      2015   -   NCT02529839   -
   Haukeland University Hospital
      2018   Phase 3   NCT03477500   Denmark;Netherlands;Norway;Sweden;
   Helse Bergen HF, Haukeland University Hospital
      2018   Phase 3   EUCTR2017-001362-25-DK   Denmark;Netherlands;
   Queen Mary University of London
      2017   -   NCT03250169   United Kingdom;
   R&D Addenbrookes Hospital
      2008   Phase 2   EUCTR2005-002305-23-GB   United Kingdom;
   Seah Lim M.D.
      2012   Phase 2   NCT01679041   United States;
   Sheffield Teaching Hospitals
      2020   Phase 3   EUCTR2019-001549-42-GB   United Kingdom;
   University Hospital Muenster
      2015   Phase 4   NCT02419378   Germany;
   University of Aarhus
      2017   -   NCT03806387   Denmark;
   University of Chicago
      2011   Phase 4   NCT01395316   -
   University of Texas Southwestern Medical Center
      2018   Phase 4   NCT03135249   United States;
   Universitätsklinikum Hamburg-Eppendorf
      2021   Phase 2   NCT04971005   Germany;
Alemtuzumab (GZ402673)   
   Genzyme, a Sanofi Company
      2015   -   NCT03774914   Austria;Belgium;Canada;Denmark;Germany;Italy;Spain;Sweden;United Kingdom;United States;
Alemtuzumab GZ402673   
   Genzyme, a Sanofi Company
      2017   Phase 3   NCT03368664   Austria;Belgium;Bulgaria;Czechia;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;
      2015   Phase 4   NCT02255656   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;Sweden;Ukraine;United Kingdom;United States;
      2015   Phase 1   NCT02583594   Spain;
      2014   Phase 4   NCT02205489   Belgium;France;Netherlands;Spain;
Alemtuzumab Injection   
   Maritime Neurology
      2016   -   NCT04633967   Canada;
Alemtuzumab Injection [Lemtrada]   
   University Hospital Muenster
      2017   -   NCT04082260   Germany;
Alemtuzumab immunotherapy   
   Samuel Forrester Hunter, MD, PhD
      2012   Phase 1   NCT01624714   United States;
Alfuzosin   
   Capital District Health Authority, Canada
      2007   Phase 2/Phase 3   NCT00688948   Canada;
All patients in the study will be treated with ocrelizumab   
   Providence Health & Services
      2020   -   NCT05081700   United States;
AlloRx   
   The Foundation for Orthopaedics and Regenerative Medicine
      2022   Phase 1   NCT05003388   Antigua and Barbuda;
Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells   
   Genesis Limited
      2015   Phase 1/Phase 2   NCT02418325   Trinidad and Tobago;
   Novo Cellular Medicine Institute LLP
      2015   Phase 1/Phase 2   NCT02587715   Trinidad and Tobago;
Allogeneic fecal microbiota   
   St. Petersburg State Pavlov Medical University
      2019   Phase 1   NCT04203017   Russian Federation;
Alpha Lipoic Acid   
   Rebecca Spain
      2018   Phase 1   NCT03493841   United States;
Alpha lipoic acid   
   University of Iowa
      2010   Phase 1   NCT01381354   United States;
Alpha-lipoic acid   
   National Center for Complementary and Integrative Health (NCCIH)
      1999   Phase 1/Phase 2   NCT00010842   United States;
Alpha1-antitrypsin   
   Stanford University
      2014   Phase 1   NCT02087813   United States;
Amantadine   
   FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR
      2011   -   EUCTR2010-023678-38-IT   Italy;
   Johns Hopkins University
      2017   Phase 3   NCT03185065   United States;
American ginseng extract HT-1001   
   Oregon Health and Science University
      2005   Phase 2   NCT00754832   United States;
Amiloride   
   UCL
      2014   Phase 2   EUCTR2012-005394-31-GB   United Kingdom;
   University College, London
      2014   Phase 2   NCT01910259   United Kingdom;
   University of Oxford
      2013   Phase 2   NCT01802489   United Kingdom;
Amiloride Hydrochloride   
   Oxford Racliffe NHS Trust
      2008   -   EUCTR2007-004051-11-GB   United Kingdom;
Amilostad HCT tablets   
   Universitätsklinik für Neurologie, Medizinische Universität Wien
      2013   -   EUCTR2012-005113-39-AT   Austria;
Amyvid radiopharmaceutical   
   Brain Health Alliance
      2021   Early Phase 1   NCT04390009   United States;
Anakinra   
   National Institute of Neurological Disorders and Stroke (NINDS)
      2019   Phase 1/Phase 2   NCT04025554   United States;
AndroGel Topical Gel   
   University of California, Los Angeles
      2018   Phase 2   NCT03000127   United States;
Androgel 10 grams of gel containing 100 mg of testosterone   
   University of California, Los Angeles
      2002   Phase 1/Phase 2   NCT00405353   United States;
Andrographolides   
   Innobioscience SpA
      2014   Phase 1/Phase 2   NCT02273635   Chile;
Anesthetic Topical Adhesive Synera   
   Brown, Theodore R., M.D., MPH
      2013   Phase 4   NCT01834586   United States;
Anti LP40 antibody, subclass IgG4 LA294   
   Eli Lilly and Company
      2010   -   EUCTR2008-007459-28-BG   Belgium;Bulgaria;Czech Republic;Denmark;Finland;France;Germany;Hungary;
      2009   Phase 2   EUCTR2008-007459-28-FR   Belgium;Bulgaria;Czech Republic;Denmark;Finland;France;Germany;Hungary;
      2009   -   EUCTR2008-007459-28-HU   Belgium;Bulgaria;Czech Republic;Denmark;Finland;France;Germany;Hungary;
      2009   -   EUCTR2008-007459-28-FI   Belgium;Bulgaria;Czech Republic;Denmark;Finland;France;Germany;Hungary;
      2009   -   EUCTR2008-007459-28-DK   Belgium;Bulgaria;Czech Republic;Denmark;Finland;France;Germany;Hungary;
      2009   -   EUCTR2008-007459-28-DE   Belgium;Bulgaria;Czech Republic;Denmark;Finland;France;Germany;Hungary;
      2009   -   EUCTR2008-007459-28-CZ   Belgium;Bulgaria;Czech Republic;Denmark;Finland;France;Germany;Hungary;
      2009   -   EUCTR2008-007459-28-BE   Belgium;Bulgaria;Czech Republic;Denmark;Finland;France;Germany;Hungary;
Anti-CD25 Humanized Monoclonal Antibody   
   Protein Design Labs, Inc.
      2006   -   EUCTR2005-001567-55-DE   Germany;Spain;United Kingdom;
      2005   Phase 2   EUCTR2005-001567-55-GB   Austria;Germany;Spain;United Kingdom;
      2005   -   EUCTR2005-001567-55-ES   Germany;Spain;United Kingdom;
      2005   -   EUCTR2005-001567-55-AT   Austria;Germany;Spain;United Kingdom;
Anti-CD52 monoclonal antibody   
   Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
      2012   Phase 2   EUCTR2011-005606-30-GB   United Kingdom;
Anti-Thymocyte Globulin   
   Fred Hutchinson Cancer Research Center
      2008   Phase 2   NCT00716066   United States;
Anti-thymocyte globulin   
   Fred Hutchinson Cancer Research Center
      1997   Phase 1   NCT00014755   United States;
Anticholinergic medication   
   Wellspect HealthCare
      2009   -   NCT00913510   Belgium;France;Germany;Netherlands;United Kingdom;
Anticuerpo monoclonal anti-LINGO-1 humano   
   Biogen Idec Research Limited
      2013   Phase 2   EUCTR2011-006262-40-ES   Canada;Czech Republic;France;Hungary;Italy;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
Antihistamine   
   Genentech, Inc.
      2016   Phase 3   NCT02688985   Canada;Germany;Sweden;United States;
   Hoffmann-La Roche
      2020   Phase 3   NCT04548999   Argentina;Belgium;Brazil;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Mexico;Peru;Poland;Portugal;Puerto Rico;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   NCT04544436   Argentina;Australia;Belgium;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
   Providence Health & Services
      2020   Phase 3   NCT04175834   United States;
Antimycotic   
   Università Popolare Homo & Natura
      2015   Phase 1   NCT02632591   Italy;
Antithymocyte   
   Dipartimento di Neuroscienze Oftalmologia e Genetica DINOG - Universita di Genova
      2006   -   EUCTR2006-002562-19-IT   Italy;
Antithymocyte immunoglobulin (rabbit)   
   AZIENDA OSPEDALIERA DI PADOVA
      -   Phase 1   EUCTR2008-005773-35-IT   Italy;
Anxiety/depression and work and activities   
   University Hospital, Strasbourg, France
      2019   Phase 2   NCT03910738   France;
Apitox - pure honeybee toxin   
   Apimeds, Inc.
      2019   Phase 3   NCT03710655   -
Arbaclofen   
   Osmotica Pharmaceutical US LLC
      2018   Phase 3   NCT03319732   United States;
      2018   Phase 3   NCT03290131   Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Moldova, Republic of;Poland;Serbia;United States;
      2013   Phase 3   NCT01844232   Russian Federation;Ukraine;United States;
      2012   Phase 3   NCT01743651   Russian Federation;Ukraine;United States;
Arbaclofen ER Tablets   
   Osmotica Pharmaceutical US LLC
      2016   Phase 3   NCT02869425   United States;
Arbaclofen Extended Release Tablets   
   Osmotica Pharmaceutical US LLC
      2018   Phase 3   EUCTR2017-004101-40-PL   Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Moldova, Republic of;Poland;Russian Federation;Serbia;Ukraine;United States;
      2018   Phase 3   EUCTR2017-004101-40-HR   Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Moldova, Republic of;Poland;Russian Federation;Serbia;Ukraine;United States;
      2018   Phase 3   EUCTR2017-004101-40-BG   Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Moldova, Republic of;Poland;Russian Federation;Serbia;Ukraine;United States;
      2018   Phase 3   EUCTR2017-004100-22-PL   Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Moldova, Republic of;Poland;Russian Federation;Serbia;Ukraine;United States;
      2018   Phase 3   EUCTR2017-004100-22-HR   Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Moldova, Republic of;Poland;Russian Federation;Serbia;Ukraine;United States;
      2018   Phase 3   EUCTR2017-004100-22-BG   Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Moldova, Republic of;Poland;Russian Federation;Serbia;Ukraine;United States;
Arbaclofen placarbil 15 mg BID   
   XenoPort, Inc.
      2011   Phase 3   NCT01359566   United States;
Arbaclofen placarbil 30 mg BID   
   XenoPort, Inc.
      2011   Phase 3   NCT01359566   United States;
Arbaclofen placarbil 45 mg BID   
   XenoPort, Inc.
      2011   Phase 3   NCT01359566   United States;
Aricept 10 mg filmdragerade tabletter   
   Neurology Unit
      2005   -   EUCTR2005-003410-15-SE   Sweden;
Aricept 5 mg filmdragerade tabletter   
   Neurology Unit
      2005   -   EUCTR2005-003410-15-SE   Sweden;
Arm 1 - GEH120714 (18F) Injection   
   GE Healthcare
      2013   Phase 1   NCT01738347   Canada;United States;
Armodafinil   
   University of Missouri, Kansas City
      2009   Phase 2/Phase 3   NCT00981084   United States;
Arzerra   
   GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
      2012   -   EUCTR2011-002333-19-IT   Canada;Czech Republic;Germany;Italy;Netherlands;Russian Federation;Spain;United States;
   NOVARTIS PHARMA AG
      2018   Phase 2   EUCTR2017-004702-17-IT   Austria;Bulgaria;Czech Republic;Czechia;Estonia;Germany;Italy;Latvia;Lithuania;Poland;Russian Federation;Spain;United States;
   Novartis Farmacéutica S.A.
      2020   Phase 3   EUCTR2019-001341-40-ES   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Lebanon;Mexico;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Slovakia;Spain;Switzerland;Turkey;United Kingdom;United States;
   Novartis Farmacéutica, S.A
      2019   Phase 3   EUCTR2017-004703-51-ES   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
   Novartis Farmacéutica, S.A.
      2018   Phase 2   EUCTR2017-004702-17-ES   Austria;Bulgaria;Czech Republic;Estonia;Germany;Italy;Latvia;Lithuania;Poland;Russian Federation;Spain;United States;
      2016   Phase 3   EUCTR2015-005419-33-ES   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Egypt;Finland;France;Germany;Hungary;India;Latvia;Lebanon;Mexico;Peru;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Arab Emirates;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005418-31-ES   Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Kuwait;Mexico;Netherlands;Poland;Russian Federation;Saudi Arabia;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
   Novartis Pharma Services AG
      2016   Phase 3   EUCTR2015-005419-33-SK   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Germany;Hungary;India;Latvia;Lithuania;Mexico;Peru;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005419-33-GB   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Germany;Hungary;India;Latvia;Lithuania;Mexico;Peru;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
   Novartis Pharma AG
      2021   Phase 3   EUCTR2019-001341-40-PL   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Italy;Lebanon;Mexico;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Slovakia;Slovenia;Spain;Switzerland;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001341-40-PT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Italy;Lebanon;Mexico;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Slovakia;Spain;Switzerland;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001341-40-IT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Italy;Lebanon;Mexico;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Slovakia;Spain;Switzerland;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001341-40-CZ   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Lebanon;Mexico;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Slovakia;Spain;Switzerland;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001341-40-BG   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Italy;Latvia;Lebanon;Mexico;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Slovakia;Slovenia;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004703-51-PT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004703-51-NL   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004703-51-LV   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004703-51-LT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004703-51-HR   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004703-51-GR   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004703-51-GB   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004703-51-FR   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004703-51-FI   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004703-51-DK   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004703-51-DE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004703-51-CZ   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004703-51-BE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2019   Phase 2   EUCTR2017-004702-17-PL   Austria;Bulgaria;Czech Republic;Estonia;Germany;Italy;Latvia;Lithuania;Poland;Russian Federation;Spain;United States;
      2018   Phase 3   EUCTR2017-004703-51-SK   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004703-51-SE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004703-51-HU   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004703-51-AT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-004702-17-LV   Austria;Bulgaria;Czech Republic;Estonia;Germany;Italy;Latvia;Lithuania;Poland;Russian Federation;Spain;United States;
      2018   Phase 2   EUCTR2017-004702-17-LT   Austria;Bulgaria;Czech Republic;Estonia;Germany;Italy;Latvia;Lithuania;Poland;Russian Federation;Spain;United States;
      2018   Phase 2   EUCTR2017-004702-17-EE   Austria;Bulgaria;Czech Republic;Estonia;Germany;Italy;Latvia;Lithuania;Poland;Russian Federation;Spain;United States;
      2018   Phase 2   EUCTR2017-004702-17-CZ   Austria;Bulgaria;Czech Republic;Estonia;Germany;Italy;Latvia;Lithuania;Poland;Russian Federation;Spain;United States;
      2018   Phase 2   EUCTR2017-004702-17-BG   Austria;Bulgaria;Czech Republic;Estonia;Germany;Italy;Latvia;Lithuania;Poland;Russian Federation;Spain;United States;
      2018   Phase 2   EUCTR2017-004702-17-AT   Austria;Bulgaria;Czech Republic;Estonia;Germany;Italy;Latvia;Lithuania;Poland;Russian Federation;Spain;United States;
      2017   Phase 3   EUCTR2015-005418-31-FR   Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Croatia;Czech Republic;Denmark;Estonia;European Union;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Kuwait;Mexico;Netherlands;Poland;Russian Federation;Saudi Arabia;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005419-33-FR   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Egypt;European Union;Finland;France;Germany;Hungary;India;Latvia;Lebanon;Lithuania;Mexico;Peru;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Arab Emirates;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005419-33-BE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Egypt;Finland;France;Germany;Hungary;India;Latvia;Lebanon;Lithuania;Mexico;Peru;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Arab Emirates;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005418-31-HU   Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Kuwait;Mexico;Netherlands;Poland;Russian Federation;Saudi Arabia;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005418-31-GR   Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Kuwait;Mexico;Netherlands;Poland;Russian Federation;Saudi Arabia;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005418-31-BE   Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Kuwait;Mexico;Netherlands;Poland;Russian Federation;Saudi Arabia;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
   Novartis Pharma Services AG
      2017   Phase 3   EUCTR2015-005419-33-HR   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Germany;Hungary;India;Latvia;Lithuania;Mexico;Peru;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005419-33-CZ   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Germany;Hungary;India;Latvia;Lithuania;Mexico;Peru;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005419-33-BG   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Germany;Hungary;India;Latvia;Lithuania;Mexico;Peru;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005418-31-NL   Argentina;Australia;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005418-31-CZ   Argentina;Australia;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Germany;Greece;Hungary;India;Israel;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005419-33-PT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Egypt;Finland;France;Germany;Hungary;India;Italy;Latvia;Lebanon;Lithuania;Mexico;Peru;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Arab Emirates;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005419-33-LV   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Egypt;Finland;France;Germany;Hungary;India;Latvia;Lebanon;Lithuania;Mexico;Peru;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Arab Emirates;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005419-33-LT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Germany;Hungary;India;Latvia;Lithuania;Mexico;Peru;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005419-33-HU   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Germany;Hungary;India;Latvia;Lithuania;Mexico;Peru;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005419-33-FI   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Germany;Hungary;India;Latvia;Lithuania;Mexico;Peru;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005419-33-DE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Germany;Hungary;India;Latvia;Lithuania;Mexico;Peru;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005419-33-AT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Germany;Hungary;India;Latvia;Lithuania;Mexico;Peru;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005418-31-SK   Argentina;Australia;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005418-31-SE   Argentina;Australia;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005418-31-PL   Argentina;Australia;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005418-31-HR   Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Croatia;Czech Republic;Denmark;Estonia;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Kuwait;Mexico;Netherlands;Poland;Russian Federation;Saudi Arabia;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005418-31-GB   Argentina;Australia;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005418-31-EE   Argentina;Australia;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005418-31-DE   Argentina;Australia;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005418-31-BG   Argentina;Australia;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
Arzerra®   
   GlaxoSmithKline Research and Development Limited
      2012   -   EUCTR2011-002333-19-CZ   Bulgaria;Canada;Czech Republic;Denmark;Germany;Italy;Netherlands;Norway;Russian Federation;Spain;United States;
      2011   Phase 2   EUCTR2011-002333-19-DK   Bulgaria;Canada;Czech Republic;Denmark;Germany;Italy;Netherlands;Norway;Russian Federation;Spain;United States;
      2011   -   EUCTR2011-002333-19-NL   Bulgaria;Canada;Czech Republic;Denmark;Germany;Italy;Netherlands;Norway;Russian Federation;Spain;United States;
   GlaxoSmithKline SA
      2011   Phase 2   EUCTR2011-002333-19-ES   Bulgaria;Canada;Czech Republic;Denmark;Germany;Italy;Netherlands;Norway;Russian Federation;Spain;United States;
Aspirin 650mg Oral Capsule   
   Columbia University
      2019   Phase 1/Phase 2   NCT03824938   United States;
Atacicept   
   EMD Serono
      2009   Phase 2   NCT00853762   Australia;Belgium;Canada;Czech Republic;France;Germany;Lebanon;Lithuania;Netherlands;New Caledonia;Russian Federation;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2008   Phase 2   NCT00642902   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Lebanon;Lithuania;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
   Merck Serono Geneva- an affiliate of Merck KGaA, Darmstadt Germany
      2008   -   EUCTR2007-003936-50-SE   Austria;Czech Republic;France;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
   Merck Serono International
      2009   Phase 2   EUCTR2008-005021-11-FR   Belgium;Czech Republic;France;Sweden;
      2009   Phase 2   EUCTR2008-005021-11-CZ   Belgium;Czech Republic;France;Sweden;
      2009   -   EUCTR2008-005021-11-SE   Belgium;Czech Republic;France;Sweden;
   Merck Serono International S.A.
      2008   Phase 2   EUCTR2007-003936-50-FR   Austria;Belgium;Czech Republic;France;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
      2008   Phase 2   EUCTR2007-003936-50-ES   Austria;Belgium;Czech Republic;France;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-003936-50-NL   Austria;Czech Republic;France;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
   Merck Serono S.A. - Geneva
      2008   -   EUCTR2007-003936-50-GB   Australia;Austria;Canada;Czech Republic;France;Lebanon;Lithuania;Netherlands;Russian Federation;Spain;Sweden;Ukraine;United Kingdom;United States;
      2008   -   EUCTR2007-003936-50-AT   Austria;Czech Republic;France;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
   Merck Serono SA - Geneva, An affiliate of Merck KGaA, Darmstadt, Germany
      2009   -   EUCTR2008-005021-11-BE   Belgium;Czech Republic;France;Sweden;
   Merck Serono SA - Geneva, an affiliate of Merck KGaA, Darmstadt, Germany
      2008   -   EUCTR2007-003936-50-CZ   Austria;Czech Republic;France;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-003936-50-BE   Austria;Belgium;Czech Republic;France;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
   Merck Serono SA-Geneva
      2008   -   EUCTR2007-003936-50-LT   Austria;Czech Republic;France;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
Atomoxetine   
   Icahn School of Medicine at Mount Sinai
      2017   Phase 2   NCT03091400   United States;
Atorvastatin   
   DR DIMENSIONE RICERCA
      2005   -   EUCTR2005-001009-25-IT   Italy;
   National Institute of Allergy and Infectious Diseases (NIAID)
      2005   Phase 2   NCT00094172   Canada;United States;
   Sun Yat-sen University
      2006   -   NCT00818103   China;
   University Hospital Inselspital, Berne
      2005   Phase 2   NCT00942591   Switzerland;
Aubagio   
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 3   EUCTR2020-001168-28-IT   Bulgaria;Denmark;Finland;France;Italy;Netherlands;United States;
      2021   Phase 3   EUCTR2019-004857-10-IT   Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;United States;
   F. Hoffman-La Roche
      2021   Phase 3   EUCTR2020-001168-28-DK   Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Greece;India;Italy;Korea, Republic of;Mexico;Poland;Portugal;Russian Federation;Turkey;United Kingdom;United States;
   F. Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-001168-28-BG   Bulgaria;Finland;France;Netherlands;United States;
      2021   Phase 3   EUCTR2019-004857-10-NL   Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;United States;
      2021   Phase 3   EUCTR2019-004857-10-HU   Finland;France;Germany;Hungary;Netherlands;Portugal;United States;
      2021   Phase 3   EUCTR2019-004857-10-DE   Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;United States;
      2020   Phase 3   EUCTR2019-004857-10-FI   Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;United States;
   GENZYME CORPORATION
      2020   Phase 3   EUCTR2020-000637-41-IT   Austria;Belarus;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Hong Kong;Italy;Japan;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United States;
   Genzyme Corporation
      2021   Phase 3   EUCTR2020-000644-55-DE   Argentina;Belgium;Brazil;Canada;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Latvia;Netherlands;Norway;Portugal;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000637-41-AT   Austria;Belarus;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Hong Kong;Italy;Japan;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2020-000644-55-SK   Argentina;Belgium;Brazil;Canada;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Latvia;Netherlands;Norway;Portugal;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000644-55-PT   Argentina;Belgium;Brazil;Canada;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Latvia;Netherlands;Norway;Portugal;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000644-55-NL   Argentina;Belgium;Brazil;Canada;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Latvia;Netherlands;Norway;Portugal;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000644-55-LV   Argentina;Belgium;Brazil;Canada;Chile;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Latvia;Netherlands;Norway;Portugal;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000644-55-HU   Argentina;Belgium;Brazil;Canada;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Latvia;Netherlands;Norway;Portugal;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000644-55-GR   Argentina;Belgium;Brazil;Canada;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Latvia;Netherlands;Norway;Portugal;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000644-55-GB   Argentina;Belgium;Brazil;Canada;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Latvia;Netherlands;Norway;Portugal;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000644-55-FR   Argentina;Belgium;Brazil;Canada;Chile;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Latvia;Netherlands;Norway;Portugal;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000644-55-CZ   Argentina;Belgium;Brazil;Canada;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Latvia;Netherlands;Norway;Portugal;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000637-41-SE   Austria;Belarus;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Hong Kong;Italy;Japan;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2020-000637-41-PL   Austria;Belarus;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Hong Kong;Italy;Japan;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2020-000637-41-LT   Austria;Belarus;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Hong Kong;Italy;Japan;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2020-000637-41-FI   Austria;Belarus;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Hong Kong;Italy;Japan;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2020-000637-41-DK   Austria;Belarus;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Hong Kong;Italy;Japan;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2020-000637-41-DE   Austria;Belarus;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Hong Kong;Italy;Japan;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2020-000637-41-CZ   Austria;Belarus;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Hong Kong;Italy;Japan;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2020-000637-41-BG   Austria;Belarus;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Hong Kong;Italy;Japan;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United States;
      2014   Phase 4   EUCTR2013-001439-34-IT   Austria;Belgium;Canada;Chile;Finland;Germany;Greece;Italy;Spain;Sweden;Switzerland;United Kingdom;United States;
      2014   Phase 4   EUCTR2013-001439-34-GR   Austria;Belgium;Canada;Chile;Finland;Germany;Greece;Spain;Sweden;Switzerland;United Kingdom;United States;
      2014   Phase 4   EUCTR2013-001439-34-GB   Austria;Belgium;Canada;Chile;Finland;Germany;Greece;Spain;Sweden;Switzerland;United Kingdom;United States;
      2014   -   EUCTR2013-001439-34-DE   Austria;Belgium;Canada;Chile;Finland;Germany;Greece;Spain;Sweden;Switzerland;United Kingdom;United States;
      2014   -   EUCTR2013-001439-34-BE   Austria;Belgium;Canada;Chile;Finland;Germany;Greece;Spain;Sweden;Switzerland;United Kingdom;United States;
      2014   -   EUCTR2013-001439-34-AT   Austria;Belgium;Canada;Chile;Finland;Germany;Greece;Spain;Sweden;Switzerland;United Kingdom;United States;
      2013   Phase 4   EUCTR2013-001439-34-SE   Austria;Belgium;Canada;Chile;Finland;Germany;Greece;Spain;Sweden;Switzerland;United Kingdom;United States;
      2013   Phase 4   EUCTR2013-001439-34-FI   Austria;Belgium;Canada;Chile;Finland;Germany;Greece;Spain;Sweden;Switzerland;United Kingdom;United States;
      2013   Phase 4   EUCTR2013-001439-34-ES   Austria;Belgium;Canada;Chile;Finland;Germany;Greece;Italy;Spain;Sweden;Switzerland;United Kingdom;United States;
   MERCK HEALTHCARE KGaA
      2020   Phase 3   EUCTR2019-004980-36-IT   Belarus;Brazil;Bulgaria;Canada;France;Germany;Greece;India;Italy;Kuwait;Latvia;Lithuania;Malaysia;Mexico;Moldova, Republic of;Norway;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;Tunisia;Turkey;Ukraine;United States;
   MS Centrum, Department of Neurology, Sshlgrenska University Hospital
      2018   Phase 4   EUCTR2016-004414-10-SE   Sweden;
   Merck Healthcare KGaA
      2021   Phase 3   EUCTR2019-004980-36-SI   Belarus;Brazil;Bulgaria;Canada;France;Germany;Greece;India;Italy;Kuwait;Latvia;Lithuania;Malaysia;Mexico;Moldova, Republic of;Norway;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;Tunisia;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2019-004980-36-SK   Belarus;Brazil;Bulgaria;Canada;France;Germany;Greece;India;Italy;Kuwait;Latvia;Lithuania;Malaysia;Mexico;Moldova, Republic of;Norway;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;Tunisia;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2019-004980-36-PT   Belarus;Brazil;Bulgaria;Canada;France;Germany;Greece;India;Italy;Kuwait;Latvia;Lithuania;Malaysia;Mexico;Moldova, Republic of;Norway;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;Tunisia;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2019-004980-36-NO   Belarus;Brazil;Bulgaria;Canada;France;Germany;Greece;India;Italy;Kuwait;Latvia;Lithuania;Malaysia;Mexico;Moldova, Republic of;Norway;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;Tunisia;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2019-004980-36-LV   Belarus;Brazil;Bulgaria;Canada;France;Germany;Greece;India;Italy;Kuwait;Latvia;Lithuania;Malaysia;Mexico;Moldova, Republic of;Norway;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;Tunisia;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2019-004980-36-LT   Belarus;Brazil;Bulgaria;Canada;France;Germany;Greece;India;Italy;Kuwait;Latvia;Lithuania;Malaysia;Mexico;Moldova, Republic of;Norway;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;Tunisia;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2019-004980-36-GR   Belarus;Brazil;Bulgaria;Canada;France;Germany;Greece;India;Italy;Kuwait;Latvia;Lithuania;Malaysia;Mexico;Moldova, Republic of;Norway;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;Tunisia;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2019-004980-36-DE   Belarus;Brazil;Bulgaria;Canada;France;Germany;Greece;India;Italy;Kuwait;Latvia;Lithuania;Malaysia;Mexico;Moldova, Republic of;Norway;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;Tunisia;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2019-004980-36-BG   Belarus;Brazil;Bulgaria;Canada;France;Germany;Greece;India;Italy;Kuwait;Latvia;Lithuania;Malaysia;Mexico;Moldova, Republic of;Norway;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;Tunisia;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2019-004972-20-HU   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Georgia;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004972-20-GB   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004972-20-FI   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Georgia;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004972-20-DE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Georgia;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004972-20-CZ   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Georgia;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004972-20-BG   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Georgia;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004972-20-AT   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Georgia;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2019-004972-20-BE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Georgia;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
   Novartis Farmacéutica S.A.
      2022   Phase 3   EUCTR2020-005929-89-ES   Argentina;Brazil;Bulgaria;Canada;China;Croatia;Czechia;Estonia;France;Germany;Greece;Hungary;India;Italy;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;United Kingdom;United States;
      2022   Phase 3   EUCTR2020-005899-36-ES   Slovakia;Spain;
   Novartis Farmacéutica, S.A.
      2016   Phase 3   EUCTR2015-005419-33-ES   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Egypt;Finland;France;Germany;Hungary;India;Latvia;Lebanon;Mexico;Peru;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Arab Emirates;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005418-31-ES   Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Kuwait;Mexico;Netherlands;Poland;Russian Federation;Saudi Arabia;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
   Novartis Pharma Services AG
      2016   Phase 3   EUCTR2015-005419-33-SK   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Germany;Hungary;India;Latvia;Lithuania;Mexico;Peru;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005419-33-GB   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Germany;Hungary;India;Latvia;Lithuania;Mexico;Peru;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
   Novartis Pharma AG
      2022   Phase 3   EUCTR2020-005929-89-SE   Argentina;Brazil;Bulgaria;Canada;China;Croatia;Czechia;Estonia;France;Germany;Greece;Hungary;India;Italy;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;United Kingdom;United States;
      2022   Phase 3   EUCTR2020-005899-36-SK   Argentina;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czechia;France;Germany;Guatemala;Hong Kong;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Netherlands;Poland;Russian Federation;Serbia;Slovakia;Spain;Switzerland;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005418-31-FR   Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Croatia;Czech Republic;Denmark;Estonia;European Union;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Kuwait;Mexico;Netherlands;Poland;Russian Federation;Saudi Arabia;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005419-33-FR   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Egypt;European Union;Finland;France;Germany;Hungary;India;Latvia;Lebanon;Lithuania;Mexico;Peru;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Arab Emirates;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005419-33-BE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Egypt;Finland;France;Germany;Hungary;India;Latvia;Lebanon;Lithuania;Mexico;Peru;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Arab Emirates;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005418-31-HU   Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Kuwait;Mexico;Netherlands;Poland;Russian Federation;Saudi Arabia;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005418-31-GR   Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Kuwait;Mexico;Netherlands;Poland;Russian Federation;Saudi Arabia;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005418-31-BE   Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Kuwait;Mexico;Netherlands;Poland;Russian Federation;Saudi Arabia;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
   Novartis Pharma Services AG
      2017   Phase 3   EUCTR2015-005419-33-HR   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Germany;Hungary;India;Latvia;Lithuania;Mexico;Peru;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005419-33-CZ   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Germany;Hungary;India;Latvia;Lithuania;Mexico;Peru;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005419-33-BG   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Germany;Hungary;India;Latvia;Lithuania;Mexico;Peru;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005418-31-NL   Argentina;Australia;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005418-31-CZ   Argentina;Australia;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Germany;Greece;Hungary;India;Israel;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005419-33-PT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Egypt;Finland;France;Germany;Hungary;India;Italy;Latvia;Lebanon;Lithuania;Mexico;Peru;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Arab Emirates;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005419-33-LV   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Egypt;Finland;France;Germany;Hungary;India;Latvia;Lebanon;Lithuania;Mexico;Peru;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Arab Emirates;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005419-33-LT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Germany;Hungary;India;Latvia;Lithuania;Mexico;Peru;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005419-33-HU   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Germany;Hungary;India;Latvia;Lithuania;Mexico;Peru;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005419-33-FI   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Germany;Hungary;India;Latvia;Lithuania;Mexico;Peru;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005419-33-DE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Germany;Hungary;India;Latvia;Lithuania;Mexico;Peru;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005419-33-AT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Germany;Hungary;India;Latvia;Lithuania;Mexico;Peru;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005418-31-SK   Argentina;Australia;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005418-31-SE   Argentina;Australia;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005418-31-PL   Argentina;Australia;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005418-31-HR   Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Croatia;Czech Republic;Denmark;Estonia;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Kuwait;Mexico;Netherlands;Poland;Russian Federation;Saudi Arabia;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005418-31-GB   Argentina;Australia;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005418-31-EE   Argentina;Australia;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005418-31-DK   Argentina;Australia;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005418-31-DE   Argentina;Australia;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005418-31-BG   Argentina;Australia;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
Aubagio 14 mg film-coated tablets   
   F. Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2019-004857-10-PT   Finland;France;Germany;Netherlands;Portugal;United States;
Aubagio®   
   Actelion Pharmaceuticals Ltd
      2015   Phase 3   EUCTR2012-000540-10-SE   Argentina;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-000540-10-PT   Argentina;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-000540-10-PL   Argentina;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-000540-10-LV   Argentina;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-000540-10-LT   Argentina;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-000540-10-HU   Argentina;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-000540-10-HR   Argentina;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-000540-10-GR   Argentina;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-000540-10-FR   Argentina;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-000540-10-FI   Argentina;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-000540-10-ES   Argentina;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-000540-10-DE   Argentina;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2012-000540-10-CZ   Argentina;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
Autologous Bone Marrow-Derived Mononuclear Stem Cells   
   Genesis Limited
      2015   Phase 1/Phase 2   NCT02418351   India;Trinidad and Tobago;
   Novo Cellular Medicine Institute LLP
      2015   Phase 1/Phase 2   NCT02587806   India;Trinidad and Tobago;
Autologous CD4+T cells stimulated and expanded ex vivo by a MOG peptide modified by the introduction of a thioreductase motif into the flanking residues of the T cell epitope   
   Imcyse SA
      2015   Phase 1/Phase 2   NCT02427776   Belgium;
Autologous Hematopoietic Stem Cell   
   Makati Medical Center
      2015   Phase 1   NCT03113162   Philippines;
Autologous Hematopoietic Stem Cell Transplantation   
   Fred Hutchinson Cancer Research Center
      2008   Phase 2   NCT00716066   United States;
   National Institute of Allergy and Infectious Diseases (NIAID)
      2019   Phase 3   NCT04047628   United Kingdom;United States;
   Universitätsklinikum Hamburg-Eppendorf
      2021   Phase 2   NCT04971005   Germany;
Autologous Mesenchymal Cell Product   
   Imperial College London
      2012   Phase 2   EUCTR2012-002357-35-GB   United Kingdom;
Autologous Mesenchymal Stem Cells   
   Antonio Uccelli
      2012   Phase 1/Phase 2   NCT01854957   Italy;
   University of Jordan
      2012   Phase 1/Phase 2   NCT01895439   Jordan;
Autologous Stem Cell Transplantation   
   Northwestern Memorial Hospital
      2001   Phase 1   NCT00017628   United States;
Autologous Stem Cells   
   Northwestern University
      2019   Phase 2/Phase 3   NCT03829566   United States;
      2017   Phase 3   NCT03342638   United States;
Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3)   
   Fundació Institut Germans Trias i Pujol
      2017   Phase 1   NCT02903537   Spain;
Autologous adipose derived mesenchymal cells   
   American CryoStem Corporation
      2014   Phase 1   NCT02326935   Cayman Islands;
Autologous adult mesenchymal stem cells from bone marrow expanded and cryopreserved   
   Banc de Sang i Teixits
      2014   -   EUCTR2012-000734-19-ES   Spain;
Autologous bone marrow transplantation   
   Hadassah Medical Organization
      2015   -   NCT02529839   -
Autologous hematopoietic stem cell transplant   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2006   Phase 2   NCT00288626   United States;
Autologous hematopoietic stem cells   
   University Medical Centre Hamburg-Eppendorf
      2020   Phase 2   EUCTR2016-001166-29-DE   Germany;
Autologous mesenchymal stem cell transplantation   
   The Cleveland Clinic
      2011   Phase 1   NCT00813969   United States;
Autologous mesenchymal stem cells   
   Albert Saiz
      2010   Phase 2   NCT01228266   Spain;
   Karolinska Institutet
      2013   Phase 1/Phase 2   NCT01730547   Sweden;
      2012   Phase 1   NCT03778333   Sweden;
   Tianjin Medical University General Hospital
      2013   Phase 2   NCT02249676   China;
Avonex   
   Biogen
      2013   Phase 2   NCT01864148   Canada;Czech Republic;France;Hungary;Italy;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
   Biogen Idec
      2010   Phase 3   NCT01181115   China;
   Biogen Idec Research Limited
      2013   Phase 2   EUCTR2011-006262-40-NL   Canada;Czech Republic;France;Hungary;Italy;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
   Celgene International II Sàrl (CIS II)
      2015   Phase 3   EUCTR2014-002320-27-PL   Austria;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Estonia;Georgia;Germany;Hungary;Latvia;Lithuania;Moldova, Republic of;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002320-27-LV   Austria;Belarus;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Georgia;Germany;Hungary;Latvia;Lithuania;Moldova, Republic of;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002320-27-LT   Austria;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Estonia;Georgia;Germany;Hungary;Latvia;Lithuania;Moldova, Republic of;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002320-27-HU   Austria;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Estonia;Georgia;Germany;Hungary;Latvia;Lithuania;Moldova, Republic of;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002320-27-HR   Austria;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Estonia;Georgia;Germany;Hungary;Latvia;Lithuania;Moldova, Republic of;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002320-27-GB   Argentina;Austria;Belarus;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;Georgia;Germany;Hungary;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002320-27-BG   Austria;Belarus;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Georgia;Germany;Hungary;Latvia;Lithuania;Moldova, Republic of;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-002320-27-PT   Austria;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Estonia;Georgia;Germany;Hungary;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-002320-27-EE   Austria;Belarus;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Georgia;Germany;Hungary;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2014   Phase 2;Phase 3   EUCTR2012-002714-40-SK   Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Georgia;Greece;Hungary;Italy;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2014   Phase 2;Phase 3   EUCTR2012-002714-40-GB   Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Georgia;Greece;Hungary;Italy;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2013   Phase 2;Phase 3   EUCTR2012-002714-40-HU   Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Georgia;Greece;Hungary;Italy;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2013   Phase 2;Phase 3   EUCTR2012-002714-40-BG   Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Georgia;Greece;Hungary;Italy;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2013   Phase 2;Phase 3   EUCTR2012-002714-40-BE   Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Georgia;Greece;Hungary;Israel;Italy;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
   Centrum Neurologii Krzysztof Selmaj
      2016   Phase 2   EUCTR2016-002180-33-PL   Poland;
   F. Hoffman-La Roche Ltd
      2008   Phase 2   EUCTR2007-006338-32-DE   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Mexico;Netherlands;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
   F.Hoffmann-La Roche Ltd.
      2008   -   EUCTR2007-006338-32-IT   Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Mexico;Netherlands;Russian Federation;Spain;Switzerland;Ukraine;United Kingdom;United States;
   Genentech, Inc.
      2008   Phase 2   NCT00676715   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Mexico;Netherlands;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
   Hoffman La Roche Ltd
      2008   Phase 2   EUCTR2007-006338-32-SK   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Mexico;Netherlands;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2008   Phase 2   EUCTR2007-006338-32-GB   Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Mexico;Netherlands;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2008   Phase 2   EUCTR2007-006338-32-FR   Belgium;Bulgaria;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Slovakia;Spain;United Kingdom;
      2008   Phase 2   EUCTR2007-006338-32-ES   Belgium;Bulgaria;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Slovakia;Spain;United Kingdom;
      2008   Phase 2   EUCTR2007-006338-32-DK   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Mexico;Netherlands;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2008   Phase 2   EUCTR2007-006338-32-CZ   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Mexico;Netherlands;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2008   Phase 2   EUCTR2007-006338-32-BG   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Mexico;Netherlands;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2008   Phase 2   EUCTR2007-006338-32-BE   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Mexico;Netherlands;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2008   -   EUCTR2007-006338-32-NL   Belgium;Bulgaria;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-006338-32-FI   Belgium;Bulgaria;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;United Kingdom;
   Karolinska Institutet
      2017   Phase 4   EUCTR2017-002634-24-SE   Sweden;
      2017   Phase 4   EUCTR2016-003587-39-SE   Sweden;
   MedImmune LLC
      2012   -   EUCTR2011-005475-16-GB   Austria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
   Medizinische Universität Innsbruck
      2014   Phase 4   EUCTR2012-005450-30-AT   Austria;Sweden;
      2014   -   EUCTR2012-005450-30-SE   Austria;Sweden;
   Merck Healthcare KGaA
      2020   Phase 3   EUCTR2018-004701-11-BG   Argentina;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Montenegro;Poland;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-004700-19-BG   Belarus;Brazil;Bulgaria;Canada;France;Germany;Greece;Italy;Kuwait;Lebanon;Lithuania;Mexico;Moldova, Republic of;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Thailand;Tunisia;Turkey;Ukraine;United States;
   Merck KGaA
      2014   Phase 3   EUCTR2013-002351-15-AT   Argentina;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Jordan;Latvia;Lebanon;Lithuania;Mexico;Morocco;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2014   -   EUCTR2013-003126-83-HU   Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2014   -   EUCTR2013-003126-83-GR   Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2014   -   EUCTR2013-003126-83-ES   Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2014   -   EUCTR2013-003126-83-DE   Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2014   -   EUCTR2013-003126-83-BG   Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2014   -   EUCTR2013-002351-15-PT   Argentina;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Jordan;Latvia;Lebanon;Lithuania;Mexico;Morocco;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2014   -   EUCTR2013-002351-15-LV   Argentina;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Jordan;Latvia;Lebanon;Lithuania;Mexico;Morocco;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2014   -   EUCTR2013-002351-15-HU   Argentina;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Jordan;Latvia;Lebanon;Lithuania;Mexico;Morocco;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2014   -   EUCTR2013-002351-15-ES   Argentina;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Jordan;Latvia;Lebanon;Lithuania;Mexico;Morocco;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2014   -   EUCTR2013-002351-15-EE   Argentina;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Jordan;Latvia;Lebanon;Lithuania;Mexico;Morocco;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2014   -   EUCTR2013-002351-15-BG   Argentina;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Jordan;Latvia;Lebanon;Lithuania;Mexico;Morocco;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-004505-32-IT   France;Germany;Italy;Spain;
   Novartis Farma
      2013   -   EUCTR2011-005677-23-IT   Brazil;Canada;Italy;Latvia;Lithuania;Mexico;Spain;United States;Venezuela, Bolivarian Republic of;
   Novartis Farmaceutica S.A.
      2013   -   EUCTR2011-005677-23-ES   Brazil;Canada;Latvia;Lithuania;Mexico;Spain;United States;Venezuela, Bolivarian Republic of;
   Novartis Pharma Service AG
      2015   Phase 3   EUCTR2011-005677-23-HR   Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Croatia;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2011-005677-23-GB   Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Croatia;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2011-005677-23-EE   Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Croatia;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2014   -   EUCTR2011-005677-23-RO   Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2011-005677-23-DE   Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Croatia;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2011-005677-23-BG   Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Croatia;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
      2013   -   EUCTR2011-005677-23-LV   Austria;Belarus;Brazil;Bulgaria;Canada;Croatia;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
   Novartis Pharma Services AG
      2014   Phase 3   EUCTR2011-005677-23-PL   Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Croatia;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2011-005677-23-NL   Austria;Brazil;Bulgaria;Canada;Croatia;Estonia;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
      2014   Phase 3   EUCTR2011-005677-23-AT   Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Croatia;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2014   -   EUCTR2011-005677-23-SE   Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Croatia;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2011-005677-23-SK   Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Croatia;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2011-005677-23-LT   Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Croatia;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2011-001437-16-DE   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
      2006   -   EUCTR2006-000704-17-PT   Austria;Belgium;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom;
   PD Dr. Marcus Müller
      2015   Phase 1   NCT02364986   Germany;
   Receptos, Inc.
      2015   Phase 3   EUCTR2014-002320-27-SE   Argentina;Austria;Belarus;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;Georgia;Germany;Hungary;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002320-27-NL   Argentina;Austria;Belarus;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;Georgia;Germany;Hungary;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002320-27-ES   Argentina;Austria;Belarus;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;Georgia;Germany;Hungary;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2014   Phase 2;Phase 3   EUCTR2012-002714-40-HR   Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Georgia;Greece;Hungary;Italy;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2013   Phase 2;Phase 3   EUCTR2012-002714-40-IT   Belgium;Bulgaria;Canada;Croatia;Georgia;Greece;Hungary;Israel;Italy;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2013   Phase 2;Phase 3   EUCTR2012-002714-40-GR   Belgium;Bulgaria;Canada;Croatia;Czech Republic;Georgia;Greece;Hungary;Israel;Italy;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2013   Phase 2;Phase 3   EUCTR2012-002714-40-ES   Belgium;Bulgaria;Canada;Croatia;Czech Republic;Georgia;Greece;Hungary;Israel;Italy;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
   Saint Francis Care
      2012   -   NCT01641120   United States;
   Teva Pharmaceutical Industries, Ltd.
      2014   -   EUCTR2013-002082-19-NL   Belgium;Denmark;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Spain;Sweden;Switzerland;United Kingdom;
      2014   -   EUCTR2013-002082-19-ES   Denmark;Finland;Netherlands;Spain;Sweden;Switzerland;United Kingdom;
      2013   Phase 3   EUCTR2013-002082-19-GB   Belgium;Denmark;Finland;Netherlands;Spain;Sweden;Switzerland;United Kingdom;
      2013   Phase 3   EUCTR2013-002082-19-BE   Belgium;Denmark;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Spain;Sweden;Switzerland;United Kingdom;
      2013   -   EUCTR2013-002082-19-SE   Denmark;Finland;Netherlands;Spain;Sweden;Switzerland;United Kingdom;
      2013   -   EUCTR2013-002082-19-FI   Denmark;Finland;Netherlands;Spain;Sweden;Switzerland;United Kingdom;
      2013   -   EUCTR2013-002082-19-DK   Denmark;Finland;Netherlands;Spain;Sweden;Switzerland;United Kingdom;
   Turku University Hospital
      2013   Phase 4   EUCTR2013-004626-28-FI   Finland;
Avonex (Interferon beta 1a)   
   University of California, San Francisco
      2006   Phase 2   NCT00501943   United States;
Avonex (interferon beta-1a), Biogen Idec Ltd   
   Bayer
      2016   -   NCT02749396   Finland;
Avonex 30 microgram/0.5 ml Solution for Injection   
   Teva Pharmaceutical Industries Ltd
      2008   Phase 3   EUCTR2007-005450-23-SK   Bulgaria;Czech Republic;Estonia;Germany;Italy;Lithuania;Slovakia;Spain;
      2008   -   EUCTR2007-005450-23-LT   Bulgaria;Czech Republic;Estonia;Germany;Italy;Lithuania;Spain;
      2008   -   EUCTR2007-005450-23-EE   Bulgaria;Czech Republic;Estonia;Germany;Italy;Lithuania;Spain;
      2008   -   EUCTR2007-005450-23-DE   Bulgaria;Czech Republic;Estonia;Germany;Italy;Lithuania;Spain;
      2008   -   EUCTR2007-005450-23-CZ   Bulgaria;Czech Republic;Estonia;Germany;Italy;Lithuania;Spain;
      2008   -   EUCTR2007-005450-23-BG   Bulgaria;Czech Republic;Estonia;Germany;Italy;Lithuania;Spain;
Avonex 30 microgramos/0.5 ml Solución para inyección   
   Teva Pharmaceutical Industries Ltd
      2008   -   EUCTR2007-005450-23-ES   Bulgaria;Czech Republic;Estonia;Germany;Italy;Lithuania;Spain;
Avonex and Topamax   
   Multiple Sclerosis Institute
      2004   Phase 2   NCT00217295   United States;
Avonex prefilled syringe via manual IM injection   
   Biogen
      2009   Phase 3   NCT00828204   United States;
Avonex/Betaseron/Copaxone/Rebif   
   Sheffield Teaching Hospitals NHS Foundation Trust
      2013   Phase 2/Phase 3   NCT03133403   United Kingdom;
Avonex/Zocor   
   University of North Carolina
      2004   Phase 4   NCT00146068   United States;
Avonex®   
   Biocad
      2017   Phase 2/Phase 3   NCT02744222   Russian Federation;
   EMD Serono
      1999   Phase 3   NCT00292266   -
   EMD Serono Research & Development Institute, Inc.
      2019   Phase 3   NCT04032171   Germany;United States;
      2019   Phase 3   NCT04032158   Argentina;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czechia;Estonia;France;Georgia;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Montenegro;Poland;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
   Teva Branded Pharmaceutical Products R&D, Inc.
      2014   Phase 3   NCT01975298   Belgium;Denmark;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Spain;Sweden;Switzerland;United Kingdom;
      2008   Phase 3   NCT00605215   Bulgaria;Croatia;Czech Republic;Czechia;Estonia;Georgia;Germany;Israel;Italy;Latvia;Lithuania;Macedonia, The Former Yugoslav Republic of;Montenegro;North Macedonia;Poland;Puerto Rico;Romania;Russian Federation;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
   University Hospital Motol
      2011   Phase 4   EUCTR2011-001956-12-CZ   Czech Republic;
Avonex® monotherapy ( administered i.m. each week)   
   State University of New York at Buffalo
      2005   -   NCT00463710   United States;
Azathioprine   
   Isfahan University of Medical Sciences
      2015   Phase 2/Phase 3   NCT03002038   Iran, Islamic Republic of;
   The Ophthalmology Department of the Chinese Peoples Liberation Army Hospital
      2019   Phase 4   ChiCTR1900025744   China;
      2014   -   ChiCTR-ICR-15007177   China;
   Tianjin Medical University General Hospital
      2017   Phase 2/Phase 3   NCT03350633   China;
   Universita di Firenze
      2006   -   EUCTR2006-004937-13-IT   Italy;
Azathioprine (AZA)   
   Hoffmann-La Roche
      2021   Phase 3   NCT04660539   Bulgaria;Canada;Croatia;Germany;Hungary;Italy;Japan;Korea, Republic of;Malaysia;Poland;Puerto Rico;Romania;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Azithromycin   
   National Center for Research Resources (NCRR)
      2001   Phase 2   NCT00043264   United States;
B001 injection   
   Shanghai Pharmaceuticals Holding Co., Ltd
      2022   Early Phase 1   NCT05145361   China;
BAF312   
   NOVARTIS FARMA
      2010   -   EUCTR2009-014392-51-IT   Finland;Germany;Hungary;Italy;Poland;Spain;
      2009   -   EUCTR2008-008719-25-IT   Finland;Germany;Hungary;Italy;Spain;
   NOVARTIS PHARMA SERVICES AG
      2021   Phase 3   EUCTR2020-002700-39-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Novartis Farmacéutica S.A.
      2021   Phase 3   EUCTR2020-002700-39-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Novartis Farmacéutica, S.A
      2009   -   EUCTR2008-008719-25-ES   Finland;Germany;Hungary;Italy;Spain;
   Novartis Pharma AG
      2021   Phase 3   EUCTR2020-002700-39-SK   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-002700-39-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-002700-39-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-002700-39-LV   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-002700-39-LT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-002700-39-HR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-002700-39-FR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-002700-39-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-002700-39-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2020-002700-39-EE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2020-002700-39-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Novartis Pharma K.K.
      2014   Phase 3   JPRN-JapicCTI-142447   -
   Novartis Pharma Services AG
      2010   Phase 2   EUCTR2009-014392-51-PL   Canada;Finland;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Turkey;United States;
      2010   Phase 2   EUCTR2009-014392-51-HU   Canada;Finland;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Turkey;United States;
      2010   Phase 2   EUCTR2009-014392-51-FI   Canada;Finland;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Turkey;United States;
      2010   -   EUCTR2009-014392-51-DE   Canada;Finland;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Turkey;United States;
      2009   -   EUCTR2008-008719-25-HU   Finland;Germany;Hungary;Italy;Spain;
      2009   -   EUCTR2008-008719-25-FI   Finland;Germany;Hungary;Italy;Spain;
      -   -   EUCTR2008-008719-25-DE   Finland;Germany;Hungary;Italy;Spain;
   Novartis Pharmaceuticals
      2021   Phase 4   NCT04792567   Germany;
      2012   Phase 3   NCT01665144   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2010   Phase 2   NCT01185821   Canada;Finland;Germany;Hungary;Italy;Norway;Poland;Russian Federation;Spain;Switzerland;Turkey;United States;
      2009   Phase 2   NCT00879658   Canada;Finland;Germany;Hungary;Italy;Norway;Poland;Russian Federation;Spain;Switzerland;Turkey;United States;
BAF312 0,25 mg tablet   
   Novartis Pharma Services AG
      2012   -   EUCTR2011-006043-30-NL   Netherlands;
BAF312 1 mg tablet   
   Novartis Pharma Services AG
      2012   -   EUCTR2011-006043-30-NL   Netherlands;
BAF312 4 mg tablet   
   Novartis Pharma Services AG
      2012   -   EUCTR2011-006043-30-NL   Netherlands;
BAF312 hemifumarate   
   NOVARTIS FARMA
      2012   -   EUCTR2012-003056-36-IT   Argentina;Australia;Austria;Bulgaria;Canada;Czech Republic;Egypt;Estonia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
   Novartis Farmacéutica S.A
      2012   -   EUCTR2012-003056-36-ES   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
   Novartis Pharma Services AG
      2015   -   EUCTR2012-003056-36-FR   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003056-36-PL   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003056-36-IE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003056-36-GR   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003056-36-GB   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003056-36-BG   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003056-36-BE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-SK   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-SE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-PT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-LT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-HU   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-EE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-DE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-CZ   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-AT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   -   EUCTR2012-003056-36-LV   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   -   EUCTR2011-006043-30-NL   Netherlands;
      -   Phase 3   EUCTR2012-003056-36-NL   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
BAF312A   
   NOVARTIS FARMA
      2012   -   EUCTR2012-003056-36-IT   Argentina;Australia;Austria;Bulgaria;Canada;Czech Republic;Egypt;Estonia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
   Novartis Farmacéutica S.A
      2012   -   EUCTR2012-003056-36-ES   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
   Novartis Pharma GmbH
      2021   Phase 4   EUCTR2020-005752-38-DE   Germany;
   Novartis Pharma Services AG
      2015   -   EUCTR2012-003056-36-FR   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003056-36-PL   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003056-36-IE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003056-36-GR   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003056-36-GB   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003056-36-BG   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003056-36-BE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-SK   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-SE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-PT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-LT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-HU   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-EE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-DE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-CZ   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-AT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   -   EUCTR2012-003056-36-LV   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      -   Phase 3   EUCTR2012-003056-36-NL   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
BAT4406F   
   Bio-Thera Solutions
      2019   Phase 1   NCT04146285   China;
BAY 79-4998   
   Bayer Vital GmbH
      2006   -   EUCTR2006-002361-39-DE   Germany;
BAY86-5046   
   Bayer AG
      2017   Phase 4   EUCTR2017-001176-31-GB   Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Norway;Poland;Portugal;Slovenia;Spain;Sweden;Switzerland;United Kingdom;
      2017   Phase 4   EUCTR2017-001176-31-FI   Austria;Belgium;Canada;Czech Republic;Denmark;Finland;Germany;Hungary;Israel;Italy;Norway;Poland;Portugal;Slovenia;Spain;Sweden;Switzerland;United Kingdom;
      2017   Phase 4   EUCTR2017-001176-31-DK   Austria;Belgium;Canada;Czech Republic;Denmark;Finland;Germany;Hungary;Israel;Italy;Norway;Poland;Portugal;Slovenia;Spain;Sweden;Switzerland;United Kingdom;
      2017   Phase 4   EUCTR2017-001176-31-CZ   Austria;Belgium;Canada;Czech Republic;Denmark;Finland;Germany;Hungary;Israel;Italy;Norway;Poland;Portugal;Slovenia;Spain;Sweden;Switzerland;United Kingdom;
      2017   Phase 4   EUCTR2017-001176-31-AT   Austria;Belgium;Canada;Czech Republic;Denmark;Finland;Germany;Hungary;Israel;Italy;Norway;Poland;Portugal;Slovenia;Spain;Sweden;Switzerland;United Kingdom;
   Bayer HealthCare AG
      2013   Phase 4   EUCTR2012-005262-35-GB   Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Portugal;Slovenia;Spain;Sweden;Switzerland;United Kingdom;
      2013   -   EUCTR2012-005262-35-IT   Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Portugal;Slovenia;Spain;Sweden;Switzerland;United Kingdom;
      -   -   EUCTR2014-004613-93-Outside-EU/EEA   China;
BAY86-5046_Interferon-beta-1b   
   Bayer
      2007   -   NCT01158183   United States;
BBR 2778   
   Fondation Charcot Stichting
      2009   Phase 1;Phase 2   EUCTR2007-003086-40-BE   Belgium;France;
      2008   -   EUCTR2007-003086-40-FR   France;
BCD-033 (interferon beta 1a)   
   Biocad
      2014   Phase 2/Phase 3   NCT02727907   Russian Federation;
BCD-054 180 mcg   
   Biocad
      2017   Phase 2/Phase 3   NCT02744222   Russian Federation;
BCD-054 240 mcg   
   Biocad
      2017   Phase 2/Phase 3   NCT02744222   Russian Federation;
BCD-063   
   Biocad
      2013   Phase 3   NCT02753088   -
BCD-132   
   Biocad
      2018   Phase 1   NCT03551275   Russian Federation;
BCD-132,   
   Biocad
      2019   Phase 2   NCT04056897   Russian Federation;
BCG20-0134   
   BTG International Ltd
      2009   Phase 2   EUCTR2009-011585-28-BE   Belgium;European Union;France;Germany;Russian Federation;Spain;
      2009   -   EUCTR2009-011585-28-FR   Belgium;France;Germany;Spain;
      2009   -   EUCTR2009-011585-28-DE   Belgium;European Union;France;Germany;Russian Federation;Spain;
BEAM Regimen   
   Makati Medical Center
      2015   Phase 1   NCT03113162   Philippines;
BETACONNECT   
   Bayer
      2019   -   NCT03808142   Germany;
      2014   -   NCT02247310   Austria;Belgium;Bosnia and Herzegovina;Croatia;Czech Republic;Czechia;France;Greece;Hungary;Italy;Netherlands;Spain;Switzerland;
BETACONNECT auto-injector.   
   Bayer
      2014   -   NCT02121444   Germany;
BETACONNECT device   
   Bayer
      2016   -   NCT02652091   United States;
BETAFERON - 15 FLACONCINI 0.25 MG + 15 FLACONCINI 2 ML   
   OSPEDALE SAN RAFFAELE
      2018   Phase 4   EUCTR2016-004819-12-IT   Italy;
BETAFERON 250 mcg   
   SCHERING
      2007   -   EUCTR2006-005270-47-IT   Austria;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
BETAFERON 500 mcg   
   SCHERING
      2007   -   EUCTR2006-005270-47-IT   Austria;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
BETAFERON SC 15F 0,25MG 15SIR   
   Universita di Firenze
      2006   -   EUCTR2006-004937-13-IT   Italy;
BETAFERON*15CONFEZ 0,25MG/ML+   
   AZIENDA OSPEDALIERA S. LUIGI GONZAGA
      2011   -   EUCTR2010-023677-19-IT   Italy;
BETAFERON® (interferon beta-1b)   
   Ospedale Regionale di Lugano
      2013   -   EUCTR2012-004040-30-AT   Austria;Switzerland;
BG-12 120   
   Northwestern University
      2013   Phase 2   EUCTR2012-004165-41-GB   United Kingdom;United States;
BG00002   
   BIOGEN IDEC LTD
      2007   -   EUCTR2005-004061-41-SE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2007   -   EUCTR2005-004061-41-AT   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Ireland;Italy;Spain;Sweden;United Kingdom;
      2006   Phase 3   EUCTR2005-004061-41-GB   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;New Zealand;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2006   Phase 3   EUCTR2005-004061-41-BE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2006   -   EUCTR2005-004061-41-IE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2006   -   EUCTR2005-004061-41-HU   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2006   -   EUCTR2005-004061-41-GR   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Ireland;Italy;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-004061-41-FI   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2006   -   EUCTR2005-004061-41-DK   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2006   -   EUCTR2005-004061-41-DE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2006   -   EUCTR2005-004061-41-CZ   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;
   Biogen Idec
      2012   Phase 4   NCT02142205   Russian Federation;
   Biogen Idec Limited
      2011   -   EUCTR2010-024000-10-ES   Belgium;Germany;Italy;Spain;
      2011   -   EUCTR2010-024000-10-DE   Belgium;Germany;Italy;Spain;
      2011   -   EUCTR2010-024000-10-BE   Belgium;Germany;Italy;Spain;
   Biogen Idec Research Limited
      2019   Phase 3   EUCTR2018-002145-11-GB   Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;New Zealand;Spain;United Kingdom;United States;
BG00002 (natalizumab)   
   Biogen
      2010   Phase 3   NCT01058005   Australia;Canada;Czech Republic;Finland;France;Hungary;Italy;Latvia;Poland;Slovenia;Spain;Sweden;United States;
      2009   Phase 4   NCT00871780   Belgium;Mexico;Poland;Romania;Saudi Arabia;Ukraine;Venezuela;
      2008   Phase 4   NCT00536120   United States;
      2006   Phase 3   NCT00306592   Canada;United States;
BG00002-E (natalizumab high titer)   
   Biogen
      2006   Phase 2   NCT00516893   United States;
BG00012   
   BIOGEN IDEC LTD
      2010   Phase 3   EUCTR2008-004753-14-IT   Austria;Belgium;Bulgaria;Czech Republic;Estonia;France;Germany;Greece;Ireland;Italy;Latvia;Netherlands;Slovakia;Spain;United Kingdom;
      2008   -   EUCTR2006-003696-12-IT   Austria;Belgium;Bulgaria;Czech Republic;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;
   BIOGEN IDEC RESEARCH LIMITED
      2015   Phase 3   EUCTR2014-005624-98-IT   Argentina;Austria;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Hungary;Israel;Italy;Kuwait;Lebanon;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
   Biogen
      2009   Phase 1   NCT00837785   Germany;United Kingdom;
      2007   Phase 3   NCT00451451   Australia;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Costa Rica;Croatia;Czech Republic;Estonia;France;Germany;Greece;India;Ireland;Israel;Italy;Kazakhstan;Latvia;Lithuania;Macedonia, The Former Yugoslav Republic of;Mexico;Moldova, Republic of;New Zealand;Poland;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United States;
      2007   Phase 3   NCT00420212   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;France;Germany;Greece;Guatemala;India;Israel;Italy;Kazakhstan;Macedonia, The Former Yugoslav Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;Virgin Islands (U.S.);
   Biogen Idec
      2004   Phase 2   NCT00168701   Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Sweden;Switzerland;Turkey;United Kingdom;
   Biogen Idec Inc.
      2004   -   EUCTR2004-000663-99-SE   Hungary;Sweden;
      2004   -   EUCTR2004-000663-99-HU   Hungary;Sweden;
      2004   -   EUCTR2004-000663-99-CZ   Czech Republic;Hungary;Sweden;
   Biogen Idec Italia S.r.l.
      2015   -   EUCTR2015-000303-21-IT   Italy;
      2013   Phase 3   EUCTR2013-001422-25-IT   Italy;
   Biogen Idec Limited
      2010   Phase 3   EUCTR2008-004753-14-BG   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;France;Germany;Greece;Guatemala;India;Ireland;Israel;Italy;Latvia;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Poland;Romania;Serbia;Slovakia;South Africa;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2009   Phase 3   EUCTR2008-004753-14-SK   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;France;Germany;Greece;Guatemala;India;Ireland;Israel;Italy;Latvia;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Poland;Romania;Serbia;Slovakia;South Africa;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2009   Phase 3   EUCTR2008-004753-14-LV   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;France;Germany;Greece;Guatemala;India;Ireland;Israel;Italy;Latvia;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Poland;Romania;Serbia;Slovakia;South Africa;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2009   Phase 3   EUCTR2008-004753-14-IE   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;France;Germany;Greece;Guatemala;India;Ireland;Israel;Italy;Latvia;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Poland;Romania;Serbia;Slovakia;South Africa;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2009   Phase 3   EUCTR2008-004753-14-GB   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;France;Germany;Greece;Guatemala;India;Ireland;Israel;Italy;Latvia;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Poland;Romania;Serbia;Slovakia;South Africa;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2009   Phase 3   EUCTR2008-004753-14-EE   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;France;Germany;Greece;Guatemala;India;Ireland;Israel;Italy;Latvia;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Poland;Romania;Serbia;Slovakia;South Africa;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2009   Phase 3   EUCTR2008-004753-14-CZ   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;France;Germany;Greece;Guatemala;India;Ireland;Israel;Italy;Latvia;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Poland;Romania;Serbia;Slovakia;South Africa;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2009   Phase 3   EUCTR2008-004753-14-BE   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;France;Germany;Greece;Guatemala;India;Ireland;Israel;Italy;Latvia;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Poland;Romania;Serbia;Slovakia;South Africa;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2009   Phase 3   EUCTR2008-004753-14-AT   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;France;Germany;Greece;Guatemala;India;Ireland;Israel;Italy;Latvia;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Poland;Romania;Serbia;Slovakia;South Africa;Spain;Switzerland;Ukraine;United Kingdom;United States;
   Biogen Idec LtD.
      2007   Phase 3   EUCTR2006-003696-12-SK   Austria;Belgium;Bulgaria;Czech Republic;Germany;Greece;Italy;Netherlands;Slovakia;Sweden;United Kingdom;
   Biogen Idec Ltd.
      2010   Phase 3   EUCTR2008-004753-14-NL   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;France;Germany;Greece;Guatemala;India;Ireland;Israel;Italy;Latvia;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Poland;Romania;Serbia;Slovakia;South Africa;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2008-004753-14-GR   Austria;Belgium;Bulgaria;Czech Republic;Estonia;France;Germany;Greece;Ireland;Italy;Latvia;Netherlands;Slovakia;Spain;United Kingdom;
      2009   Phase 3   EUCTR2008-004753-14-FR   Austria;Belgium;Bulgaria;Czech Republic;Estonia;France;Germany;Greece;Ireland;Italy;Latvia;Netherlands;Slovakia;Spain;United Kingdom;
      2009   Phase 3   EUCTR2008-004753-14-ES   Austria;Belgium;Bulgaria;Czech Republic;Estonia;France;Germany;Greece;Ireland;Italy;Latvia;Netherlands;Slovakia;Spain;United Kingdom;
      2009   Phase 3   EUCTR2008-004753-14-DE   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;France;Germany;Greece;Guatemala;India;Ireland;Israel;Italy;Latvia;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Poland;Romania;Serbia;Slovakia;South Africa;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2009   -   EUCTR2006-003696-12-BG   Austria;Belgium;Bulgaria;Czech Republic;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;
      2008   -   EUCTR2006-003697-10-BG   Bulgaria;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Spain;
      2008   -   EUCTR2006-003696-12-NL   Austria;Belgium;Bulgaria;Czech Republic;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;
      2008   -   EUCTR2006-003696-12-DE   Austria;Belgium;Bulgaria;Czech Republic;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;
      2007   Phase 3   EUCTR2006-003697-10-ES   Belgium;Bulgaria;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Spain;
      2007   Phase 3   EUCTR2006-003697-10-BE   Belgium;Bulgaria;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Spain;
      2007   Phase 3   EUCTR2006-003696-12-GB   Austria;Belgium;Bulgaria;Czech Republic;Germany;Greece;Italy;Netherlands;Slovakia;Sweden;United Kingdom;
      2007   -   EUCTR2006-003697-10-LV   Bulgaria;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Spain;
      2007   -   EUCTR2006-003697-10-IE   Bulgaria;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Spain;
      2007   -   EUCTR2006-003697-10-GR   Bulgaria;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Spain;
      2007   -   EUCTR2006-003697-10-EE   Bulgaria;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Spain;
      2007   -   EUCTR2006-003697-10-DE   Bulgaria;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Spain;
      2007   -   EUCTR2006-003697-10-CZ   Bulgaria;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Spain;
      2007   -   EUCTR2006-003696-12-SE   Austria;Belgium;Bulgaria;Czech Republic;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;
      2007   -   EUCTR2006-003696-12-GR   Austria;Belgium;Bulgaria;Czech Republic;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;
      2007   -   EUCTR2006-003696-12-CZ   Austria;Belgium;Bulgaria;Czech Republic;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;
      2007   -   EUCTR2006-003696-12-BE   Austria;Belgium;Bulgaria;Czech Republic;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;
      2007   -   EUCTR2006-003696-12-AT   Austria;Belgium;Bulgaria;Czech Republic;Germany;Greece;Italy;Netherlands;Sweden;United Kingdom;
   Biogen Idec Research Limited
      2019   Phase 3   EUCTR2018-000516-22-PT   Bulgaria;Colombia;Croatia;Estonia;Greece;Hungary;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Taiwan;Thailand;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-000516-22-HU   Bulgaria;Colombia;Croatia;Estonia;Greece;Hungary;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Taiwan;Thailand;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-000516-22-EE   Bulgaria;Colombia;Croatia;Estonia;Greece;Hungary;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Taiwan;Thailand;Tunisia;Turkey;United States;
      2017   Phase 3   EUCTR2013-002318-11-FR   Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United Kingdom;
      2016   Phase 3   EUCTR2015-003282-29-LV   Belgium;Bulgaria;Czech Republic;Germany;Kuwait;Latvia;Lebanon;Poland;Turkey;United States;
      2016   Phase 3   EUCTR2015-003282-29-DE   Belgium;Bulgaria;Czech Republic;Germany;Kuwait;Latvia;Lebanon;Poland;Turkey;United States;
      2016   Phase 3   EUCTR2015-003282-29-CZ   Belgium;Bulgaria;Czech Republic;Germany;Kuwait;Latvia;Lebanon;Poland;Turkey;United States;
      2016   Phase 3   EUCTR2015-003282-29-BG   Belgium;Bulgaria;Czech Republic;Germany;Kuwait;Latvia;Lebanon;Poland;Turkey;United States;
      2016   Phase 3   EUCTR2015-003282-29-BE   Belgium;Bulgaria;Czech Republic;Germany;Kuwait;Latvia;Lebanon;Poland;Turkey;United States;
      2016   Phase 3   EUCTR2015-001973-42-PL   Belgium;Bulgaria;Croatia;Kuwait;Lithuania;Poland;United States;
      2016   Phase 3   EUCTR2015-001973-42-LT   Belgium;Bulgaria;Croatia;Kuwait;Lithuania;Poland;United States;
      2016   Phase 3   EUCTR2015-001973-42-HR   Austria;Belgium;Bulgaria;Canada;Croatia;Kuwait;Lithuania;Poland;Slovakia;Sweden;Turkey;United States;
      2016   Phase 3   EUCTR2015-001973-42-BG   Belgium;Bulgaria;Croatia;Kuwait;Lithuania;Poland;United States;
      2016   Phase 3   EUCTR2013-002318-11-DE   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Kuwait;Poland;Serbia;Spain;Sweden;Turkey;United Kingdom;United States;
      2016   -   EUCTR2013-002318-11-ES   Argentina;Belgium;Canada;Croatia;Czech Republic;Denmark;France;Hungary;Israel;Italy;Poland;Portugal;Romania;Serbia;Spain;Sweden;Turkey;United Kingdom;
      2015   Phase 3   EUCTR2015-001973-42-BE   Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Kuwait;Lithuania;Poland;Turkey;United States;
      2015   Phase 3   EUCTR2014-004562-22-IT   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Spain;United States;
      2015   Phase 3   EUCTR2014-004562-22-DE   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Spain;United States;
      2015   Phase 3   EUCTR2014-004562-22-CZ   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Spain;United States;
      2015   Phase 3   EUCTR2014-004562-22-BE   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Spain;United States;
      2015   Phase 3   EUCTR2014-003021-18-CZ   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2013-002318-11-PL   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Kuwait;Poland;Serbia;Spain;Sweden;Turkey;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-005003-24-PL   Australia;Belgium;Bulgaria;Czech Republic;Finland;France;Germany;Israel;Italy;Kuwait;Latvia;Lebanon;Lithuania;Poland;Turkey;United Kingdom;
      2015   Phase 2   EUCTR2014-005003-24-LV   Australia;Belgium;Bulgaria;Czech Republic;Finland;France;Germany;Israel;Italy;Kuwait;Latvia;Lebanon;Lithuania;Poland;Turkey;United Kingdom;
      2015   Phase 2   EUCTR2014-005003-24-DE   Australia;Belgium;Bulgaria;Czech Republic;Finland;France;Germany;Israel;Italy;Kuwait;Latvia;Lebanon;Lithuania;Poland;Turkey;United Kingdom;
      2015   Phase 2   EUCTR2014-005003-24-CZ   Australia;Belgium;Bulgaria;Czech Republic;Germany;Israel;Italy;Kuwait;Latvia;Lebanon;Lithuania;Poland;Turkey;United States;
      2015   Phase 2   EUCTR2014-005003-24-BG   Australia;Belgium;Bulgaria;Czech Republic;France;Germany;Israel;Italy;Kuwait;Latvia;Lebanon;Poland;Turkey;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-005003-24-BE   Australia;Belgium;Bulgaria;Czech Republic;Finland;France;Germany;Israel;Italy;Kuwait;Latvia;Lebanon;Lithuania;Poland;Turkey;United Kingdom;
      2015   -   EUCTR2014-005624-98-HU   Argentina;Austria;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Hungary;Israel;Italy;Kuwait;Lebanon;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      2015   -   EUCTR2014-004562-22-HU   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Spain;United States;
      2015   -   EUCTR2014-003021-18-SK   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   -   EUCTR2014-003021-18-SE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   -   EUCTR2014-003021-18-PL   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   -   EUCTR2014-003021-18-NL   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   -   EUCTR2014-003021-18-IT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   -   EUCTR2014-003021-18-FI   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   -   EUCTR2014-003021-18-DK   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   -   EUCTR2014-003021-18-DE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   -   EUCTR2014-003021-18-BE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States;
      2015   -   EUCTR2014-003021-18-AT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States;
      2014   Phase 4   EUCTR2013-001656-35-SK   Austria;Belgium;Canada;Czech Republic;France;Hungary;Italy;Portugal;Slovakia;Slovenia;Spain;
      2014   Phase 4   EUCTR2013-001656-35-SI   Austria;Belgium;Canada;Czech Republic;France;Hungary;Italy;Portugal;Slovakia;Slovenia;Spain;
      2014   Phase 4   EUCTR2013-001656-35-PT   Austria;Belgium;Canada;Czech Republic;France;Hungary;Italy;Portugal;Slovakia;Slovenia;Spain;
      2014   Phase 4   EUCTR2013-001656-35-IT   Austria;Belgium;Canada;Czech Republic;France;Hungary;Italy;Portugal;Slovakia;Slovenia;Spain;
      2014   Phase 4   EUCTR2013-001656-35-HU   Austria;Belgium;Canada;Czech Republic;France;Hungary;Italy;Portugal;Slovakia;Slovenia;Spain;
      2014   Phase 4   EUCTR2013-001656-35-FR   Austria;Belgium;Canada;Czech Republic;France;Hungary;Italy;Portugal;Slovakia;Slovenia;Spain;
      2014   Phase 4   EUCTR2013-001656-35-ES   Austria;Belgium;Canada;Czech Republic;France;Hungary;Italy;Portugal;Slovakia;Slovenia;Spain;
      2014   Phase 4   EUCTR2013-001656-35-CZ   Austria;Belgium;Canada;Czech Republic;France;Hungary;Italy;Portugal;Slovakia;Slovenia;Spain;
      2014   Phase 4   EUCTR2013-001656-35-BE   Austria;Belgium;Canada;Czech Republic;France;Hungary;Italy;Portugal;Slovakia;Slovenia;Spain;
      2014   Phase 4   EUCTR2013-001656-35-AT   Austria;Belgium;Canada;Czech Republic;France;Hungary;Italy;Portugal;Slovakia;Slovenia;Spain;
      2014   Phase 3   EUCTR2013-004533-32-PL   Czech Republic;Japan;Korea, Republic of;Poland;Taiwan;
      2014   Phase 3   EUCTR2013-004533-32-CZ   Czech Republic;Japan;Korea, Republic of;Poland;Taiwan;
      2014   Phase 3   EUCTR2013-002318-11-SE   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Kuwait;Poland;Serbia;Spain;Sweden;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-002318-11-HU   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Turkey;United Kingdom;
      2014   Phase 3   EUCTR2013-002318-11-GB   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Kuwait;Poland;Serbia;Spain;Sweden;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-002318-11-DK   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Kuwait;Poland;Serbia;Spain;Sweden;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-002318-11-CZ   Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Kuwait;Poland;Serbia;Spain;Sweden;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-002318-11-BE   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Kuwait;Poland;Serbia;Spain;Sweden;Turkey;United Kingdom;United States;
      2014   -   EUCTR2013-002318-11-IT   Belgium;Czech Republic;Denmark;France;Hungary;Italy;Poland;Serbia;Sweden;Ukraine;United Kingdom;
      2014   -   EUCTR2013-001895-40-IE   Ireland;United Kingdom;
      2014   -   EUCTR2013-001486-17-DE   Germany;
      -   Phase 3   EUCTR2014-005624-98-EE   Argentina;Austria;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Hungary;Israel;Italy;Kuwait;Lebanon;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
      -   Phase 3   EUCTR2014-005624-98-AT   Argentina;Austria;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Hungary;Israel;Italy;Kuwait;Lebanon;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
BG00012 (DMF)   
   Biogen
      2013   Phase 4   NCT01873417   United States;
BG00012 (DMF) (Tecfidera®.)   
   Multiple Sclerosis Center of Northeastern New York
      2015   Phase 4   NCT02683863   United States;
BG0002 (natalizumab)   
   Biogen Idec
      2009   -   NCT00818038   United States;
BG9418 (interferon beta 1-a)   
   Biogen
      2008   Phase 3   NCT00784836   United States;
BG9418 (interferon beta-1a)   
   Biogen
      2009   Phase 3   NCT00828204   United States;
   Biogen Idec
      2004   -   NCT00168714   United States;
BGC20-0134   
   BTG International Ltd
      2009   -   EUCTR2009-011585-28-ES   Belgium;France;Germany;Spain;
BGG492   
   Novartis Pharmaceuticals
      2016   Phase 2   NCT01649050   Germany;Russian Federation;
BHT-3009   
   Bayhill Therapeutics
      2006   Phase 2   NCT00382629   -
      2006   -   EUCTR2005-001340-22-CZ   Czech Republic;Finland;United Kingdom;
      2005   Phase 2   EUCTR2005-001340-22-SK   Czech Republic;Finland;Slovakia;United Kingdom;
      2005   -   EUCTR2005-001340-22-GB   Czech Republic;Finland;United Kingdom;
      2005   -   EUCTR2005-001340-22-FI   Czech Republic;Finland;United Kingdom;
BHT-3009-01   
   Bayhill Therapeutics
      2004   Phase 1   NCT00103974   Canada;United States;
BIIB 017   
   BIOGEN IDEC RESEARCH LIMITED
      2019   Phase 3   EUCTR2018-003008-38-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
BIIB017   
   BIOGEN IDEC RESEARCH LIMITED
      2019   Phase 3   EUCTR2018-003008-38-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
   Biogen
      2013   Phase 3   NCT01939002   United States;
   Biogen Idec LTD
      2009   -   EUCTR2008-006333-27-LV   Belgium;Bulgaria;Czech Republic;Estonia;Germany;Greece;Latvia;Netherlands;Spain;United Kingdom;
   Biogen Idec Limited
      2012   Phase 3   EUCTR2010-024477-39-GR   Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;India;Latvia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2012   Phase 3   EUCTR2010-024477-39-GB   Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;India;Latvia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2010-024477-39-CZ   Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;India;Latvia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-024477-39-DE   Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;India;Latvia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-024477-39-BG   Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;India;Latvia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-024477-39-LV   Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;India;Latvia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-024477-39-ES   Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;India;Latvia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-024477-39-EE   Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;India;Latvia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-024477-39-BE   Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;India;Latvia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2008-006333-27-GR   Belgium;Bulgaria;Czech Republic;Estonia;Germany;Greece;Latvia;Netherlands;Spain;United Kingdom;
      2010   -   EUCTR2008-006333-27-CZ   Belarus;Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;India;Kazakhstan;Latvia;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Turkey;Ukraine;United Kingdom;United States;
      2009   Phase 3   EUCTR2008-006333-27-GB   Belarus;Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;India;Kazakhstan;Latvia;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Turkey;Ukraine;United Kingdom;United States;
      2009   Phase 3   EUCTR2008-006333-27-ES   Belgium;Bulgaria;Czech Republic;Estonia;Germany;Greece;Latvia;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2008-006333-27-NL   Belarus;Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;India;Kazakhstan;Latvia;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Turkey;Ukraine;United Kingdom;United States;
      2009   -   EUCTR2008-006333-27-EE   Belarus;Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;India;Kazakhstan;Latvia;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Turkey;Ukraine;United Kingdom;United States;
      2009   -   EUCTR2008-006333-27-BG   Belarus;Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;India;Kazakhstan;Latvia;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Turkey;Ukraine;United Kingdom;United States;
      2009   -   EUCTR2008-006333-27-BE   Belarus;Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;India;Kazakhstan;Latvia;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Turkey;Ukraine;United Kingdom;United States;
      -   -   EUCTR2008-006333-27-DE   Belarus;Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;India;Kazakhstan;Latvia;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Turkey;Ukraine;United Kingdom;United States;
   Biogen Idec Research Limited
      2020   Phase 3   EUCTR2018-003008-38-DE   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-003008-38-SK   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-003008-38-PT   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-003008-38-HU   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-003008-38-HR   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-003008-38-GR   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-003008-38-ES   Argentina;Belgium;Brazil;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;
      2019   Phase 3   EUCTR2018-003008-38-CZ   Argentina;Belgium;Brazil;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;
      2019   Phase 3   EUCTR2018-003008-38-BG   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-003008-38-BE   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-000516-22-PT   Bulgaria;Colombia;Croatia;Estonia;Greece;Hungary;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Taiwan;Thailand;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-000516-22-HU   Bulgaria;Colombia;Croatia;Estonia;Greece;Hungary;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Taiwan;Thailand;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-000516-22-EE   Bulgaria;Colombia;Croatia;Estonia;Greece;Hungary;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Taiwan;Thailand;Tunisia;Turkey;United States;
      -   Phase 3   EUCTR2018-003008-38-FR   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
   Johns Hopkins University
      2010   Phase 3   NCT01337427   United States;
BIIB017 (Peginterferon beta-1a)   
   Biogen Idec
      2014   Phase 4   NCT02234869   -
BIIB017 (peginterferon beta-1a)   
   Biogen
      2019   Phase 3   NCT03958877   Argentina;Australia;Belgium;Bulgaria;Croatia;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      2009   Phase 3   NCT00906399   Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;India;Latvia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
BIIB017 (peginterferon beta-1a) Autoinjector   
   Biogen Idec
      2012   Phase 1   NCT01610310   United States;
BIIB017 (peginterferon beta-1a) Pre-filled syringe (PFS)   
   Biogen Idec
      2012   Phase 1   NCT01610310   United States;
BIIB019   
   BIOGEN IDEC RESEARCH LIMITED
      2017   Phase 3   EUCTR2016-002820-10-IT   Canada;Denmark;France;Germany;Italy;United Kingdom;United States;
   BIOGEN IDEC RESEARCH LTD
      2013   Phase 3   EUCTR2012-003176-39-IT   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Finland;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Russian Federation;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
   Biogen
      2013   Phase 3   EUCTR2012-003176-39-HU   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2010   Phase 2   EUCTR2009-015318-23-GB   Czech Republic;Germany;Hungary;India;Russian Federation;Ukraine;United Kingdom;
   Biogen Idec Limited
      2011   -   EUCTR2010-023856-97-PL   Czech Republic;Hungary;Poland;Russian Federation;United States;
      2011   -   EUCTR2010-023856-97-HU   Czech Republic;Hungary;Poland;Russian Federation;United States;
      2011   -   EUCTR2010-023856-97-CZ   Czech Republic;Hungary;Poland;United States;
   Biogen Idec Ltd
      2012   Phase 3   EUCTR2009-012500-11-SI   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2009-012500-11-GB   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2009-012500-11-FI   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2009-012500-11-SE   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2009-012500-11-IE   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2009-012500-11-HU   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2009-012500-11-DK   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2009-012500-11-DE   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2009-012500-11-CZ   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
   Biogen Idec Ltd.
      2011   Phase 2   EUCTR2009-015318-23-DE   Czech Republic;Germany;Hungary;India;Russian Federation;Ukraine;United Kingdom;
      2010   Phase 2   EUCTR2009-015318-23-HU   Czech Republic;Germany;Hungary;India;Russian Federation;Ukraine;United Kingdom;
      2010   Phase 2   EUCTR2009-015318-23-CZ   Czech Republic;Germany;Hungary;India;Russian Federation;Ukraine;United Kingdom;
      2009   Phase 2   EUCTR2008-005559-46-GB   Czech Republic;Germany;Hungary;India;Poland;Russian Federation;Ukraine;United Kingdom;
      2009   -   EUCTR2008-005559-46-HU   Czech Republic;Germany;Hungary;India;Poland;Russian Federation;Ukraine;United Kingdom;
      2009   -   EUCTR2008-005559-46-DE   Czech Republic;Germany;Hungary;India;Poland;Russian Federation;Ukraine;United Kingdom;
      2009   -   EUCTR2008-005559-46-CZ   Czech Republic;Germany;Hungary;India;Poland;Russian Federation;Ukraine;United Kingdom;
   Biogen Idec Research Limited
      2017   Phase 3   EUCTR2016-002820-10-GB   Canada;Denmark;France;Germany;Italy;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002820-10-DE   Canada;Germany;Italy;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003176-39-SE   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003176-39-PL   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003176-39-IE   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003176-39-GR   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003176-39-GB   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003176-39-FR   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003176-39-ES   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003176-39-DK   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003176-39-DE   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003176-39-CZ   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-003176-39-FI   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
BIIB019 (Daclizumab High Yield Process)   
   Biogen
      2010   Phase 3   NCT01064401   Argentina;Australia;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Egypt;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2009   Phase 2   NCT00870740   Czech Republic;Germany;Hungary;India;Poland;Russian Federation;Ukraine;United Kingdom;
      2008   Phase 2   NCT00390221   Australia;Czech Republic;Former Serbia and Montenegro;Germany;Hungary;India;Poland;Russian Federation;Sweden;Turkey;Ukraine;United Kingdom;
BIIB019 (Daclizumab)   
   Biogen
      2013   Phase 3   NCT01797965   Argentina;Australia;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2011   Phase 3   NCT01462318   Czech Republic;Hungary;Poland;Russian Federation;United States;
      2010   Phase 2   NCT01051349   Czech Republic;Czechia;Germany;Hungary;India;Poland;Russian Federation;Ukraine;United Kingdom;
BIIB033   
   BIOGEN IDEC RESEARCH LIMITED
      2019   Phase 2   EUCTR2017-001224-22-IT   Australia;Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
   Biogen
      2016   Phase 1   NCT02641041   United Kingdom;
      2013   Phase 2   NCT01864148   Canada;Czech Republic;France;Hungary;Italy;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2010   Phase 1   NCT01244139   United States;
   Biogen Idec Research Limited
      2013   Phase 2   EUCTR2011-006262-40-NL   Canada;Czech Republic;France;Hungary;Italy;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2013   Phase 2   EUCTR2011-006262-40-IT   Canada;Czech Republic;Hungary;Italy;Netherlands;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2013   Phase 2   EUCTR2011-006262-40-HU   Canada;Czech Republic;France;Hungary;Italy;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2013   Phase 2   EUCTR2011-006262-40-GB   Canada;Czech Republic;France;Hungary;Italy;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2013   Phase 2   EUCTR2011-006262-40-ES   Canada;Czech Republic;France;Hungary;Italy;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2013   Phase 2   EUCTR2011-006262-40-CZ   Canada;Czech Republic;France;Hungary;Italy;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
BIIB033 (ANTI-LINGO)   
   Biogen Idec Research Limited
      2018   Phase 2   EUCTR2017-001224-22-PL   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-001224-22-NL   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-001224-22-DE   Australia;Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-001224-22-BE   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2017   Phase 2   EUCTR2017-001224-22-HU   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2017   Phase 2   EUCTR2017-001224-22-ES   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2017   Phase 2   EUCTR2017-001224-22-CZ   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
BIIB033 (ANTI-LINGO) - EV Substance Code SUB118957   
   Biogen Idec Research Limited
      2017   Phase 2   EUCTR2017-001224-22-GB   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
BIIB033 (opicinumab)   
   Biogen
      2017   Phase 2   NCT03222973   Australia;Belgium;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
      2016   Phase 1   NCT02833142   United States;
BIIB041   
   Biogen Idec Research Limited
      2015   Phase 3   EUCTR2013-003600-40-NL   Bulgaria;Czech Republic;Finland;Italy;Lithuania;Netherlands;Poland;Russian Federation;Serbia;Switzerland;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-003600-40-GB   Bulgaria;Czech Republic;Finland;Italy;Lithuania;Netherlands;Poland;Russian Federation;Serbia;Switzerland;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-003600-40-CZ   Bulgaria;Czech Republic;Finland;Italy;Lithuania;Netherlands;Poland;Russian Federation;Serbia;Switzerland;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-003600-40-BG   Bulgaria;Czech Republic;Finland;Italy;Lithuania;Netherlands;Poland;Russian Federation;Serbia;Switzerland;United Kingdom;United States;
      2014   -   EUCTR2013-003600-40-LT   Bulgaria;Czech Republic;Finland;Italy;Lithuania;Netherlands;Poland;Russian Federation;Serbia;Switzerland;United Kingdom;United States;
      2014   -   EUCTR2013-003600-40-IT   Bulgaria;Czech Republic;Finland;Italy;Lithuania;Netherlands;Poland;Russian Federation;Serbia;Switzerland;United Kingdom;United States;
      2014   -   EUCTR2013-003600-40-FI   Bulgaria;Czech Republic;Finland;Italy;Lithuania;Netherlands;Poland;Russian Federation;Serbia;Switzerland;United Kingdom;United States;
      2012   Phase 4   EUCTR2011-003507-38-GB   Australia;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Sweden;United Kingdom;
      2012   Phase 4   EUCTR2011-003507-38-BE   Australia;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Sweden;United Kingdom;
      2012   Phase 2   EUCTR2012-000368-90-BE   Belgium;Canada;Italy;Netherlands;Sweden;United Kingdom;
      2012   -   EUCTR2012-000368-90-NL   Belgium;Canada;Italy;Netherlands;Sweden;United Kingdom;
      2012   -   EUCTR2012-000368-90-GB   Belgium;Canada;Italy;Netherlands;Sweden;United Kingdom;
      2012   -   EUCTR2011-003507-38-PT   Australia;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Sweden;United Kingdom;
      2012   -   EUCTR2011-003507-38-NL   Australia;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Sweden;United Kingdom;
      2012   -   EUCTR2011-003507-38-DK   Australia;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Sweden;United Kingdom;
   Cliniques Universitaires Saint-Luc, Neurologie
      2013   -   EUCTR2012-005076-34-BE   Belgium;
BIIB041 (Fampridine-SR)   
   Biogen Idec
      2010   Phase 3   NCT01235221   Canada;
BIIB041 (PR Fampridine)   
   Biogen
      2012   Phase 2   NCT01597297   Belgium;Canada;Italy;Netherlands;Sweden;United Kingdom;
BIIB041 (fampridine)   
   Biogen
      2013   Phase 3   NCT01917019   Japan;
BIIB061   
   Biogen
      2021   Phase 2   NCT04079088   -
      2015   Phase 1   NCT02521545   United States;
BIIB133   
   Biogen Idec Research Limited
      2020   Phase 2   EUCTR2019-001967-58-PL   Belgium;France;Germany;Italy;Poland;Serbia;Spain;Switzerland;United States;
      2020   Phase 2   EUCTR2019-001967-58-FR   Belgium;France;Germany;Italy;Poland;Serbia;Spain;Switzerland;United States;
BIRT 2584 XX   
   BOEHRINGER ING.
      2006   -   EUCTR2005-005985-35-IT   Czech Republic;Italy;Netherlands;
   Boehringer Ingelheim
      2006   -   EUCTR2005-005985-35-NL   Czech Republic;Italy;Netherlands;
   Boehringer Ingelheim Ltd
      2006   -   EUCTR2005-005985-35-CZ   Czech Republic;Italy;Netherlands;
BIRT 2584XX   
   BOEHRINGER ING.
      2006   -   EUCTR2005-005985-35-IT   Czech Republic;Italy;Netherlands;
BMMNC   
   Chaitanya Hospital, Pune
      2014   Phase 1/Phase 2   NCT01883661   India;
BMS 188667 (Abatacept)   
   Bristol-Myers Squibb
      2001   Phase 2   NCT00035529   United States;
BNT162b2   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States;
BORAGE OIL GLA   
   PALUPA Medical Ltd
      2016   Phase 3   EUCTR2015-003147-19-GR   Greece;
BOSWELAN   
   University Medical Center Eppendorf
      -   Phase 2   EUCTR2009-014724-32-DE   Germany;
BOTOX®   
   Allergan
      2008   -   EUCTR2006-006299-39-NL   France;Netherlands;
      2008   -   EUCTR2006-006299-39-FR   France;Netherlands;
   Allergan Ltd.
      2013   -   EUCTR2012-000957-30-PT   Belgium;Canada;Czech Republic;France;Poland;Portugal;Russian Federation;United Kingdom;United States;
      2013   -   EUCTR2012-000957-30-GB   Belgium;Canada;Czech Republic;France;Poland;Portugal;Russian Federation;United Kingdom;United States;
      2012   -   EUCTR2012-000957-30-CZ   Belgium;Canada;Czech Republic;France;Poland;Portugal;Russian Federation;United Kingdom;United States;
      2012   -   EUCTR2012-000957-30-BE   Belgium;Canada;Czech Republic;France;Poland;Portugal;Russian Federation;United Kingdom;United States;
BOTULINUM TOXIN A - HAEMAGGLUTININ COMPLEX   
   Ipsen Innovation
      2016   Phase 3   EUCTR2015-003471-30-PT   Canada;Czech Republic;Italy;Korea, Republic of;Malaysia;Netherlands;Poland;Portugal;Romania;Taiwan;Turkey;United States;
      2016   Phase 3   EUCTR2015-003471-30-PL   Canada;Czech Republic;Italy;Korea, Republic of;Malaysia;Netherlands;Poland;Portugal;Romania;Taiwan;Turkey;United States;
      2016   Phase 3   EUCTR2015-003471-30-NL   Canada;Czech Republic;Italy;Korea, Republic of;Malaysia;Netherlands;Poland;Portugal;Romania;Taiwan;Turkey;United States;
      2016   Phase 3   EUCTR2015-003471-30-IT   Canada;Czech Republic;Italy;Korea, Republic of;Malaysia;Netherlands;Poland;Portugal;Romania;Taiwan;Turkey;United States;
      2016   Phase 3   EUCTR2015-003471-30-CZ   Canada;Czech Republic;Italy;Korea, Republic of;Malaysia;Netherlands;Poland;Portugal;Romania;Taiwan;Turkey;United States;
      2016   Phase 3   EUCTR2015-000507-44-LT   Argentina;Belgium;Brazil;Chile;Colombia;France;Germany;Israel;Lithuania;Mexico;New Zealand;Peru;Russian Federation;Spain;Ukraine;United Kingdom;
      2016   Phase 3   EUCTR2015-000507-44-FR   Argentina;Belgium;Brazil;Chile;Colombia;France;Germany;Israel;Lithuania;Mexico;New Zealand;Peru;Russian Federation;Spain;Ukraine;United Kingdom;
      2016   Phase 3   EUCTR2015-000507-44-ES   Argentina;Belgium;Brazil;Chile;Colombia;France;Germany;Israel;Lithuania;Mexico;New Zealand;Peru;Russian Federation;Spain;Ukraine;United Kingdom;
      2016   Phase 3   EUCTR2015-000507-44-DE   Argentina;Belgium;Brazil;Chile;Colombia;France;Germany;Israel;Lithuania;Mexico;New Zealand;Peru;Russian Federation;Spain;Ukraine;United Kingdom;
      2016   Phase 3   EUCTR2015-000507-44-BE   Argentina;Belgium;Brazil;Chile;Colombia;France;Germany;Israel;Lithuania;Mexico;New Zealand;Peru;Russian Federation;Spain;Ukraine;United Kingdom;
BX-1   
   Bionorica SE
      2020   Phase 3   EUCTR2018-000001-23-CZ   Czech Republic;Hungary;Spain;
      2019   Phase 3   NCT03756974   Czechia;Germany;Hungary;Poland;Spain;
      2018   Phase 3   EUCTR2018-000001-23-HU   Czech Republic;Hungary;Spain;
      2018   Phase 3   EUCTR2018-000001-23-ES   Hungary;Spain;
Bacille Calmette-Guerin vaccine   
   S. Andrea Hospital
      2019   Phase 2   NCT03888924   Italy;
Bacille of Calmette-Guerin   
   S. Andrea Hospital
      2001   Phase 2/Phase 3   NCT00202410   Italy;
Baclofen   
   DAIICHI SANKYO COMPANY, LIMITED
      -   Phase 4   JPRN-JapicCTI-050031   -
   Osmotica Pharmaceutical US LLC
      2012   Phase 3   NCT01743651   Russian Federation;Ukraine;United States;
Baclofen ER Capsules (GRS)   
   Sun Pharma Advanced Research Company Ltd.
      2016   Phase 3   EUCTR2016-001356-22-HU   Germany;Hungary;Russian Federation;Ukraine;United States;
Baclofen IR   
   Impax Laboratories, LLC
      2009   Phase 2   NCT00914290   United States;
Baclofen Tablets USP   
   Sun Pharma Advanced Research Company Ltd.
      2016   Phase 3   EUCTR2016-001356-22-HU   Germany;Hungary;Russian Federation;Ukraine;United States;
Bafiertam   
   Banner Life Sciences LLC
      2019   Phase 1   NCT04022473   United States;
Balance   
   Ankara Yildirim Beyazit University
      2019   -   NCT04408742   Turkey;
      2019   -   NCT04286828   Turkey;
      2019   -   NCT03945006   Turkey;
      2016   -   NCT03566251   Turkey;
   Biruni University
      2016   -   NCT03436927   -
   East Kent Hospitals University NHS Foundation Trust
      2017   Phase 1   NCT05102682   United Kingdom;
   Gazi University
      2018   -   NCT03584672   -
      2018   -   NCT03501342   Turkey;
   Lama Saad El-Din Mahmoud
      2020   -   NCT04528121   Egypt;
   Marquette University
      2017   -   NCT04719494   -
   October 6 University
      2017   -   NCT03670459   Egypt;
   Somogy Megyei Kaposi Mór Teaching Hospital
      2018   -   NCT04550650   Hungary;
   University of Aarhus
      2016   -   NCT02870023   Denmark;
   University of Colorado, Denver
      2012   -   NCT01698086   United States;
   University of Iowa
      2020   -   NCT04391023   United States;
   University of Nebraska
      2013   -   NCT01816100   United States;
   Wayne State University
      2020   -   NCT03404388   United States;
   Örebro County Council
      2014   -   NCT02209467   Sweden;
      2012   -   NCT01582126   Sweden;
Balance platform therapy   
   University Hospital of Ferrara
      2017   -   NCT03353974   Italy;
Baminercept   
   Biogen Idec
      2010   Phase 1/Phase 2   NCT01181089   Canada;United Kingdom;
Baseline Treatment   
   Hoffmann-La Roche
      2014   Phase 3   NCT02028884   France;Germany;Hungary;Italy;Japan;Poland;Spain;Taiwan;Ukraine;United Kingdom;United States;
Baseline disease modifying therapies (DMTs)   
   Novartis Pharmaceuticals
      2021   Phase 4   NCT04792567   Germany;
Bazedoxifene Acetate   
   Riley Bove, MD
      2019   Phase 2   NCT04002934   United States;
Beetainterferoni -1a   
   Turku University Hospital
      2013   Phase 4   EUCTR2013-004626-28-FI   Finland;
Belimumab   
   Johns Hopkins University
      2021   Phase 2   NCT04767698   United States;
   Tianjin Medical University General Hospital
      2021   Phase 1/Phase 2   NCT05154734   China;
Best Available Therapy (BAT)   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2019   Phase 3   NCT04047628   United Kingdom;United States;
Beta-1b interferoni   
   Schering Oy
      2006   -   EUCTR2005-005211-21-FI   Finland;
Beta-Interferon   
   Genzyme, a Sanofi Company
      2017   Phase 3   NCT03368664   Austria;Belgium;Bulgaria;Czechia;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;
Beta-alanine supplementation   
   Hasselt University
      2017   -   NCT03418376   Belgium;
Beta-interferon   
   Sun Yat-sen University
      2006   -   NCT00818103   China;
Betaconnect Autoinjector   
   Bayer
      2015   -   NCT02486640   Germany;
Betaconnect auto-injector   
   Bayer
      2017   -   NCT03134573   Germany;
Betaferon   
   Dansk Multipel Sclerose Center
      2010   -   EUCTR2009-016824-29-DK   Denmark;
   Karolinska Institutet
      2017   Phase 4   EUCTR2017-002634-24-SE   Sweden;
      2017   Phase 4   EUCTR2016-003587-39-SE   Sweden;
   Medical University Innsbruck
      2009   -   EUCTR2009-013284-19-AT   Austria;
   Medizinische Universität Innsbruck
      2014   Phase 4   EUCTR2012-005450-30-AT   Austria;Sweden;
      2014   -   EUCTR2012-005450-30-SE   Austria;Sweden;
   NURON BIOTECH INC.
      2012   -   EUCTR2011-002683-24-IT   Belarus;Bulgaria;Hungary;Italy;Russian Federation;Spain;
   Nuron Biotech, Inc.
      2012   -   EUCTR2011-002683-24-HU   Belarus;Bulgaria;Croatia;Georgia;Hungary;Italy;Lebanon;Poland;Russian Federation;Spain;Ukraine;
      2012   -   EUCTR2011-002683-24-ES   Belarus;Bulgaria;Croatia;Georgia;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine;
      2012   -   EUCTR2011-002683-24-BG   Belarus;Bulgaria;Croatia;Georgia;Hungary;Italy;Lebanon;Poland;Russian Federation;Spain;Ukraine;
   Schering Nordiska AB
      2006   -   EUCTR2005-001540-23-SE   Denmark;Sweden;
      2005   -   EUCTR2005-001540-23-DK   Denmark;Sweden;
   Schering Oy
      2006   -   EUCTR2005-005211-21-FI   Finland;
   Turku University Hospital
      2013   Phase 4   EUCTR2013-004626-28-FI   Finland;
Betaferon 250 microgram/mL, powder and solvent for solution for injection.   
   Bayer HealthCare AG
      2013   Phase 4   EUCTR2012-005262-35-ES   Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Portugal;Slovenia;Spain;Sweden;Switzerland;United Kingdom;
Betaferon 250 microgram/ml   
   Biogen Portugal
      2016   Phase 4   EUCTR2016-000434-21-PT   Portugal;
   Octapharma AG
      2015   Phase 3   EUCTR2012-005086-12-PL   Austria;Bulgaria;Germany;Hungary;Poland;Russian Federation;Serbia;Ukraine;
      2013   -   EUCTR2012-005086-12-HU   Austria;Bulgaria;Germany;Hungary;Poland;Russian Federation;
      2013   -   EUCTR2012-005086-12-DE   Austria;Bulgaria;Germany;Hungary;Poland;Russian Federation;
      2013   -   EUCTR2012-005086-12-BG   Austria;Bulgaria;Germany;Hungary;Poland;Russian Federation;
      2013   -   EUCTR2012-005086-12-AT   Austria;Bulgaria;Germany;Hungary;Poland;Russian Federation;
Betaferon 250 microgram/ml, powder and solvent for solution for injection   
   Bayer AG
      2018   Phase 4   EUCTR2017-001176-31-PT   Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Norway;Poland;Portugal;Slovenia;Spain;Sweden;Switzerland;United Kingdom;
      2017   Phase 4   EUCTR2017-001176-31-GB   Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Norway;Poland;Portugal;Slovenia;Spain;Sweden;Switzerland;United Kingdom;
      2017   Phase 4   EUCTR2017-001176-31-FR   Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Norway;Poland;Portugal;Slovenia;Spain;Sweden;Switzerland;United Kingdom;
      2017   Phase 4   EUCTR2017-001176-31-FI   Austria;Belgium;Canada;Czech Republic;Denmark;Finland;Germany;Hungary;Israel;Italy;Norway;Poland;Portugal;Slovenia;Spain;Sweden;Switzerland;United Kingdom;
      2017   Phase 4   EUCTR2017-001176-31-ES   Austria;Belgium;Canada;Czech Republic;Denmark;Finland;Germany;Hungary;Israel;Italy;Norway;Poland;Portugal;Slovenia;Spain;Sweden;Switzerland;United Kingdom;
      2017   Phase 4   EUCTR2017-001176-31-DK   Austria;Belgium;Canada;Czech Republic;Denmark;Finland;Germany;Hungary;Israel;Italy;Norway;Poland;Portugal;Slovenia;Spain;Sweden;Switzerland;United Kingdom;
      2017   Phase 4   EUCTR2017-001176-31-CZ   Austria;Belgium;Canada;Czech Republic;Denmark;Finland;Germany;Hungary;Israel;Italy;Norway;Poland;Portugal;Slovenia;Spain;Sweden;Switzerland;United Kingdom;
      2017   Phase 4   EUCTR2017-001176-31-AT   Austria;Belgium;Canada;Czech Republic;Denmark;Finland;Germany;Hungary;Israel;Italy;Norway;Poland;Portugal;Slovenia;Spain;Sweden;Switzerland;United Kingdom;
   Bayer HealthCare AG
      2013   Phase 4   EUCTR2012-005262-35-GB   Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Portugal;Slovenia;Spain;Sweden;Switzerland;United Kingdom;
      2013   Phase 4   EUCTR2012-005262-35-CZ   Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Portugal;Slovenia;Spain;Sweden;Switzerland;United Kingdom;
      2013   -   EUCTR2012-005262-35-SI   Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Portugal;Slovenia;Spain;Sweden;Switzerland;United Kingdom;
      2013   -   EUCTR2012-005262-35-IT   Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Portugal;Slovenia;Spain;Sweden;Switzerland;United Kingdom;
      2013   -   EUCTR2012-005262-35-FI   Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Portugal;Slovenia;Spain;Sweden;Switzerland;United Kingdom;
      2013   -   EUCTR2012-005262-35-AT   Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Portugal;Slovenia;Spain;Sweden;Switzerland;United Kingdom;
Betaferon 250 microgramos   
   Schering AG
      2007   Phase 3   EUCTR2006-005270-47-ES   Austria;Belgium;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
Betaferon 250mcg   
   Schering AG
      2007   -   EUCTR2006-005270-47-IE   Austria;Belgium;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
Betaferon 250µg   
   Bayer AB, Bayer Health Care, Bayer Schering Pharma
      2007   -   EUCTR2006-005270-47-SE   Austria;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
   Bayer Schering Pharma
      2007   -   EUCTR2006-005270-47-SI   Austria;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
      2007   -   EUCTR2006-005270-47-HU   Austria;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
      -   -   EUCTR2006-005270-47-DE   Austria;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
   Bayer Schering Pharma AG
      2007   -   EUCTR2006-005270-47-LV   Austria;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
      2007   -   EUCTR2006-005270-47-GR   Austria;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
      2007   -   EUCTR2006-005270-47-BE   Austria;Belgium;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
   Schering AG
      2007   Phase 3   EUCTR2006-005270-47-FR   Austria;Belgium;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
      2007   Phase 3   EUCTR2006-005270-47-FI   Austria;Belgium;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
      2007   -   EUCTR2006-005270-47-NL   Austria;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
      2007   -   EUCTR2006-005270-47-AT   Austria;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
Betaferon 500 µg   
   Schering AG
      2007   Phase 3   EUCTR2006-005270-47-ES   Austria;Belgium;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
Betaferon 500mcg   
   Schering AG
      2007   -   EUCTR2006-005270-47-IE   Austria;Belgium;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
   UCL Biomedicine R&D Unit
      2006   -   EUCTR2005-005751-18-GB   United Kingdom;
Betaferon 500µg   
   Bayer AB, Bayer Health Care, Bayer Schering Pharma
      2007   -   EUCTR2006-005270-47-SE   Austria;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
   Bayer Schering Pharma
      2007   -   EUCTR2006-005270-47-SI   Austria;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
      2007   -   EUCTR2006-005270-47-HU   Austria;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
      -   -   EUCTR2006-005270-47-DE   Austria;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
   Bayer Schering Pharma AG
      2007   -   EUCTR2006-005270-47-LV   Austria;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
      2007   -   EUCTR2006-005270-47-GR   Austria;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
      2007   -   EUCTR2006-005270-47-BE   Austria;Belgium;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
   Schering AG
      2007   Phase 3   EUCTR2006-005270-47-FR   Austria;Belgium;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
      2007   Phase 3   EUCTR2006-005270-47-FI   Austria;Belgium;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
      2007   -   EUCTR2006-005270-47-NL   Austria;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
      2007   -   EUCTR2006-005270-47-AT   Austria;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
Betaferon, BAY86-5046   
   Bayer
      2019   -   NCT03808142   Germany;
Betaferon/Betaseron   
   Bayer
      2006   Phase 4   NCT00317941   France;
      2003   Phase 4   NCT00206648   Canada;United States;
Betaferon®   
   University Hospital Motol
      2011   Phase 4   EUCTR2011-001956-12-CZ   Czech Republic;
Betaseron   
   Bayer HealthCare AG
      -   -   EUCTR2014-004613-93-Outside-EU/EEA   China;
   Stuart D Cook MD
      2003   Phase 4   NCT00176592   United States;
   Teva Pharmaceutical Industries
      2004   Phase 4   NCT00202995   Canada;United States;
Betaseron (Interferon beta-1b, BAY86-5046)   
   Bayer
      2010   -   NCT01031459   Canada;United States;
      2002   Phase 2   NCT00893217   United States;
Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG   
   Bayer
      2016   -   NCT02749396   Finland;
Bevacizumab   
   Johns Hopkins University
      2013   Phase 1   NCT01777412   United States;
Bexarotene   
   Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge
      2015   Phase 2   EUCTR2014-003145-99-GB   United Kingdom;
Bexsero   
   ALEXION PHARMACEUTICALS INCORPORATED
      2020   Phase 2;Phase 3   EUCTR2019-001829-26-IT   Canada;Germany;Italy;Japan;Korea, Republic of;Spain;United States;
Biological samples   
   Centre Hospitalier Régional d'Orléans
      2021   Phase 4   NCT04952766   France;
Biotin   
   University Hospital, Clermont-Ferrand
      2018   -   NCT03552211   France;
Bisacodyl   
   David Levinthal
      2016   Phase 2   NCT02609607   United States;
Blood sample   
   Centre Hospitalier Universitaire de Saint Etienne
      2020   Phase 2   NCT03983720   France;
   University Hospital, Bordeaux
      2021   -   NCT04798651   France;
Blood samples   
   University Hospital, Bordeaux
      2014   -   NCT02142764   France;
Blood sampling   
   Centre Hospitalier Universitaire de Nimes
      2013   Phase 3   NCT01817166   France;
   Rennes University Hospital
      2021   -   NCT04697407   France;
BodyBio Balance Oil   
   Terry L. Wahls
      2022   -   NCT05007483   United States;
BodyBio PC   
   Terry L. Wahls
      2022   -   NCT05007483   United States;
Bone marrow autologous mesenchymal stem cells transplantation   
   Germans Trias i Pujol Hospital
      2013   Phase 1/Phase 2   NCT02035514   Spain;
Bortezomib   
   Tianjin Medical University General Hospital
      2015   Phase 2   NCT02893111   China;
Boswellia serrata extract PS0201Bo capsules   
   University Medical Center Eppendorf
      -   Phase 2   EUCTR2009-014724-32-DE   Germany;
Boswellic acids (BOSWELAN)   
   Universitätsklinikum Hamburg-Eppendorf
      2011   Phase 2   NCT01450124   Germany;
Botox   
   Krajská nemocnice Liberec, a.s.
      2010   -   EUCTR2009-012431-15-CZ   Czech Republic;
Botox 100 UNT Injection   
   Brigitte Schürch
      2021   Phase 4   NCT04819360   Switzerland;
Botulinum Toxin Type A 200U   
   Allergan
      2009   Phase 3   NCT00876447   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Singapore;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
Botulinum Toxin Type A 300U   
   Allergan
      2009   Phase 3   NCT00876447   Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Singapore;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
Botulinum toxin   
   ALLERGAN
      2008   -   EUCTR2007-000192-42-IT   France;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom;
Botulinum toxin A   
   Sunnybrook Health Sciences Centre
      2006   Phase 3   NCT01091727   Canada;
Botulinum toxin type A   
   Allergan
      2008   -   EUCTR2006-006299-39-NL   France;Netherlands;
      2008   -   EUCTR2006-006299-39-FR   France;Netherlands;
   Ipsen
      2016   Phase 3   NCT02660359   Argentina;Australia;Belgium;Brazil;Chile;Colombia;France;Germany;Israel;Lithuania;Mexico;New Zealand;Peru;Russian Federation;Spain;Ukraine;United Kingdom;
      2016   Phase 3   NCT02660138   Canada;Czech Republic;Czechia;Italy;Korea, Republic of;Malaysia;Netherlands;Poland;Portugal;Romania;Turkey;United States;
      2011   Phase 2   NCT01357980   Austria;Czech Republic;Czechia;France;Germany;Italy;Poland;
Botulinum toxin type A infiltrations   
   Aránzazu Vázquez Doce
      2019   Phase 3   NCT04595045   Spain;
Brimonidine tartrate   
   Biogen
      2016   Phase 4   NCT02568111   -
C1-esterase inhibitor (Cinryze)   
   Michael Levy
      2013   Phase 1   NCT01759602   United States;
C105   
   Cognition Pharmaceuticals, LLC
      2006   Phase 2   NCT00529581   United States;
CALCIO FOLINATO DC.IT   
   AZIENDA OSPEDALIERA SAN CAMILLO FORLANINI
      2005   -   EUCTR2005-006071-12-IT   Italy;
CBD   
   Aarhus Universitetshospital
      2018   Phase 2   EUCTR2018-002315-98-DK   Denmark;
CC   
   University of Washington
      2014   -   NCT02137044   United States;
CCI-779   
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development
      2005   -   EUCTR2005-000171-18-FI   Finland;
   Wyeth is now a wholly owned subsidiary of Pfizer
      2003   Phase 2   NCT00228397   -
CD   
   Sato Toshiyuki
      2020   Phase 3   JPRN-jRCT2051210017   Japan;
CDP323   
   UCB Pharma
      2008   Phase 1/Phase 2   NCT00726648   United Kingdom;
      2007   Phase 2   NCT00484536   Belgium;Canada;Finland;France;Germany;Hungary;Netherlands;Spain;Sweden;United Kingdom;United States;
      2007   Phase 2   EUCTR2006-002204-33-ES   Belgium;Finland;France;Germany;Hungary;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-002204-33-FI   Finland;France;Germany;Hungary;Netherlands;Spain;Sweden;United Kingdom;
   UCB Pharma S.A.
      2007   Phase 2   EUCTR2006-002204-33-GB   Belgium;Finland;France;Germany;Hungary;Netherlands;Spain;Sweden;United Kingdom;
      2007   Phase 2   EUCTR2006-002204-33-FR   Belgium;Finland;France;Germany;Hungary;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-002204-33-SE   Finland;France;Germany;Hungary;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-002204-33-NL   Finland;France;Germany;Hungary;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-002204-33-HU   Finland;France;Germany;Hungary;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-002204-33-DE   Finland;France;Germany;Hungary;Netherlands;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2006-002204-33-BE   Belgium;Finland;France;Germany;Hungary;Netherlands;Spain;Sweden;United Kingdom;
CELLCEPT   
   CHU de Rennes
      2018   Phase 3   EUCTR2018-001292-21-FR   France;
CETIRIZINE HYDROCHLORIDE   
   Biogen Idec Italia S.r.l.
      2015   -   EUCTR2013-001055-12-IT   Italy;
CGP 77116   
   National Institute of Neurological Disorders and Stroke (NINDS)
      1998   Phase 2   NCT00001781   United States;
CHR-1103 / GBR500   
   Genzyme Corporation
      2015   Phase 2   EUCTR2014-003265-19-PL   Canada;Czech Republic;Germany;Italy;Mexico;Poland;Russian Federation;Sweden;Switzerland;United States;
      2015   Phase 2   EUCTR2014-001643-20-SE   Canada;Czech Republic;Germany;Italy;Mexico;Poland;Russian Federation;Sweden;Switzerland;United States;
      2015   Phase 2   EUCTR2014-001643-20-PL   Canada;Czech Republic;Germany;Italy;Mexico;Poland;Russian Federation;Sweden;Switzerland;United States;
      2015   Phase 2   EUCTR2014-001643-20-DE   Canada;Czech Republic;Germany;Italy;Mexico;Poland;Russian Federation;Sweden;Switzerland;United States;
CIANOCOBALAMINA FU DC.IT   
   AZIENDA OSPEDALIERA SAN CAMILLO FORLANINI
      2005   -   EUCTR2005-006071-12-IT   Italy;
CIC using LoFric Primo   
   Wellspect HealthCare
      2009   -   NCT00913510   Belgium;France;Germany;Netherlands;United Kingdom;
CITOCHINE ED IMMUNOMODULATORI   
   TEVA
      2005   -   EUCTR2004-003943-28-IT   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
CLOSTRIDIUM BOTULINUM TOXIN TYPE A   
   Ipsen Innovation
      2016   Phase 3   EUCTR2015-003471-30-PT   Canada;Czech Republic;Italy;Korea, Republic of;Malaysia;Netherlands;Poland;Portugal;Romania;Taiwan;Turkey;United States;
      2016   Phase 3   EUCTR2015-003471-30-PL   Canada;Czech Republic;Italy;Korea, Republic of;Malaysia;Netherlands;Poland;Portugal;Romania;Taiwan;Turkey;United States;
      2016   Phase 3   EUCTR2015-003471-30-NL   Canada;Czech Republic;Italy;Korea, Republic of;Malaysia;Netherlands;Poland;Portugal;Romania;Taiwan;Turkey;United States;
      2016   Phase 3   EUCTR2015-003471-30-IT   Canada;Czech Republic;Italy;Korea, Republic of;Malaysia;Netherlands;Poland;Portugal;Romania;Taiwan;Turkey;United States;
      2016   Phase 3   EUCTR2015-003471-30-CZ   Canada;Czech Republic;Italy;Korea, Republic of;Malaysia;Netherlands;Poland;Portugal;Romania;Taiwan;Turkey;United States;
      2016   Phase 3   EUCTR2015-000507-44-LT   Argentina;Belgium;Brazil;Chile;Colombia;France;Germany;Israel;Lithuania;Mexico;New Zealand;Peru;Russian Federation;Spain;Ukraine;United Kingdom;
      2016   Phase 3   EUCTR2015-000507-44-FR   Argentina;Belgium;Brazil;Chile;Colombia;France;Germany;Israel;Lithuania;Mexico;New Zealand;Peru;Russian Federation;Spain;Ukraine;United Kingdom;
      2016   Phase 3   EUCTR2015-000507-44-ES   Argentina;Belgium;Brazil;Chile;Colombia;France;Germany;Israel;Lithuania;Mexico;New Zealand;Peru;Russian Federation;Spain;Ukraine;United Kingdom;
      2016   Phase 3   EUCTR2015-000507-44-DE   Argentina;Belgium;Brazil;Chile;Colombia;France;Germany;Israel;Lithuania;Mexico;New Zealand;Peru;Russian Federation;Spain;Ukraine;United Kingdom;
      2016   Phase 3   EUCTR2015-000507-44-BE   Argentina;Belgium;Brazil;Chile;Colombia;France;Germany;Israel;Lithuania;Mexico;New Zealand;Peru;Russian Federation;Spain;Ukraine;United Kingdom;
      2012   -   EUCTR2010-023210-31-LT   Austria;Czech Republic;Germany;Italy;Lithuania;
      2012   -   EUCTR2010-023210-31-DE   Austria;Czech Republic;Germany;Italy;Lithuania;
      2012   -   EUCTR2010-023210-31-CZ   Austria;Czech Republic;Germany;Italy;Lithuania;
      2012   -   EUCTR2010-023210-31-AT   Austria;Czech Republic;Germany;Italy;Lithuania;
CNM-Au8   
   Clene Nanomedicine
      2020   Phase 2/Phase 3   NCT04626921   Australia;
      2018   Phase 2   NCT03536559   Australia;Canada;United States;
CNTO 1275   
   Centocor, Inc.
      2004   Phase 2   NCT00207727   Australia;Canada;Czech Republic;Hungary;Poland;United Kingdom;United States;
CO-14   
   PEPTIMMUNE Inc
      2008   -   EUCTR2007-007759-15-HU   Hungary;
COLECALCIFEROL CONCENTRATE (OILY FORM)   
   Javier Olascoaga Urtaza
      2013   Phase 2   EUCTR2012-004602-97-ES   Spain;
COP-1/Copolymer-1   
   TEVA Pharmaceutical Industries Ltd.
      2007   -   EUCTR2004-000463-94-HU   Hungary;Italy;
      2004   -   EUCTR2004-000462-13-HU   Hungary;Italy;
COPAXONE - 20 MG/ML SOLUZIONE INIETTABILE 28 SIRINGHE PRERIEMPITE   
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-004505-32-IT   France;Germany;Italy;Spain;
COPAXONE - 20 MG/ML SOLUZIONE INIETTABILE IN SIRINGHE PRERIEMPITE 30 SIRINGHE   
   TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC
      2015   Phase 4   EUCTR2015-000922-12-IT   Argentina;Austria;Belgium;Croatia;Finland;France;Germany;Ireland;Israel;Italy;Mexico;Poland;Russian Federation;Spain;Turkey;United States;
COPAXONE - 40 MG/ML SOLUZIONE INIETTABILE IN   
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-004505-32-IT   France;Germany;Italy;Spain;
COPAXONE - 40 MG/ML SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA 12 SIRINGHE PRERIEMPITE DA 1 ML CON AGO   
   OSPEDALE SAN RAFFAELE
      2018   Phase 4   EUCTR2016-004819-12-IT   Italy;
   TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC
      2015   Phase 4   EUCTR2015-000922-12-IT   Argentina;Austria;Belgium;Croatia;Finland;France;Germany;Ireland;Israel;Italy;Mexico;Poland;Russian Federation;Spain;Turkey;United States;
COPAXONE 20 mg/ml solución inyectable en jeringa precargada   
   Biogen Idec Limited
      2010   -   EUCTR2009-015556-15-ES   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
COPAXONE*SC 28SIR 20MG/ML   
   Teva Pharmaceuticals Industries Ltd.
      2006   -   EUCTR2006-002037-20-IT   Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Spain;United Kingdom;
COVID-19 mRNA Vaccine (nucleoside modified)   
   Novartis Pharma GmbH
      2021   Phase 4   EUCTR2020-005752-38-DE   Germany;
   Novartis Pharma Vertriebs GmbH
      2021   Phase 4   EUCTR2021-000307-20-DE   Germany;
COVID-19 mRNA vaccine (nucleoside-modified)   
   Novartis Pharma Vertriebs GmbH
      2021   Phase 4   EUCTR2021-000307-20-DE   Germany;
COVID-19 mRNA vaccine Moderna (CX-024414)   
   Novartis Pharma GmbH
      2021   Phase 4   EUCTR2020-005752-38-DE   Germany;
   Novartis Pharma Vertriebs GmbH
      2021   Phase 4   EUCTR2021-000307-20-DE   Germany;
COVID-19 vaccination   
   Sheba Medical Center
      2021   -   NCT05075499   Israel;
COVID19 vaccine   
   Yale University
      2021   -   NCT05286242   United States;
CS-0777 tablets   
   Daiichi Sankyo Inc.
      2008   Phase 1   NCT00616733   United States;
CSF sampling   
   Rennes University Hospital
      2021   -   NCT04697407   France;
CT103A cells   
   Tongji Hospital
      2020   Early Phase 1   NCT04561557   China;
CYCLOPHOSPHAMIDE MONOHYDRATE   
   Uppsala l?ns landsting
      2011   -   EUCTR2010-023560-40-SE   Brazil;Canada;Sweden;United States;
Caffeine   
   Biogen
      2011   Phase 3   NCT01462318   Czech Republic;Hungary;Poland;Russian Federation;United States;
Calcium   
   Centre Hospitalier Universitaire de Nimes
      2016   -   NCT02636829   France;
Calcium and Vitamin D combination   
   Novartis
      2010   Phase 3   NCT01166178   Germany;
Calcium carbonate   
   University Hospital of North Norway
      2008   Phase 4   NCT00785473   Norway;
Calcium levofolinate   
   AZIENDA OSPEDALIERA SAN CAMILLO FORLANINI
      2005   -   EUCTR2005-006071-12-IT   Italy;
Cannabidiol   
   GW Pharma Ltd
      2007   Phase 3   EUCTR2006-005910-11-CZ   Czech Republic;Germany;Italy;Spain;United Kingdom;
      2006   Phase 3   EUCTR2005-005265-11-GB   Czech Republic;France;United Kingdom;
      2006   Phase 3   EUCTR2005-005265-11-FR   Czech Republic;France;United Kingdom;
      2006   -   EUCTR2005-005265-11-CZ   Czech Republic;France;United Kingdom;
      2005   Phase 3   EUCTR2004-002509-63-GB   Czech Republic;United Kingdom;
      2005   -   EUCTR2004-002509-63-CZ   Czech Republic;United Kingdom;
   GW Pharma Ltd.
      2011   -   EUCTR2011-000926-31-CZ   Czech Republic;
      2008   Phase 3   EUCTR2006-005910-11-GB   Czech Republic;Germany;Italy;Spain;United Kingdom;
      2008   -   EUCTR2006-005910-11-DE   Germany;Italy;Spain;United Kingdom;
      2007   -   EUCTR2007-002138-13-GB   United Kingdom;
Cannabidiol (CBD)   
   Tiffany J. Braley, MD, MS
      2022   Phase 2   NCT05269628   United States;
Cannabidiol / Dronabinol capsule 5 mg+2,   
   Aarhus Universitetshospital
      2018   Phase 2   EUCTR2018-002315-98-DK   Denmark;
Cannabidiol Botanical Drug Substance (CBD BDS)   
   Almirall Hermal GmbH
      2016   Phase 4   EUCTR2015-004451-40-AT   Austria;Czech Republic;
   GW Pharma Limited
      2022   Phase 3   EUCTR2020-004306-58-LT   Bulgaria;Canada;Hungary;Italy;Lithuania;Spain;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003271-18-ES   Australia;Belgium;Czech Republic;Czechia;Poland;Spain;Sweden;United Kingdom;
      2021   Phase 3   EUCTR2020-003271-18-CZ   Australia;Belgium;Czech Republic;Czechia;Poland;Spain;Sweden;United Kingdom;
      2021   Phase 3   EUCTR2019-002625-29-CZ   Czech Republic;Czechia;Poland;United Kingdom;
      2020   Phase 3   EUCTR2019-002625-29-PL   Czech Republic;Czechia;Poland;United Kingdom;
      2020   Phase 3   EUCTR2019-002625-29-GB   Poland;United Kingdom;
   GW Pharma Ltd
      2020   Phase 3   EUCTR2019-002623-14-PL   Czech Republic;Czechia;Poland;Romania;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002623-14-GB   Czech Republic;Poland;Romania;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002623-14-CZ   Czech Republic;Czechia;Poland;Romania;United Kingdom;United States;
Cannabidiol capsule   
   Aarhus Universitetshospital
      2018   Phase 2   EUCTR2018-002315-98-DK   Denmark;
Cannabis   
   Centre hospitalier de l'Université de Montréal (CHUM)
      2021   Phase 3   NCT05092191   -
Cannabis Based Medicine Extract (Sativex)   
   AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA
      2004   -   EUCTR2005-000393-47-IT   Italy;
Cannabis, Medical   
   OMNI Medical Services, LLC
      2018   Phase 2   NCT03944447   United States;
Cannador   
   Gesellschaft fuer klinische Forschung e.V. (Society for Clinical Research)
      2006   Phase 3   EUCTR2005-005263-29-GB   United Kingdom;
Capacity of muscular oxygen extraction   
   Centre Hospitalier Universitaire de Saint Etienne
      2020   Phase 2   NCT03983720   France;
Capsules with 160 mg Teavigo (at least EGCG)   
   Charite University, Berlin, Germany
      2011   -   NCT01417312   Germany;
Carbamazepine   
   Stine Maarbjerg, MD PhD
      2012   -   NCT04371575   -
Carbidopa   
   University of Miami
      2018   Phase 1   NCT03266965   United States;
Carmustine   
   Fred Hutchinson Cancer Research Center
      2008   Phase 2   NCT00716066   United States;
Carmustine, etoposide, cytarabine, and melphalan (BEAM)   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2006   Phase 2   NCT00288626   United States;
Carnosine, capsulle, 2 g/day, 8 weeks   
   University of Novi Sad, Faculty of Sport and Physical Education
      2019   -   NCT03995810   Serbia;
Cellular therapy with EBV specific autologous CTL infusion   
   Nantes University Hospital
      2021   Phase 1   NCT02912897   France;
Ceralifimod   
   Merck KGaA
      2014   Phase 3   EUCTR2013-002351-15-AT   Argentina;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Jordan;Latvia;Lebanon;Lithuania;Mexico;Morocco;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2014   -   EUCTR2013-003126-83-HU   Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2014   -   EUCTR2013-003126-83-GR   Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2014   -   EUCTR2013-003126-83-ES   Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2014   -   EUCTR2013-003126-83-DE   Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2014   -   EUCTR2013-003126-83-BG   Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2014   -   EUCTR2013-002351-15-PT   Argentina;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Jordan;Latvia;Lebanon;Lithuania;Mexico;Morocco;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2014   -   EUCTR2013-002351-15-LV   Argentina;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Jordan;Latvia;Lebanon;Lithuania;Mexico;Morocco;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2014   -   EUCTR2013-002351-15-HU   Argentina;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Jordan;Latvia;Lebanon;Lithuania;Mexico;Morocco;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2014   -   EUCTR2013-002351-15-ES   Argentina;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Jordan;Latvia;Lebanon;Lithuania;Mexico;Morocco;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2014   -   EUCTR2013-002351-15-EE   Argentina;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Jordan;Latvia;Lebanon;Lithuania;Mexico;Morocco;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2014   -   EUCTR2013-002351-15-BG   Argentina;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Jordan;Latvia;Lebanon;Lithuania;Mexico;Morocco;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
Ceralifmod   
   Merck KGaA
      2014   Phase 3   EUCTR2013-002351-15-AT   Argentina;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Jordan;Latvia;Lebanon;Lithuania;Mexico;Morocco;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2014   -   EUCTR2013-002351-15-PT   Argentina;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Jordan;Latvia;Lebanon;Lithuania;Mexico;Morocco;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2014   -   EUCTR2013-002351-15-LV   Argentina;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Jordan;Latvia;Lebanon;Lithuania;Mexico;Morocco;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2014   -   EUCTR2013-002351-15-HU   Argentina;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Jordan;Latvia;Lebanon;Lithuania;Mexico;Morocco;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2014   -   EUCTR2013-002351-15-ES   Argentina;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Jordan;Latvia;Lebanon;Lithuania;Mexico;Morocco;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2014   -   EUCTR2013-002351-15-EE   Argentina;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Jordan;Latvia;Lebanon;Lithuania;Mexico;Morocco;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2014   -   EUCTR2013-002351-15-BG   Argentina;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Jordan;Latvia;Lebanon;Lithuania;Mexico;Morocco;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
Cerebro-spinal fluid   
   University Hospital, Bordeaux
      2021   -   NCT04798651   France;
Cesamet™ (nabilone)   
   NEMA Research, Inc.
      2006   Phase 4   NCT00381264   United States;
Ceterizine   
   Genzyme, a Sanofi Company
      2017   Phase 3   NCT03368664   Austria;Belgium;Bulgaria;Czechia;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;
      2015   Phase 1   NCT02583594   Spain;
Cetirizina Mylan Generics   
   Biogen Idec Italia S.r.l.
      2015   -   EUCTR2013-001055-12-IT   Italy;
Cetirizine   
   Genzyme, a Sanofi Company
      2014   Phase 4   NCT02205489   Belgium;France;Netherlands;Spain;
   Icahn School of Medicine at Mount Sinai
      2014   Phase 1/Phase 2   NCT02865018   United States;
Charcoal   
   Sanofi
      2013   Phase 3   NCT01863888   Belgium;Germany;Netherlands;
Cholecalciferol   
   Academic MS Center Limburg
      2014   Phase 2   NCT02096133   Netherlands;
   Johns Hopkins University
      2010   Phase 1   NCT01024777   United States;
   University Hospital of North Norway
      2008   Phase 4   NCT00785473   Norway;
Cholecalciferol (Vitamin D3)   
   Merck KGaA
      2009   Phase 2   NCT01198132   France;
Cholecalciferol, Vitamin D3   
   Merck Serono
      2011   -   EUCTR2010-020328-23-LV   Austria;Belgium;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;Netherlands;Norway;Portugal;Switzerland;
      2011   -   EUCTR2010-020328-23-LT   Austria;Belgium;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;Netherlands;Norway;Portugal;Switzerland;
      2011   -   EUCTR2010-020328-23-EE   Austria;Belgium;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;Netherlands;Norway;Portugal;Switzerland;
      2011   -   EUCTR2010-020328-23-DE   Austria;Belgium;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;Netherlands;Norway;Portugal;Switzerland;
      2010   Phase 2   EUCTR2010-020328-23-DK   Austria;Belgium;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;Netherlands;Norway;Portugal;Switzerland;
      2010   -   EUCTR2010-020328-23-FI   Austria;Belgium;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;Netherlands;Norway;Portugal;Switzerland;
   Merck Serono SA - Geneva, an affiliate of Merck KGaA
      2012   Phase 2   EUCTR2010-020328-23-PT   Austria;Belgium;Denmark;Estonia;Finland;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Portugal;Switzerland;
      2011   -   EUCTR2010-020328-23-AT   Austria;Belgium;Denmark;Estonia;Finland;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Portugal;Switzerland;
   Merck Serono SA-Geneva an affiliate of Merck KgaA, Darmstadt
      2011   -   EUCTR2010-020328-23-BE   Austria;Belgium;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;Netherlands;Portugal;
   Merck Serono The Netherlands - a division of Merck B.V.
      2011   -   EUCTR2010-020328-23-NL   Austria;Belgium;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;Netherlands;Portugal;
Cholestyramine   
   Sanofi
      2014   Phase 1   NCT02046629   China;
      2013   Phase 3   NCT01863888   Belgium;Germany;Netherlands;
Circadin ( INN= Melatonin)   
   North Bristol NHS Trust
      2013   Phase 2   EUCTR2012-004183-21-GB   United Kingdom;
Citalopram   
   Novartis Pharmaceuticals
      2011   Phase 4   NCT01436643   Germany;
Cladribina   
   MERCK KGAA
      2019   Phase 4   EUCTR2019-000069-19-IT   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Estonia;Finland;France;Georgia;Germany;Greece;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Morocco;Norway;Poland;Portugal;Romania;Russian Federation;Spain;Sweden;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
Cladribina oral   
   Serono International, S.A.
      2007   -   EUCTR2006-003366-33-ES   Italy;Spain;
Cladribine   
   Department of Neurology, Division of Clinical Neuroscience, Oslo University Hospital
      2019   Phase 3   EUCTR2019-001505-24-NO   Norway;
   EMD Serono
      2008   Phase 3   NCT00725985   Argentina;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czechia;Estonia;Finland;France;Georgia;Germany;India;Italy;Korea, Republic of;Lebanon;Macedonia, The Former Yugoslav Republic of;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2005   Phase 3   NCT00213135   Canada;Switzerland;
   EMD Serono Research & Development Institute, Inc.
      2019   Phase 4   NCT03961204   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czechia;Estonia;Finland;France;Georgia;Germany;Italy;Korea, Republic of;Lebanon;Lithuania;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2008   Phase 3   NCT00641537   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;Former Serbia and Montenegro;France;Germany;Greece;Italy;Latvia;Lebanon;Lithuania;Morocco;Netherlands;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Switzerland;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2006   Phase 2   NCT00436826   Italy;Russian Federation;Spain;United States;
   Helse Bergen HF, Haukeland University Hospital
      2018   Phase 3   EUCTR2017-001362-25-DK   Denmark;Netherlands;
   MERCK SERONO INTERNATIONAL SA
      2008   -   EUCTR2006-003366-33-IT   Italy;Spain;
   MERCK SERONO SA
      2008   -   EUCTR2007-000381-20-IT   Austria;Bulgaria;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Italy;Lithuania;Netherlands;Portugal;United Kingdom;
      2005   -   EUCTR2004-005148-28-IT   Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;United Kingdom;
   Merck Healthcare KGaA, Darmstadt Germany, an affiliate of Merck KGaA, Darmstadt, Germany
      2019   Phase 1   NCT04086225   Germany;Poland;
   Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
      2019   -   NCT04934800   Austria;Greece;Italy;Norway;Poland;Portugal;Switzerland;
   Merck KGaA
      2008   Phase 1   NCT00938366   -
   Merck KGaA, Darmstadt, Germany
      2019   Phase 1   NCT03745144   Germany;Poland;
   Merck Serono International S.A.
      2006   -   EUCTR2004-005148-28-LT   Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;United Kingdom;
      2005   -   EUCTR2004-005148-28-FI   Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;United Kingdom;
      2005   -   EUCTR2004-005148-28-EE   Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;United Kingdom;
      2005   -   EUCTR2004-005148-28-DK   Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;United Kingdom;
      2005   -   EUCTR2004-005148-28-CZ   Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;United Kingdom;
      2005   -   EUCTR2004-005148-28-BE   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;United Kingdom;
   Merck Serono International, a branch of Laboratoires Serono S.A.
      2005   Phase 3   EUCTR2004-005148-28-GB   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;Slovakia;United Kingdom;
   Merck Serono International, a branch of Laboratories Serono S.A.
      2005   -   EUCTR2004-005148-28-DE   Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;United Kingdom;
   Oslo University Hospital
      2019   Phase 3   NCT04121403   Norway;
   Queen Mary University of London
      2020   Phase 2   EUCTR2018-005038-39-GB   United Kingdom;
   Serono International S.A.
      2006   Phase 3   EUCTR2004-005148-28-SK   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;Slovakia;United Kingdom;
      2006   -   EUCTR2004-005148-28-LV   Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;United Kingdom;
      2005   -   EUCTR2004-005148-28-AT   Austria;Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;United Kingdom;
   Serono International, S.A.
      2007   -   EUCTR2006-003366-33-ES   Italy;Spain;
   University of Texas Southwestern Medical Center
      2020   Phase 4   NCT04178005   United States;
   Washington University School of Medicine
      2019   Phase 4   NCT03963375   United States;
Cladribine (MAVENCLAD®)   
   Queen Mary University of London
      2021   Phase 2/Phase 3   NCT04695080   United Kingdom;
Cladribine Oral Tablet   
   Claudio Gobbi
      2020   -   NCT04640818   Switzerland;
Cladribine Tablet   
   MERCK SERONO SA
      2011   Phase 3   EUCTR2009-017978-21-IT   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Estonia;Finland;Georgia;Germany;Greece;India;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Poland;Portugal;Russian Federation;Saudi Arabia;Singapore;Spain;Sweden;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States Minor Outlying Islands;
Cladribine Tablets   
   EMD Serono Research & Development Institute, Inc.
      2019   -   NCT03933215   United States;
      2019   -   NCT03933202   United States;
   Keith Edwards, M.D.
      2020   Phase 4   NCT04550455   United States;
Cladribine tablets   
   MERCK KGAA
      2021   Phase 4   EUCTR2020-003995-42-IT   Australia;Canada;Czech Republic;Finland;Germany;Hungary;Israel;Italy;Poland;
      2021   Phase 4   EUCTR2020-003874-30-IT   Austria;Czechia;Denmark;France;Hungary;Italy;Netherlands;Poland;Slovakia;Spain;
   Merck Healthcare KGaA
      2021   Phase 4   EUCTR2020-003995-42-HU   Australia;Canada;Czech Republic;Finland;Germany;Hungary;Israel;
      2021   Phase 4   EUCTR2020-003995-42-CZ   Australia;Canada;Czech Republic;Finland;Germany;Hungary;Israel;
      2021   Phase 4   EUCTR2020-003874-30-HU   Hungary;
      2021   Phase 4   EUCTR2020-003874-30-DK   Denmark;Hungary;
      2021   Phase 4   EUCTR2020-003874-30-CZ   Czech Republic;Denmark;Hungary;Italy;
      2020   Phase 4   EUCTR2020-003995-42-FI   Australia;Canada;Finland;Germany;Israel;
      2020   Phase 4   EUCTR2020-003995-42-DE   Australia;Canada;Czech Republic;Finland;Germany;Hungary;Israel;Poland;
   Merck KGaA
      2019   Phase 4   EUCTR2019-000069-19-SE   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Georgia;Germany;Greece;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Morocco;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2019   Phase 4   EUCTR2019-000069-19-PT   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Georgia;Germany;Greece;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Morocco;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2019   Phase 4   EUCTR2019-000069-19-PL   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Georgia;Germany;Greece;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Morocco;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2019   Phase 4   EUCTR2019-000069-19-LT   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Georgia;Germany;Greece;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Morocco;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2019   Phase 4   EUCTR2019-000069-19-HR   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Georgia;Germany;Greece;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Morocco;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2019   Phase 4   EUCTR2019-000069-19-ES   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Georgia;Germany;Greece;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Morocco;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2019   Phase 4   EUCTR2019-000069-19-EE   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Georgia;Germany;Greece;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Morocco;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2019   Phase 4   EUCTR2019-000069-19-CZ   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Georgia;Germany;Italy;Korea, Republic of;Lebanon;Lithuania;Morocco;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2019   Phase 4   EUCTR2019-000069-19-BG   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Georgia;Germany;Greece;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Morocco;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
   Merck Serono S.A. - Geneva
      2012   Phase 3   EUCTR2009-017978-21-PT   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2012   Phase 3   EUCTR2009-017978-21-PL   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2012   Phase 3   EUCTR2009-017978-21-GR   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-017978-21-SE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-017978-21-LV   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-017978-21-GB   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-017978-21-FI   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-017978-21-ES   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-017978-21-EE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-017978-21-DK   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-017978-21-BG   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-017978-21-BE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2011   Phase 3   EUCTR2009-017978-21-AT   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2011   -   EUCTR2009-017978-21-LT   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2011   -   EUCTR2009-017978-21-CZ   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2010   Phase 3   EUCTR2009-017978-21-DE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Latvia;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
   Merck, S.L.
      2019   Phase 4   EUCTR2019-000069-19-AT   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Georgia;Germany;Italy;Korea, Republic of;Lebanon;Lithuania;Morocco;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
Clemastine   
   University of California, San Francisco
      2014   Phase 2   NCT02040298   United States;
Clemastine Milstein 1 mg, tabletten   
   Amsterdam University Medical Center
      2022   Phase 3   EUCTR2021-003677-66-NL   Netherlands;
Clemastine fumarate   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2017   Phase 1/Phase 2   NCT03109288   United States;
Cnp-MS-0601   
   Bionorica research GmbH
      2007   Phase 3   EUCTR2006-004255-38-DK   Austria;Denmark;Germany;
      2007   -   EUCTR2006-004255-38-DE   Austria;Germany;
      2007   -   EUCTR2006-004255-38-AT   Austria;Germany;
Coconut oil   
   University of Iowa
      2010   Phase 1   NCT01381354   United States;
Coconut oil and epigallocatechin gallate   
   Fundación Universidad Católica de Valencia San Vicente Mártir
      2018   Phase 2   NCT03740295   Spain;
Coenzyme Q   
   University of Iowa
      2010   Phase 1   NCT01381354   United States;
Colecalciferol   
   AZIENDA OSPEDALIERA S. LUIGI GONZAGA
      2011   -   EUCTR2010-023677-19-IT   Italy;
   MERCK SERONO SA
      2011   -   EUCTR2010-020328-23-IT   Austria;Belgium;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;Netherlands;Portugal;
   University of Turku
      2008   Phase 4   NCT01339676   Finland;
      2008   Phase 2/Phase 3   NCT01432704   -
Combination Product: ofatumumab with AI   
   Novartis Pharmaceuticals
      2018   Phase 2   NCT03560739   Austria;Bulgaria;Czechia;Estonia;Latvia;Lithuania;Russian Federation;Spain;United States;
Combination Product: ofatumumab with PRF   
   Novartis Pharmaceuticals
      2018   Phase 2   NCT03560739   Austria;Bulgaria;Czechia;Estonia;Latvia;Lithuania;Russian Federation;Spain;United States;
Comirnaty Konzentrat zur Herstellung einer Injektionsdispersion   
   Novartis Pharma Vertriebs GmbH
      2021   Phase 4   EUCTR2021-000307-20-DE   Germany;
Continued Ocrelizumab   
   Johns Hopkins University
      2021   Phase 2   NCT04767698   United States;
Copaxone   
   Amphia Ziekenhuis
      2009   -   EUCTR2009-013129-41-NL   Netherlands;
   Bayer
      2003   Phase 3   NCT00099502   Argentina;Australia;Austria;Belgium;Brazil;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Latvia;Netherlands;Norway;Poland;Russian Federation;Slovenia;Spain;Sweden;Switzerland;Ukraine;United States;
   Biogen Idec Limited
      2010   -   EUCTR2009-015556-15-SI   Austria;Canada;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;United States;
      2010   -   EUCTR2009-015556-15-SE   Austria;Canada;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;United States;
      2010   -   EUCTR2009-015556-15-PT   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015556-15-NL   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015556-15-LV   Austria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Italy;Latvia;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;United States;
      2010   -   EUCTR2009-015556-15-HU   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015556-15-GR   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015556-15-GB   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015556-15-FI   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015556-15-DK   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015556-15-DE   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015556-15-CZ   Austria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Italy;Latvia;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;United States;
      2010   -   EUCTR2009-015556-15-AT   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
   Biogen Idec Ltd.
      2008   -   EUCTR2006-003697-10-BG   Bulgaria;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Spain;
      2007   Phase 3   EUCTR2006-003697-10-ES   Belgium;Bulgaria;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Spain;
      2007   Phase 3   EUCTR2006-003697-10-BE   Belgium;Bulgaria;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Spain;
      2007   -   EUCTR2006-003697-10-LV   Bulgaria;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Spain;
      2007   -   EUCTR2006-003697-10-IE   Bulgaria;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Spain;
      2007   -   EUCTR2006-003697-10-GR   Bulgaria;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Spain;
      2007   -   EUCTR2006-003697-10-EE   Bulgaria;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Spain;
      2007   -   EUCTR2006-003697-10-DE   Bulgaria;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Spain;
      2007   -   EUCTR2006-003697-10-CZ   Bulgaria;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Spain;
   EMD Serono
      2013   Phase 2   NCT01963611   Bulgaria;Croatia;Czech Republic;Finland;Germany;Greece;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
   Glostrup Hospital, Dep. of Neurology
      2009   -   EUCTR2006-001827-21-DK   Denmark;
   Karolinska Institutet
      2017   Phase 4   EUCTR2017-002634-24-SE   Sweden;
      2017   Phase 4   EUCTR2016-003587-39-SE   Sweden;
   Merck KGaA
      2014   Phase 2   EUCTR2013-002283-25-GB   Bulgaria;Colombia;Croatia;Czech Republic;Finland;Greece;Hungary;Italy;Mexico;Poland;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2014   -   EUCTR2013-002283-25-PL   Bulgaria;Colombia;Croatia;Czech Republic;Finland;Greece;Hungary;Italy;Mexico;Poland;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2014   -   EUCTR2013-002283-25-GR   Bulgaria;Colombia;Croatia;Czech Republic;Finland;Greece;Hungary;Italy;Mexico;Poland;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2014   -   EUCTR2013-002283-25-ES   Bulgaria;Colombia;Croatia;Czech Republic;Finland;Greece;Hungary;Italy;Mexico;Poland;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2014   -   EUCTR2013-002283-25-BG   Bulgaria;Croatia;Czech Republic;Finland;Greece;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2013-002283-25-IT   Bulgaria;Colombia;Croatia;Czech Republic;Finland;Greece;Hungary;Italy;Mexico;Poland;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2013   -   EUCTR2013-002283-25-HU   Bulgaria;Colombia;Croatia;Czech Republic;Finland;Greece;Hungary;Italy;Mexico;Poland;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2013   -   EUCTR2013-002283-25-FI   Bulgaria;Colombia;Croatia;Czech Republic;Finland;Greece;Hungary;Italy;Mexico;Poland;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2013   -   EUCTR2013-002283-25-CZ   Bulgaria;Colombia;Croatia;Czech Republic;Finland;Greece;Hungary;Italy;Mexico;Poland;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
   Merck Serono S.A. - Geneva
      2010   -   EUCTR2009-016087-37-GB   France;Ireland;Italy;Spain;United Kingdom;
      2009   -   EUCTR2009-016087-37-ES   France;Ireland;Italy;Spain;United Kingdom;
   Nancy Hammond, MD
      2007   -   NCT00490906   United States;
   Novartis Pharma Services AG
      2012   -   EUCTR2011-001437-16-DE   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
   Peptimmune Inc.
      2010   Phase 2   EUCTR2009-012716-40-SK   Bulgaria;Czech Republic;Estonia;France;Germany;Poland;Slovakia;
      2010   Phase 2   EUCTR2009-012716-40-DE   Bulgaria;Czech Republic;Estonia;France;Germany;Poland;Slovakia;
      2010   -   EUCTR2009-012716-40-PL   Bulgaria;Czech Republic;Estonia;France;Germany;Poland;
      2010   -   EUCTR2009-012716-40-FR   Bulgaria;Czech Republic;Estonia;France;Germany;Poland;
      2010   -   EUCTR2009-012716-40-CZ   Bulgaria;Czech Republic;Estonia;France;Germany;Poland;
      2010   -   EUCTR2009-012716-40-BG   Bulgaria;Czech Republic;Estonia;France;Germany;Poland;
      2009   -   EUCTR2009-012716-40-EE   Bulgaria;Czech Republic;Estonia;France;Germany;Poland;
   Philipps-Universität Marburg
      2010   -   EUCTR2009-011088-35-DE   Germany;
   SYNTHON BV
      2011   -   EUCTR2011-000888-27-IT   Bulgaria;Croatia;Czech Republic;Estonia;Germany;Greece;Italy;Romania;Russian Federation;Ukraine;United Kingdom;United States;
   Stuart D Cook MD
      2003   Phase 4   NCT00176592   United States;
   Synthon BV
      2012   -   EUCTR2011-000888-27-GR   Belarus;Bulgaria;Croatia;Czech Republic;Estonia;Germany;Greece;Italy;Lithuania;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2011-000888-27-DE   Belarus;Bulgaria;Croatia;Czech Republic;Estonia;Germany;Greece;Italy;Lithuania;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2011-000888-27-RO   Belarus;Bulgaria;Croatia;Czech Republic;Estonia;Germany;Greece;Italy;Lithuania;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2011-000888-27-GB   Belarus;Bulgaria;Croatia;Czech Republic;Estonia;Germany;Greece;Italy;Lithuania;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2011-000888-27-EE   Belarus;Bulgaria;Croatia;Czech Republic;Estonia;Germany;Greece;Italy;Lithuania;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2011-000888-27-CZ   Belarus;Bulgaria;Croatia;Czech Republic;Estonia;Germany;Greece;Italy;Lithuania;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2011-000888-27-BG   Belarus;Bulgaria;Croatia;Czech Republic;Estonia;Germany;Greece;Italy;Lithuania;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
   The Walton Centre for Neurology and Neurosurgery
      2005   Phase 4   EUCTR2004-004903-39-GB   United Kingdom;
   Turku University Hospital
      2013   Phase 4   EUCTR2013-004626-28-FI   Finland;
   University at Buffalo
      2007   -   NCT00937157   United States;
   University of California, Los Angeles
      2007   Phase 2   NCT00451204   Canada;United States;
   Università Popolare Homo & Natura
      2015   Phase 1   NCT02632591   Italy;
   VU University Medical Center
      2014   -   EUCTR2014-001012-19-NL   Netherlands;
Copaxone 20 mg/ml   
   Octapharma AG
      2015   Phase 3   EUCTR2012-005086-12-PL   Austria;Bulgaria;Germany;Hungary;Poland;Russian Federation;Serbia;Ukraine;
      2013   -   EUCTR2012-005086-12-HU   Austria;Bulgaria;Germany;Hungary;Poland;Russian Federation;
      2013   -   EUCTR2012-005086-12-DE   Austria;Bulgaria;Germany;Hungary;Poland;Russian Federation;
      2013   -   EUCTR2012-005086-12-BG   Austria;Bulgaria;Germany;Hungary;Poland;Russian Federation;
      2013   -   EUCTR2012-005086-12-AT   Austria;Bulgaria;Germany;Hungary;Poland;Russian Federation;
   Teva Pharmaceutical Industries, Ltd
      2016   Phase 4   EUCTR2015-000922-12-PL   Argentina;Austria;Belgium;Croatia;Finland;France;Germany;Ireland;Israel;Italy;Mexico;Poland;Russian Federation;Spain;Turkey;United States;
      2016   Phase 4   EUCTR2015-000922-12-FR   Argentina;Austria;Belgium;Croatia;Finland;France;Germany;Ireland;Italy;Mexico;Poland;Russian Federation;Spain;Turkey;United States;
      2016   Phase 4   EUCTR2015-000922-12-ES   Argentina;Austria;Belgium;Croatia;Finland;France;Germany;Ireland;Italy;Mexico;Poland;Russian Federation;Spain;Turkey;United States;
      2016   Phase 4   EUCTR2015-000922-12-DE   Argentina;Austria;Belgium;Croatia;Finland;France;Germany;Ireland;Israel;Italy;Mexico;Poland;Russian Federation;Spain;Turkey;United States;
      2016   Phase 4   EUCTR2015-000922-12-BE   Argentina;Austria;Belgium;Croatia;Finland;France;Germany;Ireland;Israel;Italy;Mexico;Poland;Russian Federation;Spain;Turkey;United States;
      2015   Phase 4   EUCTR2015-000922-12-IE   Argentina;Austria;Belgium;Croatia;Finland;France;Germany;Ireland;Israel;Italy;Mexico;Poland;Russian Federation;Spain;Turkey;United States;
      2015   Phase 4   EUCTR2015-000922-12-HR   Argentina;Austria;Belgium;Croatia;Finland;France;Germany;Ireland;Israel;Italy;Mexico;Poland;Russian Federation;Spain;Turkey;United States;
      2015   Phase 4   EUCTR2015-000922-12-FI   Argentina;Austria;Belgium;Croatia;Finland;France;Germany;Ireland;Israel;Italy;Mexico;Poland;Russian Federation;Spain;Turkey;United States;
      2015   Phase 4   EUCTR2015-000922-12-AT   Argentina;Austria;Belgium;Croatia;Finland;France;Germany;Ireland;Israel;Italy;Mexico;Poland;Russian Federation;Spain;Turkey;United States;
Copaxone 20 mg/ml Solution for Injection, pre-filled syringe   
   Teva Pharmaceutical Industries, Ltd.
      2007   -   EUCTR2006-002037-20-EE   Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2006   Phase 3   EUCTR2006-002037-20-FI   Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2006   Phase 3   EUCTR2006-002037-20-ES   Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2006   -   EUCTR2006-002037-20-LV   Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2006   -   EUCTR2006-002037-20-LT   Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2006   -   EUCTR2006-002037-20-HU   Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2006   -   EUCTR2006-002037-20-GB   Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2006   -   EUCTR2006-002037-20-DE   Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2006   -   EUCTR2006-002037-20-CZ   Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2006   -   EUCTR2006-002037-20-BE   Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Spain;United Kingdom;
Copaxone 20 mg/ml solución para inyección en jeringa precargada   
   Teva Pharmaceutical Industries, Ltd.
      2006   Phase 3   EUCTR2006-002037-20-ES   Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;Lithuania;Spain;United Kingdom;
Copaxone 20 mg/ml, Solution for Injection, pre-filled syringes   
   Teva Pharmaceutical Industries, Ltd.
      2006   -   EUCTR2006-002037-20-CZ   Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Spain;United Kingdom;
Copaxone 20mg/ml Solution for Injection, pre-filled syringe   
   Teva Pharmaceutical Industries, Ltd.
      2006   -   EUCTR2006-002037-20-LT   Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Spain;United Kingdom;
Copaxone 40 mg/ml   
   Teva Pharmaceutical Industries, Ltd
      2016   Phase 4   EUCTR2015-000922-12-PL   Argentina;Austria;Belgium;Croatia;Finland;France;Germany;Ireland;Israel;Italy;Mexico;Poland;Russian Federation;Spain;Turkey;United States;
      2016   Phase 4   EUCTR2015-000922-12-FR   Argentina;Austria;Belgium;Croatia;Finland;France;Germany;Ireland;Italy;Mexico;Poland;Russian Federation;Spain;Turkey;United States;
      2016   Phase 4   EUCTR2015-000922-12-ES   Argentina;Austria;Belgium;Croatia;Finland;France;Germany;Ireland;Italy;Mexico;Poland;Russian Federation;Spain;Turkey;United States;
      2016   Phase 4   EUCTR2015-000922-12-DE   Argentina;Austria;Belgium;Croatia;Finland;France;Germany;Ireland;Israel;Italy;Mexico;Poland;Russian Federation;Spain;Turkey;United States;
      2016   Phase 4   EUCTR2015-000922-12-BE   Argentina;Austria;Belgium;Croatia;Finland;France;Germany;Ireland;Israel;Italy;Mexico;Poland;Russian Federation;Spain;Turkey;United States;
      2015   Phase 4   EUCTR2015-000922-12-IE   Argentina;Austria;Belgium;Croatia;Finland;France;Germany;Ireland;Israel;Italy;Mexico;Poland;Russian Federation;Spain;Turkey;United States;
      2015   Phase 4   EUCTR2015-000922-12-HR   Argentina;Austria;Belgium;Croatia;Finland;France;Germany;Ireland;Israel;Italy;Mexico;Poland;Russian Federation;Spain;Turkey;United States;
      2015   Phase 4   EUCTR2015-000922-12-FI   Argentina;Austria;Belgium;Croatia;Finland;France;Germany;Ireland;Israel;Italy;Mexico;Poland;Russian Federation;Spain;Turkey;United States;
      2015   Phase 4   EUCTR2015-000922-12-AT   Argentina;Austria;Belgium;Croatia;Finland;France;Germany;Ireland;Israel;Italy;Mexico;Poland;Russian Federation;Spain;Turkey;United States;
Copaxone 40 mg/ml solution for injection, pre-filled syringe   
   Università degli Studi Aldo Moro
      2019   Phase 3   EUCTR2017-005129-18-IT   Italy;
Copaxone subcutaneous injection syringe   
   TAKEDA PHARMACEUTICAL COMPANY LTD.
      2015   -   JPRN-JapicCTI-153058   -
Copaxone-Teva   
   Biocad
      2013   Phase 3   NCT02753088   -
Copaxone®   
   Teva Branded Pharmaceutical Products R&D, Inc.
      2015   Phase 4   NCT02499900   Argentina;Austria;Belgium;Croatia;Finland;France;Germany;Ireland;Italy;Mexico;Poland;Puerto Rico;Russian Federation;Spain;Turkey;United States;
Copolymer 1   
   National Center for Research Resources (NCRR)
      1991   Phase 3   NCT00004814   -
Corticosteroid   
   University of New Mexico
      2019   Phase 1/Phase 2   NCT03752307   United States;
Corticosteroids & tanCART19/20   
   Chinese PLA General Hospital
      2018   Phase 1   NCT03605238   China;
Cranberry   
   Rennes University Hospital
      2006   Phase 3   NCT00280592   France;
Creatine   
   University of Iowa
      2010   Phase 1   NCT01381354   United States;
Curcumin   
   Merck KGaA, Darmstadt, Germany
      2012   Phase 2   NCT01514370   Italy;
Cyclophosfamide   
   Dipartimento di Neuroscienze Oftalmologia e Genetica DINOG - Universita di Genova
      2006   -   EUCTR2006-002562-19-IT   Italy;
Cyclophosphamide   
   AZIENDA OSPEDALIERA DI PADOVA
      -   Phase 1   EUCTR2008-005773-35-IT   Italy;
   Baylor College of Medicine
      1999   Phase 2   NCT00040482   United States;
   Fred Hutchinson Cancer Research Center
      1997   Phase 1   NCT00014755   United States;
   Hadassah Medical Organization
      2015   -   NCT02529839   -
   Helse Bergen HF, Haukeland University Hospital
      2018   Phase 3   EUCTR2017-001362-25-DK   Denmark;Netherlands;
   Northwestern Memorial Hospital
      2001   Phase 1   NCT00017628   United States;
   Northwestern University
      2019   Phase 2/Phase 3   NCT03829566   United States;
      2017   Phase 3   NCT03342638   United States;
   OSPEDALE S. RAFFAELE
      2007   Phase 2   EUCTR2007-000586-38-IT   Italy;
   Seah Lim M.D.
      2012   Phase 2   NCT01679041   United States;
   Stony Brook University
      2003   Phase 2   NCT00296205   United States;
Cyclophosphamide (drug)   
   University Hospital, Bordeaux
      2005   Phase 3   NCT00241254   France;
Cyclophosphamide and ATG   
   Haukeland University Hospital
      2018   Phase 3   NCT03477500   Denmark;Netherlands;Norway;Sweden;
Cyclophosphamide and fludarabine   
   Tongji Hospital
      2020   Early Phase 1   NCT04561557   China;
Cyclophosphamide monohydrate   
   Sheffield Teaching Hospitals
      2020   Phase 3   EUCTR2019-001549-42-GB   United Kingdom;
Cyclophosphamide/Glatiramer acetate   
   Johns Hopkins University
      2010   Phase 2   NCT00939549   United States;
Cymbalta   
   Eli Lilly and Company
      2008   -   EUCTR2008-002560-34-BE   Belgium;
Cytarabine   
   Fred Hutchinson Cancer Research Center
      2008   Phase 2   NCT00716066   United States;
Cytolytic CD4+ T cells   
   ImCyse S.A
      2014   Phase 1;Phase 2   EUCTR2014-001081-99-BE   Belgium;
Cápsulas de Laquinimod   
   Teva Pharmaceutical Industries Ltd
      2008   -   EUCTR2007-005450-23-ES   Bulgaria;Czech Republic;Estonia;Germany;Italy;Lithuania;Spain;
Células madre mesenquimales   
   Fundació Clínic per a la Recerca Biomèdica
      -   -   EUCTR2009-016442-74-ES   Spain;
D Mannose   
   University College, London
      2015   Phase 1   NCT02490046   United Kingdom;
D-BIOTINA   
   MEDDAY PHARMACEUTICALS
      2017   Phase 3   EUCTR2016-000700-29-IT   Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States;
D-Biotin   
   MEDDAY PHARMACEUTICALS
      2017   Phase 3   EUCTR2016-000700-29-IT   Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States;
D-aspartate   
   Merck KGaA, Darmstadt, Germany
      2018   Phase 2   NCT03387046   Germany;Italy;
DAC HYP   
   BIOGEN IDEC RESEARCH LIMITED
      2017   Phase 3   EUCTR2016-002820-10-IT   Canada;Denmark;France;Germany;Italy;United Kingdom;United States;
   Biogen Idec Research Limited
      2017   Phase 3   EUCTR2016-002820-10-GB   Canada;Denmark;France;Germany;Italy;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002820-10-DE   Canada;Germany;Italy;United Kingdom;United States;
DAC-HYP   
   National Institute of Neurological Disorders and Stroke (NINDS)
      2010   Phase 1   NCT01143441   United States;
DC-TAB   
   Delta Crystallon B.V.
      2012   -   EUCTR2011-004475-36-BG   Bulgaria;
DEMESTRIL SEPTEM   
   OSPEDALI CIVILI DI LIONE
      2007   -   EUCTR2006-005460-30-IT   Italy;
DEXTROMETHORPHAN HYDROBROMIDE   
   Avanir Pharmaceuticals, Inc.
      2012   Phase 2   EUCTR2011-002178-22-GB   Argentina;Bulgaria;Czech Republic;Germany;Poland;Spain;United Kingdom;United States;
      2012   -   EUCTR2011-002178-22-PL   Argentina;Bulgaria;Czech Republic;Germany;Poland;Spain;United Kingdom;United States;
      2012   -   EUCTR2011-002178-22-CZ   Argentina;Bulgaria;Czech Republic;Germany;Poland;Spain;United Kingdom;United States;
DIBASE   
   AZIENDA OSPEDALIERA S. LUIGI GONZAGA
      2011   -   EUCTR2010-023677-19-IT   Italy;
DIMETIL-FUMARATO   
   FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
      2017   Phase 4   EUCTR2017-000559-26-IT   Israel;Italy;Switzerland;United States;
DMT   
   Merck KGaA
      2012   -   NCT01601119   United Kingdom;
   VU University Medical Center
      2020   -   NCT04260711   Netherlands;
DMT continuation   
   Rennes University Hospital
      2019   Phase 3   NCT03653273   France;
DPA-714 PET/MRI   
   University of Alabama at Birmingham
      2019   Phase 1   NCT03759522   United States;
DUOC-01   
   Joanne Kurtzberg, MD
      2021   Phase 1   NCT04943289   United States;
DYSPORT*SC IM 2FL 500U   
   IPSEN INNOVATION
      2012   -   EUCTR2010-023210-31-IT   Austria;Czech Republic;Germany;Italy;Lithuania;
DYSPORT®   
   Ipsen Innovation
      2016   Phase 3   EUCTR2015-003471-30-PT   Canada;Czech Republic;Italy;Korea, Republic of;Malaysia;Netherlands;Poland;Portugal;Romania;Taiwan;Turkey;United States;
      2016   Phase 3   EUCTR2015-003471-30-PL   Canada;Czech Republic;Italy;Korea, Republic of;Malaysia;Netherlands;Poland;Portugal;Romania;Taiwan;Turkey;United States;
      2016   Phase 3   EUCTR2015-003471-30-NL   Canada;Czech Republic;Italy;Korea, Republic of;Malaysia;Netherlands;Poland;Portugal;Romania;Taiwan;Turkey;United States;
      2016   Phase 3   EUCTR2015-003471-30-IT   Canada;Czech Republic;Italy;Korea, Republic of;Malaysia;Netherlands;Poland;Portugal;Romania;Taiwan;Turkey;United States;
      2016   Phase 3   EUCTR2015-003471-30-CZ   Canada;Czech Republic;Italy;Korea, Republic of;Malaysia;Netherlands;Poland;Portugal;Romania;Taiwan;Turkey;United States;
Daclizumab   
   Biogen
      2017   Phase 3   NCT02881567   Canada;France;Germany;Italy;Puerto Rico;United Kingdom;United States;
   Biogen Idec Research Limited
      2017   Phase 3   EUCTR2016-002820-10-GB   Canada;Denmark;France;Germany;Italy;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002820-10-DE   Canada;Germany;Italy;United Kingdom;United States;
   National Institute of Neurological Disorders and Stroke (NINDS)
      2003   Phase 2   NCT00071838   United States;
   Protein Design Labs, Inc.
      2006   -   EUCTR2005-001567-55-DE   Germany;Spain;United Kingdom;
      2005   Phase 2   EUCTR2005-001567-55-GB   Austria;Germany;Spain;United Kingdom;
      2005   -   EUCTR2005-001567-55-ES   Germany;Spain;United Kingdom;
      2005   -   EUCTR2005-001567-55-AT   Austria;Germany;Spain;United Kingdom;
Daclizumab (Anti-CD25 Humanized Monoclonal Antibody)   
   PDL BioPharma, Inc.
      2005   Phase 2   NCT00109161   Canada;United States;
Daclizumab HYP   
   BIOGEN IDEC LTD
      2010   -   EUCTR2009-012500-11-IT   Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Slovenia;Spain;Sweden;United Kingdom;
Daclizumab HYP (DAC HYP   
   BIOGEN IDEC RESEARCH LTD
      2013   Phase 3   EUCTR2012-003176-39-IT   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Finland;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Russian Federation;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
Daclizumab HYP (DAC HYP)   
   Biogen
      2013   Phase 3   EUCTR2012-003176-39-HU   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2010   Phase 2   EUCTR2009-015318-23-GB   Czech Republic;Germany;Hungary;India;Russian Federation;Ukraine;United Kingdom;
   Biogen Idec Limited
      2011   -   EUCTR2010-023856-97-PL   Czech Republic;Hungary;Poland;Russian Federation;United States;
      2011   -   EUCTR2010-023856-97-HU   Czech Republic;Hungary;Poland;Russian Federation;United States;
      2011   -   EUCTR2010-023856-97-CZ   Czech Republic;Hungary;Poland;United States;
   Biogen Idec Ltd
      2012   Phase 3   EUCTR2009-012500-11-SI   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2009-012500-11-GB   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2009-012500-11-FR   Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Slovenia;Spain;Sweden;United Kingdom;
      2010   Phase 3   EUCTR2009-012500-11-FI   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2009-012500-11-ES   Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Slovenia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-012500-11-SE   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2009-012500-11-IE   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2009-012500-11-HU   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2009-012500-11-GR   Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Slovenia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-012500-11-DK   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2009-012500-11-DE   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2009-012500-11-CZ   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2006   Phase 2   EUCTR2006-001161-42-GB   Czech Republic;Germany;Hungary;Sweden;United Kingdom;
   Biogen Idec Ltd.
      2011   Phase 2   EUCTR2009-015318-23-DE   Czech Republic;Germany;Hungary;India;Russian Federation;Ukraine;United Kingdom;
      2010   Phase 2   EUCTR2009-015318-23-HU   Czech Republic;Germany;Hungary;India;Russian Federation;Ukraine;United Kingdom;
      2010   Phase 2   EUCTR2009-015318-23-CZ   Czech Republic;Germany;Hungary;India;Russian Federation;Ukraine;United Kingdom;
      2009   Phase 2   EUCTR2008-005559-46-GB   Czech Republic;Germany;Hungary;India;Poland;Russian Federation;Ukraine;United Kingdom;
      2009   -   EUCTR2008-005559-46-HU   Czech Republic;Germany;Hungary;India;Poland;Russian Federation;Ukraine;United Kingdom;
      2009   -   EUCTR2008-005559-46-DE   Czech Republic;Germany;Hungary;India;Poland;Russian Federation;Ukraine;United Kingdom;
      2009   -   EUCTR2008-005559-46-CZ   Czech Republic;Germany;Hungary;India;Poland;Russian Federation;Ukraine;United Kingdom;
      2008   -   EUCTR2006-001161-42-HU   Germany;Hungary;Sweden;United Kingdom;
      2008   -   EUCTR2006-001161-42-DE   Czech Republic;Germany;Hungary;India;Poland;Russian Federation;Sweden;Ukraine;United Kingdom;
      2006   -   EUCTR2006-001161-42-SE   Germany;Hungary;Sweden;United Kingdom;
      2006   -   EUCTR2006-001161-42-CZ   Czech Republic;Germany;Hungary;Sweden;United Kingdom;
   Biogen Idec Research Limited
      2013   Phase 3   EUCTR2012-003176-39-SE   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003176-39-PL   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003176-39-IE   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003176-39-GR   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003176-39-GB   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003176-39-FR   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003176-39-ES   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003176-39-DK   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003176-39-DE   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003176-39-CZ   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-003176-39-FI   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
Daclizumab High Yield Process   
   Biogen Idec Ltd.
      2011   Phase 2   EUCTR2009-015318-23-DE   Czech Republic;Germany;Hungary;India;Russian Federation;Ukraine;United Kingdom;
      2010   Phase 2   EUCTR2009-015318-23-HU   Czech Republic;Germany;Hungary;India;Russian Federation;Ukraine;United Kingdom;
      2010   Phase 2   EUCTR2009-015318-23-CZ   Czech Republic;Germany;Hungary;India;Russian Federation;Ukraine;United Kingdom;
Daclizumab wih Greek suffix   
   Biogen Idec Ltd
      2012   Phase 3   EUCTR2009-012500-11-SI   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
Daclizumab with Greek suufix   
   Biogen Idec Ltd.
      2009   Phase 2   EUCTR2008-005559-46-GB   Czech Republic;Germany;Hungary;India;Poland;Russian Federation;Ukraine;United Kingdom;
      2009   -   EUCTR2008-005559-46-HU   Czech Republic;Germany;Hungary;India;Poland;Russian Federation;Ukraine;United Kingdom;
      2009   -   EUCTR2008-005559-46-DE   Czech Republic;Germany;Hungary;India;Poland;Russian Federation;Ukraine;United Kingdom;
      2009   -   EUCTR2008-005559-46-CZ   Czech Republic;Germany;Hungary;India;Poland;Russian Federation;Ukraine;United Kingdom;
Dalfampridine   
   Acorda Therapeutics
      2012   -   NCT01535664   United States;
   Johns Hopkins University
      2014   Phase 2   NCT02166346   United States;
   Oregon Health and Science University
      2011   Phase 2   NCT01444300   United States;
   State University of New York at Buffalo
      2011   Phase 2/Phase 3   NCT02006160   United States;
   VA Office of Research and Development
      2015   Phase 2   NCT02391961   United States;
   Washington University School of Medicine
      2011   Phase 2/Phase 3   NCT01337986   United States;
Dalfampridine ER   
   Brown, Theodore R., M.D., MPH
      2010   Phase 4   NCT01356940   United States;
Dalfampridine-ER   
   Acorda Therapeutics
      2011   Phase 3   NCT01328379   United States;
Dantrolene   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2017   Phase 1/Phase 2   NCT03109288   United States;
Darifenacin   
   Bayer Vital GmbH
      2006   -   EUCTR2006-002361-39-DE   Germany;
Darifenacin (BAY79-4998)   
   Bayer
      2007   Phase 2   NCT00845338   Germany;
Dekristol 20000 IE   
   Merja Soilu Häninen
      2007   -   EUCTR2007-001958-99-FI   Finland;
Dekristol® 400-Tabletten   
   Charité - Universitätsmedizin Berlin
      2011   Phase 2   EUCTR2011-002785-20-DE   Germany;
Dekristol®-Tablette 1 (400 IE)   
   Charité - Universitätsmedizin Berlin
      2011   Phase 2   EUCTR2011-002785-20-DE   Germany;
Delta-9-tetrahydrocannabinol   
   GW Pharma Ltd
      2007   Phase 3   EUCTR2006-005910-11-CZ   Czech Republic;Germany;Italy;Spain;United Kingdom;
      2006   Phase 3   EUCTR2005-005265-11-GB   Czech Republic;France;United Kingdom;
      2006   Phase 3   EUCTR2005-005265-11-FR   Czech Republic;France;United Kingdom;
      2006   -   EUCTR2005-005265-11-CZ   Czech Republic;France;United Kingdom;
      2005   Phase 3   EUCTR2004-002509-63-GB   Czech Republic;United Kingdom;
      2005   -   EUCTR2004-002509-63-CZ   Czech Republic;United Kingdom;
   GW Pharma Ltd.
      2011   -   EUCTR2011-000926-31-CZ   Czech Republic;
      2008   Phase 3   EUCTR2006-005910-11-GB   Czech Republic;Germany;Italy;Spain;United Kingdom;
      2008   -   EUCTR2006-005910-11-DE   Germany;Italy;Spain;United Kingdom;
      2007   -   EUCTR2007-002138-13-GB   United Kingdom;
Desloratadine given orally   
   Hoffmann-La Roche
      2022   Phase 3   NCT05232825   Brazil;Canada;Czechia;Italy;Poland;Russian Federation;Spain;Turkey;Ukraine;United States;
Dexamethason   
   Department of Neurology UMCG
      2006   -   EUCTR2006-003113-40-NL   Netherlands;
Dexamethasone   
   Department of Neurology UMCG
      2006   -   EUCTR2006-003113-40-NL   Netherlands;
Dexamethasone given orally   
   Hoffmann-La Roche
      2022   Phase 3   NCT05232825   Brazil;Canada;Czechia;Italy;Poland;Russian Federation;Spain;Turkey;Ukraine;United States;
Dexamethasone soduim phosphate   
   Hadassah Medical Organization
      2008   Phase 1   NCT00674141   Israel;
Dexchlorpheniramine   
   Genzyme, a Sanofi Company
      2017   Phase 3   NCT03368664   Austria;Belgium;Bulgaria;Czechia;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;
      2015   Phase 1   NCT02583594   Spain;
Dexrazoxane (DRZ) plus Mitoxantrone (MX)   
   PD Dr. Andrew Chan
      2012   Phase 2   NCT01627938   Germany;
Dextromethorphan   
   Biogen
      2011   Phase 3   NCT01462318   Czech Republic;Hungary;Poland;Russian Federation;United States;
Dextromethorphan hydrobromide 20 mg and quinidine sulfate   
   Avanir Pharmaceuticals
      2007   Phase 3   NCT00573443   Argentina;Brazil;United States;
Dextromethorphan hydrobromide 30 mg and quinidine sulfate   
   Avanir Pharmaceuticals
      2007   Phase 3   NCT00573443   Argentina;Brazil;United States;
Dextromethorphan/Quinidine   
   Avanir Pharmaceuticals, Inc.
      2012   Phase 2   EUCTR2011-002178-22-GB   Argentina;Bulgaria;Czech Republic;Germany;Poland;Spain;United Kingdom;United States;
      2012   -   EUCTR2011-002178-22-PL   Argentina;Bulgaria;Czech Republic;Germany;Poland;Spain;United Kingdom;United States;
      2012   -   EUCTR2011-002178-22-CZ   Argentina;Bulgaria;Czech Republic;Germany;Poland;Spain;United Kingdom;United States;
Dextrometorfano/Quinidina   
   Avanir Pharmaceuticals, Inc.
      2011   Phase 2   EUCTR2011-002178-22-ES   Argentina;Bulgaria;Czech Republic;Poland;Spain;United Kingdom;United States;
Diazoxide   
   NEUROTEC PHARMA, S.L
      2011   -   EUCTR2010-023048-34-DE   Germany;Spain;
Diclofenac sodium topical gel   
   Brown, Theodore R., M.D., MPH
      2011   Phase 4   NCT01454791   United States;
Dietary Supplement: vitamin A   
   Tehran University of Medical Sciences
      2010   Phase 4   NCT01705457   Iran, Islamic Republic of;
Dimethyl Fumarate (DMF)   
   Genesis Pharma CNS & Specialty
      2016   -   NCT03101735   Greece;
   Hikma Pharmaceuticals LLC
      2021   -   NCT04468165   Algeria;Egypt;Jordan;
Dimethyl fumarate   
   Anders Svenningsson
      2016   Phase 3   NCT02746744   Sweden;
   Banner Life Sciences LLC
      2017   Phase 1   NCT04570670   -
   Biogen
      2021   -   NCT04756687   France;
      2016   Phase 3   NCT02555215   Belgium;Bulgaria;Czech Republic;Czechia;Germany;Kuwait;Latvia;Lebanon;Poland;Turkey;United States;
      2016   Phase 3   NCT02428218   -
      2016   -   NCT02969304   Germany;
      2015   Phase 4   NCT02472938   -
      2015   Phase 4   NCT02471560   Norway;
      2015   Phase 4   NCT02410278   United States;
      2015   Phase 4   NCT02343159   United States;
      2015   Phase 4   NCT02090348   -
      2015   Phase 3   NCT02525874   Belgium;Bulgaria;Croatia;Kuwait;Lithuania;Poland;Turkey;United States;
      2015   Phase 3   NCT02430532   Austria;Belgium;Czech Republic;Netherlands;Poland;Slovakia;Sweden;United States;
      2015   Phase 3   NCT02428231   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Spain;United States;
      2015   Phase 2   NCT02410200   Belgium;Bulgaria;Czech Republic;Czechia;Germany;Kuwait;Latvia;Lebanon;Poland;Turkey;United States;
      2015   Phase 2   NCT02097849   United States;
      2015   -   NCT02519413   United States;
      2015   -   NCT02323269   Canada;
      2014   Phase 4   NCT02125604   Germany;
      2014   Phase 4   NCT02090413   Ireland;United Kingdom;
      2014   Phase 3   NCT02579681   Italy;
      2014   Phase 3   NCT02283853   Argentina;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Kuwait;Poland;Romania;Serbia;Spain;Sweden;Turkey;United Kingdom;United States;
      2014   -   NCT02159573   United States;
      2013   Phase 4   NCT01930708   Austria;Belgium;Canada;Czech Republic;Czechia;France;Hungary;Italy;Portugal;Slovakia;Slovenia;Spain;
      2013   Phase 3   NCT01838668   Czech Republic;Czechia;Japan;Korea, Republic of;Poland;Taiwan;
      2013   -   NCT02047097   Argentina;Australia;Austria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Slovakia;Spain;Switzerland;United Kingdom;United States;
      2013   -   NCT01911767   Australia;Canada;France;Germany;Ireland;Italy;Poland;Spain;United Kingdom;United States;
      2013   -   NCT01903291   United States;
      2010   Phase 2   NCT01156311   United States;
      2009   Phase 3   NCT00835770   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Guatemala;India;Ireland;Israel;Italy;Latvia;Macedonia, The Former Yugoslav Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;North Macedonia;Poland;Puerto Rico;Romania;Serbia;Slovakia;South Africa;Spain;Switzerland;Ukraine;United Kingdom;United States;
   Biogen Idec Inc.
      2004   -   EUCTR2004-000663-99-SE   Hungary;Sweden;
      2004   -   EUCTR2004-000663-99-HU   Hungary;Sweden;
      2004   -   EUCTR2004-000663-99-CZ   Czech Republic;Hungary;Sweden;
   Biogen Idec Italia S.r.l.
      2015   -   EUCTR2015-000303-21-IT   Italy;
   Fondation Ophtalmologique Adolphe de Rothschild
      2017   Phase 4   NCT02901106   France;
   Multiple Sclerosis Center of Northeastern New York
      2015   Phase 4   NCT03092544   United States;
   Northwestern University
      2013   Phase 2   EUCTR2012-004165-41-GB   United Kingdom;United States;
   Oregon Health and Science University
      2016   -   NCT02644083   United States;
   University Hospital Muenster
      2015   Phase 4   NCT02461069   Germany;
   University at Buffalo
      2015   -   NCT02686684   -
   Virginia Simnad
      2015   -   NCT02736279   United States;
Dimethyl fumarate [DMF]   
   Biogen Idec Italia S.r.l.
      2013   Phase 3   EUCTR2013-001422-25-IT   Italy;
Dimetilfumarato   
   Biogen Idec Italia S.r.l.
      2013   Phase 3   EUCTR2013-001422-25-IT   Italy;
Diphenhydramine IV   
   Hoffmann-La Roche
      2022   Phase 3   NCT05232825   Brazil;Canada;Czechia;Italy;Poland;Russian Federation;Spain;Turkey;Ukraine;United States;
Diphenydramine   
   Genzyme, a Sanofi Company
      2017   Phase 3   NCT03368664   Austria;Belgium;Bulgaria;Czechia;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;
Diroximel Fumarate (DRF)   
   Alkermes, Inc.
      2017   Phase 3   EUCTR2017-001294-16-PL   Germany;Poland;United States;
Diroximel fumarate   
   Alkermes, Inc.
      2019   Phase 3   EUCTR2017-001294-16-DE   Germany;Poland;United States;
   Hanna Jerome Thomas
      2021   Phase 3   JPRN-jRCT2051210115   China;Japan;
Dirucotide   
   Eli Lilly and Company
      2007   Phase 2/Phase 3   NCT00870155   Canada;Denmark;Estonia;Finland;Germany;Latvia;Netherlands;Spain;Sweden;United Kingdom;
      2006   Phase 2/Phase 3   NCT00869986   Bulgaria;Poland;Russian Federation;Serbia;Slovakia;Ukraine;
      2004   Phase 2/Phase 3   NCT00869726   Canada;Denmark;Estonia;Finland;Germany;Latvia;Netherlands;Spain;Sweden;United Kingdom;
Dirucotide acetate   
   BioMS Technology Corp
      2007   -   EUCTR2004-002571-16-GB   Denmark;Estonia;Finland;Latvia;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2004-002571-16-FI   Denmark;Estonia;Finland;Latvia;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2004-002571-16-EE   Denmark;Estonia;Finland;Latvia;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2004-002571-16-DK   Denmark;Estonia;Finland;Latvia;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-002571-16-SE   Denmark;Estonia;Finland;Latvia;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
Discontinuation of disease modifying therapy   
   University of Colorado, Denver
      2017   Phase 4   NCT03073603   United States;
Disease Modifying therapy   
   Novartis Pharmaceuticals
      2012   Phase 4   NCT01623596   Puerto Rico;United States;
Disease modifying treatment (DMT)   
   Novartis Pharmaceuticals
      2022   Phase 4   NCT05090371   United States;
Domperidone   
   University of Calgary
      2015   Phase 2   NCT02493049   Canada;
      2015   Phase 2   NCT02308137   Canada;
Donepezil   
   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
      1999   Phase 3   NCT00062972   United States;
   Neurology Unit
      2005   -   EUCTR2005-003410-15-SE   Sweden;
   OSPEDALE S. RAFFAELE
      2008   -   EUCTR2008-001940-38-IT   Italy;
Donepezil HCI (drug)   
   Neurognostics
      2004   Phase 4   NCT00315367   United States;
Dosing Interruption of Natalizumab   
   Berkovich, Regina MD, PhD Inc.
      2019   Phase 4   NCT04048577   United States;
Dotarem 0,5mmol/ml,   
   Universitätsklinikum Erlangen
      2010   -   EUCTR2009-014857-34-DE   Germany;
Dronabinol   
   Bionorica Research GmbH
      2007   Phase 3   NCT00959218   Germany;
   Bionorica SE
      2018   Phase 3   EUCTR2018-000001-23-ES   Hungary;Spain;
   Bionorica research GmbH
      2007   Phase 3   EUCTR2006-004255-38-DK   Austria;Denmark;Germany;
      2007   -   EUCTR2006-004255-38-DE   Austria;Germany;
      2007   -   EUCTR2006-004255-38-AT   Austria;Germany;
   Echo Pharmaceuticals B.V.
      2011   -   EUCTR2010-022033-28-NL   Netherlands;
   Plymouth Hospitals NHS Trust
      2006   -   EUCTR2005-002728-33-GB   United Kingdom;
Dronabinol 25 mg/ml, oral drops   
   Bionorica SE
      2020   Phase 3   EUCTR2018-000001-23-CZ   Czech Republic;Hungary;Spain;
      2018   Phase 3   EUCTR2018-000001-23-HU   Czech Republic;Hungary;Spain;
Dronabinol capsule 2,   
   Aarhus Universitetshospital
      2018   Phase 2   EUCTR2018-002315-98-DK   Denmark;
Drug - SHR1459   
   Reistone Biopharma Company Limited
      2020   Phase 2   NCT04670770   China;
Duloxetine   
   Brown, Theodore R., M.D., MPH
      2007   Phase 2/Phase 3   NCT00457730   United States;
Duloxetine Hydrochloride (HCI)   
   Eli Lilly and Company
      2008   Phase 3   NCT00755807   Belgium;Canada;Poland;United States;
Dynamic Contrast-Enhanced Magnetic Resonance Imaging   
   University of Southern California
      2011   -   NCT02967380   United States;
Dynamic Vessel Analyzer (DVA)   
   Medical University of Vienna
      2018   -   NCT03401879   Austria;
Dysport   
   Aránzazu Vázquez Doce
      2018   Phase 3   EUCTR2018-003231-30-ES   Spain;
   Ipsen Innovation
      2012   -   EUCTR2010-023210-31-LT   Austria;Czech Republic;Germany;Italy;Lithuania;
      2012   -   EUCTR2010-023210-31-DE   Austria;Czech Republic;Germany;Italy;Lithuania;
      2012   -   EUCTR2010-023210-31-CZ   Austria;Czech Republic;Germany;Italy;Lithuania;
      2012   -   EUCTR2010-023210-31-AT   Austria;Czech Republic;Germany;Italy;Lithuania;
Dysport®   
   Ipsen Innovation
      2016   Phase 3   EUCTR2015-000507-44-LT   Argentina;Belgium;Brazil;Chile;Colombia;France;Germany;Israel;Lithuania;Mexico;New Zealand;Peru;Russian Federation;Spain;Ukraine;United Kingdom;
      2016   Phase 3   EUCTR2015-000507-44-FR   Argentina;Belgium;Brazil;Chile;Colombia;France;Germany;Israel;Lithuania;Mexico;New Zealand;Peru;Russian Federation;Spain;Ukraine;United Kingdom;
      2016   Phase 3   EUCTR2015-000507-44-ES   Argentina;Belgium;Brazil;Chile;Colombia;France;Germany;Israel;Lithuania;Mexico;New Zealand;Peru;Russian Federation;Spain;Ukraine;United Kingdom;
      2016   Phase 3   EUCTR2015-000507-44-DE   Argentina;Belgium;Brazil;Chile;Colombia;France;Germany;Israel;Lithuania;Mexico;New Zealand;Peru;Russian Federation;Spain;Ukraine;United Kingdom;
      2016   Phase 3   EUCTR2015-000507-44-BE   Argentina;Belgium;Brazil;Chile;Colombia;France;Germany;Israel;Lithuania;Mexico;New Zealand;Peru;Russian Federation;Spain;Ukraine;United Kingdom;
EBIXA   
   AZ. OSPEDALIERA GARIBALDI, S.LUIGI CURRO , ASCOLI TOMASELLI
      2007   -   EUCTR2007-000503-15-IT   Italy;
   HOSPICES CIVILS DE LYON
      2015   Phase 2   EUCTR2014-005548-17-FR   France;
   OSPEDALE S. RAFFAELE
      2008   Phase 2   EUCTR2008-000490-37-IT   Italy;
ECP002A   
   Echo Pharmaceuticals B.V.
      2011   -   EUCTR2010-022033-28-NL   Netherlands;
EGb 761® (Tanakan®)   
   Ipsen
      2003   Phase 3   NCT00276341   France;
EHP-101 25 mg BID   
   Emerald Health Pharmaceuticals
      2021   Phase 2   NCT04909502   -
EHP-101 25 mg OD   
   Emerald Health Pharmaceuticals
      2021   Phase 2   NCT04909502   -
EHP-101 50 mg BID   
   Emerald Health Pharmaceuticals
      2021   Phase 2   NCT04909502   -
EHP-101 50 mg OD   
   Emerald Health Pharmaceuticals
      2021   Phase 2   NCT04909502   -
EK-12   
   Bosnalijek D.D
      2019   Phase 3   NCT03283397   Turkey;
ELND002   
   Elan Pharmaceuticals
      2010   Phase 1   NCT01318421   -
      2010   Phase 1   NCT01144351   Canada;United States;
EMD 28162   
   Academic MS Center Limburg
      -   Phase 2   EUCTR2014-000728-97-NL   Netherlands;
   Merck Serono
      2011   -   EUCTR2010-020328-23-EE   Austria;Belgium;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;Netherlands;Norway;Portugal;Switzerland;
      2011   -   EUCTR2010-020328-23-DE   Austria;Belgium;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;Netherlands;Norway;Portugal;Switzerland;
   Merck Serono SA-Geneva an affiliate of Merck KgaA, Darmstadt
      2011   -   EUCTR2010-020328-23-BE   Austria;Belgium;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;Netherlands;Portugal;
   Merck Serono The Netherlands - a division of Merck B.V.
      2011   -   EUCTR2010-020328-23-NL   Austria;Belgium;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;Netherlands;Portugal;
EMSELEX 15 mg Retardtabletten   
   Bayer Vital GmbH
      2006   -   EUCTR2006-002361-39-DE   Germany;
EMSELEX 7,5 mg Retardtabletten   
   Bayer Vital GmbH
      2006   -   EUCTR2006-002361-39-DE   Germany;
ENA713   
   Novartis Pharma GmbH
      -   -   EUCTR2008-007015-32-DE   Germany;
ENDOXAN BAXTER   
   AZIENDA OSPEDALIERA DI PADOVA
      -   Phase 1   EUCTR2008-005773-35-IT   Italy;
   OSPEDALE S. RAFFAELE
      2007   Phase 2   EUCTR2007-000586-38-IT   Italy;
EPARMEFOLIN 30 CPR 0,1/0,   
   AZIENDA OSPEDALIERA SAN CAMILLO FORLANINI
      2005   -   EUCTR2005-006071-12-IT   Italy;
EPO   
   Sun Yat-sen University
      2006   -   NCT00818103   China;
ESTRADIOL HEMIHYDRATE   
   Irina Elovaara
      2015   -   EUCTR2014-005129-10-FI   Finland;
ETIMS   
   Universitätsklinikum Hamburg-Eppendorf
      2010   Phase 1/Phase 2   NCT01414634   -
ETIMS (EDC-fixed autologous PBMCs coupled with 7 immunodominant myelin peptides in MS patients)   
   University Medical Center Hamburg-Eppendorf
      2009   -   EUCTR2008-004408-29-DE   Germany;
EU/1/08/454/001-002, EU/1/08/454/005-007   
   University Hospital Motol
      2011   Phase 4   EUCTR2011-001956-12-CZ   Czech Republic;
EU/1/95/003/005-010   
   University Hospital Motol
      2011   Phase 4   EUCTR2011-001956-12-CZ   Czech Republic;
EU/1/97/033/002   
   University Hospital Motol
      2011   Phase 4   EUCTR2011-001956-12-CZ   Czech Republic;
EU/1/98/063/001-003   
   University Hospital Motol
      2011   Phase 4   EUCTR2011-001956-12-CZ   Czech Republic;
EU/1/98/063/004-006   
   University Hospital Motol
      2011   Phase 4   EUCTR2011-001956-12-CZ   Czech Republic;
EXTAVIA*SC 15FL 250MCG/ML+15SI   
   AZIENDA OSPEDALIERA S. LUIGI GONZAGA
      2011   -   EUCTR2010-023677-19-IT   Italy;
Early Harvest Extra Virgin Olive Oil   
   Aristotle University Of Thessaloniki
      2018   -   NCT04120675   Greece;
Early Highly Effective Therapies Group   
   The Cleveland Clinic
      2019   Phase 4   NCT03535298   United Kingdom;United States;
Eculizumab   
   Alexion Pharmaceuticals
      2020   Phase 2/Phase 3   NCT04155424   Canada;Germany;Italy;Japan;Korea, Republic of;Spain;United States;
      2015   Phase 3   NCT02003144   Argentina;Australia;Austria;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Italy;Japan;Korea, Republic of;Malaysia;Russian Federation;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2014   Phase 3   NCT01892345   Argentina;Australia;Austria;Canada;Colombia;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Italy;Japan;Korea, Republic of;Malaysia;Russian Federation;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
   Mayo Clinic
      2009   Phase 1/Phase 2   NCT00904826   United States;
Elezanumab   
   AbbVie
      2019   Phase 2   NCT03737812   Canada;United States;
      2018   Phase 2   NCT03737851   Canada;United States;
Encapsulated Baclofen   
   Impax Laboratories, LLC
      2007   Phase 3   NCT00488839   Canada;Estonia;Latvia;Ukraine;United States;
Encapsulated Simvastatin tablets   
   Imperial College London
      2007   Phase 2   EUCTR2006-006347-31-GB   United Kingdom;
Endoxan - ciclofosfamide   
   Dipartimento di Neuroscienze Oftalmologia e Genetica DINOG - Universita di Genova
      2006   -   EUCTR2006-002562-19-IT   Italy;
Enriched Hematopoetic Stem Cell Infusion   
   Talaris Therapeutics Inc.
      2014   -   NCT02084121   United States;
Enspryng   
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 3   EUCTR2021-001088-26-IT   Canada;France;Germany;India;Italy;Korea, Republic of;Turkey;United States;
      2021   Phase 3   EUCTR2020-003413-35-IT   Bulgaria;Canada;Croatia;Georgia;Germany;Hungary;Italy;Japan;Korea, Republic of;Malaysia;Poland;Romania;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   F. Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-003413-35-HU   Bulgaria;Canada;Croatia;Georgia;Germany;Hungary;Italy;Japan;Korea, Republic of;Malaysia;Poland;Romania;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003413-35-BG   Bulgaria;Canada;Croatia;Georgia;Germany;Hungary;Italy;Japan;Korea, Republic of;Malaysia;Poland;Romania;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2020-003413-35-PL   Bulgaria;Canada;Croatia;Georgia;Germany;Hungary;Italy;Japan;Korea, Republic of;Malaysia;Poland;Romania;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Epigallocatechin-gallate (Sunphenon)   
   Charite University, Berlin, Germany
      2007   Phase 1/Phase 2   NCT00525668   Germany;
Epo   
   IFSgGmbH, Institute for clinical research
      2006   -   EUCTR2005-005592-14-DE   Germany;
Epoetin alfa   
   IFSgGmbH, Institute for clinical research
      2006   -   EUCTR2005-005592-14-DE   Germany;
Epoetin beta   
   Walton Centre for Neurology and Neurosurgery
      2008   -   EUCTR2008-005125-11-GB   United Kingdom;
Equal   
   GENEURO SA
      2016   Phase 2   EUCTR2015-004059-29-IT   Bulgaria;Croatia;Czech Republic;Estonia;France;Germany;Hungary;Italy;Poland;Russian Federation;Serbia;Spain;Ukraine;
Erypo/Erypo FS   
   IFSgGmbH, Institute for clinical research
      2006   -   EUCTR2005-005592-14-DE   Germany;
Erythropoietin   
   Rigshospitalet, Denmark
      2009   Phase 2   NCT01144117   Denmark;
Escalation Therapies Group   
   The Cleveland Clinic
      2019   Phase 4   NCT03535298   United Kingdom;United States;
Escitalopram   
   University of South Carolina
      2009   Phase 3   NCT00965497   United States;
Escitalopram oxalate antidepressant   
   Weill Medical College of Cornell University
      2004   Phase 4   NCT00151294   United States;
Esomeprazole   
   Genzyme, a Sanofi Company
      2014   Phase 4   NCT02205489   Belgium;France;Netherlands;Spain;
Essential - hydroxytyrosol   
   University of Iowa
      2010   Phase 1   NCT01381354   United States;
Essential fatty acids   
   National Center for Complementary and Integrative Health (NCCIH)
      1999   Phase 1/Phase 2   NCT00010842   United States;
Estradiol   
   Hospices Civils de Lyon
      2005   Phase 3   NCT00127075   France;
   OSPEDALI CIVILI DI LIONE
      2007   -   EUCTR2006-005460-30-IT   Italy;
Estriol   
   University of California, Los Angeles
      2011   Phase 2   NCT01466114   United States;
      2007   Phase 2   NCT00451204   Canada;United States;
Estroprogestins   
   S. Andrea Hospital
      2002   Phase 2   NCT00151801   Italy;
Eszopiclone   
   University of Vermont
      2006   -   NCT00594087   United States;
Etifoxine   
   Imperial College London
      2018   -   NCT03850301   United Kingdom;
Etoposide   
   Fred Hutchinson Cancer Research Center
      2008   Phase 2   NCT00716066   United States;
Evobrutinib   
   EMD Serono Research & Development Institute, Inc.
      2019   Phase 3   NCT04032171   Germany;United States;
      2019   Phase 3   NCT04032158   Argentina;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czechia;Estonia;France;Georgia;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Montenegro;Poland;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
   MERCK HEALTHCARE KGaA
      2020   Phase 3   EUCTR2019-004980-36-IT   Belarus;Brazil;Bulgaria;Canada;France;Germany;Greece;India;Italy;Kuwait;Latvia;Lithuania;Malaysia;Mexico;Moldova, Republic of;Norway;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;Tunisia;Turkey;Ukraine;United States;
   Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
      2020   Phase 3   NCT04338061   Belarus;Brazil;Bulgaria;Canada;France;Germany;Greece;India;Italy;Latvia;Lithuania;Malaysia;Moldova, Republic of;Norway;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United States;
      2020   Phase 3   NCT04338022   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Colombia;Croatia;Czechia;Estonia;Finland;France;Georgia;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
Exelon transdermales Pflaster   
   Novartis Pharma GmbH
      -   -   EUCTR2008-007015-32-DE   Germany;
Exergame   
   University of Arizona
      2014   -   NCT02777060   United States;
Experimental Glatiramer Acetate   
   Teva Pharmaceutical Industries
      2009   Phase 3   NCT00947752   United States;
Exposure to one or more disease-modifying drug(s)(DMDs) used to treat MS   
   University of British Columbia
      1996   -   NCT04472975   -
Extavia   
   Karolinska Institutet
      2017   Phase 4   EUCTR2017-002634-24-SE   Sweden;
      2017   Phase 4   EUCTR2016-003587-39-SE   Sweden;
   Medizinische Universität Innsbruck
      2014   Phase 4   EUCTR2012-005450-30-AT   Austria;Sweden;
      2014   -   EUCTR2012-005450-30-SE   Austria;Sweden;
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-004505-32-IT   France;Germany;Italy;Spain;
   Novartis Farma S.p.A.
      2012   -   EUCTR2010-023023-19-DE   Germany;Italy;
   Novartis Pharma Services AG
      2012   -   EUCTR2011-001437-16-DE   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
Extavia (interferon beta-1b), Novartis Pharma AG   
   Bayer
      2016   -   NCT02749396   Finland;
Extavia 250 microgram/ml   
   Octapharma AG
      2013   -   EUCTR2012-005086-12-HU   Austria;Bulgaria;Germany;Hungary;Poland;Russian Federation;
      2013   -   EUCTR2012-005086-12-DE   Austria;Bulgaria;Germany;Hungary;Poland;Russian Federation;
      2013   -   EUCTR2012-005086-12-BG   Austria;Bulgaria;Germany;Hungary;Poland;Russian Federation;
      2013   -   EUCTR2012-005086-12-AT   Austria;Bulgaria;Germany;Hungary;Poland;Russian Federation;
Extavia 250 micrograms/ml   
   Biogen Portugal
      2016   Phase 4   EUCTR2016-000434-21-PT   Portugal;
Extavia®   
   Charite Universitaetsmedizin Berlin
      2012   Phase 3   EUCTR2011-004787-30-DE   Germany;
   University Hospital Motol
      2011   Phase 4   EUCTR2011-001956-12-CZ   Czech Republic;
Extended release fampridine   
   Clinique Neuro-Outaouais
      2013   Phase 4   NCT02146534   Canada;
Extended-release oxycodone   
   University of Rochester
      2007   Phase 4   NCT00414453   United States;
Extended-release quetiapine fumarate   
   University of Calgary
      2014   Phase 1/Phase 2   NCT02087631   Canada;
Extracorporeal Photopheresis   
   University of Utah
      2014   -   NCT02296346   United States;
F-18 3F4AP   
   Massachusetts General Hospital
      2021   Phase 1   NCT04699747   United States;
F-18 FEDAA1106 (BAY85-8101)   
   Bayer
      2009   Phase 1   NCT01031199   Australia;Sweden;
FAMPYRA - 10 MG - COMPRESSA A RILASCIO PROLUNGATO - USO ORALE - FLACONE (HDPE) 56 COMPRESSE (4 FLACONI DA 14)   
   IRCCS FONDAZIONE ISTITUTO NEUROLOGICO NAZIONALE C. MONDINO
      2016   Phase 4   EUCTR2014-004650-34-IT   Italy;
FINGOLIMOD HYDROCHLORIDE   
   Biogen Idec Research Limited
      2015   Phase 4   EUCTR2013-004622-29-DK   Australia;Czech Republic;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
      2015   Phase 4   EUCTR2013-004622-29-DE   Australia;Czech Republic;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
      2014   Phase 4   EUCTR2013-004622-29-SE   Australia;Czech Republic;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
      2014   Phase 4   EUCTR2013-004622-29-GB   Australia;Czech Republic;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
      2014   Phase 4   EUCTR2013-004622-29-ES   Australia;Canada;Czech Republic;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
      2014   Phase 4   EUCTR2013-004622-29-CZ   Australia;Czech Republic;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
      2014   -   EUCTR2013-004622-29-IT   Australia;Canada;Czech Republic;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
   NOVARTIS FARMA
      2013   -   EUCTR2012-000835-18-IT   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
   NOVARTIS FARMA S.p.A
      2013   -   EUCTR2012-005507-40-IT   Italy;
   NOVARTIS PHARMA SERVICES AG
      2021   Phase 3   EUCTR2020-002700-39-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Novartis Farma
      2013   -   EUCTR2011-005677-23-IT   Brazil;Canada;Italy;Latvia;Lithuania;Mexico;Spain;United States;Venezuela, Bolivarian Republic of;
   Novartis Farma S.p.A.
      2012   -   EUCTR2010-023023-19-DE   Germany;Italy;
   Novartis Farma SpA
      2014   -   EUCTR2013-002660-17-IT   Canada;Denmark;Finland;France;Germany;Italy;Poland;Portugal;Spain;Switzerland;United Kingdom;
   Novartis Farmaceutica S.A.
      2013   -   EUCTR2011-005677-23-ES   Brazil;Canada;Latvia;Lithuania;Mexico;Spain;United States;Venezuela, Bolivarian Republic of;
   Novartis Pharma GmbH
      -   -   EUCTR2011-001692-39-DE   Germany;
   Novartis Pharma S.A.S
      2011   Phase 4   EUCTR2011-001280-49-FR   France;
   Novartis Pharma Service AG
      2015   Phase 3   EUCTR2011-005677-23-HR   Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Croatia;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2011-005677-23-GB   Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Croatia;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2011-005677-23-EE   Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Croatia;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2014   -   EUCTR2011-005677-23-RO   Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2011-005677-23-DE   Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Croatia;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2011-005677-23-BG   Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Croatia;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
      2013   -   EUCTR2011-005677-23-LV   Austria;Belarus;Brazil;Bulgaria;Canada;Croatia;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
   Novartis Pharma Services AG
      2015   -   EUCTR2013-002660-17-PT   Canada;Denmark;Finland;France;Germany;Italy;Poland;Portugal;Spain;Switzerland;United Kingdom;
      2015   -   EUCTR2013-002660-17-DK   Canada;Denmark;Finland;France;Germany;Italy;Poland;Portugal;Spain;Switzerland;United Kingdom;
      2014   Phase 3   EUCTR2011-005677-23-PL   Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Croatia;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2011-005677-23-NL   Austria;Brazil;Bulgaria;Canada;Croatia;Estonia;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
      2014   Phase 3   EUCTR2011-005677-23-AT   Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Croatia;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2014   -   EUCTR2011-005677-23-SE   Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Croatia;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2011-005677-23-SK   Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Croatia;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2011-005677-23-LT   Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Croatia;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2011-001442-15-SE   Australia;Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Norway;Spain;Sweden;Switzerland;United Kingdom;
      2012   -   EUCTR2011-001437-16-DE   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
      2011   -   EUCTR2011-001442-15-HU   Australia;Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Norway;Spain;Sweden;Switzerland;United Kingdom;
      2011   -   EUCTR2011-001442-15-GR   Austria;Czech Republic;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Spain;Sweden;Switzerland;United Kingdom;
      2011   -   EUCTR2011-001442-15-GB   Australia;Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Norway;Spain;Sweden;Switzerland;United Kingdom;
      2011   -   EUCTR2011-001442-15-FI   Australia;Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Norway;Spain;Sweden;Switzerland;United Kingdom;
      2011   -   EUCTR2011-001442-15-DE   Australia;Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Norway;Spain;Sweden;Switzerland;United Kingdom;
      2011   -   EUCTR2011-001442-15-CZ   Austria;Czech Republic;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Spain;Sweden;Switzerland;United Kingdom;
      2011   -   EUCTR2011-001442-15-AT   Australia;Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Norway;Spain;Sweden;Switzerland;United Kingdom;
   Universitätsklinikum Münster
      2014   -   EUCTR2013-004616-21-DE   Germany;
FISH OIL, RICH IN OMEGA-3-ACIDS   
   PALUPA Medical Ltd
      2016   Phase 3   EUCTR2015-003147-19-GR   Greece;
FISH OIL,RICH IN OMEGA 3 ACIDS   
   PALUPA Medical Ltd
      2016   Phase 3   EUCTR2015-003147-19-GR   Greece;
FLUOXETINE HYDROCHLORIDE   
   Novartis Pharma GmbH
      -   -   EUCTR2011-001692-39-DE   Germany;
FORMISTIN - 10 MG COMPRESSE RIVESTITE CON FILM 20 COMPRESSE   
   NOVARTIS PHARMA AG
      2018   Phase 2   EUCTR2017-004702-17-IT   Austria;Bulgaria;Czech Republic;Czechia;Estonia;Germany;Italy;Latvia;Lithuania;Poland;Russian Federation;Spain;United States;
FTY720   
   NOVARTIS FARMA S.p.A
      2013   -   EUCTR2012-005507-40-IT   Italy;
   NOVARTIS PHARMA SERVICES AG
      2021   Phase 3   EUCTR2020-002700-39-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Novartis
      2010   Phase 3   NCT01127750   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2007   Phase 2   NCT00537082   Japan;
      2003   Phase 2   NCT00333138   Canada;Denmark;Finland;France;Germany;Italy;Poland;Portugal;Spain;Switzerland;United Kingdom;
   Novartis Farma
      2013   -   EUCTR2011-005677-23-IT   Brazil;Canada;Italy;Latvia;Lithuania;Mexico;Spain;United States;Venezuela, Bolivarian Republic of;
   Novartis Farma S.p.A.
      2012   -   EUCTR2010-023023-19-DE   Germany;Italy;
   Novartis Farmaceutica S.A.
      2013   -   EUCTR2012-000835-18-ES   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2011-005677-23-ES   Brazil;Canada;Latvia;Lithuania;Mexico;Spain;United States;Venezuela, Bolivarian Republic of;
   Novartis Farmacéutica S.A
      2008   -   EUCTR2007-002627-32-ES   Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
   Novartis Farmacéutica, S.A.
      2011   -   EUCTR2011-001442-15-ES   Austria;Czech Republic;Finland;France;Germany;Greece;Hungary;Israel;Italy;Spain;Sweden;Switzerland;United Kingdom;
      2010   Phase 3   EUCTR2010-020515-37-ES   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
   Novartis Pharma AG
      2013   -   EUCTR2012-000835-18-BE   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-000835-18-FR   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2010   -   EUCTR2007-002627-32-HU   Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2007-002627-32-DK   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2009   Phase 3   EUCTR2007-002627-32-GB   Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2009   -   EUCTR2007-004122-24-HU   Belgium;Czech Republic;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Netherlands;Slovakia;Sweden;United Kingdom;
      2009   -   EUCTR2007-004122-24-GR   Belgium;Czech Republic;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Netherlands;Slovakia;Sweden;United Kingdom;
      2009   -   EUCTR2007-004122-24-EE   Belgium;Czech Republic;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Netherlands;Slovakia;Sweden;United Kingdom;
      2008   Phase 3   EUCTR2007-002627-32-FR   Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-004122-24-NL   Belgium;Czech Republic;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Netherlands;Slovakia;Sweden;United Kingdom;
      2008   -   EUCTR2007-004122-24-CZ   Belgium;Czech Republic;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Netherlands;Slovakia;Sweden;United Kingdom;
      2008   -   EUCTR2007-004122-24-BE   Belgium;Czech Republic;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Netherlands;Slovakia;Sweden;United Kingdom;
      2008   -   EUCTR2007-002627-32-NL   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2008   -   EUCTR2007-002627-32-FI   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2008   -   EUCTR2007-002627-32-BE   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2007   -   EUCTR2005-000365-19-HU   Czech Republic;Estonia;Finland;Germany;Greece;Hungary;Ireland;Lithuania;Sweden;United Kingdom;
      2006   -   EUCTR2005-000365-19-CZ   Czech Republic;Estonia;Finland;Germany;Greece;Hungary;Ireland;Lithuania;Sweden;United Kingdom;
   Novartis Pharma GmbH
      2012   Phase 4   EUCTR2012-000674-31-DE   Germany;Switzerland;
      2012   Phase 4   EUCTR2012-000653-32-DE   Germany;
      2012   -   EUCTR2012-002637-11-DE   Germany;
      2011   -   EUCTR2011-002969-38-DE   Germany;
   Novartis Pharma S.A.S
      2011   Phase 4   EUCTR2011-001280-49-FR   France;
   Novartis Pharma Service AG
      2015   Phase 3   EUCTR2011-005677-23-HR   Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Croatia;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2011-005677-23-GB   Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Croatia;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2011-005677-23-EE   Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Croatia;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2014   -   EUCTR2011-005677-23-RO   Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2011-005677-23-DE   Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Croatia;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2011-005677-23-BG   Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Croatia;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
      2013   -   EUCTR2011-005677-23-LV   Austria;Belarus;Brazil;Bulgaria;Canada;Croatia;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
   Novartis Pharma Services AG
      2014   Phase 3   EUCTR2012-000835-18-DK   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2011-005677-23-PL   Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Croatia;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2011-005677-23-NL   Austria;Brazil;Bulgaria;Canada;Croatia;Estonia;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
      2014   Phase 3   EUCTR2011-005677-23-AT   Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Croatia;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2014   -   EUCTR2012-000835-18-PL   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2014   -   EUCTR2011-005677-23-SE   Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Croatia;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-000835-18-DE   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2011-005677-23-SK   Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Croatia;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2011-005677-23-LT   Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Croatia;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-000835-18-NL   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2012-000835-18-HU   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2012-000835-18-GB   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2012-000835-18-CZ   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2010-020515-37-NO   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Norway;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2012   -   EUCTR2012-000835-18-SE   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   -   EUCTR2012-000835-18-FI   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020515-37-IE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020515-37-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2011   -   EUCTR2011-001442-15-DE   Australia;Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Norway;Spain;Sweden;Switzerland;United Kingdom;
      2011   -   EUCTR2010-020515-37-DK   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2011   -   EUCTR2010-019029-32-SK   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   Phase 3   EUCTR2010-020515-37-SK   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   Phase 3   EUCTR2010-020515-37-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020515-37-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020515-37-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Comoros;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Korea, Republic of;Malaysia;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2010   Phase 3   EUCTR2010-020515-37-HU   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020515-37-GR   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   Phase 3   EUCTR2010-020515-37-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020515-37-FR   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Norway;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   Phase 3   EUCTR2010-020515-37-FI   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020515-37-EE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020515-37-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020515-37-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Costa Rica;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;Venezuela, Bolivarian Republic of;
      2010   Phase 3   EUCTR2010-020515-37-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2010   Phase 2   EUCTR2010-019029-32-GR   Austria;Belgium;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   Phase 2   EUCTR2010-019029-32-BE   Austria;Belgium;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2010-019029-32-SE   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2010-019029-32-PT   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2010-019029-32-NL   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2010-019029-32-IE   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2010-019029-32-HU   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2010-019029-32-GB   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2010-019029-32-FI   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2010-019029-32-DK   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2010-019029-32-DE   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2010-019029-32-CZ   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2010-019029-32-AT   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2010-019028-30-GB   Finland;France;Spain;United Kingdom;
      2010   -   EUCTR2010-019028-30-FR   Belgium;Finland;France;Spain;United Kingdom;
      2010   -   EUCTR2010-019028-30-FI   Finland;France;Spain;United Kingdom;
      2010   -   EUCTR2010-019028-30-BE   Belgium;Finland;France;Spain;United Kingdom;
      2009   -   EUCTR2008-002096-27-AT   Austria;Lithuania;Poland;United Kingdom;
      2009   -   EUCTR2007-002627-32-CZ   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Poland;Russian Federation;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2008   Phase 3   EUCTR2005-000365-19-GB   Czech Republic;Estonia;Finland;Germany;Greece;Hungary;Ireland;Lithuania;Slovakia;Sweden;United Kingdom;
      2008   -   EUCTR2008-002096-27-PL   Austria;Lithuania;Poland;United Kingdom;
      2008   -   EUCTR2008-002096-27-LT   Austria;Lithuania;Poland;United Kingdom;
      2008   -   EUCTR2008-002096-27-GB   Austria;Lithuania;Poland;United Kingdom;
      2007   -   EUCTR2006-000704-17-HU   Austria;Belgium;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom;
      2007   -   EUCTR2006-000704-17-BE   Austria;Belgium;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom;
      2007   -   EUCTR2005-000365-19-IE   Czech Republic;Estonia;Finland;Germany;Greece;Hungary;Ireland;Lithuania;Sweden;United Kingdom;
      2007   -   EUCTR2005-000365-19-GR   Czech Republic;Estonia;Finland;Germany;Greece;Hungary;Ireland;Lithuania;Sweden;United Kingdom;
      2007   -   EUCTR2005-000365-19-EE   Czech Republic;Estonia;Finland;Germany;Greece;Hungary;Ireland;Lithuania;Sweden;United Kingdom;
      2006   Phase 3   EUCTR2006-000704-17-GR   Austria;Belgium;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom;
      2006   Phase 3   EUCTR2005-000365-19-SK   Czech Republic;Estonia;Finland;Germany;Greece;Hungary;Ireland;Lithuania;Slovakia;Sweden;United Kingdom;
      2006   -   EUCTR2006-000704-17-PT   Austria;Belgium;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom;
      2006   -   EUCTR2006-000704-17-GB   Austria;Belgium;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom;
      2006   -   EUCTR2006-000704-17-DE   Austria;Belgium;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom;
      2006   -   EUCTR2006-000704-17-AT   Austria;Belgium;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom;
      2006   -   EUCTR2005-000365-19-FI   Czech Republic;Estonia;Finland;Germany;Greece;Hungary;Ireland;Lithuania;Sweden;United Kingdom;
      2006   -   EUCTR2005-000365-19-DE   Czech Republic;Estonia;Finland;Germany;Greece;Hungary;Ireland;Lithuania;Sweden;United Kingdom;
      2005   -   EUCTR2005-000365-19-SE   Czech Republic;Estonia;Finland;Germany;Greece;Hungary;Ireland;Lithuania;Sweden;United Kingdom;
      -   -   EUCTR2007-002627-32-DE   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
   Novartis Pharmaceuticals
      2013   Phase 3   NCT01779934   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 4   NCT01585298   Germany;
      2008   Phase 3   NCT00731692   Australia;Belgium;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
   Novartis Services Pharma AG
      2008   -   EUCTR2007-002627-32-SE   Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
   NovartisPharma Services AG
      2007   -   EUCTR2005-000365-19-LT   Czech Republic;Estonia;Finland;Germany;Greece;Hungary;Ireland;Lithuania;Sweden;United Kingdom;
   Universitätsklinikum Münster
      2014   -   EUCTR2013-004616-21-DE   Germany;
FTY720D   
   NOVARTIS FARMA
      2013   -   EUCTR2012-000835-18-IT   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2011   -   EUCTR2011-000770-60-IT   Italy;
      2011   -   EUCTR2010-024017-31-IT   Italy;
      2010   Phase 3   EUCTR2010-020515-37-IT   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Norway;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2010-023023-19-IT   Germany;Italy;
      2010   -   EUCTR2010-019029-32-IT   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-002627-32-IT   Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2006-000704-17-IT   Austria;Belgium;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom;
   Novartis Farma SpA
      2014   -   EUCTR2013-002660-17-IT   Canada;Denmark;Finland;France;Germany;Italy;Poland;Portugal;Spain;Switzerland;United Kingdom;
   Novartis Farmaceutica S.A.
      2013   -   EUCTR2012-000835-18-ES   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
   Novartis Farmacéutica S.A
      2008   -   EUCTR2007-002627-32-ES   Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
   Novartis Farmacéutica, S.A.
      2010   Phase 3   EUCTR2010-020515-37-ES   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
   Novartis Pharma AG
      2013   -   EUCTR2012-000835-18-BE   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-000835-18-FR   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2010   -   EUCTR2007-002627-32-HU   Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2007-002627-32-DK   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2009   Phase 3   EUCTR2007-002627-32-GB   Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2009   -   EUCTR2007-004122-24-HU   Belgium;Czech Republic;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Netherlands;Slovakia;Sweden;United Kingdom;
      2009   -   EUCTR2007-004122-24-GR   Belgium;Czech Republic;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Netherlands;Slovakia;Sweden;United Kingdom;
      2009   -   EUCTR2007-004122-24-FI   Belgium;Czech Republic;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Netherlands;Slovakia;Sweden;United Kingdom;
      2008   Phase 3   EUCTR2007-002627-32-FR   Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-004122-24-NL   Belgium;Czech Republic;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Netherlands;Slovakia;Sweden;United Kingdom;
      2008   -   EUCTR2007-004122-24-FR   Belgium;Czech Republic;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Netherlands;Slovakia;Sweden;United Kingdom;
      2008   -   EUCTR2007-004122-24-CZ   Belgium;Czech Republic;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Netherlands;Slovakia;Sweden;United Kingdom;
      2008   -   EUCTR2007-004122-24-BE   Belgium;Czech Republic;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Netherlands;Slovakia;Sweden;United Kingdom;
      2008   -   EUCTR2007-002627-32-NL   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2008   -   EUCTR2007-002627-32-FI   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2008   -   EUCTR2007-002627-32-BE   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2007   -   EUCTR2005-000365-19-HU   Czech Republic;Estonia;Finland;Germany;Greece;Hungary;Ireland;Lithuania;Sweden;United Kingdom;
      2006   -   EUCTR2005-000365-19-CZ   Czech Republic;Estonia;Finland;Germany;Greece;Hungary;Ireland;Lithuania;Sweden;United Kingdom;
   Novartis Pharma Services AG
      2015   -   EUCTR2013-002660-17-PT   Canada;Denmark;Finland;France;Germany;Italy;Poland;Portugal;Spain;Switzerland;United Kingdom;
      2015   -   EUCTR2013-002660-17-DK   Canada;Denmark;Finland;France;Germany;Italy;Poland;Portugal;Spain;Switzerland;United Kingdom;
      2013   Phase 3   EUCTR2012-000835-18-DE   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2012-000835-18-NL   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2012-000835-18-GB   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2012-000835-18-CZ   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2010-020515-37-NO   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Norway;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2012   -   EUCTR2012-000835-18-SE   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   -   EUCTR2012-000835-18-FI   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020515-37-IE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020515-37-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2011   -   EUCTR2010-020515-37-DK   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2011   -   EUCTR2010-019029-32-SK   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   Phase 3   EUCTR2010-020515-37-SK   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   Phase 3   EUCTR2010-020515-37-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020515-37-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020515-37-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Comoros;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Korea, Republic of;Malaysia;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2010   Phase 3   EUCTR2010-020515-37-HU   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020515-37-GR   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   Phase 3   EUCTR2010-020515-37-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020515-37-FR   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Norway;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   Phase 3   EUCTR2010-020515-37-FI   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020515-37-EE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020515-37-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020515-37-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Costa Rica;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;Venezuela, Bolivarian Republic of;
      2010   Phase 3   EUCTR2010-020515-37-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2010   Phase 2   EUCTR2010-019029-32-GR   Austria;Belgium;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   Phase 2   EUCTR2010-019029-32-BE   Austria;Belgium;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2010-019029-32-SE   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2010-019029-32-PT   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2010-019029-32-NL   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2010-019029-32-IE   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2010-019029-32-HU   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2010-019029-32-GB   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2010-019029-32-FI   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2010-019029-32-DK   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2010-019029-32-DE   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2010-019029-32-CZ   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2010-019029-32-AT   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2010-019028-30-GB   Finland;France;Spain;United Kingdom;
      2010   -   EUCTR2010-019028-30-FR   Belgium;Finland;France;Spain;United Kingdom;
      2010   -   EUCTR2010-019028-30-FI   Finland;France;Spain;United Kingdom;
      2010   -   EUCTR2010-019028-30-BE   Belgium;Finland;France;Spain;United Kingdom;
      2009   -   EUCTR2008-002096-27-AT   Austria;Lithuania;Poland;United Kingdom;
      2009   -   EUCTR2007-002627-32-CZ   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Poland;Russian Federation;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2008   Phase 3   EUCTR2005-000365-19-GB   Czech Republic;Estonia;Finland;Germany;Greece;Hungary;Ireland;Lithuania;Slovakia;Sweden;United Kingdom;
      2008   -   EUCTR2008-002096-27-PL   Austria;Lithuania;Poland;United Kingdom;
      2008   -   EUCTR2008-002096-27-LT   Austria;Lithuania;Poland;United Kingdom;
      2008   -   EUCTR2008-002096-27-GB   Austria;Lithuania;Poland;United Kingdom;
      -   -   EUCTR2007-002627-32-DE   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
   Novartis Services Pharma AG
      2008   -   EUCTR2007-002627-32-SE   Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
Famciclovir   
   Queen Mary University London
      2019   Phase 2   EUCTR2019-000169-19-GB   United Kingdom;
   Queen Mary University of London
      2020   Phase 2   NCT05283551   United Kingdom;
Fampridine   
   Amsterdam University Medical Center
      2022   Phase 3   EUCTR2021-003677-66-NL   Netherlands;
   Biogen
      2015   -   NCT01532154   France;Germany;United Kingdom;United States;
      2014   Phase 3   NCT02219932   Argentina;Bulgaria;Czech Republic;Finland;Germany;Italy;Lithuania;Netherlands;Poland;Russian Federation;Serbia;Switzerland;United Kingdom;United States;
      2012   Phase 4   NCT01480076   Australia;Belgium;Denmark;France;Germany;Italy;Netherlands;Portugal;United Kingdom;United States;
      2012   -   NCT01480063   Argentina;Australia;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Ireland;Israel;Lebanon;Netherlands;Norway;Portugal;Spain;United Arab Emirates;
   Centre Hospitalier Universitaire de Besancon
      2014   Phase 4   NCT02849782   France;
   Cliniques Universitaires Saint-Luc, Neurologie
      2013   -   EUCTR2012-005076-34-BE   Belgium;
   Genesis Pharma CNS & Specialty
      2017   -   NCT03164018   Greece;
   University College Dublin
      2014   Phase 4   NCT02208050   Ireland;
   University of Southern Denmark
      2018   -   NCT03847545   Denmark;
Fampridine SR   
   London Health Sciences Centre
      2012   Phase 2/Phase 3   NCT01667497   Canada;
Fampridine-SR   
   Acorda Therapeutics
      2007   Phase 3   NCT00649792   Canada;United States;
      2007   Phase 3   NCT00483652   Canada;United States;
      2006   Phase 3   NCT00648908   Canada;United States;
      2005   Phase 3   NCT00127530   Canada;United States;
   University of Southern Denmark
      2012   Phase 4   NCT01656148   Denmark;
Fampridine-SR b.i.d. (Twice Daily)   
   Acorda Therapeutics
      2003   Phase 3   NCT00654927   Canada;United States;
Fampyra   
   BIOGEN IDEC RESEARCH LTD
      2012   -   EUCTR2012-000368-90-IT   Belgium;Canada;Italy;Netherlands;Switzerland;United Kingdom;
      2012   -   EUCTR2011-003507-38-IT   Australia;Denmark;Italy;Netherlands;Portugal;United Kingdom;
   Biogen Idec Research Limited
      2015   Phase 3   EUCTR2013-003600-40-NL   Bulgaria;Czech Republic;Finland;Italy;Lithuania;Netherlands;Poland;Russian Federation;Serbia;Switzerland;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-003600-40-GB   Bulgaria;Czech Republic;Finland;Italy;Lithuania;Netherlands;Poland;Russian Federation;Serbia;Switzerland;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-003600-40-CZ   Bulgaria;Czech Republic;Finland;Italy;Lithuania;Netherlands;Poland;Russian Federation;Serbia;Switzerland;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-003600-40-BG   Bulgaria;Czech Republic;Finland;Italy;Lithuania;Netherlands;Poland;Russian Federation;Serbia;Switzerland;United Kingdom;United States;
      2014   -   EUCTR2013-003600-40-LT   Bulgaria;Czech Republic;Finland;Italy;Lithuania;Netherlands;Poland;Russian Federation;Serbia;Switzerland;United Kingdom;United States;
      2014   -   EUCTR2013-003600-40-IT   Bulgaria;Czech Republic;Finland;Italy;Lithuania;Netherlands;Poland;Russian Federation;Serbia;Switzerland;United Kingdom;United States;
      2014   -   EUCTR2013-003600-40-FI   Bulgaria;Czech Republic;Finland;Italy;Lithuania;Netherlands;Poland;Russian Federation;Serbia;Switzerland;United Kingdom;United States;
      2012   Phase 4   EUCTR2011-003507-38-GB   Australia;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Sweden;United Kingdom;
      2012   Phase 4   EUCTR2011-003507-38-BE   Australia;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Sweden;United Kingdom;
      2012   Phase 2   EUCTR2012-000368-90-BE   Belgium;Canada;Italy;Netherlands;Sweden;United Kingdom;
      2012   -   EUCTR2012-000368-90-NL   Belgium;Canada;Italy;Netherlands;Sweden;United Kingdom;
      2012   -   EUCTR2012-000368-90-GB   Belgium;Canada;Italy;Netherlands;Sweden;United Kingdom;
      2012   -   EUCTR2011-003507-38-PT   Australia;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Sweden;United Kingdom;
      2012   -   EUCTR2011-003507-38-NL   Australia;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Sweden;United Kingdom;
      2012   -   EUCTR2011-003507-38-DK   Australia;Belgium;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Sweden;United Kingdom;
   Cliniques Universitaires Saint-Luc, Neurologie
      2013   -   EUCTR2012-005076-34-BE   Belgium;
   Medical University of Vienna
      2015   -   EUCTR2014-003498-41-AT   Austria;
   Odense University Hospital
      2013   Phase 4   EUCTR2013-001409-10-DK   Denmark;
   St. Vincent's University Hospital
      2012   Phase 4   EUCTR2011-002561-38-IE   Ireland;
   Sønderjylland Hospital, department of neurology
      2013   Phase 4   EUCTR2011-002959-34-DK   Denmark;
      2012   -   EUCTR2011-006151-10-DK   Denmark;
   Vestre Viken Hospital Trust
      2012   -   NCT01720849   Norway;
Fampyra 10 mg prolonged-release tablets   
   Amsterdam University Medical Center
      2022   Phase 3   EUCTR2021-003677-66-NL   Netherlands;
   CHDR
      2015   -   EUCTR2015-000182-31-NL   Netherlands;
Fampyra 10mg prolonged release tablets   
   Walton Centre Foundation Trust
      2013   Phase 4   EUCTR2013-000529-30-GB   United Kingdom;
Fatigue   
   University Hospital, Strasbourg, France
      2019   Phase 2   NCT03910738   France;
Febuxostat   
   Tsukuba International Clinical Pharmacology Clinic
      2016   -   JPRN-UMIN000024312   Japan;
Fecal Microbial Transplants   
   Lawson Health Research Institute
      2020   Phase 2   NCT04150549   -
Fecal Microbiota Transplantation (FMT) of FMP30 Donor Stool   
   Jeffrey Gelfand
      2018   Phase 1   NCT03594487   United States;
Fecal microbial transplant (FMT)   
   Griffin Hospital
      2019   Early Phase 1   NCT04096443   United States;
Fecal microbiota   
   Lawson Health Research Institute
      2017   Phase 2   NCT03183869   Canada;
Femoston 1/10   
   Irina Elovaara
      2015   -   EUCTR2014-005129-10-FI   Finland;
Femoston 2/10   
   Irina Elovaara
      2015   -   EUCTR2014-005129-10-FI   Finland;
Fenebrutinib   
   Hoffmann-La Roche
      2022   Phase 2   NCT05119569   -
      2021   Phase 3   NCT04586023   Austria;Brazil;Bulgaria;Canada;Denmark;France;Greece;Guatemala;India;Italy;Korea, Republic of;Mexico;Poland;Russian Federation;Turkey;United Kingdom;United States;
      2021   Phase 3   NCT04586010   Argentina;China;Finland;Germany;Hong Kong;Hungary;Italy;Netherlands;Peru;Portugal;Russian Federation;Spain;Switzerland;Taiwan;Ukraine;United States;
      2020   Phase 3   NCT04544449   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Puerto Rico;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
Feraheme   
   Stanford University
      2014   -   NCT01973517   United States;
Ferumoxytol   
   National Institute of Neurological Disorders and Stroke (NINDS)
      2015   Phase 1   NCT02511028   United States;
Fexofenadine   
   Rigshospitalet, Denmark
      2021   Phase 3   NCT04688788   Denmark;
Filgrastim   
   Fred Hutchinson Cancer Research Center
      1997   Phase 1   NCT00014755   United States;
   Northwestern Memorial Hospital
      2001   Phase 1   NCT00017628   United States;
   OSPEDALE S. RAFFAELE
      2007   Phase 2   EUCTR2007-000586-38-IT   Italy;
   Sheffield Teaching Hospitals
      2020   Phase 3   EUCTR2019-001549-42-GB   United Kingdom;
Fingolimob   
   NOVARTIS PHARMA SERVICES AG
      2021   Phase 3   EUCTR2020-002700-39-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Fingolimob (FTY)   
   University Hospital, Clermont-Ferrand
      2016   Phase 4   NCT02769689   France;
Fingolimod   
   Biogen
      2014   Phase 4   NCT02342704   Australia;Czech Republic;Czechia;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
   FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
      2016   Phase 4   EUCTR2016-000708-26-IT   Italy;
   Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
      2017   Phase 4   NCT03345940   Italy;
   Heinrich-Heine University, Duesseldorf
      2013   Phase 4   NCT01755871   Germany;
   Hoffmann-La Roche
      2022   Phase 3   NCT05123703   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Germany;Greece;Hungary;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
   Isfahan University of Medical Sciences
      2015   Phase 2/Phase 3   NCT02939079   -
   Mitsubishi Tanabe Pharma Corporation
      2014   Phase 1   NCT02193217   United Kingdom;
   NOVARTIS FARMA
      2011   -   EUCTR2011-000770-60-IT   Italy;
      2010   Phase 3   EUCTR2010-020515-37-IT   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Norway;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2010-019029-32-IT   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-002627-32-IT   Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2006-000704-17-IT   Austria;Belgium;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom;
   Northwestern University
      2013   Phase 2   EUCTR2012-004165-41-GB   United Kingdom;United States;
   Novartis
      2011   -   NCT01281657   Canada;United States;
      2010   Phase 3   NCT01199861   Austria;Belgium;Canada;Finland;France;Guatemala;Poland;Spain;Switzerland;United Kingdom;
      2008   Phase 3   NCT00662649   Australia;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Sweden;Switzerland;Turkey;United Kingdom;
      2008   Phase 2   NCT00670449   Japan;
      2006   Phase 3   NCT00355134   Australia;Austria;Canada;Lithuania;Poland;Romania;Turkey;United Kingdom;United States;
      2006   Phase 3   NCT00340834   Argentina;Australia;Austria;Belgium;Brazil;Canada;Egypt;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Portugal;Puerto Rico;Spain;Switzerland;United Kingdom;United States;
      2006   Phase 3   NCT00289978   Australia;Belgium;Canada;Czech Republic;Finland;France;Germany;Greece;Israel;Italy;Lithuania;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Sweden;Switzerland;Turkey;United Kingdom;
   Novartis Farmaceutica S.A.
      2013   -   EUCTR2012-000835-18-ES   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
   Novartis Farmacéutica S.A
      2008   -   EUCTR2007-002627-32-ES   Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
   Novartis Farmacéutica S.A.
      2011   Phase 3   EUCTR2011-003484-30-ES   Australia;Spain;
   Novartis Farmacéutica, S.A.
      2010   Phase 3   EUCTR2010-020515-37-ES   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
   Novartis Pharma AG
      2013   -   EUCTR2012-000835-18-BE   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-000835-18-FR   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2010   -   EUCTR2007-002627-32-HU   Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2007-002627-32-DK   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2009   Phase 3   EUCTR2007-002627-32-GB   Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2009   -   EUCTR2007-004122-24-IE   Belgium;Czech Republic;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Netherlands;Slovakia;Sweden;United Kingdom;
      2009   -   EUCTR2007-004122-24-EE   Belgium;Czech Republic;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Netherlands;Slovakia;Sweden;United Kingdom;
      2008   Phase 3   EUCTR2007-002627-32-FR   Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-002627-32-NL   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2008   -   EUCTR2007-002627-32-FI   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2008   -   EUCTR2007-002627-32-BE   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2007   -   EUCTR2005-000365-19-HU   Czech Republic;Estonia;Finland;Germany;Greece;Hungary;Ireland;Lithuania;Sweden;United Kingdom;
      2006   -   EUCTR2005-000365-19-CZ   Czech Republic;Estonia;Finland;Germany;Greece;Hungary;Ireland;Lithuania;Sweden;United Kingdom;
   Novartis Pharma GmbH
      2011   Phase 3   EUCTR2010-022066-28-DE   Germany;
   Novartis Pharma K.K.
      2019   -   JPRN-JapicCTI-194838   Japan;
   Novartis Pharma Services AG
      2014   Phase 3   EUCTR2012-000835-18-DK   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-000835-18-DE   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2012-000835-18-NL   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2012-000835-18-HU   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2012-000835-18-GB   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2012-000835-18-CZ   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2010-020515-37-NO   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Norway;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2012   -   EUCTR2012-000835-18-SE   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   -   EUCTR2012-000835-18-FI   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020515-37-IE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020515-37-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2011   -   EUCTR2010-020515-37-DK   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2010   Phase 3   EUCTR2010-020515-37-SK   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   Phase 3   EUCTR2010-020515-37-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020515-37-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020515-37-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Comoros;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Korea, Republic of;Malaysia;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2010   Phase 3   EUCTR2010-020515-37-HU   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020515-37-GR   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   Phase 3   EUCTR2010-020515-37-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020515-37-FR   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Norway;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   Phase 3   EUCTR2010-020515-37-FI   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020515-37-EE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020515-37-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020515-37-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Costa Rica;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;Venezuela, Bolivarian Republic of;
      2010   Phase 3   EUCTR2010-020515-37-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2010   -   EUCTR2010-019028-30-GB   Finland;France;Spain;United Kingdom;
      2010   -   EUCTR2010-019028-30-FR   Belgium;Finland;France;Spain;United Kingdom;
      2010   -   EUCTR2010-019028-30-FI   Finland;France;Spain;United Kingdom;
      2010   -   EUCTR2010-019028-30-BE   Belgium;Finland;France;Spain;United Kingdom;
      2009   -   EUCTR2008-002096-27-AT   Austria;Lithuania;Poland;United Kingdom;
      2009   -   EUCTR2007-002627-32-CZ   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Poland;Russian Federation;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2008   Phase 3   EUCTR2005-000365-19-GB   Czech Republic;Estonia;Finland;Germany;Greece;Hungary;Ireland;Lithuania;Slovakia;Sweden;United Kingdom;
      2008   -   EUCTR2008-002096-27-PL   Austria;Lithuania;Poland;United Kingdom;
      2008   -   EUCTR2008-002096-27-LT   Austria;Lithuania;Poland;United Kingdom;
      2008   -   EUCTR2008-002096-27-GB   Austria;Lithuania;Poland;United Kingdom;
      2007   -   EUCTR2006-000704-17-HU   Austria;Belgium;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom;
      2007   -   EUCTR2006-000704-17-BE   Austria;Belgium;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom;
      2006   Phase 3   EUCTR2006-000704-17-GR   Austria;Belgium;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom;
      2006   Phase 3   EUCTR2005-000365-19-SK   Czech Republic;Estonia;Finland;Germany;Greece;Hungary;Ireland;Lithuania;Slovakia;Sweden;United Kingdom;
      2006   -   EUCTR2006-000704-17-PT   Austria;Belgium;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom;
      2006   -   EUCTR2006-000704-17-GB   Austria;Belgium;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom;
      2006   -   EUCTR2006-000704-17-DE   Austria;Belgium;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom;
      2006   -   EUCTR2006-000704-17-AT   Austria;Belgium;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom;
      -   -   EUCTR2007-002627-32-DE   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
   Novartis Pharmaceuticals
      2021   Phase 4   NCT04667949   China;
      2021   Phase 3   NCT04926818   Australia;Austria;Belgium;France;Germany;India;Latvia;Mexico;Poland;Portugal;Russian Federation;Slovakia;Spain;Turkey;United States;
      2020   Phase 4   NCT04480853   Taiwan;
      2020   -   NCT05141669   United States;
      2017   Phase 4   NCT03257358   United States;
      2016   Phase 4   NCT02720107   Germany;
      2015   Phase 4   NCT02373098   Turkey;
      2014   Phase 4   NCT02232061   Belgium;Germany;Italy;
      2014   Phase 3   NCT01941004   -
      2013   Phase 4   NCT01621269   Germany;
      2013   Phase 3   NCT01892722   Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2012   Phase 4   NCT01705236   Germany;Switzerland;
      2012   Phase 4   NCT01623596   Puerto Rico;United States;
      2012   Phase 4   NCT01578330   Turkey;
      2012   Phase 4   NCT01534182   Russian Federation;
      2012   Phase 3   NCT01633112   Argentina;Brazil;Canada;Chile;Mexico;Puerto Rico;United States;
      2012   Phase 3   NCT01497262   Argentina;Brazil;Colombia;Costa Rica;Jordan;Malaysia;Mexico;Panama;Peru;
      2011   Phase 4   NCT01436643   Germany;
      2011   Phase 4   NCT01420055   France;
      2011   Phase 4   NCT01333501   Germany;Italy;
      2011   Phase 4   NCT01317004   Italy;
      2011   Phase 4   NCT01310166   Germany;
      2011   Phase 3   NCT01499667   Australia;Austria;Czech Republic;Finland;Germany;Greece;Hungary;Israel;Italy;Spain;Switzerland;
      2011   -   NCT01442194   Argentina;Australia;Canada;Chile;Mexico;Puerto Rico;United States;
      2011   -   NCT01285479   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Cyprus;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Lebanon;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Slovakia;Slovenia;Spain;Sweden;Switzerland;United Arab Emirates;United Kingdom;United States;
      2010   Phase 4   NCT01216072   Canada;Puerto Rico;United States;
      2010   Phase 3   NCT01201356   Argentina;Australia;Austria;Belgium;Brazil;Canada;Costa Rica;Czech Republic;Czechia;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
   Novartis Services Pharma AG
      2008   -   EUCTR2007-002627-32-SE   Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
   University Hospital Muenster
      2014   Phase 4   NCT02325440   Germany;
   Università Popolare Homo & Natura
      2015   Phase 1   NCT02632591   Italy;
   VU University Medical Center
      2014   -   EUCTR2014-001012-19-NL   Netherlands;
Fingolimod (FTY720)   
   Novartis Pharmaceuticals
      2011   Phase 4   NCT01498887   Australia;Spain;
Fingolimod Hydrochloride   
   Novartis Pharma GmbH
      2012   Phase 4   EUCTR2012-000674-31-DE   Germany;Switzerland;
      2012   Phase 4   EUCTR2012-000653-32-DE   Germany;
      2012   -   EUCTR2012-002637-11-DE   Germany;
      2011   -   EUCTR2011-002969-38-DE   Germany;
Fingolimod hydrochloride   
   Novartis Pharma AG
      2009   -   EUCTR2007-004122-24-HU   Belgium;Czech Republic;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Netherlands;Slovakia;Sweden;United Kingdom;
      2009   -   EUCTR2007-004122-24-GR   Belgium;Czech Republic;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Netherlands;Slovakia;Sweden;United Kingdom;
      2009   -   EUCTR2007-004122-24-FI   Belgium;Czech Republic;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Netherlands;Slovakia;Sweden;United Kingdom;
      2008   -   EUCTR2007-004122-24-SE   Belgium;Czech Republic;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Netherlands;Slovakia;Sweden;United Kingdom;
      2008   -   EUCTR2007-004122-24-NL   Belgium;Czech Republic;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Netherlands;Slovakia;Sweden;United Kingdom;
      2008   -   EUCTR2007-004122-24-GB   Belgium;Czech Republic;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Netherlands;Slovakia;Sweden;United Kingdom;
      2008   -   EUCTR2007-004122-24-FR   Belgium;Czech Republic;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Netherlands;Slovakia;Sweden;United Kingdom;
      2008   -   EUCTR2007-004122-24-CZ   Belgium;Czech Republic;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Netherlands;Slovakia;Sweden;United Kingdom;
      2008   -   EUCTR2007-004122-24-BE   Belgium;Czech Republic;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Netherlands;Slovakia;Sweden;United Kingdom;
   Novartis Pharma Services AG
      2014   -   EUCTR2012-000835-18-PL   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2011   -   EUCTR2010-019029-32-SK   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   Phase 2   EUCTR2010-019029-32-GR   Austria;Belgium;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   Phase 2   EUCTR2010-019029-32-BE   Austria;Belgium;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2010-019029-32-SE   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2010-019029-32-PT   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2010-019029-32-NL   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2010-019029-32-IE   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2010-019029-32-HU   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2010-019029-32-GB   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2010-019029-32-FI   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2010-019029-32-DK   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2010-019029-32-DE   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2010-019029-32-CZ   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2010-019029-32-AT   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-004122-24-SK   Belgium;Czech Republic;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Netherlands;Slovakia;Sweden;United Kingdom;
      2008   -   EUCTR2007-004122-24-DE   Belgium;Czech Republic;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Netherlands;Slovakia;Sweden;United Kingdom;
Fingolimodi   
   Turku University Hospital
      2014   Phase 4   EUCTR2014-000296-12-FI   Finland;
      2013   Phase 4   EUCTR2013-004626-28-FI   Finland;
Fingolmod   
   Novartis Farma SpA
      2014   -   EUCTR2013-002660-17-IT   Canada;Denmark;Finland;France;Germany;Italy;Poland;Portugal;Spain;Switzerland;United Kingdom;
   Novartis Pharma Services AG
      2015   -   EUCTR2013-002660-17-PT   Canada;Denmark;Finland;France;Germany;Italy;Poland;Portugal;Spain;Switzerland;United Kingdom;
      2015   -   EUCTR2013-002660-17-DK   Canada;Denmark;Finland;France;Germany;Italy;Poland;Portugal;Spain;Switzerland;United Kingdom;
Firategrast   
   GlaxoSmithKline
      2007   Phase 2   NCT00469378   Belgium;Czech Republic;Denmark;Norway;Sweden;
      2006   Phase 2   NCT00395317   Australia;Austria;Canada;Finland;France;Germany;Italy;Lithuania;Netherlands;New Zealand;Norway;Poland;Russian Federation;Spain;United Kingdom;
Firategrast (USAN approved name)   
   GlaxoSmithKline Research & Development Ltd
      2007   Phase 2   EUCTR2006-007057-42-CZ   Belgium;Czech Republic;Denmark;Sweden;
      2007   Phase 2   EUCTR2006-002633-20-GB   Austria;Finland;France;Germany;Italy;Lithuania;Netherlands;Spain;United Kingdom;
      2007   Phase 2   EUCTR2006-002633-20-FR   Austria;Finland;France;Germany;Italy;Lithuania;Netherlands;Spain;United Kingdom;
      2007   -   EUCTR2006-007057-42-SE   Czech Republic;Denmark;Sweden;
      2007   -   EUCTR2006-007057-42-DK   Czech Republic;Denmark;Sweden;
      2007   -   EUCTR2006-007057-42-BE   Belgium;Czech Republic;Denmark;Sweden;
      2007   -   EUCTR2006-002633-20-LT   Austria;Finland;France;Germany;Italy;Lithuania;Netherlands;Spain;United Kingdom;
      2007   -   EUCTR2006-002633-20-IT   Austria;Finland;France;Germany;Italy;Lithuania;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2006-002633-20-NL   Austria;Finland;France;Germany;Italy;Lithuania;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2006-002633-20-FI   Austria;Finland;France;Germany;Italy;Lithuania;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2006-002633-20-DE   Austria;Finland;France;Germany;Italy;Lithuania;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2006-002633-20-AT   Austria;Finland;France;Germany;Italy;Lithuania;Netherlands;Spain;United Kingdom;
   GlaxoSmithKline S.A
      2006   Phase 2   EUCTR2006-002633-20-ES   Australia;Austria;Canada;Finland;France;Germany;Italy;Lithuania;Netherlands;New Zealand;Norway;Poland;Russian Federation;Spain;United Kingdom;
Firategrast gastro-retentive solution   
   GlaxoSmithKline
      2011   Phase 1   NCT01416363   Australia;
Firategrast immediate release tablet   
   GlaxoSmithKline
      2011   Phase 1   NCT01416363   Australia;
Firategrast modified release tablet   
   GlaxoSmithKline
      2011   Phase 1   NCT01416363   Australia;
First line DMT   
   Novartis Pharmaceuticals
      2021   Phase 3   NCT04788615   France;Germany;Spain;United Kingdom;
Fish oil concentrate   
   Oregon Health and Science University
      2005   Phase 1/Phase 2   NCT00122954   United States;
Fludarabine   
   AZIENDA OSPEDALIERA DI PADOVA
      -   Phase 1   EUCTR2008-005773-35-IT   Italy;
   Hadassah Medical Organization
      2015   -   NCT02529839   -
   Seah Lim M.D.
      2012   Phase 2   NCT01679041   United States;
Flumazenil   
   Institut National de la Santé Et de la Recherche Médicale, France
      2019   -   NCT03825601   -
   Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
      2013   -   JPRN-UMIN000011111   Japan;
Fluoxetin Hexal   
   Novartis Pharma GmbH
      -   -   EUCTR2011-001692-39-DE   Germany;
Fluoxetine   
   Novartis Pharmaceuticals
      2011   Phase 4   NCT01436643   Germany;
   University College, London
      2014   Phase 2   NCT01910259   United Kingdom;
Fluoxetine hydrochloride   
   UCL
      2014   Phase 2   EUCTR2012-005394-31-GB   United Kingdom;
Flupirtin   
   Charité-Universitätsmedizin Berlin
      2007   Phase 2   EUCTR2006-005262-39-DE   Germany;
Flupirtine   
   Charite University, Berlin, Germany
      2007   Phase 2   NCT00623415   Germany;
Flupirtinmaleat   
   Charité-Universitätsmedizin Berlin
      2007   Phase 2   EUCTR2006-005262-39-DE   Germany;
FolateScan (Technetium Tc 99mEC20)   
   Mayo Clinic
      2006   Phase 2   NCT00588393   United States;
Formulation A   
   GlaxoSmithKline
      2007   Phase 1   NCT00548769   Czech Republic;Czechia;Germany;Poland;
Formulation B   
   GlaxoSmithKline
      2007   Phase 1   NCT00548769   Czech Republic;Czechia;Germany;Poland;
Formulation C   
   GlaxoSmithKline
      2007   Phase 1   NCT00548769   Czech Republic;Czechia;Germany;Poland;
Formulation D   
   GlaxoSmithKline
      2007   Phase 1   NCT00548769   Czech Republic;Czechia;Germany;Poland;
Four-point cane (FPC)   
   Rowan University
      2014   -   NCT02227524   United States;
Fourier Domain Doppler Optical Coherence Tomography (FDOCT)   
   Medical University of Vienna
      2018   -   NCT03401879   Austria;
Full Spectrum vitamin   
   University of Iowa
      2010   Phase 1   NCT01381354   United States;
Fully humanized anti-human IL-6 receptor (IL-6R) neutralizing monoclonal antibody   
   Chugai Pharmaceutical Co. Ltd
      2015   Phase 3   EUCTR2013-003752-21-HU   France;Germany;Hungary;Italy;Japan;Poland;Spain;Taiwan;United Kingdom;United States;
      2015   -   EUCTR2013-003752-21-ES   France;Germany;Hungary;Italy;Japan;Poland;Spain;Taiwan;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-003752-21-IT   France;Germany;Hungary;Italy;Japan;Poland;Spain;Taiwan;United Kingdom;
G-CSF   
   Northwestern University
      2019   Phase 2/Phase 3   NCT03829566   United States;
      2017   Phase 3   NCT03342638   United States;
G2-SFM (IFN-beta-1a from clone 484-39,FBS-free process)   
   Serono International SA
      2005   Phase 3   EUCTR2004-003799-13-GB   Denmark;Ireland;Lithuania;Spain;Sweden;United Kingdom;
      2005   Phase 3   EUCTR2004-003799-13-ES   Denmark;Ireland;Lithuania;Spain;Sweden;United Kingdom;
      2005   Phase 3   EUCTR2004-003799-13-DK   Denmark;Ireland;Lithuania;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-003799-13-SE   Ireland;Lithuania;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-003799-13-LT   Ireland;Lithuania;Spain;Sweden;United Kingdom;
      -   Phase 3   EUCTR2004-003799-13-IE   Denmark;Ireland;Lithuania;Spain;Sweden;United Kingdom;
GA   
   TEVA
      2004   -   EUCTR2004-000463-94-IT   Hungary;Italy;
      2004   -   EUCTR2004-000462-13-IT   Hungary;Italy;
   Teva Pharmaceutical Industries Ltd.
      2010   Phase 3   EUCTR2009-018084-27-IT   Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;United Kingdom;
   Teva Pharmaceutical Industries, Ltd.
      2010   Phase 3   EUCTR2009-018084-27-LT   Bulgaria;Croatia;Czech Republic;Estonia;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Poland;Romania;Russian Federation;South Africa;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2009-018084-27-HU   Bulgaria;Croatia;Czech Republic;Estonia;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Poland;Romania;Russian Federation;South Africa;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2009-018084-27-GB   Bulgaria;Croatia;Czech Republic;Estonia;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Poland;Romania;Russian Federation;South Africa;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2009-018084-27-EE   Bulgaria;Croatia;Czech Republic;Estonia;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Poland;Romania;Russian Federation;South Africa;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2009-018084-27-DE   Bulgaria;Croatia;Czech Republic;Estonia;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Poland;Romania;Russian Federation;South Africa;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2009-018084-27-CZ   Bulgaria;Croatia;Czech Republic;Estonia;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Poland;Romania;Russian Federation;South Africa;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2009-018084-27-BG   Bulgaria;Croatia;Czech Republic;Estonia;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Poland;Romania;Russian Federation;South Africa;Ukraine;United Kingdom;United States;
      2007   -   EUCTR2006-002037-20-EE   Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2006   Phase 3   EUCTR2006-002037-20-FI   Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2006   Phase 3   EUCTR2006-002037-20-ES   Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2006   -   EUCTR2006-002037-20-LV   Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2006   -   EUCTR2006-002037-20-LT   Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2006   -   EUCTR2006-002037-20-HU   Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2006   -   EUCTR2006-002037-20-GB   Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2006   -   EUCTR2006-002037-20-DE   Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2006   -   EUCTR2006-002037-20-CZ   Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2006   -   EUCTR2006-002037-20-BE   Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Spain;United Kingdom;
   Teva Pharmaceuticals Industries Ltd.
      2006   -   EUCTR2006-002037-20-IT   Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Spain;United Kingdom;
GA 20 mg/mL   
   Teva Pharmaceutical Industries
      2013   Phase 3   NCT01874145   United States;
GA 40 mg/mL   
   Teva Pharmaceutical Industries
      2013   Phase 3   NCT01874145   United States;
GA Depot   
   Mapi Pharma Ltd.
      2019   Phase 3   NCT04121221   Belarus;Bosnia and Herzegovina;Bulgaria;Estonia;Georgia;Israel;Moldova, Republic of;Russian Federation;Ukraine;United States;
      2019   Phase 3   EUCTR2018-000284-93-EE   Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;Estonia;Georgia;Israel;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Montenegro;Poland;Romania;Russian Federation;Serbia;Ukraine;United States;
      2019   Phase 3   EUCTR2018-000284-93-BG   Belarus;Bosnia and Herzegovina;Bulgaria;Estonia;Georgia;Israel;Moldova, Republic of;Montenegro;Russian Federation;Ukraine;United States;
      2014   Phase 1/Phase 2   NCT02212886   Israel;
GA Depot 25mg once monthly   
   Mapi Pharma Ltd.
      2017   Phase 2   NCT03362294   Israel;Moldova, Republic of;
GA Depot 40mg once monthly   
   Mapi Pharma Ltd.
      2017   Phase 2   NCT03362294   Israel;Moldova, Republic of;
GADOVIST 1 mmol/ml solución inyectable en jeringa precargada/ cartucho precargado   
   Institut Diagnostic per la Imatge
      2010   -   EUCTR2009-016140-39-ES   Spain;
GBP   
   Charité University Medicine Berlin
      2010   Phase 4   EUCTR2008-005167-33-DE   Germany;
GDC-0853   
   F. Hoffmann-La Roche Ltd
      2022   Phase 2   EUCTR2021-003772-14-HR   Croatia;Czechia;Egypt;Japan;Kenya;Morocco;Norway;Serbia;Slovakia;Slovenia;
GDC-0853 RO7010939   
   F. Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2019-003919-53-PT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-003919-53-HU   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-003919-53-GR   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-003919-53-DK   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-003919-53-DE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-003919-53-BG   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-003919-53-AT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-003919-53-GB   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
GILENYA   
   CHU de Rennes
      2018   Phase 3   EUCTR2018-001292-21-FR   France;
GILENYA - 0.25 MG - CAPSULE RIGIDE - USO ORALE   
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 3   EUCTR2020-004128-41-IT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
GILENYA - 0.5 MG - CAPSULE RIGIDE - USO ORALE   
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 3   EUCTR2020-004128-41-IT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
GILENYA - 0.5 MG - CAPSULE RIGIDE - USO ORALE - BLISTER DIVISIBILE PER DOSE UNITARIA(PVC/PVDC/ALU) SCATOLA DA 7X1 CAPSULE   
   FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
      2017   Phase 4   EUCTR2017-000559-26-IT   Israel;Italy;Switzerland;United States;
GILENYA - 0.5 MG - CAPSULE RIGIDE - USO ORALE - BLISTER(PVC/PVDC/ALU) SCATOLA DA 28 CAPSULE   
   FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
      2016   Phase 4   EUCTR2016-000708-26-IT   Italy;
GLATIRAMER ACETATE   
   Amphia Ziekenhuis
      2009   -   EUCTR2009-013129-41-NL   Netherlands;
   Biogen Idec
      2010   -   EUCTR2009-017490-38-DE   Germany;Spain;
   Biogen Idec Limited
      2010   -   EUCTR2009-015556-15-SI   Austria;Canada;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;United States;
      2010   -   EUCTR2009-015556-15-SE   Austria;Canada;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;United States;
      2010   -   EUCTR2009-015556-15-PT   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015556-15-NL   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015556-15-LV   Austria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Italy;Latvia;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;United States;
      2010   -   EUCTR2009-015556-15-HU   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015556-15-GR   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015556-15-GB   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015556-15-FI   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015556-15-ES   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015556-15-DK   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015556-15-DE   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015556-15-CZ   Austria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Italy;Latvia;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;United States;
      2010   -   EUCTR2009-015556-15-AT   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
   Biogen Idec Ltd.
      2007   Phase 3   EUCTR2006-003697-10-BE   Belgium;Bulgaria;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Spain;
      2007   -   EUCTR2006-003697-10-LV   Bulgaria;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Spain;
   Karolinska Institutet
      2017   Phase 4   EUCTR2017-002634-24-SE   Sweden;
      2017   Phase 4   EUCTR2016-003587-39-SE   Sweden;
   Mapi Pharma Ltd.
      2019   Phase 3   EUCTR2018-000284-93-EE   Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;Estonia;Georgia;Israel;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Montenegro;Poland;Romania;Russian Federation;Serbia;Ukraine;United States;
      2019   Phase 3   EUCTR2018-000284-93-BG   Belarus;Bosnia and Herzegovina;Bulgaria;Estonia;Georgia;Israel;Moldova, Republic of;Montenegro;Russian Federation;Ukraine;United States;
   Novartis Pharma GmbH
      2021   Phase 4   EUCTR2020-005752-38-DE   Germany;
   Peptimmune Inc.
      2010   Phase 2   EUCTR2009-012716-40-SK   Bulgaria;Czech Republic;Estonia;France;Germany;Poland;Slovakia;
      2010   Phase 2   EUCTR2009-012716-40-DE   Bulgaria;Czech Republic;Estonia;France;Germany;Poland;Slovakia;
      2010   -   EUCTR2009-012716-40-PL   Bulgaria;Czech Republic;Estonia;France;Germany;Poland;
      2010   -   EUCTR2009-012716-40-FR   Bulgaria;Czech Republic;Estonia;France;Germany;Poland;
      2010   -   EUCTR2009-012716-40-CZ   Bulgaria;Czech Republic;Estonia;France;Germany;Poland;
      2010   -   EUCTR2009-012716-40-BG   Bulgaria;Czech Republic;Estonia;France;Germany;Poland;
      2009   -   EUCTR2009-012716-40-EE   Bulgaria;Czech Republic;Estonia;France;Germany;Poland;
   Teva Pharmaceutical Industries, Ltd
      2016   Phase 4   EUCTR2015-000922-12-PL   Argentina;Austria;Belgium;Croatia;Finland;France;Germany;Ireland;Israel;Italy;Mexico;Poland;Russian Federation;Spain;Turkey;United States;
      2016   Phase 4   EUCTR2015-000922-12-FR   Argentina;Austria;Belgium;Croatia;Finland;France;Germany;Ireland;Italy;Mexico;Poland;Russian Federation;Spain;Turkey;United States;
      2016   Phase 4   EUCTR2015-000922-12-ES   Argentina;Austria;Belgium;Croatia;Finland;France;Germany;Ireland;Italy;Mexico;Poland;Russian Federation;Spain;Turkey;United States;
      2016   Phase 4   EUCTR2015-000922-12-DE   Argentina;Austria;Belgium;Croatia;Finland;France;Germany;Ireland;Israel;Italy;Mexico;Poland;Russian Federation;Spain;Turkey;United States;
      2016   Phase 4   EUCTR2015-000922-12-BE   Argentina;Austria;Belgium;Croatia;Finland;France;Germany;Ireland;Israel;Italy;Mexico;Poland;Russian Federation;Spain;Turkey;United States;
      2015   Phase 4   EUCTR2015-000922-12-IE   Argentina;Austria;Belgium;Croatia;Finland;France;Germany;Ireland;Israel;Italy;Mexico;Poland;Russian Federation;Spain;Turkey;United States;
      2015   Phase 4   EUCTR2015-000922-12-HR   Argentina;Austria;Belgium;Croatia;Finland;France;Germany;Ireland;Israel;Italy;Mexico;Poland;Russian Federation;Spain;Turkey;United States;
      2015   Phase 4   EUCTR2015-000922-12-FI   Argentina;Austria;Belgium;Croatia;Finland;France;Germany;Ireland;Israel;Italy;Mexico;Poland;Russian Federation;Spain;Turkey;United States;
      2015   Phase 4   EUCTR2015-000922-12-AT   Argentina;Austria;Belgium;Croatia;Finland;France;Germany;Ireland;Israel;Italy;Mexico;Poland;Russian Federation;Spain;Turkey;United States;
   Turku University Hospital
      2013   Phase 4   EUCTR2013-004626-28-FI   Finland;
GLATIRAMER ACETATO   
   TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC
      2015   Phase 4   EUCTR2015-000922-12-IT   Argentina;Austria;Belgium;Croatia;Finland;France;Germany;Ireland;Israel;Italy;Mexico;Poland;Russian Federation;Spain;Turkey;United States;
GLATIRAMERO ACETATO   
   Biogen Idec Limited
      2010   -   EUCTR2009-015556-15-ES   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
   Teva Pharmaceutical Industries, Ltd.
      2006   Phase 3   EUCTR2006-002037-20-ES   Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;Lithuania;Spain;United Kingdom;
GNbAC1   
   GENEURO SA
      2017   Phase 2   EUCTR2016-004935-18-IT   Bulgaria;Croatia;Czech Republic;Czechia;Estonia;Germany;Hungary;Italy;Poland;Russian Federation;Serbia;Spain;Ukraine;
   GeNeuro Australia PTY Ltd
      2018   Phase 1   NCT03574428   Australia;
   GeNeuro Innovation SAS
      2021   Phase 2   EUCTR2021-001973-21-SE   Sweden;
      2020   Phase 2   EUCTR2019-004822-15-SE   Sweden;
      2012   Phase 2   NCT01639300   Switzerland;
      2011   Phase 1   NCT01699555   -
   GeNeuro SA
      2017   Phase 2   EUCTR2016-004935-18-PL   Bulgaria;Croatia;Czech Republic;Estonia;Germany;Hungary;Italy;Poland;Russian Federation;Serbia;Spain;Ukraine;
      2017   Phase 2   EUCTR2016-004935-18-HU   Bulgaria;Croatia;Czech Republic;Estonia;Germany;Hungary;Italy;Poland;Russian Federation;Serbia;Spain;Ukraine;
      2017   Phase 2   EUCTR2016-004935-18-HR   Bulgaria;Croatia;Czech Republic;Estonia;Germany;Hungary;Italy;Poland;Russian Federation;Serbia;Spain;Ukraine;
      2017   Phase 2   EUCTR2016-004935-18-ES   Bulgaria;Croatia;Czech Republic;Estonia;Germany;Hungary;Italy;Poland;Russian Federation;Serbia;Spain;Ukraine;
      2017   Phase 2   EUCTR2016-004935-18-DE   Bulgaria;Croatia;Czech Republic;Estonia;Germany;Hungary;Italy;Poland;Russian Federation;Serbia;Spain;Ukraine;
      2017   Phase 2   EUCTR2016-004935-18-CZ   Bulgaria;Croatia;Czech Republic;Estonia;Germany;Hungary;Italy;Poland;Russian Federation;Serbia;Spain;Ukraine;
      2017   Phase 2   EUCTR2016-004935-18-BG   Bulgaria;Croatia;Czech Republic;Estonia;Germany;Hungary;Italy;Poland;Russian Federation;Serbia;Spain;Ukraine;
      2016   Phase 2   NCT02782858   Bulgaria;Croatia;Czechia;Estonia;Germany;Hungary;Italy;Poland;Russian Federation;Serbia;Spain;Ukraine;
      2016   Phase 2   EUCTR2015-004059-29-PL   Bulgaria;Croatia;Czech Republic;Estonia;France;Germany;Hungary;Italy;Poland;Russian Federation;Serbia;Spain;Ukraine;
      2016   Phase 2   EUCTR2015-004059-29-HU   Bulgaria;Croatia;Czech Republic;Estonia;France;Germany;Hungary;Italy;Poland;Russian Federation;Serbia;Spain;Ukraine;
      2016   Phase 2   EUCTR2015-004059-29-HR   Bulgaria;Croatia;Czech Republic;Estonia;France;Germany;Hungary;Italy;Poland;Russian Federation;Serbia;Spain;Ukraine;
      2016   Phase 2   EUCTR2015-004059-29-ES   Bulgaria;Croatia;Czech Republic;Estonia;France;Germany;Hungary;Italy;Poland;Russian Federation;Serbia;Spain;Ukraine;
      2016   Phase 2   EUCTR2015-004059-29-EE   Bulgaria;Croatia;Czech Republic;Estonia;France;Germany;Hungary;Italy;Poland;Russian Federation;Serbia;Spain;Ukraine;
      2016   Phase 2   EUCTR2015-004059-29-DE   Bulgaria;Croatia;Czech Republic;Estonia;France;Germany;Hungary;Italy;Poland;Russian Federation;Serbia;Spain;Ukraine;
      2016   Phase 2   EUCTR2015-004059-29-CZ   Bulgaria;Croatia;Czech Republic;Estonia;France;Germany;Hungary;Italy;Poland;Russian Federation;Serbia;Spain;Ukraine;
      2016   Phase 2   EUCTR2015-004059-29-BG   Bulgaria;Croatia;Czech Republic;Estonia;France;Germany;Hungary;Italy;Poland;Russian Federation;Serbia;Spain;Ukraine;
GNbAC1 Monoclonal Antibody   
   GeNeuro SA
      2017   Phase 2   NCT03239860   Bulgaria;Croatia;Czechia;Estonia;Germany;Hungary;Italy;Poland;Russian Federation;Serbia;Spain;Ukraine;
GSK1223249   
   GlaxoSmithKline
      2011   Phase 1   NCT01435993   Germany;Italy;Norway;
      2010   Phase 1   NCT01424423   Australia;
GSK1841157   
   GlaxoSmithKline Research and Development Limited
      2012   -   EUCTR2011-002333-19-CZ   Bulgaria;Canada;Czech Republic;Denmark;Germany;Italy;Netherlands;Norway;Russian Federation;Spain;United States;
      2011   Phase 2   EUCTR2011-002333-19-DK   Bulgaria;Canada;Czech Republic;Denmark;Germany;Italy;Netherlands;Norway;Russian Federation;Spain;United States;
      2011   -   EUCTR2011-002333-19-NL   Bulgaria;Canada;Czech Republic;Denmark;Germany;Italy;Netherlands;Norway;Russian Federation;Spain;United States;
      2011   -   EUCTR2011-002333-19-DE   Bulgaria;Canada;Czech Republic;Denmark;Germany;Italy;Netherlands;Norway;Russian Federation;Spain;United States;
   GlaxoSmithKline SA
      2011   Phase 2   EUCTR2011-002333-19-ES   Bulgaria;Canada;Czech Republic;Denmark;Germany;Italy;Netherlands;Norway;Russian Federation;Spain;United States;
GSK2018682   
   GlaxoSmithKline
      2010   Phase 1   NCT01431937   Australia;
      2010   Phase 1   NCT01387217   Australia;
GSK2018682 CD2 Capsule   
   GlaxoSmithKline
      2010   Phase 1   NCT01466322   Australia;
GSK2018682 CD3 micronised Tablet   
   GlaxoSmithKline
      2010   Phase 1   NCT01466322   Australia;
GSK2018682 CD3 non-micronised Tablet in fed state   
   GlaxoSmithKline
      2010   Phase 1   NCT01466322   Australia;
GSK239512   
   GlaxoSmithKline
      2013   Phase 2   NCT01772199   Bulgaria;Canada;Czech Republic;Germany;Spain;Sweden;Ukraine;United Kingdom;
      2013   Phase 1   NCT01802931   Australia;
   GlaxoSmithKline Research & Development Ltd
      2013   Phase 2   EUCTR2012-003627-38-GB   Bulgaria;Canada;Czech Republic;Germany;Spain;Sweden;Ukraine;United Kingdom;
      2013   Phase 2   EUCTR2012-003627-38-BG   Bulgaria;Canada;Czech Republic;Germany;Spain;Sweden;Ukraine;United Kingdom;
      2013   -   EUCTR2012-003627-38-SE   Bulgaria;Canada;Czech Republic;Germany;Spain;Sweden;Ukraine;United Kingdom;
      2013   -   EUCTR2012-003627-38-DE   Bulgaria;Canada;Czech Republic;Germany;Spain;Sweden;Ukraine;United Kingdom;
      2013   -   EUCTR2012-003627-38-CZ   Bulgaria;Canada;Czech Republic;Germany;Spain;Sweden;Ukraine;United Kingdom;
   GlaxoSmithKline, S.A.
      2012   -   EUCTR2012-003627-38-ES   Bulgaria;Canada;Czech Republic;Germany;Spain;Sweden;Ukraine;United Kingdom;
GSK2395612   
   GlaxoSmithKline Research & Development Ltd
      2013   Phase 2   EUCTR2012-003627-38-BG   Bulgaria;Canada;Czech Republic;Germany;Spain;Sweden;Ukraine;United Kingdom;
      2013   -   EUCTR2012-003627-38-SE   Bulgaria;Canada;Czech Republic;Germany;Spain;Sweden;Ukraine;United Kingdom;
      2013   -   EUCTR2012-003627-38-DE   Bulgaria;Canada;Czech Republic;Germany;Spain;Sweden;Ukraine;United Kingdom;
      2013   -   EUCTR2012-003627-38-CZ   Bulgaria;Canada;Czech Republic;Germany;Spain;Sweden;Ukraine;United Kingdom;
   GlaxoSmithKline, S.A.
      2012   -   EUCTR2012-003627-38-ES   Bulgaria;Canada;Czech Republic;Germany;Spain;Sweden;Ukraine;United Kingdom;
GSK3888130B   
   GlaxoSmithKline
      2021   Phase 1   NCT05131971   United Kingdom;
GTR.ace   
   SYNTHON BV
      2011   -   EUCTR2011-000888-27-IT   Bulgaria;Croatia;Czech Republic;Estonia;Germany;Greece;Italy;Romania;Russian Federation;Ukraine;United Kingdom;United States;
   Synthon BV
      2012   -   EUCTR2011-000888-27-GR   Belarus;Bulgaria;Croatia;Czech Republic;Estonia;Germany;Greece;Italy;Lithuania;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2011-000888-27-DE   Belarus;Bulgaria;Croatia;Czech Republic;Estonia;Germany;Greece;Italy;Lithuania;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2011-000888-27-RO   Belarus;Bulgaria;Croatia;Czech Republic;Estonia;Germany;Greece;Italy;Lithuania;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2011-000888-27-GB   Belarus;Bulgaria;Croatia;Czech Republic;Estonia;Germany;Greece;Italy;Lithuania;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2011-000888-27-EE   Belarus;Bulgaria;Croatia;Czech Republic;Estonia;Germany;Greece;Italy;Lithuania;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2011-000888-27-CZ   Belarus;Bulgaria;Croatia;Czech Republic;Estonia;Germany;Greece;Italy;Lithuania;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2011-000888-27-BG   Belarus;Bulgaria;Croatia;Czech Republic;Estonia;Germany;Greece;Italy;Lithuania;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
GW-1000-02   
   GW Pharma Ltd
      2007   Phase 3   EUCTR2006-005910-11-CZ   Czech Republic;Germany;Italy;Spain;United Kingdom;
      2006   Phase 3   EUCTR2005-005265-11-GB   Czech Republic;France;United Kingdom;
      2006   Phase 3   EUCTR2005-005265-11-FR   Czech Republic;France;United Kingdom;
      2006   -   EUCTR2005-005265-11-CZ   Czech Republic;France;United Kingdom;
      2005   Phase 3   EUCTR2004-002509-63-GB   Czech Republic;United Kingdom;
      2005   -   EUCTR2004-002509-63-CZ   Czech Republic;United Kingdom;
   GW Pharma Ltd.
      2008   Phase 3   EUCTR2006-005910-11-GB   Czech Republic;Germany;Italy;Spain;United Kingdom;
      2008   -   EUCTR2006-005910-11-DE   Germany;Italy;Spain;United Kingdom;
      2007   -   EUCTR2007-002138-13-GB   United Kingdom;
   GW Pharmaceuticals Ltd.
      2002   Phase 3   NCT01606176   United Kingdom;
      2002   Phase 3   NCT01606137   United Kingdom;
      2001   Phase 3   NCT01610713   United Kingdom;
      2001   Phase 3   NCT01610700   United Kingdom;
      2001   Phase 3   NCT01610687   United Kingdom;
GYLENIA   
   NOVARTIS FARMA
      2011   -   EUCTR2011-001442-15-IT   Australia;Austria;Czech Republic;Finland;Germany;Greece;Hungary;Israel;Italy;Spain;Sweden;United Kingdom;
GYLENIA 0,   
   Novartis Farmaceutica S.A.
      2013   -   EUCTR2012-000835-18-ES   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
GZ402668   
   Genzyme, a Sanofi Company
      2014   Phase 1   NCT02282826   Germany;
   Sanofi
      2016   Phase 1   NCT02977533   Germany;
GZ402673   
   Genzyme Corporation
      2017   Phase 3   EUCTR2016-003100-30-PT   Austria;Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2017   Phase 3   EUCTR2016-003100-30-NO   Austria;Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2017   Phase 3   EUCTR2016-003100-30-NL   Austria;Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2017   Phase 3   EUCTR2016-003100-30-GR   Austria;Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2017   Phase 3   EUCTR2016-003100-30-GB   Austria;Belgium;Bulgaria;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;
      2017   Phase 3   EUCTR2016-003100-30-ES   Austria;Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2017   Phase 3   EUCTR2016-003100-30-DE   Austria;Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2017   Phase 3   EUCTR2016-003100-30-BE   Austria;Belgium;Bulgaria;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;
      2017   Phase 3   EUCTR2016-003100-30-AT   Austria;Belgium;Bulgaria;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;
      2015   Phase 3;Phase 4   EUCTR2013-003884-71-NL   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2015   Phase 3;Phase 4   EUCTR2013-003884-71-DK   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2015   -   EUCTR2013-003884-71-BE   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;France;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;
      2014   Phase 4   EUCTR2014-000092-62-NL   Belgium;France;Netherlands;Spain;Switzerland;
      2014   Phase 4   EUCTR2014-000092-62-FR   Belgium;France;Netherlands;Spain;Switzerland;
      2014   Phase 4   EUCTR2014-000092-62-ES   Belgium;France;Netherlands;Spain;Switzerland;
      2014   Phase 4   EUCTR2014-000092-62-BE   Belgium;France;Netherlands;Spain;Switzerland;
      2014   Phase 3;Phase 4   EUCTR2013-003884-71-IT   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;France;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;
      2014   Phase 3;Phase 4   EUCTR2013-003884-71-HR   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2013-003884-71-DE   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2013-003884-71-CZ   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2014   -   EUCTR2013-003884-71-ES   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;France;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;
      -   Phase 3   EUCTR2016-003100-30-PL   Austria;Belgium;Bulgaria;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;
      -   Phase 3   EUCTR2016-003100-30-Outside-EU/EEA   Austria;Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      -   Phase 3   EUCTR2016-003100-30-FR   Austria;Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      -   Phase 3   EUCTR2016-003100-30-BG   Austria;Belgium;Bulgaria;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;
   Genzyme GmbH
      2016   Phase 3   EUCTR2016-000464-42-DE   Germany;
Gabapentin   
   Hospices Civils de Lyon
      2012   Phase 2   NCT01744444   France;
Gabapentine   
   Charité University Medicine Berlin
      2010   Phase 4   EUCTR2008-005167-33-DE   Germany;
   HOSPICES CIVILS DE LYON
      2015   Phase 2   EUCTR2014-005548-17-FR   France;
Gadobenate Dimeglumine   
   University of Southern California
      2011   -   NCT02967380   United States;
Gadobutrol   
   University of Southern California
      2011   -   NCT02967380   United States;
Gadolinium   
   Rennes University Hospital
      2009   -   NCT01567553   France;
Gadolinium-based contrast   
   Stanford University
      2014   -   NCT01973517   United States;
Gadopentetate   
   University of Southern California
      2011   -   NCT02967380   United States;
Gadoteric acid   
   Universitätsklinikum Erlangen
      2010   -   EUCTR2009-014857-34-DE   Germany;
Gadoteridol   
   University of Maryland, Baltimore
      2018   -   NCT03396822   United States;
Gadovist 1.0 mmol/ml Injektionslösung   
   Universitätsklinikum Erlangen
      2010   -   EUCTR2009-014857-34-DE   Germany;
Genotropin   
   University of Leipzig
      -   Phase 2   EUCTR2006-006465-16-DE   Germany;
GentleCath™ Air catheter   
   ConvaTec Inc.
      2021   -   NCT04847609   -
Gilenya   
   Biogen Idec Research Limited
      2015   Phase 4   EUCTR2013-004622-29-DK   Australia;Czech Republic;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
      2015   Phase 4   EUCTR2013-004622-29-DE   Australia;Czech Republic;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
      2014   Phase 4   EUCTR2013-004622-29-SE   Australia;Czech Republic;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
      2014   Phase 4   EUCTR2013-004622-29-GB   Australia;Czech Republic;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
      2014   Phase 4   EUCTR2013-004622-29-ES   Australia;Canada;Czech Republic;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
      2014   Phase 4   EUCTR2013-004622-29-CZ   Australia;Czech Republic;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
      2014   -   EUCTR2013-004622-29-IT   Australia;Canada;Czech Republic;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
   F. Hoffmann-La Roche Ltd
      2022   Phase 3   EUCTR2020-004128-41-BG   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004128-41-PL   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004128-41-NL   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004128-41-HU   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004128-41-GR   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004128-41-BE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2020-004128-41-FR   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2020-004128-41-DK   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2020-004128-41-AT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
   Jochen Vehoff
      2013   Phase 4   NCT02048072   Switzerland;
   Karolinska Institutet
      2017   Phase 4   EUCTR2017-002634-24-SE   Sweden;
      2017   Phase 4   EUCTR2016-003587-39-SE   Sweden;
   McGill University
      2012   -   NCT02137707   Canada;
   NOVARTIS FARMA
      2011   -   EUCTR2011-001442-15-IT   Australia;Austria;Czech Republic;Finland;Germany;Greece;Hungary;Israel;Italy;Spain;Sweden;United Kingdom;
   NOVARTIS FARMA S.p.A
      2013   -   EUCTR2012-005507-40-IT   Italy;
   Northwestern University
      2013   Phase 2   EUCTR2012-004165-41-GB   United Kingdom;United States;
   Novartis Farma
      2013   -   EUCTR2011-005677-23-IT   Brazil;Canada;Italy;Latvia;Lithuania;Mexico;Spain;United States;Venezuela, Bolivarian Republic of;
   Novartis Farma S.p.A.
      2012   -   EUCTR2010-023023-19-DE   Germany;Italy;
   Novartis Farma SpA
      2014   -   EUCTR2013-002660-17-IT   Canada;Denmark;Finland;France;Germany;Italy;Poland;Portugal;Spain;Switzerland;United Kingdom;
   Novartis Farmaceutica S.A.
      2013   -   EUCTR2011-005677-23-ES   Brazil;Canada;Latvia;Lithuania;Mexico;Spain;United States;Venezuela, Bolivarian Republic of;
   Novartis Farmacéutica S.A.
      2011   Phase 3   EUCTR2011-003484-30-ES   Australia;Spain;
   Novartis Pharma AG
      2012   Phase 3   EUCTR2012-000835-18-FR   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2008   -   EUCTR2007-002627-32-NL   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2008   -   EUCTR2007-002627-32-BE   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
   Novartis Pharma GmbH
      2012   Phase 4   EUCTR2012-000674-31-DE   Germany;Switzerland;
      2012   Phase 4   EUCTR2012-000653-32-DE   Germany;
      2012   -   EUCTR2012-002637-11-DE   Germany;
      2011   Phase 3   EUCTR2010-022066-28-DE   Germany;
      2011   -   EUCTR2011-002969-38-DE   Germany;
      -   -   EUCTR2011-001692-39-DE   Germany;
   Novartis Pharma S.A.S
      2011   Phase 4   EUCTR2011-001280-49-FR   France;
   Novartis Pharma Service AG
      2015   Phase 3   EUCTR2011-005677-23-HR   Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Croatia;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2011-005677-23-GB   Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Croatia;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2011-005677-23-EE   Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Croatia;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2014   -   EUCTR2011-005677-23-RO   Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2011-005677-23-DE   Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Croatia;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2011-005677-23-BG   Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Croatia;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
      2013   -   EUCTR2011-005677-23-LV   Austria;Belarus;Brazil;Bulgaria;Canada;Croatia;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
   Novartis Pharma Services AG
      2015   -   EUCTR2013-002660-17-PT   Canada;Denmark;Finland;France;Germany;Italy;Poland;Portugal;Spain;Switzerland;United Kingdom;
      2015   -   EUCTR2013-002660-17-DK   Canada;Denmark;Finland;France;Germany;Italy;Poland;Portugal;Spain;Switzerland;United Kingdom;
      2014   Phase 3   EUCTR2012-000835-18-DK   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2011-005677-23-PL   Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Croatia;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2011-005677-23-NL   Austria;Brazil;Bulgaria;Canada;Croatia;Estonia;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Slovakia;Spain;Sweden;United Kingdom;United States;
      2014   Phase 3   EUCTR2011-005677-23-AT   Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Croatia;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2014   -   EUCTR2012-000835-18-PL   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2014   -   EUCTR2011-005677-23-SE   Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Croatia;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-000835-18-DE   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2011-005677-23-SK   Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Croatia;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2011-005677-23-LT   Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Croatia;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2012-000835-18-NL   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2012-000835-18-HU   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   -   EUCTR2012-000835-18-SE   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   -   EUCTR2011-001442-15-SE   Australia;Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Norway;Spain;Sweden;Switzerland;United Kingdom;
      2012   -   EUCTR2011-001437-16-DE   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020515-37-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2011   -   EUCTR2011-001442-15-GR   Austria;Czech Republic;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Spain;Sweden;Switzerland;United Kingdom;
      2011   -   EUCTR2011-001442-15-GB   Australia;Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Norway;Spain;Sweden;Switzerland;United Kingdom;
      2011   -   EUCTR2011-001442-15-DE   Australia;Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Norway;Spain;Sweden;Switzerland;United Kingdom;
      2011   -   EUCTR2011-001442-15-AT   Australia;Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Norway;Spain;Sweden;Switzerland;United Kingdom;
      2010   Phase 3   EUCTR2010-020515-37-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020515-37-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Comoros;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Korea, Republic of;Malaysia;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2010   Phase 3   EUCTR2010-020515-37-HU   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020515-37-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020515-37-FI   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020515-37-EE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020515-37-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2009   -   EUCTR2007-002627-32-CZ   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Poland;Russian Federation;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;
   Novartis Services Pharma AG
      2008   -   EUCTR2007-002627-32-SE   Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
   Sakari Simula
      2012   Phase 4   EUCTR2012-002694-66-FI   Finland;
   Sheffield Teaching Hospitals NHS Foundation Trust
      2013   Phase 2/Phase 3   NCT03133403   United Kingdom;
   Turku University Hospital
      2014   Phase 4   EUCTR2014-000296-12-FI   Finland;
      2013   Phase 4   EUCTR2013-004626-28-FI   Finland;
   University of Southern California
      2013   -   NCT02225977   United States;
   Universitätsklinikum Münster
      2014   -   EUCTR2013-004616-21-DE   Germany;
   VU University Medical Center
      2014   -   EUCTR2014-001012-19-NL   Netherlands;
Gilenya / Imusera   
   Novartis Pharma K.K.
      2019   -   JPRN-JapicCTI-194838   Japan;
Gilenya 0,5 mg Hartkapseln   
   Novartis Pharma Services AG
      2010   Phase 3   EUCTR2010-020515-37-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Ireland;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Netherlands;Norway;Panama;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      -   -   EUCTR2007-002627-32-DE   Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
Gilenya®   
   Charite Universitaetsmedizin Berlin
      2012   Phase 3   EUCTR2011-004787-30-DE   Germany;
   Charité - Universitätsmedizin Berlin
      2013   Phase 4   EUCTR2012-000411-91-DE   Germany;
   Universitätsklinikum Hamburg-Eppendorf
      2013   -   NCT03216915   Germany;
Gileyna   
   Stony Brook University
      2013   -   NCT02141022   United States;
Ginkgo biloba   
   National Center for Complementary and Integrative Health (NCCIH)
      1999   Phase 1/Phase 2   NCT00010842   United States;
   VA Office of Research and Development
      2009   Phase 2   NCT00841321   United States;
Ginseng   
   Isfahan University of Medical Sciences
      2010   Phase 2   NCT01712373   Iran, Islamic Republic of;
Glatiramer Acetate   
   Biogen
      2007   Phase 3   NCT00451451   Australia;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Costa Rica;Croatia;Czech Republic;Estonia;France;Germany;Greece;India;Ireland;Israel;Italy;Kazakhstan;Latvia;Lithuania;Macedonia, The Former Yugoslav Republic of;Mexico;Moldova, Republic of;New Zealand;Poland;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United States;
   Biogen Idec Ltd.
      2008   -   EUCTR2006-003697-10-BG   Bulgaria;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Spain;
      2007   -   EUCTR2006-003697-10-IE   Bulgaria;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Spain;
      2007   -   EUCTR2006-003697-10-GR   Bulgaria;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Spain;
      2007   -   EUCTR2006-003697-10-DE   Bulgaria;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Spain;
      2007   -   EUCTR2006-003697-10-CZ   Bulgaria;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Spain;
   Cinnagen
      2015   -   NCT04928313   -
   Isfahan University of Medical Sciences
      2017   Phase 2/Phase 3   NCT03315923   Iran, Islamic Republic of;
   Teva Pharmaceutical Industries
      2012   Phase 3   NCT01578785   Albania;Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Estonia;Georgia;Greece;Latvia;Lithuania;Macedonia, The Former Yugoslav Republic of;Mexico;Moldova, Republic of;Montenegro;Poland;Romania;Russian Federation;Serbia;Ukraine;United States;
      2005   Phase 4   NCT00203047   Canada;United States;
      2004   Phase 4   NCT00202995   Canada;United States;
   The Walton Centre for Neurology and Neurosurgery
      2005   Phase 4   EUCTR2004-004903-39-GB   United Kingdom;
   University of Colorado, Denver
      2012   Phase 2   NCT01569451   United States;
Glatiramer Acetate (Copaxone®)   
   Synthon BV
      2011   Phase 3   NCT01489254   Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;Estonia;Georgia;Germany;Greece;Italy;Kazakhstan;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;South Africa;Ukraine;United Kingdom;United States;
Glatiramer Acetate (DB)   
   Teva Pharmaceutical Industries
      2004   Phase 3   NCT00666224   Argentina;Australia;Austria;Denmark;Finland;France;Germany;Hungary;Israel;Italy;New Zealand;Norway;Romania;Spain;Sweden;United Kingdom;United States;
Glatiramer Acetate (GA)   
   Sanofi
      2007   Phase 2   NCT00475865   Austria;Canada;Germany;Italy;United Kingdom;United States;
   Teva Pharmaceutical Industries
      2006   Phase 3   NCT00337779   Argentina;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
Glatiramer Acetate (GTR)   
   Synthon BV
      2011   Phase 3   NCT01489254   Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;Estonia;Georgia;Germany;Greece;Italy;Kazakhstan;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;South Africa;Ukraine;United Kingdom;United States;
Glatiramer Acetate (OL)   
   Teva Pharmaceutical Industries
      2004   Phase 3   NCT00666224   Argentina;Australia;Austria;Denmark;Finland;France;Germany;Hungary;Israel;Italy;New Zealand;Norway;Romania;Spain;Sweden;United Kingdom;United States;
Glatiramer Acetate [GA]   
   Sanofi
      2007   Phase 2   NCT00811395   Austria;Canada;Germany;Italy;Spain;United Kingdom;United States;
Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b   
   Teva Neuroscience, Inc.
      2008   -   NCT00819000   United States;
Glatiramer Acetate, N-Acetylcysteine   
   Teva Pharmaceutical Industries
      2004   Phase 2   NCT00203099   Canada;
Glatiramer acetate   
   AZIENDA OSPEDALIERA UNIVERSITARIA DELLA SECONDA UNIVERSITA` DEGLI STUDI DI NAPOLI
      2009   -   EUCTR2009-010661-23-IT   Italy;
   Amphia Hospital
      2009   Phase 4   NCT00910598   Netherlands;
   BIOGEN IDEC LTD
      2010   -   EUCTR2009-015556-15-IT   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
   Biogen
      2021   Phase 2   NCT04079088   -
      2010   Phase 3   NCT01058005   Australia;Canada;Czech Republic;Finland;France;Hungary;Italy;Latvia;Poland;Slovenia;Spain;Sweden;United States;
      2010   Phase 2   NCT01071083   Germany;Spain;United States;
   Biogen Idec Ltd.
      2007   Phase 3   EUCTR2006-003697-10-ES   Belgium;Bulgaria;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Spain;
   FONDAZIONE DON CARLO GNOCCHI ONLUS
      2011   -   EUCTR2011-000150-31-IT   Italy;
   Fred Lublin
      2005   Phase 3   NCT00211887   Canada;United States;
   Genzyme, a Sanofi Company
      2017   Phase 3   NCT03368664   Austria;Belgium;Bulgaria;Czechia;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;
   Glostrup Hospital, Dep. of Neurology
      2009   -   EUCTR2006-001827-21-DK   Denmark;
   ISTITUTO C. MONDINO
      2007   -   EUCTR2008-007162-32-IT   Italy;
   NOVARTIS FARMA
      2011   -   EUCTR2010-024017-31-IT   Italy;
   National Institute of Allergy and Infectious Diseases (NIAID)
      2001   -   NCT00039988   United States;
   Novartis Pharmaceuticals
      2012   Phase 3   NCT01633112   Argentina;Brazil;Canada;Chile;Mexico;Puerto Rico;United States;
   OSPEDALE SAN RAFFAELE
      2018   Phase 4   EUCTR2016-004819-12-IT   Italy;
   Philipps-Universität Marburg
      2010   -   EUCTR2009-011088-35-DE   Germany;
   Sanofi
      2003   Phase 4   NCT00267319   Czech Republic;
   Sheba Medical Center
      2006   -   NCT00331747   Israel;
   TEVA
      2004   -   EUCTR2004-000759-40-IT   Italy;
      2004   -   EUCTR2004-000463-94-IT   Hungary;Italy;
      2004   -   EUCTR2004-000462-13-IT   Hungary;Italy;
   TEVA ITALIA srl
      2004   -   EUCTR2004-000762-13-IT   Italy;
   Takeda
      2015   -   NCT03209479   Japan;
   Teva Branded Pharmaceutical Products R&D, Inc.
      1994   Phase 4   NCT00203021   United States;
   Teva Pharmaceutical Industries
      2003   Phase 2   NCT00202982   United States;
   Teva Pharmaceuticals Industries Ltd.
      2006   -   EUCTR2006-002037-20-IT   Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Spain;United Kingdom;
   University of California, San Francisco
      2008   -   NCT00819195   United States;
   VU University Medical Center
      2014   -   EUCTR2014-001012-19-NL   Netherlands;
Glatiramer acetate (GA)   
   Novartis Pharmaceuticals
      2012   Phase 4   NCT01534182   Russian Federation;
   Teva Branded Pharmaceutical Products R&D, Inc.
      2010   Phase 3   NCT01067521   Bulgaria;Croatia;Czech Republic;Czechia;Estonia;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Poland;Romania;Russian Federation;South Africa;Turkey;Ukraine;United Kingdom;United States;
Glatiramer acetate 150mg enteric coated tablets   
   TEVA Pharmaceutical Industries Ltd.
      2007   -   EUCTR2004-000463-94-HU   Hungary;Italy;
Glatiramer acetate 150mg enteric-coated (gastro-resistant) tablets   
   TEVA Pharmaceutical Industries Ltd.
      2004   -   EUCTR2004-000462-13-HU   Hungary;Italy;
Glatiramer acetate 20 mg, with mitoxantrone   
   Teva Pharmaceutical Industries
      2003   Phase 2   NCT00203073   Canada;United States;
Glatiramer acetate injection with oral cetirizine hydrochloride   
   Teva Pharmaceutical Industries
      2004   Phase 4   NCT00240032   United States;
Glatiramer acetate with minocycline   
   Teva Pharmaceutical Industries
      2004   Phase 2   NCT00203112   Canada;
Glatiramer acetate, (Copaxone®)   
   Neurognostics
      2006   -   NCT00398528   United States;
Glatiramer acetato   
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-004505-32-IT   France;Germany;Italy;Spain;
   Teva Pharmaceutical Industries, Ltd.
      2006   Phase 3   EUCTR2006-002037-20-ES   Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;Lithuania;Spain;United Kingdom;
   Teva Pharmaceuticals Industries Ltd.
      2006   -   EUCTR2006-002037-20-IT   Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Spain;United Kingdom;
Glicerol-1,3-didecanoato-2-octadeca-(6Z,9Z,12Z)-trienoato   
   BTG International Ltd
      2009   -   EUCTR2009-011585-28-ES   Belgium;France;Germany;Spain;
Glucose   
   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
      1999   Phase 3   NCT00062972   United States;
   Slovak Academy of Sciences
      2017   -   NCT03052595   Slovakia;
Glutamate and aspartate   
   University Hospital, Caen
      2007   -   NCT02523703   -
Glycerol-1,3-didecanoate-2-octadeca-(6Z,9Z,12Z)-trienoate   
   BTG International Ltd
      2009   Phase 2   EUCTR2009-011585-28-BE   Belgium;European Union;France;Germany;Russian Federation;Spain;
      2009   -   EUCTR2009-011585-28-FR   Belgium;France;Germany;Spain;
      2009   -   EUCTR2009-011585-28-DE   Belgium;European Union;France;Germany;Russian Federation;Spain;
Gold   
   Children's Hospital of Chongqing Medical University
      2017   -   ChiCTR-DND-17013749   China;
   Huashan Hospital, Fudan University
      2020   -   ChiCTR2000040363   China;
   The First Hospital of Jilin University
      2020   Phase 0   ChiCTR2000034098   China;
Gold nanocrystals   
   Clene Nanomedicine
      2019   Phase 2   NCT03993171   United States;
Granulocyte-colony stimulating factor (G-CSF) and prednisone   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2006   Phase 2   NCT00288626   United States;
Guanabenz   
   National Institute of Neurological Disorders and Stroke (NINDS)
      2015   Phase 1   NCT02423083   United States;
H.P. Acthar Gel (repository corticotropin injection)   
   The University of Texas Health Science Center, Houston
      2013   Phase 4   NCT01888354   United States;
H5G1.1-mAb   
   Alexion Pharmaceuticals Inc.
      2020   Phase 2;Phase 3   EUCTR2019-001829-26-DE   Canada;Germany;Italy;Japan;Korea, Republic of;Spain;United States;
      2019   Phase 2;Phase 3   EUCTR2019-001829-26-ES   Canada;Germany;Italy;Japan;Korea, Republic of;Spain;United States;
HAEMOPHILUS TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE)   
   ALEXION PHARMACEUTICALS INCORPORATED
      2020   Phase 2;Phase 3   EUCTR2019-001829-26-IT   Canada;Germany;Italy;Japan;Korea, Republic of;Spain;United States;
HB-adMSCs   
   Hope Biosciences Stem Cell Research Foundation
      2021   Phase 2   NCT05116540   United States;
HBM9161 Injection   
   Harbour BioMed (Guangzhou) Co. Ltd.
      2020   Phase 1   NCT04227470   China;
HMR 1726D   
   Sanofi-Aventis recherche & développement
      2008   -   EUCTR2007-003997-24-GB   Austria;Italy;Spain;United Kingdom;
      2007   -   EUCTR2007-003997-24-ES   Austria;Italy;Spain;United Kingdom;
      2007   -   EUCTR2007-003997-24-AT   Austria;Italy;Spain;United Kingdom;
   Sanofi-aventis recherche & développement
      2010   -   EUCTR2007-004452-36-SK   Austria;Belgium;Czech Republic;Estonia;France;Germany;Greece;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2007-004452-36-SE   Austria;Belgium;Czech Republic;Estonia;France;Germany;Greece;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2007-004452-36-GR   Austria;Belgium;Czech Republic;Estonia;France;Germany;Greece;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2007-004452-36-GB   Australia;Austria;Belarus;Belgium;Canada;Chile;China;Czech Republic;Estonia;France;Germany;Greece;Mexico;Netherlands;Philippines;Poland;Romania;Slovakia;Spain;Sweden;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2008   -   EUCTR2007-004452-36-FR   Austria;Belgium;Czech Republic;Estonia;France;Germany;Greece;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-004452-36-ES   Austria;Belgium;Czech Republic;Estonia;France;Germany;Greece;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-004452-36-EE   Austria;Belgium;Czech Republic;Estonia;France;Germany;Greece;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-004452-36-DE   Austria;Belgium;Czech Republic;Estonia;France;Germany;Greece;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
   sanofi-aventis recherche & développement
      2009   -   EUCTR2007-004452-36-AT   Australia;Austria;Belarus;Belgium;Canada;Chile;China;Czech Republic;Estonia;France;Germany;Greece;Mexico;Netherlands;Philippines;Poland;Romania;Slovakia;Spain;Sweden;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2008   Phase 3   EUCTR2007-004452-36-BE   Australia;Austria;Belarus;Belgium;Canada;Chile;China;Czech Republic;Estonia;France;Germany;Greece;Mexico;Netherlands;Philippines;Poland;Romania;Slovakia;Spain;Sweden;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2008   -   EUCTR2007-004452-36-NL   Australia;Austria;Belarus;Belgium;Canada;Chile;China;Czech Republic;Estonia;France;Germany;Greece;Mexico;Netherlands;Philippines;Poland;Romania;Slovakia;Spain;Sweden;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2008   -   EUCTR2007-004452-36-CZ   Australia;Austria;Belarus;Belgium;Canada;Chile;China;Czech Republic;Estonia;France;Germany;Greece;Mexico;Netherlands;Philippines;Poland;Romania;Slovakia;Spain;Sweden;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
HMR1726   
   Aventis Pharmaceuticals Inc.
      2006   -   EUCTR2004-000555-42-PT   Czech Republic;Denmark;Estonia;Italy;Norway;Portugal;Sweden;United Kingdom;
   GENZYME CORPORATION
      2020   Phase 3   EUCTR2020-000637-41-IT   Austria;Belarus;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Hong Kong;Italy;Japan;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United States;
      2017   Phase 3   EUCTR2011-005249-12-IT   Australia;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;China;Estonia;France;Greece;Ireland;Israel;Italy;Lebanon;Lithuania;Morocco;Netherlands;North Macedonia;Poland;Portugal;Russian Federation;Serbia;Slovenia;Spain;Tunisia;Turkey;United Kingdom;United States;
   Genzyme Corporation
      2021   Phase 3   EUCTR2020-000644-55-DE   Argentina;Belgium;Brazil;Canada;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Latvia;Netherlands;Norway;Portugal;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000637-41-AT   Austria;Belarus;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Hong Kong;Italy;Japan;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2020-000644-55-SK   Argentina;Belgium;Brazil;Canada;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Latvia;Netherlands;Norway;Portugal;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000644-55-PT   Argentina;Belgium;Brazil;Canada;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Latvia;Netherlands;Norway;Portugal;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000644-55-NL   Argentina;Belgium;Brazil;Canada;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Latvia;Netherlands;Norway;Portugal;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000644-55-LV   Argentina;Belgium;Brazil;Canada;Chile;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Latvia;Netherlands;Norway;Portugal;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000644-55-HU   Argentina;Belgium;Brazil;Canada;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Latvia;Netherlands;Norway;Portugal;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000644-55-GR   Argentina;Belgium;Brazil;Canada;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Latvia;Netherlands;Norway;Portugal;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000644-55-GB   Argentina;Belgium;Brazil;Canada;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Latvia;Netherlands;Norway;Portugal;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000644-55-FR   Argentina;Belgium;Brazil;Canada;Chile;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Latvia;Netherlands;Norway;Portugal;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000644-55-CZ   Argentina;Belgium;Brazil;Canada;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Latvia;Netherlands;Norway;Portugal;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000637-41-SE   Austria;Belarus;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Hong Kong;Italy;Japan;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2020-000637-41-PL   Austria;Belarus;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Hong Kong;Italy;Japan;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2020-000637-41-LT   Austria;Belarus;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Hong Kong;Italy;Japan;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2020-000637-41-FI   Austria;Belarus;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Hong Kong;Italy;Japan;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2020-000637-41-DK   Austria;Belarus;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Hong Kong;Italy;Japan;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2020-000637-41-DE   Austria;Belarus;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Hong Kong;Italy;Japan;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2020-000637-41-CZ   Austria;Belarus;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Hong Kong;Italy;Japan;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2020-000637-41-BG   Austria;Belarus;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Hong Kong;Italy;Japan;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United States;
      2017   Phase 3   EUCTR2011-005249-12-SI   Australia;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;China;Egypt;Estonia;France;Greece;Ireland;Israel;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovenia;Spain;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2011-005249-12-PT   Australia;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;China;Egypt;Estonia;France;Greece;Ireland;Israel;Italy;Lebanon;Lithuania;Morocco;Netherlands;North Macedonia;Poland;Portugal;Russian Federation;Serbia;Slovenia;Spain;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2011-005249-12-NL   Australia;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;China;Estonia;France;Greece;Ireland;Israel;Italy;Lebanon;Lithuania;Morocco;Netherlands;North Macedonia;Poland;Portugal;Russian Federation;Serbia;Slovenia;Spain;Tunisia;Turkey;United Kingdom;United States;
      2015   Phase 3   EUCTR2011-005249-12-LT   Australia;Belgium;Bulgaria;Canada;China;Estonia;France;Greece;Ireland;Israel;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovenia;Spain;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2015   -   EUCTR2011-005249-12-PL   Australia;Belgium;Canada;China;Estonia;Greece;Israel;Lebanon;Lithuania;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2014   Phase 4   EUCTR2013-001439-34-IT   Austria;Belgium;Canada;Chile;Finland;Germany;Greece;Italy;Spain;Sweden;Switzerland;United Kingdom;United States;
      2014   Phase 4   EUCTR2013-001439-34-GR   Austria;Belgium;Canada;Chile;Finland;Germany;Greece;Spain;Sweden;Switzerland;United Kingdom;United States;
      2014   Phase 4   EUCTR2013-001439-34-GB   Austria;Belgium;Canada;Chile;Finland;Germany;Greece;Spain;Sweden;Switzerland;United Kingdom;United States;
      2014   Phase 3   EUCTR2011-005249-12-GR   Australia;Belgium;Bulgaria;Canada;China;Estonia;France;Greece;Ireland;Israel;Italy;Lebanon;Lithuania;Morocco;Netherlands;North Macedonia;Poland;Portugal;Russian Federation;Serbia;Slovenia;Spain;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2011-005249-12-GB   Australia;Belgium;Bulgaria;Canada;China;Estonia;France;Greece;Ireland;Israel;Lebanon;Lithuania;Macedonia, the former Yugoslav Republic of;Morocco;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovenia;Spain;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2011-005249-12-ES   Australia;Belgium;Bulgaria;Canada;China;Estonia;France;Greece;Ireland;Israel;Lebanon;Lithuania;Netherlands;Poland;Portugal;Russian Federation;Slovenia;Spain;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2011-005249-12-EE   Australia;Belgium;Bulgaria;Canada;China;Estonia;France;Greece;Ireland;Israel;Italy;Lebanon;Lithuania;Netherlands;Poland;Portugal;Russian Federation;Slovenia;Spain;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2011-005249-12-BE   Australia;Belgium;Bulgaria;Canada;China;Estonia;France;Greece;Ireland;Israel;Italy;Lebanon;Lithuania;Morocco;Netherlands;North Macedonia;Poland;Portugal;Russian Federation;Serbia;Slovenia;Spain;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2014   -   EUCTR2013-001439-34-DE   Austria;Belgium;Canada;Chile;Finland;Germany;Greece;Spain;Sweden;Switzerland;United Kingdom;United States;
      2014   -   EUCTR2013-001439-34-BE   Austria;Belgium;Canada;Chile;Finland;Germany;Greece;Spain;Sweden;Switzerland;United Kingdom;United States;
      2014   -   EUCTR2013-001439-34-AT   Austria;Belgium;Canada;Chile;Finland;Germany;Greece;Spain;Sweden;Switzerland;United Kingdom;United States;
      2013   Phase 4   EUCTR2013-001439-34-SE   Austria;Belgium;Canada;Chile;Finland;Germany;Greece;Spain;Sweden;Switzerland;United Kingdom;United States;
      2013   Phase 4   EUCTR2013-001439-34-FI   Austria;Belgium;Canada;Chile;Finland;Germany;Greece;Spain;Sweden;Switzerland;United Kingdom;United States;
      2013   Phase 4   EUCTR2013-001439-34-ES   Austria;Belgium;Canada;Chile;Finland;Germany;Greece;Italy;Spain;Sweden;Switzerland;United Kingdom;United States;
      2013   -   EUCTR2012-005324-16-NL   Belgium;Germany;Netherlands;
      2013   -   EUCTR2012-005324-16-DE   Belgium;Germany;Netherlands;
      2013   -   EUCTR2012-005324-16-BE   Belgium;Germany;Netherlands;
      -   Phase 3   EUCTR2011-005249-12-Outside-EU/EEA   Australia;Bosnia and Herzegovina;Canada;China;Israel;Lebanon;Morocco;Russian Federation;Tunisia;Turkey;United States;
      -   Phase 3   EUCTR2011-005249-12-IE   Australia;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;China;Estonia;France;Greece;Ireland;Israel;Italy;Lebanon;Lithuania;Morocco;Netherlands;Poland;Portugal;Russian Federation;Slovenia;Spain;Tunisia;Turkey;United Kingdom;United States;
      -   Phase 3   EUCTR2011-005249-12-FR   Australia;Belgium;Bulgaria;Canada;China;Estonia;France;Greece;Ireland;Israel;Italy;Lebanon;Lithuania;Netherlands;Poland;Portugal;Russian Federation;Slovenia;Spain;Turkey;United Kingdom;United States;
      -   Phase 3   EUCTR2011-005249-12-BG   Australia;Belgium;Bulgaria;Canada;China;Estonia;France;Greece;Ireland;Israel;Italy;Lebanon;Lithuania;Morocco;Netherlands;North Macedonia;Poland;Portugal;Russian Federation;Serbia;Slovenia;Spain;Tunisia;Turkey;Ukraine;United Kingdom;United States;
   Sanofi-Aventis US, Inc.
      2004   -   EUCTR2004-000555-42-AT   Austria;Czech Republic;Denmark;Estonia;Italy;Norway;Portugal;Sweden;United Kingdom;
   Sanofi-aventis US, Inc
      2008   Phase 3   EUCTR2004-000555-42-GB   Austria;Czech Republic;Denmark;Estonia;Italy;Norway;Portugal;Sweden;United Kingdom;
      2005   -   EUCTR2004-000555-42-DK   Czech Republic;Denmark;Estonia;Italy;Norway;Portugal;Sweden;United Kingdom;
      2004   -   EUCTR2004-000555-42-SE   Czech Republic;Denmark;Estonia;Italy;Norway;Portugal;Sweden;United Kingdom;
      2004   -   EUCTR2004-000555-42-NO   Czech Republic;Denmark;Estonia;Italy;Norway;Portugal;Sweden;United Kingdom;
   sanofi-aventis Recherche & De`veloppement
      2004   -   EUCTR2004-000555-42-IT   Czech Republic;Denmark;Estonia;Italy;Norway;Portugal;Sweden;United Kingdom;
   sanofi-aventis Recherche & Dévelopment
      2009   -   EUCTR2008-006226-34-FR   Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
   sanofi-aventis U.S Inc
      2007   -   EUCTR2004-000555-42-CZ   Czech Republic;Denmark;Estonia;Italy;Norway;Portugal;Sweden;United Kingdom;
   sanofi-aventis group
      2011   -   EUCTR2010-023172-12-GR   Austria;Belgium;Denmark;Estonia;Finland;Germany;Greece;Hungary;Italy;Lithuania;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;
   sanofi-aventis recherche et development
      2012   -   EUCTR2010-023172-12-LT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Italy;Korea, Republic of;Lithuania;Netherlands;Norway;Portugal;Russian Federation;Slovakia;Spain;Sweden;Tunisia;Turkey;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-023172-12-SK   Austria;Belgium;Denmark;Estonia;Finland;Germany;Greece;Hungary;Italy;Lithuania;Netherlands;Norway;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2011   Phase 3   EUCTR2010-023172-12-HU   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Italy;Korea, Republic of;Lithuania;Netherlands;Norway;Portugal;Russian Federation;Slovakia;Spain;Sweden;Tunisia;Turkey;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-023172-12-BE   Austria;Belgium;Denmark;Estonia;Finland;Germany;Greece;Hungary;Italy;Lithuania;Netherlands;Norway;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2011   -   EUCTR2010-023172-12-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Italy;Korea, Republic of;Lithuania;Netherlands;Norway;Portugal;Russian Federation;Slovakia;Spain;Sweden;Tunisia;Turkey;United Kingdom;United States;
      2011   -   EUCTR2010-023172-12-PT   Austria;Belgium;Denmark;Estonia;Finland;Germany;Greece;Hungary;Italy;Lithuania;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;
      2011   -   EUCTR2010-023172-12-NO   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Italy;Korea, Republic of;Lithuania;Netherlands;Norway;Portugal;Russian Federation;Slovakia;Spain;Sweden;Tunisia;Turkey;United Kingdom;United States;
      2011   -   EUCTR2010-023172-12-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Italy;Korea, Republic of;Lithuania;Netherlands;Norway;Portugal;Russian Federation;Slovakia;Spain;Sweden;Tunisia;Turkey;United Kingdom;United States;
      2011   -   EUCTR2010-023172-12-IT   Austria;Belgium;Denmark;Estonia;Finland;Germany;Greece;Hungary;Italy;Lithuania;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;
      2011   -   EUCTR2010-023172-12-GB   Austria;Belgium;Denmark;Estonia;Finland;Germany;Greece;Hungary;Italy;Lithuania;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;
      2011   -   EUCTR2010-023172-12-FI   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Italy;Korea, Republic of;Lithuania;Netherlands;Norway;Portugal;Russian Federation;Slovakia;Spain;Sweden;Tunisia;Turkey;United Kingdom;United States;
      2011   -   EUCTR2010-023172-12-ES   Austria;Belgium;Denmark;Estonia;Finland;Germany;Greece;Hungary;Italy;Lithuania;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;
      2011   -   EUCTR2010-023172-12-EE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Italy;Korea, Republic of;Lithuania;Netherlands;Norway;Portugal;Russian Federation;Slovakia;Spain;Sweden;Tunisia;Turkey;United Kingdom;United States;
      2011   -   EUCTR2010-023172-12-DK   Austria;Belgium;Denmark;Estonia;Finland;Germany;Greece;Hungary;Italy;Lithuania;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;
      2011   -   EUCTR2010-023172-12-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;Estonia;Finland;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Netherlands;Norway;Portugal;Russian Federation;Slovakia;Spain;Sweden;Tunisia;Turkey;United Kingdom;United States;
      2011   -   EUCTR2010-023172-12-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Italy;Korea, Republic of;Lithuania;Netherlands;Norway;Portugal;Russian Federation;Slovakia;Spain;Sweden;Tunisia;Turkey;United Kingdom;United States;
      2009   Phase 3   EUCTR2008-006226-34-GR   Belgium;Czech Republic;France;Germany;Greece;Hungary;Italy;Spain;United Kingdom;
      2009   -   EUCTR2008-006226-34-IT   Belgium;Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
      2009   -   EUCTR2008-006226-34-ES   Belgium;Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
      2009   -   EUCTR2008-006226-34-BE   Belgium;Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
   sanofi-aventis recherche et developpement
      2010   -   EUCTR2008-006226-34-GB   Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Spain;Tunisia;United Kingdom;
      2009   -   EUCTR2008-006226-34-HU   Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Spain;Tunisia;United Kingdom;
      2009   -   EUCTR2008-006226-34-DE   Belgium;Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
      2009   -   EUCTR2008-006226-34-CZ   Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Spain;Tunisia;United Kingdom;
HMR1726D   
   Sanofi-Aventis recherche & de'veloppement
      2008   -   EUCTR2007-003997-24-IT   Austria;Italy;Spain;United Kingdom;
   Sanofi-Aventis recherche & développement
      2008   -   EUCTR2007-003997-24-GB   Austria;Italy;Spain;United Kingdom;
      2007   -   EUCTR2007-003997-24-ES   Austria;Italy;Spain;United Kingdom;
      2007   -   EUCTR2007-003997-24-AT   Austria;Italy;Spain;United Kingdom;
   Sanofi-aventis U.S. Inc
      2007   -   EUCTR2006-003134-14-IT   Germany;Italy;Spain;
      2007   -   EUCTR2004-000555-42-EE   Czech Republic;Denmark;Estonia;Italy;Norway;Portugal;Sweden;United Kingdom;
   Sanofi-aventis U.S. Inc.
      2007   Phase 2   EUCTR2006-004893-29-GB   Austria;Germany;Italy;United Kingdom;
      2007   Phase 2   EUCTR2006-003134-14-ES   Germany;Italy;Spain;
      2007   -   EUCTR2006-004893-29-IT   Austria;Germany;Italy;United Kingdom;
      2007   -   EUCTR2006-004893-29-AT   Austria;Germany;Italy;United Kingdom;
      2007   -   EUCTR2006-003134-14-DE   Germany;Italy;Spain;
      -   -   EUCTR2006-004893-29-DE   Austria;Germany;Italy;United Kingdom;
   Sanofi-aventis recherche & développement
      2010   -   EUCTR2007-004452-36-SK   Austria;Belgium;Czech Republic;Estonia;France;Germany;Greece;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2007-004452-36-SE   Austria;Belgium;Czech Republic;Estonia;France;Germany;Greece;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2007-004452-36-GR   Austria;Belgium;Czech Republic;Estonia;France;Germany;Greece;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2007-004452-36-GB   Australia;Austria;Belarus;Belgium;Canada;Chile;China;Czech Republic;Estonia;France;Germany;Greece;Mexico;Netherlands;Philippines;Poland;Romania;Slovakia;Spain;Sweden;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2008   Phase 3   EUCTR2006-001152-12-FR   Austria;Bulgaria;Czech Republic;Denmark;Estonia;Finland;France;Germany;Hungary;Lithuania;Slovakia;United Kingdom;
      2008   -   EUCTR2007-004452-36-FR   Austria;Belgium;Czech Republic;Estonia;France;Germany;Greece;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-004452-36-ES   Austria;Belgium;Czech Republic;Estonia;France;Germany;Greece;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-004452-36-EE   Austria;Belgium;Czech Republic;Estonia;France;Germany;Greece;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-004452-36-DE   Austria;Belgium;Czech Republic;Estonia;France;Germany;Greece;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2006-001152-12-SK   Austria;Bulgaria;Czech Republic;Denmark;Estonia;Finland;France;Germany;Hungary;Lithuania;Slovakia;United Kingdom;
   sanofi-aventis recherche de veloppement
      2007   -   EUCTR2006-003361-14-IT   Austria;Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Netherlands;Portugal;Sweden;United Kingdom;
   sanofi-aventis recherche & developpement
      2011   -   EUCTR2011-001160-21-DE   Austria;Canada;Germany;Russian Federation;Ukraine;
      2011   -   EUCTR2011-001160-21-AT   Austria;Canada;Germany;Russian Federation;Ukraine;
   sanofi-aventis recherche & développement
      2009   -   EUCTR2007-004452-36-AT   Australia;Austria;Belarus;Belgium;Canada;Chile;China;Czech Republic;Estonia;France;Germany;Greece;Mexico;Netherlands;Philippines;Poland;Romania;Slovakia;Spain;Sweden;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2009   -   EUCTR2006-003361-14-EE   Austria;Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Netherlands;Portugal;Sweden;United Kingdom;
      2009   -   EUCTR2006-003361-14-CZ   Austria;Canada;Chile;Czech Republic;Denmark;Estonia;Finland;France;Germany;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2009   -   EUCTR2006-001152-12-LT   Australia;Austria;Belarus;Bulgaria;Canada;Chile;Czech Republic;Denmark;Estonia;Finland;France;Germany;Hungary;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;Turkey;Ukraine;United Kingdom;United States;
      2009   -   EUCTR2006-001152-12-DE   Austria;Bulgaria;Czech Republic;Denmark;Estonia;Finland;France;Germany;Hungary;Lithuania;Slovakia;United Kingdom;
      2008   Phase 3   EUCTR2007-004452-36-BE   Australia;Austria;Belarus;Belgium;Canada;Chile;China;Czech Republic;Estonia;France;Germany;Greece;Mexico;Netherlands;Philippines;Poland;Romania;Slovakia;Spain;Sweden;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2008   Phase 3   EUCTR2006-003361-14-PT   Austria;Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Netherlands;Portugal;Sweden;United Kingdom;
      2008   Phase 3   EUCTR2006-001152-12-BG   Austria;Bulgaria;Czech Republic;Denmark;Estonia;Finland;France;Germany;Hungary;Lithuania;Slovakia;United Kingdom;
      2008   -   EUCTR2007-004452-36-NL   Australia;Austria;Belarus;Belgium;Canada;Chile;China;Czech Republic;Estonia;France;Germany;Greece;Mexico;Netherlands;Philippines;Poland;Romania;Slovakia;Spain;Sweden;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2008   -   EUCTR2007-004452-36-CZ   Australia;Austria;Belarus;Belgium;Canada;Chile;China;Czech Republic;Estonia;France;Germany;Greece;Mexico;Netherlands;Philippines;Poland;Romania;Slovakia;Spain;Sweden;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2008   -   EUCTR2006-003361-14-NL   Austria;Canada;Chile;Czech Republic;Denmark;Estonia;Finland;France;Germany;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2008   -   EUCTR2006-003361-14-DK   Austria;Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Netherlands;Portugal;Sweden;United Kingdom;
      2008   -   EUCTR2006-001152-12-HU   Australia;Austria;Belarus;Bulgaria;Canada;Chile;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Hungary;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;Turkey;Ukraine;United Kingdom;United States;
      2008   -   EUCTR2006-001152-12-EE   Australia;Austria;Belarus;Bulgaria;Canada;Chile;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Hungary;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;Turkey;Ukraine;United Kingdom;United States;
      2007   Phase 3   EUCTR2006-003361-14-SE   Austria;Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Netherlands;Portugal;Sweden;United Kingdom;
      2007   Phase 3   EUCTR2006-003361-14-GB   Austria;Canada;Czech Republic;Denmark;Estonia;Finland;France;Germany;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2007   Phase 3   EUCTR2006-001152-12-GB   Australia;Austria;Belarus;Bulgaria;Canada;Chile;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Hungary;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;Turkey;Ukraine;United Kingdom;United States;
      2007   Phase 3   EUCTR2006-001152-12-FI   Austria;Bulgaria;Czech Republic;Denmark;Estonia;Finland;France;Germany;Hungary;Lithuania;Slovakia;United Kingdom;
      2007   Phase 3   EUCTR2006-001152-12-CZ   Australia;Austria;Belarus;Bulgaria;Canada;Chile;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Hungary;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;Turkey;Ukraine;United Kingdom;United States;
      2007   -   EUCTR2006-003361-14-DE   Austria;Canada;Chile;Czech Republic;Denmark;Estonia;Finland;France;Germany;Italy;Netherlands;Poland;Portugal;Russian Federation;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2007   -   EUCTR2006-001152-12-DK   Australia;Austria;Belarus;Bulgaria;Canada;Chile;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Hungary;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;Turkey;Ukraine;United Kingdom;United States;
      2007   -   EUCTR2006-001152-12-AT   Austria;Bulgaria;Czech Republic;Denmark;Estonia;Finland;France;Germany;Hungary;Lithuania;Slovakia;United Kingdom;
      2006   Phase 3   EUCTR2006-003361-14-FI   Austria;Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Netherlands;Portugal;Sweden;United Kingdom;
      2006   -   EUCTR2006-003361-14-AT   Austria;Canada;Chile;Czech Republic;Denmark;Estonia;Finland;France;Germany;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
HP184   
   sanofi-aventis Recherche & Développement
      2009   Phase 2   EUCTR2008-001999-67-FR   Finland;France;Germany;Spain;
      2009   Phase 2   EUCTR2008-001999-67-ES   Finland;France;Germany;Spain;
      2009   -   EUCTR2008-001999-67-FI   Finland;France;Germany;Spain;
      2009   -   EUCTR2008-001999-67-DE   Finland;France;Germany;Spain;
HUMAN LEUCOCYTE INTERFERON-ALPHA   
   Dansk Multipel Sclerose Center
      2010   -   EUCTR2009-016824-29-DK   Denmark;
Helminth ova   
   University of Wisconsin, Madison
      2008   Phase 1   NCT00645749   United States;
Hematopoetic stem cell infusion   
   Talaris Therapeutics Inc.
      2007   Phase 1/Phase 2   NCT00497952   United States;
Hematopoietic Stem Cell Therapy   
   Northwestern University
      2005   Phase 2   NCT00273364   United States;
Hematopoietic stem cell transplantation   
   Northwestern University
      2003   Phase 1/Phase 2   NCT00278655   United States;
Hematopoietic stem cell transplantation (HSCT)   
   Sheffield Teaching Hospitals NHS Foundation Trust
      2013   Phase 2/Phase 3   NCT03133403   United Kingdom;
Heterologous booster   
   Griffin Hospital
      2021   -   NCT05081271   -
Hiberix   
   ALEXION PHARMACEUTICALS INCORPORATED
      2020   Phase 2;Phase 3   EUCTR2019-001829-26-IT   Canada;Germany;Italy;Japan;Korea, Republic of;Spain;United States;
Hidrocloruro de fingolimod   
   Novartis Farmacéutica, S.A.
      2011   -   EUCTR2011-001442-15-ES   Austria;Czech Republic;Finland;France;Germany;Greece;Hungary;Israel;Italy;Spain;Sweden;Switzerland;United Kingdom;
High Dose Aspirin (1300 mg/day)   
   Mayo Clinic
      2007   Phase 3   NCT00467584   United States;
High Phenolic Extra Virgin Olive Oil   
   University of Cyprus
      2021   -   NCT04787497   -
High/Low Sodium Diet   
   Yale University
      2014   -   NCT02282878   United States;
Histamine   
   University of Nottingham
      2008   Phase 2   NCT00630383   United Kingdom;
Home based balance training   
   University of Arizona
      2014   -   NCT02777060   United States;
Homologous booster   
   Griffin Hospital
      2021   -   NCT05081271   -
Hookworm larvae   
   University of Nottingham
      2011   Phase 2   NCT01470521   United Kingdom;
HuL001   
   HuniLife Biotechnology, Inc.
      2021   Phase 1   NCT04540770   Taiwan;
HuMax-CD20   
   Genmab A/S
      2008   Phase 2   EUCTR2007-004223-38-DE   Belgium;Czech Republic;Denmark;Germany;Sweden;United Kingdom;
      2008   -   EUCTR2007-004223-38-BE   Belgium;Czech Republic;Denmark;Germany;Sweden;United Kingdom;
   GlaxoSmithKline
      2008   -   EUCTR2007-004223-38-DK   Czech Republic;Denmark;Germany;Sweden;United Kingdom;
   GlaxoSmithKline AB
      2008   -   EUCTR2007-004223-38-SE   Czech Republic;Denmark;Germany;Sweden;United Kingdom;
   GlaxoSmithKline UK
      2009   Phase 2   EUCTR2007-004223-38-GB   Belgium;Czech Republic;Denmark;Germany;Sweden;United Kingdom;
   GlaxoSmithKline s.r.o.
      2008   -   EUCTR2007-004223-38-CZ   Czech Republic;Denmark;Germany;Sweden;United Kingdom;
Human Neural Stem Cells   
   Casa Sollievo della Sofferenza IRCCS
      2017   Phase 1   NCT03282760   Italy;Switzerland;
Human anti-IL-12 IgG1 Mab   
   Centocor B.V.
      2005   Phase 2   EUCTR2004-000145-38-GB   Czech Republic;Hungary;United Kingdom;
      2004   Phase 2   EUCTR2004-000145-38-CZ   Czech Republic;Hungary;United Kingdom;
      2004   -   EUCTR2004-000145-38-HU   Czech Republic;Hungary;United Kingdom;
Human anti-IL-12 Mab   
   Centocor B.V.
      2005   Phase 2   EUCTR2004-000145-38-GB   Czech Republic;Hungary;United Kingdom;
      2004   Phase 2   EUCTR2004-000145-38-CZ   Czech Republic;Hungary;United Kingdom;
      2004   -   EUCTR2004-000145-38-HU   Czech Republic;Hungary;United Kingdom;
Human anti-LINGO-1 monoclonal antibody   
   Biogen Idec Research Limited
      2013   Phase 2   EUCTR2011-006262-40-NL   Canada;Czech Republic;France;Hungary;Italy;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2013   Phase 2   EUCTR2011-006262-40-IT   Canada;Czech Republic;Hungary;Italy;Netherlands;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2013   Phase 2   EUCTR2011-006262-40-HU   Canada;Czech Republic;France;Hungary;Italy;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2013   Phase 2   EUCTR2011-006262-40-GB   Canada;Czech Republic;France;Hungary;Italy;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2013   Phase 2   EUCTR2011-006262-40-CZ   Canada;Czech Republic;France;Hungary;Italy;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
Human autologous mesenchymal stem cells   
   SALK - Gemeinnützige Salzburger Landeskliniken Betriebsges. m.b.H., Christian-Doppler-Klinik, UK für Neurologie der PMU
      -   -   EUCTR2015-000137-78-AT   Austria;
Human fetal-derived Neural Stem Cells (hNSCs)   
   IRCCS San Raffaele
      2017   Phase 1   NCT03269071   Italy;
Human interferon beta 1a (Rebif)   
   Aaron Boster
      2006   Phase 0   NCT00618527   United States;
Human interferon beta-1a and glatiramer acetate   
   EMD Serono
      2004   Phase 4   NCT00078338   Argentina;Austria;Brazil;France;Germany;Italy;Netherlands;Russian Federation;Spain;Switzerland;United Kingdom;United States;
Human monoclonal antibody (CNTO 1275) to interleukin-12p40   
   Centocor B.V.
      2005   Phase 2   EUCTR2004-000145-38-GB   Czech Republic;Hungary;United Kingdom;
      2004   Phase 2   EUCTR2004-000145-38-CZ   Czech Republic;Hungary;United Kingdom;
      2004   -   EUCTR2004-000145-38-HU   Czech Republic;Hungary;United Kingdom;
Human normal immunoglobulin   
   Octapharma AG
      2015   Phase 3   EUCTR2012-005086-12-PL   Austria;Bulgaria;Germany;Hungary;Poland;Russian Federation;Serbia;Ukraine;
      2013   -   EUCTR2012-005086-12-HU   Austria;Bulgaria;Germany;Hungary;Poland;Russian Federation;
      2013   -   EUCTR2012-005086-12-DE   Austria;Bulgaria;Germany;Hungary;Poland;Russian Federation;
      2013   -   EUCTR2012-005086-12-BG   Austria;Bulgaria;Germany;Hungary;Poland;Russian Federation;
      2013   -   EUCTR2012-005086-12-AT   Austria;Bulgaria;Germany;Hungary;Poland;Russian Federation;
Human recombinant growth hormone   
   University of Leipzig
      -   Phase 2   EUCTR2006-006465-16-DE   Germany;
Hydrogen peroxide   
   Tehran University of Medical Sciences
      2012   -   NCT02463318   Iran, Islamic Republic of;
Hydroxychloroquine   
   University of Calgary
      2016   Phase 2   NCT02913157   Canada;
Hydroxychloroquine and Indapamide   
   University of Calgary
      2021   Phase 2   NCT05013463   -
Hydroxyurea   
   S. Andrea Hospital
      2011   Phase 2/Phase 3   NCT01103583   Italy;
Hyperimmune caprine serum against HIV lysate   
   Daval International Limited
      2009   Phase 2   NCT01228396   United Kingdom;
IFA Incomplete Freund's Adjuvant   
   Immune Response BioPharma, Inc.
      2020   Phase 2   NCT02149706   United States;
      2020   Phase 1   NCT02200718   United States;
IFN beta 1a 44 mcg TIW   
   Merck KGaA, Darmstadt, Germany
      2012   Phase 2   NCT01514370   Italy;
IFN beta-1a   
   BIOGEN IDEC RESEARCH LIMITED
      2019   Phase 3   EUCTR2018-003008-38-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
   Biogen Idec Research Limited
      2020   Phase 3   EUCTR2018-003008-38-DE   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-003008-38-SK   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-003008-38-PT   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-003008-38-HU   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-003008-38-HR   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-003008-38-GR   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-003008-38-ES   Argentina;Belgium;Brazil;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;
      2019   Phase 3   EUCTR2018-003008-38-CZ   Argentina;Belgium;Brazil;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;
      2019   Phase 3   EUCTR2018-003008-38-BG   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-003008-38-BE   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      -   Phase 3   EUCTR2018-003008-38-FR   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
   Merck KGaA, Darmstadt, Germany
      2018   Phase 2   NCT03387046   Germany;Italy;
IFN ß-1a   
   BIOGEN IDEC RESEARCH LIMITED
      2019   Phase 3   EUCTR2018-003008-38-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
   Biogen Idec Research Limited
      2020   Phase 3   EUCTR2018-003008-38-DE   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-003008-38-SK   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-003008-38-PT   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-003008-38-HU   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-003008-38-HR   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-003008-38-GR   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-003008-38-ES   Argentina;Belgium;Brazil;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;
      2019   Phase 3   EUCTR2018-003008-38-CZ   Argentina;Belgium;Brazil;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;
      2019   Phase 3   EUCTR2018-003008-38-BG   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-003008-38-BE   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      -   Phase 3   EUCTR2018-003008-38-FR   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
IFN-beta-1a (Rebif®)   
   Waukesha Memorial Hospital
      2008   -   NCT00391352   United States;
IFN-beta-1a, (Avonex®)   
   Neurognostics
      2006   -   NCT00398528   United States;
IFN-ß-1a (Rebif®)   
   Waukesha Memorial Hospital
      2008   -   NCT00391352   United States;
IFN-ß-1a, (Avonex®)   
   Neurognostics
      2006   -   NCT00398528   United States;
IL2   
   Assistance Publique - Hôpitaux de Paris
      2016   Phase 2   NCT02424396   France;
IM90838   
   Immunic AG
      2022   Phase 2   EUCTR2021-000048-23-NL   Bulgaria;Canada;Czechia;Finland;Germany;Hungary;Moldova, Republic of;Netherlands;North Macedonia;Poland;Romania;Russian Federation;Serbia;Ukraine;United States;
      2022   Phase 2   EUCTR2021-000048-23-DE   Bulgaria;Canada;Czechia;Finland;Germany;Hungary;Moldova, Republic of;Netherlands;North Macedonia;Poland;Romania;Russian Federation;Serbia;Ukraine;United States;
      2021   Phase 2   EUCTR2021-000048-23-BG   Bulgaria;Czechia;Finland;Germany;Hungary;Moldova, Republic of;Netherlands;North Macedonia;Poland;Romania;Russian Federation;Serbia;Ukraine;
IMATINIB MESILATE   
   Department of Clinical Neuroscience, Karolinska Institutet
      2020   Phase 2   EUCTR2018-000620-34-DE   Germany;Sweden;
      2018   Phase 2   EUCTR2018-000620-34-SE   Sweden;
IMMUNOGLOBULIN G   
   Octapharma AG
      2015   Phase 3   EUCTR2012-005086-12-PL   Austria;Bulgaria;Germany;Hungary;Poland;Russian Federation;Serbia;Ukraine;
      2013   -   EUCTR2012-005086-12-HU   Austria;Bulgaria;Germany;Hungary;Poland;Russian Federation;
      2013   -   EUCTR2012-005086-12-DE   Austria;Bulgaria;Germany;Hungary;Poland;Russian Federation;
      2013   -   EUCTR2012-005086-12-BG   Austria;Bulgaria;Germany;Hungary;Poland;Russian Federation;
      2013   -   EUCTR2012-005086-12-AT   Austria;Bulgaria;Germany;Hungary;Poland;Russian Federation;
IMMUNOSUPPRESSIVE AGENTS   
   Actelion Pharmaceuticals Ltd
      2010   -   EUCTR2009-011470-15-IT   Austria;Bulgaria;Czech Republic;Finland;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;
IMS001   
   ImStem Biotechnology
      2021   Phase 1   NCT04956744   United States;
IMU-838   
   Immunic AG
      2022   Phase 3   EUCTR2021-000028-36-BG   Albania;Belarus;Bulgaria;Colombia;Georgia;Greece;India;Lithuania;Mexico;Moldova, Republic of;North Macedonia;Poland;Russian Federation;Ukraine;United States;
      2022   Phase 2   EUCTR2021-000048-23-NL   Bulgaria;Canada;Czechia;Finland;Germany;Hungary;Moldova, Republic of;Netherlands;North Macedonia;Poland;Romania;Russian Federation;Serbia;Ukraine;United States;
      2022   Phase 2   EUCTR2021-000048-23-DE   Bulgaria;Canada;Czechia;Finland;Germany;Hungary;Moldova, Republic of;Netherlands;North Macedonia;Poland;Romania;Russian Federation;Serbia;Ukraine;United States;
      2021   Phase 2   NCT05054140   Bulgaria;Poland;Ukraine;United States;
      2021   Phase 2   EUCTR2021-000048-23-BG   Bulgaria;Czechia;Finland;Germany;Hungary;Moldova, Republic of;Netherlands;North Macedonia;Poland;Romania;Russian Federation;Serbia;Ukraine;
      2018   Phase 2   EUCTR2018-001896-19-BG   Bulgaria;Poland;Romania;Ukraine;
IMU-838 (30 mg/day)   
   Immunic AG
      2019   Phase 2   NCT03846219   Bulgaria;Poland;Romania;Ukraine;
IMU-838 (45 mg/day)   
   Immunic AG
      2019   Phase 2   NCT03846219   Bulgaria;Poland;Romania;Ukraine;
IMU-838 tablets   
   Immunic AG
      2022   Phase 3   NCT05201638   -
      2021   Phase 3   NCT05134441   -
INF beta-1a   
   Bosnalijek D.D
      2019   Phase 3   NCT03283397   Turkey;
INN COLECALCIFEROL   
   Merja Soilu Häninen
      2007   -   EUCTR2007-001958-99-FI   Finland;
INT131   
   InteKrin Therapeutics, Inc.
      2015   Phase 2   NCT02638038   -
INTERFERON BETA - 1A   
   BIOGEN IDEC RESEARCH LIMITED
      2019   Phase 3   EUCTR2018-003008-38-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
   OSPEDALE SAN RAFFAELE
      2018   Phase 4   EUCTR2016-004819-12-IT   Italy;
INTERFERON BETA-1A (Avonex®)   
   Teva Pharmaceutical Industries Ltd
      2008   -   EUCTR2007-005450-23-LT   Bulgaria;Czech Republic;Estonia;Germany;Italy;Lithuania;Spain;
INTERFERON BETA1A   
   Biogen Idec Limited
      2010   -   EUCTR2009-015556-15-ES   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
   Biogen Idec Ltd
      2010   Phase 3   EUCTR2009-012500-11-ES   Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Slovenia;Spain;Sweden;United Kingdom;
   Merck Serono International, a branch of Laboratoires Serono SA an affiliate of Merck KGaA, Darmstadt
      2009   Phase 3   EUCTR2008-004954-34-ES   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Greece;Italy;Latvia;Poland;Portugal;Slovakia;Spain;
   Merck Serono S.A. - Geneva, an affiliate of Merck KGaA Darmstadt, Germany
      2006   -   EUCTR2006-002982-38-ES   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Italy;Lithuania;Portugal;Spain;
   sanofi-aventis recherche et development
      2009   -   EUCTR2008-006226-34-ES   Belgium;Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
INTERFERONE BETA 1B   
   OSPEDALE SAN RAFFAELE
      2018   Phase 4   EUCTR2016-004819-12-IT   Italy;
IPX056   
   Impax Laboratories, LLC
      2009   Phase 2   NCT00914290   United States;
      2007   Phase 3   NCT00488839   Canada;Estonia;Latvia;Ukraine;United States;
IPX056-   
   IMPAX Laboratories, Inc.
      2007   -   EUCTR2007-000236-16-LV   Estonia;Latvia;
      2007   -   EUCTR2007-000236-16-EE   Estonia;Latvia;
IR902   
   The Immune Response Corporation
      2007   Phase 2   EUCTR2006-003384-30-SK   Slovakia;
IS (B cell depletion therapy)   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States;
IS (MMF or MPA)   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States;
IS (MTX)   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States;
IV methylprednisolone   
   Biogen Idec
      2003   Phase 4   NCT00112034   United States;
   Fred Lublin
      2003   Phase 3   NCT00418145   United States;
IV methylprednisolone (steroids)   
   University of Colorado, Denver
      2013   Phase 4   NCT01838174   United States;
IVIg   
   Northwestern University
      2019   Phase 2/Phase 3   NCT03829566   United States;
      2017   Phase 3   NCT03342638   United States;
Ibudilast   
   MediciNova
      2013   Phase 2   NCT01982942   United States;
Ibuprofen   
   Genzyme, a Sanofi Company
      2014   Phase 4   NCT02205489   Belgium;France;Netherlands;Spain;
Ibuprofen Sandoz 400 mg Filmtabletten   
   Merck Serono International SA
      2007   -   EUCTR2006-005972-42-DE   France;Germany;
Idebenone   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2013   Phase 1/Phase 2   NCT01854359   United States;
      2009   Phase 1/Phase 2   NCT00950248   United States;
Imatinib Mesylate   
   Tomas Olsson
      2018   Phase 2   NCT03674099   Denmark;Germany;Norway;Sweden;
Immune Globulin IV [Human], Caprylate/Chromatography Purified   
   Grifols Therapeutics Inc.
      2002   Phase 2   NCT00220779   Austria;Canada;Czech Republic;Germany;Greece;Hungary;Israel;Poland;Slovakia;Sweden;United Kingdom;United States;
Immune globulin   
   National Institute of Neurological Disorders and Stroke (NINDS)
      1993   Phase 3   NCT00004744   -
Immunoadsorption   
   University Hospital Muenster
      2018   -   NCT04450030   Germany;
Immunoglobulin   
   Octapharma AG
      2008   -   EUCTR2008-004579-22-AT   Austria;
Impact   
   Fondazione Don Carlo Gnocchi Onlus
      2018   -   NCT04881422   Italy;
   Nelson Mandela Metropolitan University
      2011   Phase 0   NCT01453868   United States;
   University Hospital, Strasbourg, France
      2019   Phase 2   NCT03910738   France;
   University of Alabama at Birmingham
      2022   -   NCT05165238   -
IncabotulinumtoxinA   
   Multiple Sclerosis Center of Northeastern New York
      2013   Phase 4   NCT01968902   United States;
Incobotulinum toxin A   
   Pôle Saint Hélier
      2014   -   NCT04265092   -
Inebilizumab   
   MedImmune LLC
      2018   Phase 2;Phase 3   EUCTR2014-000253-36-NL   Australia;Bulgaria;Canada;China;Colombia;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;India;Israel;Japan;Korea, Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;Ukraine;United States;
      2017   Phase 2;Phase 3   EUCTR2014-000253-36-HU   Australia;Bulgaria;Canada;Colombia;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;Israel;Japan;Korea, Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;Ukraine;United States;
      2015   Phase 2;Phase 3   EUCTR2014-000253-36-DE   Australia;Bulgaria;Canada;Colombia;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;Israel;Japan;Korea, Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;Ukraine;United States;
      2015   Phase 2;Phase 3   EUCTR2014-000253-36-BG   Australia;Bulgaria;Canada;Colombia;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;Israel;Japan;Korea, Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;Ukraine;United States;
      2015   Phase 2/Phase 3   NCT02200770   Australia;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;Estonia;Germany;Greece;Hong Kong;Hungary;India;Israel;Japan;Korea, Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;Ukraine;United States;
      2014   Phase 2;Phase 3   EUCTR2014-000253-36-PL   Australia;Bulgaria;Canada;Colombia;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;Israel;Japan;Korea, Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;Ukraine;United States;
      2014   Phase 2;Phase 3   EUCTR2014-000253-36-EE   Australia;Bulgaria;Canada;Colombia;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;Israel;Japan;Korea, Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;Ukraine;United States;
      2014   Phase 2;Phase 3   EUCTR2014-000253-36-CZ   Australia;Bulgaria;Canada;Colombia;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;Israel;Japan;Korea, Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;Ukraine;United States;
   Sato Toshiyuki
      2020   Phase 3   JPRN-jRCT2051210017   Japan;
Influenza Vaccine   
   Hoffmann-La Roche
      2015   Phase 3   NCT02545868   Canada;United States;
Influenza vaccine   
   Sanofi
      2011   Phase 2   NCT01403376   Austria;Canada;Germany;Russian Federation;Ukraine;
Inhaled Cannabis   
   University of California, Davis
      2004   Phase 1/Phase 2   NCT00682929   United States;
Injectable MS DMT   
   Biogen
      2015   Phase 4   NCT02471560   Norway;
Injection of autologous bone marrow derived mesenchymal stem cells   
   Hadassah Medical Organization
      2006   Phase 1/Phase 2   NCT00781872   -
Injection of cell free media   
   Royan Institute
      2011   Phase 1/Phase 2   NCT01377870   Iran, Islamic Republic of;
Inosine   
   National Center for Complementary and Integrative Health (NCCIH)
      2002   Phase 2   NCT00067327   United States;
   Tsukuba International Clinical Pharmacology Clinic
      2016   -   JPRN-UMIN000024312   Japan;
Insulin   
   Johns Hopkins University
      2017   Phase 1/Phase 2   NCT02988401   United States;
Inteferone Beta-1A   
   OSPEDALE SAN RAFFAELE
      2018   Phase 4   EUCTR2016-004819-12-IT   Italy;
Interferon Beta 1   
   University of Turin, Italy
      1999   Phase 3   NCT00473213   -
Interferon Beta 1a pegilado   
   Biogen Idec Limited
      2011   -   EUCTR2010-024477-39-ES   Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;India;Latvia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
Interferon Beta Therapy   
   Biogen
      2021   -   NCT04655222   Germany;
Interferon Beta-1A Prefilled Syringe   
   Cinnagen
      2017   Phase 3   NCT05242133   Iran, Islamic Republic of;
Interferon beta   
   Heidelberg University
      2006   Phase 3   NCT00344253   Germany;
Interferon beta - 1a (IFN)   
   Novartis Pharmaceuticals
      2012   Phase 4   NCT01534182   Russian Federation;
Interferon beta -1b   
   EMD Serono
      2006   Phase 3   NCT00428584   United States;
Interferon beta 1-a   
   Biogen
      2010   Phase 2   NCT01071083   Germany;Spain;United States;
   Fred Lublin
      2005   Phase 3   NCT00211887   Canada;United States;
   Merck Healthcare KGaA
      2020   Phase 3   EUCTR2018-004701-11-BG   Argentina;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Montenegro;Poland;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-004700-19-BG   Belarus;Brazil;Bulgaria;Canada;France;Germany;Greece;Italy;Kuwait;Lebanon;Lithuania;Mexico;Moldova, Republic of;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Thailand;Tunisia;Turkey;Ukraine;United States;
Interferon beta 1-b (Betaferon/Betaseron, BAY86-5046)   
   Bayer
      2011   -   NCT01071694   Korea, Republic of;
Interferon beta 1B   
   Charite Universitaetsmedizin Berlin
      2012   Phase 3   EUCTR2011-004787-30-DE   Germany;
Interferon beta 1a   
   Biogen Idec Limited
      2012   Phase 3   EUCTR2010-024477-39-GR   Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;India;Latvia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2012   Phase 3   EUCTR2010-024477-39-GB   Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;India;Latvia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2010-024477-39-CZ   Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;India;Latvia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-024477-39-DE   Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;India;Latvia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-024477-39-BG   Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;India;Latvia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-024477-39-LV   Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;India;Latvia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-024477-39-EE   Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;India;Latvia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-024477-39-BE   Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;India;Latvia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2008-006333-27-CZ   Belarus;Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;India;Kazakhstan;Latvia;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Turkey;Ukraine;United Kingdom;United States;
      2009   Phase 3   EUCTR2008-006333-27-GB   Belarus;Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;India;Kazakhstan;Latvia;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Turkey;Ukraine;United Kingdom;United States;
      2009   -   EUCTR2008-006333-27-NL   Belarus;Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;India;Kazakhstan;Latvia;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Turkey;Ukraine;United Kingdom;United States;
      2009   -   EUCTR2008-006333-27-EE   Belarus;Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;India;Kazakhstan;Latvia;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Turkey;Ukraine;United Kingdom;United States;
      2009   -   EUCTR2008-006333-27-BG   Belarus;Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;India;Kazakhstan;Latvia;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Turkey;Ukraine;United Kingdom;United States;
      2009   -   EUCTR2008-006333-27-BE   Belarus;Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;India;Kazakhstan;Latvia;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Turkey;Ukraine;United Kingdom;United States;
      -   -   EUCTR2008-006333-27-DE   Belarus;Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;India;Kazakhstan;Latvia;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Turkey;Ukraine;United Kingdom;United States;
   Biogen Idec Ltd
      2009   -   EUCTR2008-003098-42-CZ   Czech Republic;
   Merck KGaA
      2005   -   NCT01142518   -
      2005   -   NCT01142453   -
   MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute
      2002   Phase 4   NCT00037115   United States;
      2001   Phase 4   NCT00037102   United States;
   Rennes University Hospital
      2010   Phase 3   NCT02937285   France;
   Revalesio Corporation
      2013   Phase 2   NCT01714089   United States;
   Trio Medicines Ltd.
      2001   Phase 1   NCT01863069   United Kingdom;
   UCL Biomedicine R&D Unit
      2006   -   EUCTR2005-005751-18-GB   United Kingdom;
Interferon beta 1a 30 ug IM once weekly   
   Beth Israel Deaconess Medical Center
      2001   Phase 4   NCT00179478   Canada;United States;
Interferon beta 1a, oral doxycycline   
   Louisiana State University Health Sciences Center Shreveport
      2003   Phase 4   NCT00246324   United States;
Interferon beta 1b   
   Novartis Pharmaceuticals
      2011   Phase 4   NCT01333501   Germany;Italy;
   Schering AG
      2007   Phase 3   EUCTR2006-005270-47-ES   Austria;Belgium;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
   UCL Biomedicine R&D Unit
      2006   -   EUCTR2005-005751-18-GB   United Kingdom;
   University Hospital Inselspital, Berne
      2005   Phase 2   NCT00942591   Switzerland;
Interferon beta 1b (Betaseron, BAY86-5046)   
   Bayer
      2003   Phase 2   NCT00235989   United States;
Interferon beta treatment to add-on atorvastatin treatment   
   Charite University, Berlin, Germany
      2003   Phase 2   NCT00616187   -
Interferon beta type 1a   
   Biogen
      2019   Phase 3   NCT03958877   Argentina;Australia;Belgium;Bulgaria;Croatia;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
Interferon beta-1 a   
   Serono GmbH
      2005   -   EUCTR2005-001026-89-DE   Germany;
Interferon beta-1a   
   BIOGEN IDEC LTD
      2010   -   EUCTR2009-015556-15-IT   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-012500-11-IT   Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Slovenia;Spain;Sweden;United Kingdom;
   BIOGEN-DOMPE` SRL
      2010   -   EUCTR2009-017003-28-IT   Italy;
   Biogen
      2017   Phase 4   NCT03177083   Portugal;
      2014   Phase 3   NCT02283853   Argentina;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Kuwait;Poland;Romania;Serbia;Spain;Sweden;Turkey;United Kingdom;United States;
      2013   -   NCT02076841   Czech Republic;Switzerland;
      2012   -   NCT01272128   Belgium;United States;
      2010   Phase 3   NCT01064401   Argentina;Australia;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Egypt;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Slovenia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2010   Phase 3   NCT01058005   Australia;Canada;Czech Republic;Finland;France;Hungary;Italy;Latvia;Poland;Slovenia;Spain;Sweden;United States;
   Biogen Idec
      2007   Phase 4   NCT00574041   Australia;
      2005   Phase 3   NCT00915577   -
      2003   Phase 2   NCT00912860   -
      2002   -   NCT00599274   Australia;Austria;Canada;United States;
      1999   Phase 4   NCT00534261   Belgium;Luxembourg;United Kingdom;
   Biogen Idec GmbH
      2005   -   EUCTR2004-004130-14-AT   Austria;
   Biogen Idec Research Limited
      2013   Phase 2   EUCTR2011-006262-40-NL   Canada;Czech Republic;France;Hungary;Italy;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2013   Phase 2   EUCTR2011-006262-40-IT   Canada;Czech Republic;Hungary;Italy;Netherlands;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2013   Phase 2   EUCTR2011-006262-40-HU   Canada;Czech Republic;France;Hungary;Italy;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2013   Phase 2   EUCTR2011-006262-40-GB   Canada;Czech Republic;France;Hungary;Italy;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
      2013   Phase 2   EUCTR2011-006262-40-CZ   Canada;Czech Republic;France;Hungary;Italy;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
   Celgene
      2014   Phase 3   NCT02294058   Argentina;Austria;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;Georgia;Germany;Hungary;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2013   Phase 3   NCT02047734   Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Georgia;Greece;Hungary;Italy;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
   Centre Hospitalier Universitaire Vaudois
      2005   Phase 1   NCT02515695   -
   Genzyme Corporation
      2008   -   EUCTR2007-001162-32-IT   Austria;Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;
   Genzyme, a Sanofi Company
      2007   Phase 3   NCT00548405   Argentina;Australia;Austria;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;France;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2007   Phase 3   NCT00530348   Argentina;Australia;Brazil;Canada;Croatia;Czech Republic;Former Serbia and Montenegro;France;Germany;Mexico;Poland;Russian Federation;Serbia;Sweden;Ukraine;United Kingdom;United States;
      2002   Phase 2   NCT00050778   Croatia;Poland;Russian Federation;United Kingdom;United States;
   Hoffmann-La Roche
      2011   Phase 3   NCT01412333   Argentina;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;France;Germany;Ireland;Italy;Mexico;Morocco;Norway;Poland;Russian Federation;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   NCT01247324   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Czechia;Estonia;Finland;France;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
   ISTITUTO C. MONDINO
      2007   -   EUCTR2008-007162-32-IT   Italy;
   MERCK SERONO SA
      2010   -   EUCTR2009-016087-37-IT   France;Ireland;Italy;Spain;United Kingdom;
      2009   -   EUCTR2008-004954-34-IT   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Greece;Italy;Latvia;Poland;Portugal;Spain;
      2009   -   EUCTR2008-003706-33-IT   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Greece;Italy;Norway;Portugal;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-000499-25-IT   Germany;Italy;Spain;Sweden;
   MERCK SERONO SPA
      2009   -   EUCTR2009-013333-24-IT   Italy;
   MedImmune LLC
      2012   -   EUCTR2011-005475-16-GB   Austria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
   Merck KGaA
      2005   Phase 4   NCT01201343   -
      2005   -   NCT01142492   -
   Merck Serono International SA
      2007   -   EUCTR2006-005972-42-DE   France;Germany;
   NOVARTIS FARMA
      2011   -   EUCTR2010-024017-31-IT   Italy;
      2006   -   EUCTR2006-000704-17-IT   Austria;Belgium;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom;
   Novartis Pharma AG
      2021   Phase 3   EUCTR2020-004505-32-FR   France;Germany;
      2021   Phase 3   EUCTR2020-004505-32-DE   France;Germany;Italy;Spain;
   Novartis Pharma Services AG
      2006   Phase 3   EUCTR2006-000704-17-GR   Austria;Belgium;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom;
      2006   -   EUCTR2006-000704-17-PT   Austria;Belgium;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom;
      2006   -   EUCTR2006-000704-17-GB   Austria;Belgium;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom;
   Novartis Pharmaceuticals
      2013   Phase 3   NCT01892722   Australia;Austria;Belarus;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Estonia;France;Germany;Italy;Latvia;Lithuania;Mexico;Netherlands;Poland;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
   OSPEDALE S. RAFFAELE
      2004   -   EUCTR2004-001601-10-IT   France;Italy;
   Sahlgrenska University Hospital
      2005   -   EUCTR2005-001008-37-SE   Sweden;
   Sanofi
      2009   Phase 3   NCT00883337   Belgium;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Spain;Switzerland;Tunisia;United Kingdom;
   Serono International SA
      2004   -   EUCTR2004-000337-12-HU   Hungary;
   TEVA ITALIA srl
      2008   -   EUCTR2007-005450-23-IT   Bulgaria;Czech Republic;Estonia;Germany;Italy;Lithuania;Spain;
   Teva Pharmaceutical Industries Ltd
      2008   -   EUCTR2007-005450-23-EE   Bulgaria;Czech Republic;Estonia;Germany;Italy;Lithuania;Spain;
   Universita di Firenze
      2006   -   EUCTR2006-004937-13-IT   Italy;
   Universitätsklinikum Heidelberg
      2006   Phase 3   EUCTR2004-004403-37-DE   Germany;
   VU University Medical Center
      2011   -   EUCTR2011-003570-89-NL   Netherlands;
Interferon beta-1a (Avonex)   
   Biogen Idec
      2002   Phase 4   NCT00913666   -
      1999   Phase 4   NCT00915460   -
Interferon beta-1a (Rebif)   
   Merck KGaA
      2010   -   NCT01101776   Australia;
      2005   Phase 4   NCT01142466   -
      2004   -   NCT01142557   Germany;
Interferon beta-1a (Rebif®) alone   
   Merck KGaA
      2011   Phase 2   NCT01285401   Austria;Belgium;Denmark;Estonia;Finland;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Portugal;Switzerland;
Interferon beta-1a (current approved manufacturing process invloving FBS)   
   Biogen Idec
      2012   Phase 1   NCT01500408   United States;
Interferon beta-1a (new process, manufactured without FBS)   
   Biogen Idec
      2012   Phase 1   NCT01500408   United States;
Interferon beta-1a 30 µg   
   Novartis
      2006   Phase 3   NCT00340834   Argentina;Australia;Austria;Belgium;Brazil;Canada;Egypt;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Portugal;Puerto Rico;Spain;Switzerland;United Kingdom;United States;
Interferon beta-1a FBS-free/HSA free, RNF   
   Serono International, S.A.
      2007   -   EUCTR2006-003366-33-ES   Italy;Spain;
Interferon beta-1a FBS-free/HSA-free   
   Merck Serono International
      2010   -   EUCTR2008-003706-33-GR   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Greece;Italy;Norway;Portugal;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2008-003706-33-FR   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Greece;Italy;Norway;Portugal;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-003706-33-ES   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Greece;Italy;Norway;Portugal;Spain;Sweden;United Kingdom;
   Merck Serono S.A. - Geneva
      2009   Phase 3   EUCTR2008-003706-33-GB   Argentina;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Lebanon;Macedonia, the former Yugoslav Republic of;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2009   Phase 3   EUCTR2008-003706-33-BE   Argentina;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Lebanon;Macedonia, the former Yugoslav Republic of;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2009   -   EUCTR2008-003706-33-SE   Argentina;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Lebanon;Macedonia, the former Yugoslav Republic of;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2009   -   EUCTR2008-003706-33-NO   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Greece;Italy;Norway;Portugal;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-003706-33-DE   Argentina;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Lebanon;Macedonia, the former Yugoslav Republic of;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2009   -   EUCTR2008-003706-33-CZ   Argentina;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Lebanon;Macedonia, the former Yugoslav Republic of;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2009   -   EUCTR2008-003706-33-BG   Argentina;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Lebanon;Macedonia, the former Yugoslav Republic of;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2009   -   EUCTR2008-003706-33-AT   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Greece;Italy;Norway;Portugal;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-003706-33-FI   Argentina;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Lebanon;Macedonia, the former Yugoslav Republic of;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2008   -   EUCTR2008-003706-33-EE   Argentina;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Lebanon;Macedonia, the former Yugoslav Republic of;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
   Merck Serono SA - Geneva
      2009   -   EUCTR2008-003706-33-PT   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Greece;Italy;Norway;Portugal;Spain;Sweden;United Kingdom;
Interferon beta-1a FBS-free/HSA-free, RNF   
   MERCK SERONO INTERNATIONAL SA
      2007   -   EUCTR2006-003037-32-IT   Estonia;Germany;Italy;Lithuania;Spain;
   Merck Serono International SA
      2007   Phase 3   EUCTR2006-003037-32-ES   Estonia;Germany;Italy;Lithuania;Spain;
      2007   -   EUCTR2006-003037-32-LT   Estonia;Germany;Italy;Lithuania;Spain;
      2007   -   EUCTR2006-003037-32-EE   Estonia;Germany;Italy;Lithuania;Spain;
   Merck Serono SA
      2007   -   EUCTR2006-003037-32-DE   Estonia;Germany;Italy;Lithuania;Spain;
   Serono International SA
      2006   -   EUCTR2006-002982-38-IT   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Italy;Lithuania;Portugal;Spain;
Interferon beta-1a HSA+ biosimilar   
   Centre Hospitalier Universitaire Vaudois
      2006   Phase 1   NCT02517788   -
Interferon beta-1a HSA-free biosimilar   
   Centre Hospitalier Universitaire Vaudois
      2006   Phase 1   NCT02517788   -
Interferon beta-1a original   
   Centre Hospitalier Universitaire Vaudois
      2006   Phase 1   NCT02517788   -
Interferon beta-1a, 30 µg/0.5 ml   
   Biogen Idec Research Limited
      2019   Phase 3   EUCTR2018-003008-38-BG   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
Interferon beta-1b   
   AZIENDA OSPEDALIERA S. LUIGI GONZAGA
      2011   -   EUCTR2010-023677-19-IT   Italy;
   Bayer AB, Bayer Health Care, Bayer Schering Pharma
      2007   -   EUCTR2006-005270-47-SE   Austria;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
   Bayer Schering Pharma
      2007   -   EUCTR2006-005270-47-SI   Austria;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
      2007   -   EUCTR2006-005270-47-HU   Austria;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
      -   -   EUCTR2006-005270-47-DE   Austria;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
   Bayer Schering Pharma AG
      2007   -   EUCTR2006-005270-47-LV   Austria;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
      2007   -   EUCTR2006-005270-47-GR   Austria;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
      2007   -   EUCTR2006-005270-47-BE   Austria;Belgium;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
   Biogen
      2017   Phase 4   NCT03177083   Portugal;
   Claudio Gobbi
      2012   Phase 4   NCT01701856   Switzerland;
      2010   Phase 4   NCT01144052   Switzerland;
   NOVARTIS FARMA
      2011   -   EUCTR2010-024017-31-IT   Italy;
      2010   -   EUCTR2010-023023-19-IT   Germany;Italy;
   S. Andrea Hospital
      2005   Phase 2/Phase 3   NCT00270816   Italy;
   SCHERING
      2007   -   EUCTR2006-005270-47-IT   Austria;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
   Schering AG
      2007   Phase 3   EUCTR2006-005270-47-FR   Austria;Belgium;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
      2007   Phase 3   EUCTR2006-005270-47-FI   Austria;Belgium;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
      2007   -   EUCTR2006-005270-47-NL   Austria;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
      2007   -   EUCTR2006-005270-47-AT   Austria;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
   Universita di Firenze
      2006   -   EUCTR2006-004937-13-IT   Italy;
Interferon beta-1b (Betaferon, BAY 86-5046)   
   Bayer
      2014   -   NCT02121444   Germany;
      2012   -   NCT01766063   Germany;
Interferon beta-1b (Betaferon, BAY86-5046)   
   Bayer
      2017   -   NCT03134573   Germany;
      2015   -   NCT02486640   Germany;
      2010   -   NCT01354665   Poland;
Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)   
   Bayer
      2005   Phase 3   NCT00313976   Denmark;Sweden;
      2003   Phase 3   NCT00099502   Argentina;Australia;Austria;Belgium;Brazil;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Latvia;Netherlands;Norway;Poland;Russian Federation;Slovenia;Spain;Sweden;Switzerland;Ukraine;United States;
Interferon beta-1b (Betaferon®, BAY 86-5046)   
   Bayer
      2014   -   NCT02247310   Austria;Belgium;Bosnia and Herzegovina;Croatia;Czech Republic;Czechia;France;Greece;Hungary;Italy;Netherlands;Spain;Switzerland;
Interferon beta-1b (Betaseron, BAY86-5046)   
   Bayer
      2016   -   NCT02652091   United States;
      2012   -   NCT01706055   Poland;
      2012   -   NCT01491100   Albania;Algeria;Argentina;Belgium;Bosnia and Herzegovina;Czech Republic;Czechia;Egypt;France;Germany;Greece;Hungary;Israel;Jordan;Kazakhstan;Lebanon;Mexico;Netherlands;Poland;Portugal;Saudi Arabia;Syrian Arab Republic;Tunisia;Turkey;
      2012   -   NCT01436838   China;
      2010   -   NCT01076595   France;
      2009   -   NCT03408093   -
      2009   -   NCT00963833   Austria;Belgium;Finland;Germany;Israel;Italy;Portugal;United Kingdom;
      2009   -   NCT00902135   Germany;
      2008   -   NCT01414816   Korea, Republic of;
      2008   -   NCT01184833   Poland;
      2008   -   NCT00787657   Argentina;Bahrain;Belgium;Bosnia and Herzegovina;Canada;China;Colombia;Czech Republic;Egypt;Estonia;France;Germany;Iran, Islamic Republic of;Israel;Italy;Jordan;Korea, Republic of;Kuwait;Lebanon;Libyan Arab Jamahiriya;Mexico;Netherlands;New Zealand;Norway;Pakistan;Portugal;Saudi Arabia;Singapore;Slovakia;Slovenia;Sweden;Syrian Arab Republic;Taiwan;United Arab Emirates;United Kingdom;Venezuela;
      2007   Phase 3   NCT00459667   Argentina;Australia;Austria;Belgium;Brazil;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Latvia;Netherlands;Norway;Poland;Russian Federation;Slovenia;Spain;Sweden;Switzerland;Ukraine;United States;
      2007   -   NCT01235455   Portugal;
      2007   -   NCT00544037   Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Portugal;Slovenia;Spain;Sweden;Switzerland;United Kingdom;
      2006   Phase 3   NCT00370071   China;
      2006   -   NCT00882453   Australia;Austria;Bahrain;Belgium;Canada;Colombia;Czech Republic;Denmark;Egypt;France;Germany;Greece;Indonesia;Israel;Italy;Jordan;Kazakhstan;Korea, Republic of;Kuwait;Lebanon;Mexico;Netherlands;Norway;Oman;Portugal;Slovenia;Spain;Sweden;Switzerland;Taiwan;Thailand;United Arab Emirates;United Kingdom;
      2005   -   NCT00206635   Canada;United Kingdom;United States;
      2004   -   NCT01233245   Czech Republic;France;Germany;Iran, Islamic Republic of;Israel;Italy;Jordan;Korea, Republic of;Lebanon;Netherlands;Portugal;Saudi Arabia;Spain;Taiwan;Turkey;
      2002   Phase 3   NCT00185211   Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Portugal;Slovenia;Spain;Sweden;Switzerland;United Kingdom;
Interferon beta-1b (Betaseron, Betaferon, BAY86-5046)   
   Bayer
      2008   -   NCT03577977   Russian Federation;
Interferon beta-1b (PF530, Betaferon)   
   Pfenex, Inc
      2015   Phase 1   NCT02474134   Australia;
Interferon beta-1b and Tacrolimus   
   Clinique de sclérose en plaques et neuromusculaire de l'Outaouais
      2003   Phase 2   NCT00298662   Canada;
Interferon beta-1b group   
   University Hospital Inselspital, Berne
      2007   Phase 2   NCT01111656   Switzerland;
Interferon beta-1b, (Betaseron BAY86-5046)   
   Bayer
      2007   -   NCT00928967   France;
Interferon beta-1b, FRP about 6 weeks after randomization   
   Bayer
      2008   Phase 4   NCT00780455   France;
Interferon beta-1b, FRP within 15 days after randomization   
   Bayer
      2008   Phase 4   NCT00780455   France;
Interferon beta-1b/Atorvastatin group   
   University Hospital Inselspital, Berne
      2007   Phase 2   NCT01111656   Switzerland;
Interferon or glatiramer acetate   
   Novartis Pharmaceuticals
      2021   Phase 4   NCT04878211   United States;
Interferon ß-1a   
   Biogen
      2014   Phase 3   NCT02283853   Argentina;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Kuwait;Poland;Romania;Serbia;Spain;Sweden;Turkey;United Kingdom;United States;
   Celgene
      2013   Phase 3   NCT02047734   Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Georgia;Greece;Hungary;Italy;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
   Novartis Pharma AG
      2021   Phase 3   EUCTR2020-004505-32-FR   France;Germany;
      2021   Phase 3   EUCTR2020-004505-32-DE   France;Germany;Italy;Spain;
   Sanofi
      2009   Phase 3   NCT00883337   Belgium;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Spain;Switzerland;Tunisia;United Kingdom;
Interferon ß-1a 30 µg   
   Novartis
      2006   Phase 3   NCT00340834   Argentina;Australia;Austria;Belgium;Brazil;Canada;Egypt;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Portugal;Puerto Rico;Spain;Switzerland;United Kingdom;United States;
Interferon ß-1b   
   Novartis Pharma AG
      2021   Phase 3   EUCTR2020-004505-32-FR   France;Germany;
      2021   Phase 3   EUCTR2020-004505-32-DE   France;Germany;Italy;Spain;
   S. Andrea Hospital
      2005   Phase 2/Phase 3   NCT00270816   Italy;
Interferon-1beta (Betaseron, BAY86-5046)   
   Bayer
      2007   -   NCT00873340   Colombia;
      2007   -   NCT00461396   United States;
Interferon-beta   
   Fundació Institut Germans Trias i Pujol
      2017   Phase 1   NCT02903537   Spain;
   Sanofi
      2007   Phase 2   NCT00489489   Canada;Germany;Italy;Poland;Spain;United States;
Interferon-beta (IFN-beta)   
   EMD Serono Research & Development Institute, Inc.
      2006   Phase 2   NCT00436826   Italy;Russian Federation;Spain;United States;
   Sanofi
      2011   Phase 3   NCT01252355   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Colombia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Netherlands;Norway;Portugal;Russian Federation;Slovakia;Spain;Sweden;Tunisia;Turkey;United Kingdom;United States;
Interferon-beta 1a   
   Medizinische Universität Innsbruck
      2014   Phase 4   EUCTR2012-005450-30-AT   Austria;Sweden;
   Merck Serono International SA
      2007   Phase 3   EUCTR2006-003037-32-ES   Estonia;Germany;Italy;Lithuania;Spain;
      2007   -   EUCTR2006-003037-32-LT   Estonia;Germany;Italy;Lithuania;Spain;
      2007   -   EUCTR2006-003037-32-EE   Estonia;Germany;Italy;Lithuania;Spain;
   Merck Serono International, a branch of Laboratoires Serono SA an affiliate of Merck KGaA, Darmstadt
      2009   -   EUCTR2008-004954-34-GR   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Greece;Italy;Latvia;Poland;Portugal;Spain;
   Merck Serono S.A. - Geneva, an affiliate of Merck KGaA, Darmstadt, Germany
      2010   -   EUCTR2008-004954-34-AT   Argentina;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Germany;Greece;Israel;Italy;Latvia;Lebanon;Morocco;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Turkey;
      2009   Phase 3   EUCTR2008-004954-34-SK   Argentina;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Germany;Greece;Israel;Italy;Latvia;Lebanon;Morocco;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Turkey;
      2009   Phase 3   EUCTR2008-004954-34-PT   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Greece;Italy;Latvia;Poland;Portugal;Spain;
      2009   Phase 3   EUCTR2008-004954-34-BE   Argentina;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Germany;Greece;Israel;Italy;Latvia;Lebanon;Morocco;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Turkey;
      2009   -   EUCTR2008-004954-34-PL   Argentina;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Germany;Greece;Israel;Italy;Latvia;Lebanon;Morocco;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Turkey;
      2009   -   EUCTR2008-004954-34-LV   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Greece;Italy;Latvia;Poland;Portugal;Spain;
      2009   -   EUCTR2008-004954-34-FI   Argentina;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Germany;Greece;Israel;Italy;Latvia;Lebanon;Morocco;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Turkey;
      2009   -   EUCTR2008-004954-34-EE   Argentina;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Germany;Greece;Israel;Italy;Latvia;Lebanon;Morocco;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Turkey;
      2009   -   EUCTR2008-004954-34-DE   Argentina;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Germany;Greece;Israel;Italy;Latvia;Lebanon;Morocco;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Turkey;
      2009   -   EUCTR2008-004954-34-BG   Argentina;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Germany;Greece;Israel;Italy;Latvia;Lebanon;Morocco;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Turkey;
      2008   -   EUCTR2008-004954-34-CZ   Argentina;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Germany;Greece;Israel;Italy;Latvia;Lebanon;Morocco;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Turkey;
   Merck Serono S.A.- Geneva, an affiliate of Merck KGaA, Darmstadt, Germany
      2009   Phase 3   EUCTR2008-004954-34-FR   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Greece;Italy;Latvia;Poland;Portugal;Slovakia;Spain;
   Merck Serono SA
      2007   -   EUCTR2006-003037-32-DE   Estonia;Germany;Italy;Lithuania;Spain;
   Nancy Hammond, MD
      2007   -   NCT00490906   United States;
   S. Andrea Hospital
      2002   Phase 2   NCT00151801   Italy;
Interferon-beta 1a FBS-free/HSA free, RNF   
   Merck Serono International S.A.
      2007   -   EUCTR2006-002982-38-LT   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Italy;Lithuania;Portugal;Spain;
      2007   -   EUCTR2006-002982-38-GR   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Italy;Lithuania;Portugal;Spain;
      2006   -   EUCTR2006-002982-38-DK   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Italy;Lithuania;Portugal;Spain;
      2006   -   EUCTR2006-002982-38-AT   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Italy;Lithuania;Portugal;Spain;
   Merck Serono International, a branch of Laboratoires Serono SA An affiliate of Merck KGaA
      2007   Phase 3   EUCTR2006-002982-38-SK   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Italy;Lithuania;Portugal;Slovakia;Spain;
      2007   -   EUCTR2006-002982-38-EE   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Italy;Lithuania;Portugal;Spain;
   Merck Serono S.A. - Geneva, an affiliate of Merck KGaA Darmstadt, Germany
      2007   -   EUCTR2006-002982-38-PT   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Italy;Lithuania;Portugal;Spain;
      2007   -   EUCTR2006-002982-38-DE   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Italy;Lithuania;Portugal;Spain;
      2006   -   EUCTR2006-002982-38-FI   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Italy;Lithuania;Portugal;Spain;
      2006   -   EUCTR2006-002982-38-CZ   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Italy;Lithuania;Portugal;Spain;
   Merck Serono S.A.-Geneva, an affiliate of Merck KGaA Darmstadt, Germany
      2006   Phase 3   EUCTR2006-002982-38-BE   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Italy;Lithuania;Portugal;Slovakia;Spain;
   Serono International SA
      2007   Phase 3   EUCTR2006-002982-38-FR   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Italy;Lithuania;Portugal;Slovakia;Spain;
Interferon-beta 1a FBS-free/HSA-free, RNF   
   Merck Serono International SA
      2007   Phase 3   EUCTR2006-005972-42-FR   France;Germany;
      2007   -   EUCTR2006-005972-42-DE   France;Germany;
Interferon-beta 1b   
   Medizinische Universität Innsbruck
      2014   Phase 4   EUCTR2012-005450-30-AT   Austria;Sweden;
   Nancy Hammond, MD
      2007   -   NCT00490906   United States;
Interferon-beta 1b (Betaseron)   
   Rutgers, The State University of New Jersey
      2007   -   NCT00468182   United States;
Interferon-beta [IFN-beta]   
   Sanofi
      2007   Phase 2   NCT00811395   Austria;Canada;Germany;Italy;Spain;United Kingdom;United States;
Interferon-beta and human leukocyte Interferon-a   
   Melinda Magyari
      2010   Phase 2   NCT01171209   Denmark;
Interferon-beta-1   
   Sanofi
      2011   Phase 2   NCT01403376   Austria;Canada;Germany;Russian Federation;Ukraine;
Interferon-beta-1a   
   Biogen Idec
      2006   Phase 4   NCT00492765   Denmark;
      2003   Phase 4   NCT00493116   Australia;New Zealand;
      2003   Phase 4   NCT00492466   Finland;
   Merck KGaA
      2014   -   EUCTR2013-003126-83-BG   Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2014   -   EUCTR2013-002351-15-BG   Argentina;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Jordan;Latvia;Lebanon;Lithuania;Mexico;Morocco;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2008   -   NCT01074346   Korea, Republic of;
   Merck, S.L.
      2006   -   EUCTR2006-000606-23-ES   Spain;
Interferon-beta-1a (Avonex) plus methylprednisolone   
   Biogen Idec
      2003   Phase 4   NCT00168766   Belgium;Denmark;Finland;Netherlands;Norway;Sweden;Switzerland;United Kingdom;
Interferon-beta-1a FBS-free/HSA free, RNF   
   Serono International SA
      2005   Phase 3   EUCTR2004-003799-13-GB   Denmark;Ireland;Lithuania;Spain;Sweden;United Kingdom;
      2005   Phase 3   EUCTR2004-003799-13-ES   Denmark;Ireland;Lithuania;Spain;Sweden;United Kingdom;
      2005   Phase 3   EUCTR2004-003799-13-DK   Denmark;Ireland;Lithuania;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-003799-13-SE   Ireland;Lithuania;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-003799-13-LT   Ireland;Lithuania;Spain;Sweden;United Kingdom;
      -   Phase 3   EUCTR2004-003799-13-IE   Denmark;Ireland;Lithuania;Spain;Sweden;United Kingdom;
Interferon-beta-1a FBS-free/HSA-free   
   EMD Serono
      2005   Phase 3   NCT00110396   United States;
Interferon-beta-1b   
   S. Andrea Hospital
      2005   Phase 2/Phase 3   NCT00270816   Italy;
Interferon-beta-1b (BETASERON, BAY 86-5046)   
   Bayer
      2020   -   NCT04356339   United States;
Interferon-beta1   
   Biogen
      2021   Phase 2   NCT04079088   -
Interferon-ß   
   Sanofi
      2007   Phase 2   NCT00489489   Canada;Germany;Italy;Poland;Spain;United States;
Interferon-ß [IFN-ß]   
   Sanofi
      2007   Phase 2   NCT00811395   Austria;Canada;Germany;Italy;Spain;United Kingdom;United States;
Interferon-ß-1   
   Sanofi
      2011   Phase 2   NCT01403376   Austria;Canada;Germany;Russian Federation;Ukraine;
Interferon-ß-1a   
   Merck KGaA
      2014   -   EUCTR2013-003126-83-BG   Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2014   -   EUCTR2013-002351-15-BG   Argentina;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Jordan;Latvia;Lebanon;Lithuania;Mexico;Morocco;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2008   -   NCT01074346   Korea, Republic of;
Interferon-ß-1b   
   S. Andrea Hospital
      2005   Phase 2/Phase 3   NCT00270816   Italy;
Interferone   
   sanofi-aventis recherche et development
      2009   -   EUCTR2008-006226-34-IT   Belgium;Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
Interferone Beta-1B   
   OSPEDALE SAN RAFFAELE
      2018   Phase 4   EUCTR2016-004819-12-IT   Italy;
Interferone beta 1a   
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-004505-32-IT   France;Germany;Italy;Spain;
Interferone beta-1a   
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-004505-32-IT   France;Germany;Italy;Spain;
Interferone beta-1b   
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-004505-32-IT   France;Germany;Italy;Spain;
Interferón Beta-1a pegilado   
   Biogen Idec Limited
      2009   Phase 3   EUCTR2008-006333-27-ES   Belgium;Bulgaria;Czech Republic;Estonia;Germany;Greece;Latvia;Netherlands;Spain;United Kingdom;
Interferón beta 1a pegilado   
   Biogen Idec Limited
      2011   -   EUCTR2010-024477-39-ES   Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;India;Latvia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
Intradetrusor injection of Botulinum Toxin-A   
   Rose Khavari, M.D.
      2014   -   NCT03033355   United States;
Intranasal Foralumab Solution   
   Tiziana Life Sciences, PLC
      2021   Phase 1   NCT05029609   -
Intratect   
   Guy's and St Thomas NHS Foundation Trust
      2014   Phase 3   EUCTR2014-002335-34-GB   United Kingdom;
Intrathecal MSC-NP injection   
   Tisch Multiple Sclerosis Research Center of New York
      2018   Phase 2   NCT03355365   United States;
      2011   -   NCT03822858   United States;
Intrathecal administration of autologous MSC-NP   
   Tisch Multiple Sclerosis Research Center of New York
      2014   Phase 1   NCT01933802   United States;
Intrathecal methotrexate   
   Tel-Aviv Sourasky Medical Center
      2016   Phase 0   NCT02644044   -
Intravenous (IV) infusions   
   Polpharma Biologics S.A.
      2019   Phase 3   NCT04115488   Belarus;Croatia;Georgia;Moldova, Republic of;Poland;Serbia;Ukraine;
Intravenous Immunoglobulin   
   Guy's and St Thomas' NHS Foundation Trust
      2015   Phase 3   NCT02398994   United Kingdom;
Intravenous Methylprednisolone   
   Guy's and St Thomas' NHS Foundation Trust
      2015   Phase 3   NCT02398994   United Kingdom;
Intravenous injection of mesenchymal stem cells   
   Royan Institute
      2011   Phase 1/Phase 2   NCT01377870   Iran, Islamic Republic of;
Intravenous steroid   
   Beijing Tiantan Hospital
      2019   -   NCT04106830   China;
Irradiation   
   Fred Hutchinson Cancer Research Center
      1997   Phase 1   NCT00014755   United States;
Isoxsuprine Hydrochloride   
   University of New Mexico
      2019   Phase 1/Phase 2   NCT03752307   United States;
Ixazomib (NINLARO®) capsules   
   Queen Mary University of London
      2019   Phase 1   NCT03783416   United Kingdom;
JM-4   
   Cook, Stuart, MD
      2019   Early Phase 1   NCT03887065   -
KEPPRA   
   AZIENDA SANITARIA N. 3 GENOVESE
      2007   -   EUCTR2007-005414-40-IT   Italy;
KLH   
   Hoffmann-La Roche
      2015   Phase 3   NCT02545868   Canada;United States;
Kemstro   
   UCB Pharma
      2005   Phase 3   NCT00139789   United States;
Kepivance   
   Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
      2012   Phase 2   EUCTR2011-005606-30-GB   United Kingdom;
Keppra   
   Søren H. Sindrup, Department of Neurology, Odense University Hospital
      2006   -   EUCTR2006-000397-71-DK   Denmark;
Keppra ®   
   Newcastle-upon-Tyne Hospitals NHS Trust
      2006   Phase 4   EUCTR2005-003903-35-GB   United Kingdom;
Kesimpta   
   Novartis Farmacéutica S.A.
      2021   Phase 3   EUCTR2020-002700-39-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Novartis Pharma AG
      2021   Phase 3   EUCTR2020-004505-32-FR   France;Germany;
      2021   Phase 3   EUCTR2020-004505-32-DE   France;Germany;Italy;Spain;
      2021   Phase 3   EUCTR2020-002700-39-SK   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-002700-39-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-002700-39-LV   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-002700-39-LT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-002700-39-HR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-002700-39-FR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-002700-39-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-002700-39-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-001341-40-SI   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Estonia;Germany;Greece;Hungary;Italy;Latvia;Lebanon;Mexico;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Slovakia;Slovenia;Spain;Switzerland;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-001341-40-LV   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Estonia;Germany;Greece;Hungary;Italy;Latvia;Lebanon;Mexico;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Slovakia;Slovenia;Spain;Switzerland;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001341-40-HU   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Italy;Latvia;Lebanon;Mexico;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Slovakia;Slovenia;Spain;Switzerland;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001341-40-GR   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Italy;Latvia;Lebanon;Mexico;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Slovakia;Slovenia;Spain;Switzerland;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001341-40-DE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Italy;Latvia;Lebanon;Mexico;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Slovakia;Slovenia;Spain;Switzerland;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001341-40-BE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Italy;Latvia;Lebanon;Mexico;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Slovakia;Slovenia;Spain;Switzerland;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001341-40-AT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Italy;Latvia;Lebanon;Mexico;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Slovakia;Slovenia;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004703-51-NL   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004703-51-LV   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004703-51-LT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004703-51-GR   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004703-51-FI   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004703-51-DK   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004703-51-DE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004703-51-CZ   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004703-51-BE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004703-51-SE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004703-51-AT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
      -   Phase 3   EUCTR2020-002700-39-EE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2020-002700-39-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Novartis Pharmaceuticals
      2021   -   NCT04940065   Japan;
Kesimpta 20 mg Injektionslösung im Fertigpen   
   Novartis Pharma Vertriebs GmbH
      2021   Phase 4   EUCTR2021-000307-20-DE   Germany;
Kesimpta 20 mg solution for injection in pre-filled pen   
   Novartis Pharma AG
      2021   Phase 3   EUCTR2020-002700-39-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Ketamine   
   Johns Hopkins University
      2018   Phase 1/Phase 2   NCT03500289   United States;
Ketoconazole   
   GlaxoSmithKline
      2013   Phase 1   NCT01802931   Australia;
Keyhole limpet hemocyanin (KLH)   
   Biogen
      2008   Phase 4   NCT00536120   United States;
Keyhole limpet hemocyanin (KLH) neo-antigen   
   Novartis Pharmaceuticals
      2018   Phase 3   NCT03650114   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
Kirunal Fish Oil   
   Terry L. Wahls
      2022   -   NCT05007483   United States;
L acetyl carnitine   
   University of Iowa
      2010   Phase 1   NCT01381354   United States;
L-000124467   
   Merck & Co., Inc./Suomen MSD Oy
      2004   Phase 2   EUCTR2004-000073-64-FI   Finland;
L-Carnitine   
   University Hospital, Bordeaux
      2010   Phase 3   NCT01149525   France;
L-Histidine   
   University of Miami
      2022   Phase 2   NCT04764383   United States;
      2018   Phase 1   NCT03266965   United States;
L01BB04   
   Merck Serono S.A. - Geneva
      2009   Phase 3   EUCTR2008-003706-33-BE   Argentina;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Lebanon;Macedonia, the former Yugoslav Republic of;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
L03 AB   
   sanofi-aventis recherche et development
      2009   -   EUCTR2008-006226-34-BE   Belgium;Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
L03 AB 08   
   CHU de Rennes
      2018   Phase 3   EUCTR2018-001292-21-FR   France;
L03 AB07   
   Merck Serono SA – Geneva
      2010   -   EUCTR2009-015502-19-GB   Belgium;Finland;Germany;Sweden;United Kingdom;
L03AB13   
   BIOGEN IDEC ITALIA S.R.L.
      2015   Phase 4   EUCTR2015-002201-11-IT   Italy;
L04AA04 - IMMUNOGLOBULINA ANTITIMOCITARIA (DI CONIGLIO) IMMUNOGLOBULINA DI CONIGLIO ANTITIMOCITI UMANI THYMOGLOBULINE   
   Dipartimento di Neuroscienze Oftalmologia e Genetica DINOG - Universita di Genova
      2006   -   EUCTR2006-002562-19-IT   Italy;
L04AA31   
   Turku University Hospital
      2017   Phase 4   EUCTR2016-003622-16-FI   Finland;
LEMTRADA 12 mg Konzentrat zur Herstellung einer Infusionslösung   
   Universitätsklinikum Münster
      2014   Phase 4   EUCTR2014-000709-10-DE   Germany;
LEVOFOLENE 4 MG 30 CPR   
   AZIENDA OSPEDALIERA SAN CAMILLO FORLANINI
      2005   -   EUCTR2005-006071-12-IT   Italy;
LFB-R603   
   TG Therapeutics
      2017   Phase 3   EUCTR2017-000639-15-HR   Belarus;Croatia;Georgia;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-000639-15-GB   Belarus;Croatia;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-000639-15-ES   Belarus;Croatia;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-000638-75-GB   Belarus;Georgia;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-000638-75-ES   Belarus;Georgia;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
   TG Therapeutics, Inc.
      2017   Phase 3   EUCTR2017-000639-15-PL   Belarus;Croatia;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-000638-75-PL   Belarus;Georgia;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
LFB-R603, TGTX1101   
   TG Therapeutics, Inc.
      2020   Phase 3   EUCTR2019-003625-16-HR   Belarus;Croatia;Georgia;Poland;Romania;Russian Federation;Serbia;Ukraine;United States;
LOU064   
   Novartis Farmacéutica S.A.
      2022   Phase 3   EUCTR2020-005929-89-ES   Argentina;Brazil;Bulgaria;Canada;China;Croatia;Czechia;Estonia;France;Germany;Greece;Hungary;India;Italy;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;United Kingdom;United States;
      2022   Phase 3   EUCTR2020-005899-36-ES   Slovakia;Spain;
   Novartis Pharma AG
      2022   Phase 3   EUCTR2020-005929-89-SE   Argentina;Brazil;Bulgaria;Canada;China;Croatia;Czechia;Estonia;France;Germany;Greece;Hungary;India;Italy;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;United Kingdom;United States;
      2022   Phase 3   EUCTR2020-005899-36-SK   Argentina;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czechia;France;Germany;Guatemala;Hong Kong;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Netherlands;Poland;Russian Federation;Serbia;Slovakia;Spain;Switzerland;United Kingdom;United States;
LUTENYL   
   OSPEDALI CIVILI DI LIONE
      2007   -   EUCTR2006-005460-30-IT   Italy;
LY2127399   
   Eli Lilly and Company
      2010   -   EUCTR2008-007459-28-BG   Belgium;Bulgaria;Czech Republic;Denmark;Finland;France;Germany;Hungary;
      2009   Phase 2   NCT00882999   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Israel;Poland;Romania;Russian Federation;Serbia;Slovakia;Switzerland;Ukraine;United States;
      2009   Phase 2   EUCTR2008-007459-28-FR   Belgium;Bulgaria;Czech Republic;Denmark;Finland;France;Germany;Hungary;
      2009   -   EUCTR2008-007459-28-HU   Belgium;Bulgaria;Czech Republic;Denmark;Finland;France;Germany;Hungary;
      2009   -   EUCTR2008-007459-28-FI   Belgium;Bulgaria;Czech Republic;Denmark;Finland;France;Germany;Hungary;
      2009   -   EUCTR2008-007459-28-DK   Belgium;Bulgaria;Czech Republic;Denmark;Finland;France;Germany;Hungary;
      2009   -   EUCTR2008-007459-28-DE   Belgium;Bulgaria;Czech Republic;Denmark;Finland;France;Germany;Hungary;
      2009   -   EUCTR2008-007459-28-CZ   Belgium;Bulgaria;Czech Republic;Denmark;Finland;France;Germany;Hungary;
      2009   -   EUCTR2008-007459-28-BE   Belgium;Bulgaria;Czech Republic;Denmark;Finland;France;Germany;Hungary;
LY248686   
   Eli Lilly and Company
      2008   -   EUCTR2008-002560-34-BE   Belgium;
Lactose monohydrate   
   Queen Mary University of London
      2013   -   EUCTR2012-004847-61-GB   United Kingdom;
Lactulose   
   Department of Neurology and Neurological Science, Tokyo Medical and Dental University
      2021   -   JPRN-UMIN000043910   Japan;
Lamotrigine   
   Cantonal Hospital of St. Gallen
      2009   Phase 2   NCT00917839   Switzerland;
   University College London Hospitals
      2005   Phase 2   NCT00257855   United Kingdom;
Lamotrigine extended release tablets   
   University College London
      2005   Phase 2   EUCTR2005-001949-42-GB   United Kingdom;
Laquinimod   
   TEVA ITALIA srl
      2008   -   EUCTR2007-005450-23-IT   Bulgaria;Czech Republic;Estonia;Germany;Italy;Lithuania;Spain;
      2007   -   EUCTR2007-003226-19-IT   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;Sweden;United Kingdom;
   Teva Branded Pharmaceutical Products R&D, Inc.
      2015   Phase 2   NCT02284568   Canada;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2014   Phase 3   NCT01975298   Belgium;Denmark;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Spain;Sweden;Switzerland;United Kingdom;
      2013   Phase 3   NCT01707992   Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Estonia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Macedonia, The Former Yugoslav Republic of;Mexico;Moldova, Republic of;Montenegro;North Macedonia;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2010   Phase 3   NCT01047319   Bulgaria;Croatia;Czech Republic;Czechia;Estonia;Georgia;Germany;Israel;Italy;Lithuania;Macedonia, The Former Yugoslav Republic of;North Macedonia;Poland;Puerto Rico;Romania;Russian Federation;Slovakia;South Africa;Spain;Ukraine;United States;
      2009   Phase 3   NCT00988052   Austria;Bulgaria;Canada;Czech Republic;Czechia;Estonia;France;Georgia;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2008   Phase 3   NCT00605215   Bulgaria;Croatia;Czech Republic;Czechia;Estonia;Georgia;Germany;Israel;Italy;Latvia;Lithuania;Macedonia, The Former Yugoslav Republic of;Montenegro;North Macedonia;Poland;Puerto Rico;Romania;Russian Federation;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
   Teva Pharmaceutical Industries
      2007   Phase 3   NCT00509145   Austria;Bulgaria;Canada;Czech Republic;Estonia;Former Serbia and Montenegro;France;Georgia;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
   Teva Pharmaceutical Industries Ltd
      2010   Phase 3   EUCTR2009-015815-42-IT   Bulgaria;Czech Republic;Estonia;Germany;Italy;Lithuania;Poland;Slovakia;Spain;
      2009   Phase 3   EUCTR2009-012989-30-IT   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
   Teva Pharmaceutical Industries, Ltd.
      2005   Phase 2   NCT00745615   Czech Republic;Czechia;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Spain;United Kingdom;
Laquinimod 0.3   
   Teva Pharmaceutical Industries
      2005   Phase 2   NCT00349193   Italy;
Laquinimod 0.6   
   Teva Pharmaceutical Industries
      2012   Phase 2   NCT01404117   -
      2005   Phase 2   NCT00349193   Italy;
Laquinimod 1.2   
   Teva Pharmaceutical Industries
      2012   Phase 2   NCT01404117   -
Laquinimod Capsulas   
   Teva Pharmaceutical Industries Ltd
      2009   Phase 3   EUCTR2009-012989-30-ES   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
Laquinimod Capsules   
   Teva Pharmaceutical Industries Ltd
      2010   Phase 3   EUCTR2009-015815-42-SK   Bulgaria;Czech Republic;Estonia;Germany;Italy;Lithuania;Poland;Slovakia;Spain;
      2010   Phase 3   EUCTR2009-015815-42-PL   Bulgaria;Czech Republic;Estonia;Georgia;Germany;Israel;Italy;Lithuania;Macedonia, the former Yugoslav Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;United States;
      2010   Phase 3   EUCTR2009-015815-42-LT   Bulgaria;Czech Republic;Estonia;Georgia;Germany;Israel;Italy;Lithuania;Macedonia, the former Yugoslav Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;United States;
      2010   Phase 3   EUCTR2009-015815-42-EE   Bulgaria;Czech Republic;Estonia;Georgia;Germany;Israel;Italy;Lithuania;Macedonia, the former Yugoslav Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;United States;
      2010   Phase 3   EUCTR2009-015815-42-CZ   Bulgaria;Czech Republic;Estonia;Georgia;Germany;Israel;Italy;Lithuania;Macedonia, the former Yugoslav Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;United States;
      2010   Phase 3   EUCTR2009-015815-42-BG   Bulgaria;Czech Republic;Estonia;Georgia;Germany;Israel;Italy;Lithuania;Macedonia, the former Yugoslav Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;United States;
      2010   Phase 3   EUCTR2009-012989-30-SE   Austria;Bulgaria;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2009-012989-30-FR   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
      2010   Phase 3   EUCTR2009-012989-30-BG   Austria;Bulgaria;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2009-012989-30-AT   Austria;Bulgaria;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2009   Phase 3   EUCTR2009-012989-30-NL   Austria;Bulgaria;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2009   Phase 3   EUCTR2009-012989-30-LT   Austria;Bulgaria;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2009   Phase 3   EUCTR2009-012989-30-HU   Austria;Bulgaria;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2009   Phase 3   EUCTR2009-012989-30-GB   Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2009   Phase 3   EUCTR2009-012989-30-EE   Austria;Bulgaria;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2009   Phase 3   EUCTR2009-012989-30-CZ   Austria;Bulgaria;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2009   -   EUCTR2009-011234-99-DE   Germany;
      2008   Phase 3   EUCTR2007-005450-23-SK   Bulgaria;Czech Republic;Estonia;Germany;Italy;Lithuania;Slovakia;Spain;
      2008   -   EUCTR2007-005450-23-LT   Bulgaria;Czech Republic;Estonia;Germany;Italy;Lithuania;Spain;
      2008   -   EUCTR2007-005450-23-EE   Bulgaria;Czech Republic;Estonia;Germany;Italy;Lithuania;Spain;
      2008   -   EUCTR2007-005450-23-DE   Bulgaria;Czech Republic;Estonia;Germany;Italy;Lithuania;Spain;
      2008   -   EUCTR2007-005450-23-CZ   Bulgaria;Czech Republic;Estonia;Germany;Italy;Lithuania;Spain;
      2008   -   EUCTR2007-005450-23-BG   Bulgaria;Czech Republic;Estonia;Germany;Italy;Lithuania;Spain;
      2008   -   EUCTR2007-003226-19-PT   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-003226-19-LT   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-003226-19-BG   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2007   Phase 3   EUCTR2007-003226-19-FR   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2007   Phase 3   EUCTR2007-003226-19-ES   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-003226-19-SE   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-003226-19-NL   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-003226-19-LV   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-003226-19-HU   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-003226-19-GB   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-003226-19-EE   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-003226-19-DE   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-003226-19-CZ   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-003226-19-AT   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2006   Phase 2   EUCTR2005-004334-41-GB   Czech Republic;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Spain;United Kingdom;
      2006   Phase 2   EUCTR2005-004334-41-DE   Czech Republic;Germany;Hungary;Israel;Italy;Russian Federation;Spain;United Kingdom;
      2006   Phase 2   EUCTR2005-004334-41-CZ   Czech Republic;Germany;Hungary;Israel;Italy;Russian Federation;Spain;United Kingdom;
      2005   Phase 2   EUCTR2005-004334-41-HU   Czech Republic;Germany;Hungary;Israel;Italy;Russian Federation;Spain;United Kingdom;
Laquinimod Sodium (USAN)   
   TEVA PHARMACEUTICALS INDUSTRIES LTD
      2013   Phase 3   EUCTR2012-003647-30-IT   Albania;Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Georgia;Germany;Greece;Hungary;Israel;Italy;Kazakhstan;Korea, Democratic People's Republic of;Korea, Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Puerto Rico;Russian Federation;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
   Teva Pharmaceutical Industries Ltd
      2013   Phase 3   EUCTR2012-003647-30-PL   Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Chile;Croatia;Czech Republic;Estonia;Georgia;Germany;Greece;Hungary;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Montenegro;Poland;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003647-30-HU   Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Chile;Croatia;Czech Republic;Estonia;Georgia;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Montenegro;Poland;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003647-30-ES   Albania;Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Georgia;Germany;Greece;Hungary;Israel;Italy;Kazakhstan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Montenegro;Poland;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003647-30-EE   Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Chile;Croatia;Czech Republic;Estonia;Georgia;Germany;Greece;Hungary;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Montenegro;Poland;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003647-30-CZ   Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Chile;Croatia;Czech Republic;Estonia;Georgia;Germany;Greece;Hungary;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Montenegro;Poland;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003647-30-BE   Albania;Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Georgia;Germany;Greece;Hungary;Israel;Italy;Kazakhstan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Montenegro;Poland;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003647-30-AT   Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Montenegro;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003647-30-SK   Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Chile;Croatia;Czech Republic;Estonia;Georgia;Germany;Greece;Hungary;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Montenegro;Poland;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003647-30-LV   Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Chile;Croatia;Czech Republic;Estonia;Georgia;Germany;Greece;Hungary;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Montenegro;Poland;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003647-30-GR   Albania;Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Montenegro;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003647-30-GB   Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Montenegro;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2008   Phase 3   EUCTR2007-005450-23-SK   Bulgaria;Czech Republic;Estonia;Germany;Italy;Lithuania;Slovakia;Spain;
      2008   -   EUCTR2007-005450-23-LT   Bulgaria;Czech Republic;Estonia;Germany;Italy;Lithuania;Spain;
      2008   -   EUCTR2007-005450-23-ES   Bulgaria;Czech Republic;Estonia;Germany;Italy;Lithuania;Spain;
      2008   -   EUCTR2007-005450-23-EE   Bulgaria;Czech Republic;Estonia;Germany;Italy;Lithuania;Spain;
      2008   -   EUCTR2007-005450-23-DE   Bulgaria;Czech Republic;Estonia;Germany;Italy;Lithuania;Spain;
      2008   -   EUCTR2007-005450-23-CZ   Bulgaria;Czech Republic;Estonia;Germany;Italy;Lithuania;Spain;
      2008   -   EUCTR2007-005450-23-BG   Bulgaria;Czech Republic;Estonia;Germany;Italy;Lithuania;Spain;
   Teva Pharmaceutical Industries Ltd.
      2015   Phase 2   EUCTR2014-001579-30-DE   Canada;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2015   -   EUCTR2014-001579-30-NL   Canada;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-001579-30-IT   Canada;Germany;Italy;Netherlands;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-001579-30-GB   Canada;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-001579-30-ES   Canada;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
   Teva Pharmaceutical Industries, Ltd.
      2014   -   EUCTR2013-002082-19-NL   Belgium;Denmark;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Spain;Sweden;Switzerland;United Kingdom;
      2014   -   EUCTR2013-002082-19-ES   Denmark;Finland;Netherlands;Spain;Sweden;Switzerland;United Kingdom;
      2013   Phase 3   EUCTR2013-002082-19-GB   Belgium;Denmark;Finland;Netherlands;Spain;Sweden;Switzerland;United Kingdom;
      2013   Phase 3   EUCTR2013-002082-19-BE   Belgium;Denmark;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Spain;Sweden;Switzerland;United Kingdom;
      2013   -   EUCTR2013-002082-19-SE   Denmark;Finland;Netherlands;Spain;Sweden;Switzerland;United Kingdom;
      2013   -   EUCTR2013-002082-19-FI   Denmark;Finland;Netherlands;Spain;Sweden;Switzerland;United Kingdom;
      2013   -   EUCTR2013-002082-19-DK   Denmark;Finland;Netherlands;Spain;Sweden;Switzerland;United Kingdom;
Laquinimod Tablets   
   Teva Pharmaceutical Industries Ltd
      2006   Phase 2   EUCTR2005-004334-41-ES   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
      2005   Phase 2   EUCTR2004-003943-28-GB   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
      2005   Phase 2   EUCTR2004-003943-28-ES   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-003943-28-HU   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-003943-28-DE   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-003943-28-CZ   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
Laquinimod capsules   
   TEVA PHARMACEUTICALS INDUSTRIES LTD
      2013   Phase 3   EUCTR2012-003647-30-IT   Albania;Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Georgia;Germany;Greece;Hungary;Israel;Italy;Kazakhstan;Korea, Democratic People's Republic of;Korea, Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Puerto Rico;Russian Federation;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
   Teva Pharmaceutical Industries Ltd
      2013   Phase 3   EUCTR2012-003647-30-PL   Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Chile;Croatia;Czech Republic;Estonia;Georgia;Germany;Greece;Hungary;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Montenegro;Poland;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003647-30-HU   Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Chile;Croatia;Czech Republic;Estonia;Georgia;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Montenegro;Poland;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003647-30-ES   Albania;Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Georgia;Germany;Greece;Hungary;Israel;Italy;Kazakhstan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Montenegro;Poland;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003647-30-EE   Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Chile;Croatia;Czech Republic;Estonia;Georgia;Germany;Greece;Hungary;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Montenegro;Poland;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003647-30-CZ   Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Chile;Croatia;Czech Republic;Estonia;Georgia;Germany;Greece;Hungary;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Montenegro;Poland;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003647-30-BE   Albania;Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Georgia;Germany;Greece;Hungary;Israel;Italy;Kazakhstan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Montenegro;Poland;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003647-30-AT   Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Montenegro;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003647-30-SK   Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Chile;Croatia;Czech Republic;Estonia;Georgia;Germany;Greece;Hungary;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Montenegro;Poland;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003647-30-LV   Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Chile;Croatia;Czech Republic;Estonia;Georgia;Germany;Greece;Hungary;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Montenegro;Poland;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003647-30-GR   Albania;Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Montenegro;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003647-30-GB   Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Montenegro;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
   Teva Pharmaceutical Industries, Ltd.
      2014   -   EUCTR2013-002082-19-NL   Belgium;Denmark;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Spain;Sweden;Switzerland;United Kingdom;
      2014   -   EUCTR2013-002082-19-ES   Denmark;Finland;Netherlands;Spain;Sweden;Switzerland;United Kingdom;
      2013   Phase 3   EUCTR2013-002082-19-GB   Belgium;Denmark;Finland;Netherlands;Spain;Sweden;Switzerland;United Kingdom;
      2013   Phase 3   EUCTR2013-002082-19-BE   Belgium;Denmark;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Spain;Sweden;Switzerland;United Kingdom;
      2013   -   EUCTR2013-002082-19-SE   Denmark;Finland;Netherlands;Spain;Sweden;Switzerland;United Kingdom;
      2013   -   EUCTR2013-002082-19-FI   Denmark;Finland;Netherlands;Spain;Sweden;Switzerland;United Kingdom;
      2013   -   EUCTR2013-002082-19-DK   Denmark;Finland;Netherlands;Spain;Sweden;Switzerland;United Kingdom;
Lemtrada   
   GENZYME CORPORATION
      2017   Phase 3   EUCTR2016-003100-30-IT   Austria;Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;
   Genzyme Corporation
      2017   Phase 3   EUCTR2016-003100-30-PT   Austria;Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2017   Phase 3   EUCTR2016-003100-30-NO   Austria;Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2017   Phase 3   EUCTR2016-003100-30-NL   Austria;Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2017   Phase 3   EUCTR2016-003100-30-GR   Austria;Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2017   Phase 3   EUCTR2016-003100-30-GB   Austria;Belgium;Bulgaria;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;
      2017   Phase 3   EUCTR2016-003100-30-ES   Austria;Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2017   Phase 3   EUCTR2016-003100-30-DE   Austria;Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2017   Phase 3   EUCTR2016-003100-30-BE   Austria;Belgium;Bulgaria;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;
      2017   Phase 3   EUCTR2016-003100-30-AT   Austria;Belgium;Bulgaria;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;
      2015   Phase 3;Phase 4   EUCTR2013-003884-71-NL   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2015   Phase 3;Phase 4   EUCTR2013-003884-71-DK   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2015   -   EUCTR2013-003884-71-BE   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;France;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;
      2014   Phase 4   EUCTR2014-000092-62-NL   Belgium;France;Netherlands;Spain;Switzerland;
      2014   Phase 4   EUCTR2014-000092-62-FR   Belgium;France;Netherlands;Spain;Switzerland;
      2014   Phase 4   EUCTR2014-000092-62-ES   Belgium;France;Netherlands;Spain;Switzerland;
      2014   Phase 4   EUCTR2014-000092-62-BE   Belgium;France;Netherlands;Spain;Switzerland;
      2014   Phase 3;Phase 4   EUCTR2013-003884-71-IT   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;France;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;
      2014   Phase 3;Phase 4   EUCTR2013-003884-71-HR   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2013-003884-71-DE   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2014   Phase 3;Phase 4   EUCTR2013-003884-71-CZ   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2014   -   EUCTR2013-003884-71-ES   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;France;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;
      -   Phase 3   EUCTR2016-003100-30-PL   Austria;Belgium;Bulgaria;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;
      -   Phase 3   EUCTR2016-003100-30-Outside-EU/EEA   Austria;Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      -   Phase 3   EUCTR2016-003100-30-FR   Austria;Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      -   Phase 3   EUCTR2016-003100-30-BG   Austria;Belgium;Bulgaria;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;
   Genzyme GmbH
      2016   Phase 3   EUCTR2016-000464-42-DE   Germany;
   Helse Bergen HF, Haukeland University Hospital
      2019   Phase 3   EUCTR2017-001362-25-NL   Denmark;Netherlands;
      2018   Phase 3   EUCTR2017-001362-25-DK   Denmark;Netherlands;
   Turku University Hospital
      2013   Phase 4   EUCTR2013-004626-28-FI   Finland;
   University Medical Centre Hamburg-Eppendorf
      2020   Phase 2   EUCTR2016-001166-29-DE   Germany;
Lenograstim   
   Sheffield Teaching Hospitals
      2020   Phase 3   EUCTR2019-001549-42-GB   United Kingdom;
Levetiracetam   
   AZIENDA SANITARIA N. 3 GENOVESE
      2007   -   EUCTR2007-005414-40-IT   Italy;
   Newcastle-upon-Tyne Hospitals NHS Trust
      2006   Phase 4   EUCTR2005-003903-35-GB   United Kingdom;
   Odense University Hospital
      2007   Phase 4   NCT00423527   Denmark;
   Organisation name was not entered
      2005   -   EUCTR2005-001776-13-DE   Germany;
   Søren H. Sindrup, Department of Neurology, Odense University Hospital
      2006   -   EUCTR2006-000397-71-DK   Denmark;
Levitra   
   Unidad de Neuroinmunología
      2005   Phase 4   EUCTR2004-003761-33-ES   Spain;
Levocarnil   
   CHU de Bordeaux
      2010   Phase 3   EUCTR2009-015934-30-FR   France;
Lidocaine patch   
   University of Rochester
      2007   Phase 4   NCT00414453   United States;
Linoleic Acid/Oleic Acid   
   University of Rochester
      2008   Phase 1   NCT00638196   United States;
Liofen XL   
   Sun Pharma Advanced Research Company Ltd.
      2016   Phase 3   EUCTR2016-001356-22-HU   Germany;Hungary;Russian Federation;Ukraine;United States;
Liothyronine   
   Johns Hopkins University
      2015   Phase 1   NCT02506751   United States;
Liothyronine sodium   
   Oregon Health and Science University
      2016   Phase 1   NCT02760056   United States;
Lipoic acid   
   VA Office of Research and Development
      2018   Phase 2   NCT03161028   Canada;United States;
      2010   Phase 2/Phase 3   NCT01188811   United States;
Lipoic acid (LA) with fish oil and LA without fish oil   
   Oregon Health and Science University
      2005   Phase 1   NCT00676156   United States;
Lipoic acid and omega-3 fatty acids   
   Oregon Health and Science University
      2014   Phase 1/Phase 2   NCT02133664   United States;
Lisdexamfetamine sulfate   
   State University of New York at Buffalo
      2009   Phase 2   NCT01615887   United States;
Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field   
   NorthShore University HealthSystem
      2016   Phase 4   NCT02670161   -
Live Hookworm Larvae   
   University of Nottingham
      2008   Phase 2   NCT00630383   United Kingdom;
Live Necator americanus larvae   
   University of Nottingham
      2011   Phase 2   EUCTR2008-005008-24-GB   United Kingdom;
Locally approved intravenous contrast medium for contrast enhanced magnetic resonance imaging (MRI)   
   Sanofi
      2019   Phase 2   NCT03889639   Canada;Czechia;Estonia;France;Netherlands;Russian Federation;Slovakia;Spain;Sweden;Ukraine;United States;
Lodosyn   
   University of Miami
      2022   Phase 2   NCT04764383   United States;
Lokomat training   
   IRCCS Centro Neurolesi Bonino-Pulejo
      2016   -   NCT03186664   Italy;
Loperamide   
   Rocky Mountain MS Research Group, LLC
      2014   Phase 4   NCT02217982   United States;
Loratadine   
   Genzyme, a Sanofi Company
      2015   Phase 1   NCT02583594   Spain;
Low Dose Aspirin (162 mg/day)   
   Mayo Clinic
      2007   Phase 3   NCT00467584   United States;
Low dose arm receiving neutral oil and 400 IU/g of Vitamin D every second day   
   Charite University, Berlin, Germany
      2011   Phase 2   NCT01440062   Germany;
Low dose cannabis   
   University of California, Davis
      2009   Phase 1/Phase 2   NCT01037088   United States;
Low immunogenic interferon-beta-1a   
   Biogen Idec
      2004   Phase 4   NCT00493077   Sweden;
Lu AG06466   
   H. Lundbeck A/S
      2021   Phase 1   NCT04990219   United States;
Lubiprostone   
   University of Rochester
      2010   Phase 4   NCT01236534   United States;
Lumbar Puncture   
   Genentech, Inc.
      2016   Phase 3   NCT02688985   Canada;Germany;Sweden;United States;
Lumbar puncture   
   Centre Hospitalier Universitaire de Nimes
      2013   Phase 3   NCT01817166   France;
Lutein   
   University of Illinois at Urbana-Champaign
      2021   -   NCT04843813   United States;
M2951   
   EMD Serono Research & Development Institute, Inc.
      2017   Phase 2   NCT02975349   Bulgaria;Czechia;Germany;Poland;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United States;
   MERCK HEALTHCARE KGaA
      2020   Phase 3   EUCTR2019-004980-36-IT   Belarus;Brazil;Bulgaria;Canada;France;Germany;Greece;India;Italy;Kuwait;Latvia;Lithuania;Malaysia;Mexico;Moldova, Republic of;Norway;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;Tunisia;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2019-004972-20-IT   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Georgia;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
   Merck Healthcare KGaA
      2021   Phase 3   EUCTR2019-004980-36-SI   Belarus;Brazil;Bulgaria;Canada;France;Germany;Greece;India;Italy;Kuwait;Latvia;Lithuania;Malaysia;Mexico;Moldova, Republic of;Norway;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;Tunisia;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2019-004980-36-SK   Belarus;Brazil;Bulgaria;Canada;France;Germany;Greece;India;Italy;Kuwait;Latvia;Lithuania;Malaysia;Mexico;Moldova, Republic of;Norway;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;Tunisia;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2019-004980-36-PT   Belarus;Brazil;Bulgaria;Canada;France;Germany;Greece;India;Italy;Kuwait;Latvia;Lithuania;Malaysia;Mexico;Moldova, Republic of;Norway;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;Tunisia;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2019-004980-36-NO   Belarus;Brazil;Bulgaria;Canada;France;Germany;Greece;India;Italy;Kuwait;Latvia;Lithuania;Malaysia;Mexico;Moldova, Republic of;Norway;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;Tunisia;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2019-004980-36-LV   Belarus;Brazil;Bulgaria;Canada;France;Germany;Greece;India;Italy;Kuwait;Latvia;Lithuania;Malaysia;Mexico;Moldova, Republic of;Norway;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;Tunisia;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2019-004980-36-LT   Belarus;Brazil;Bulgaria;Canada;France;Germany;Greece;India;Italy;Kuwait;Latvia;Lithuania;Malaysia;Mexico;Moldova, Republic of;Norway;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;Tunisia;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2019-004980-36-GR   Belarus;Brazil;Bulgaria;Canada;France;Germany;Greece;India;Italy;Kuwait;Latvia;Lithuania;Malaysia;Mexico;Moldova, Republic of;Norway;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;Tunisia;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2019-004980-36-DE   Belarus;Brazil;Bulgaria;Canada;France;Germany;Greece;India;Italy;Kuwait;Latvia;Lithuania;Malaysia;Mexico;Moldova, Republic of;Norway;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;Tunisia;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2019-004980-36-BG   Belarus;Brazil;Bulgaria;Canada;France;Germany;Greece;India;Italy;Kuwait;Latvia;Lithuania;Malaysia;Mexico;Moldova, Republic of;Norway;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;Tunisia;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2019-004972-20-HU   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Georgia;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004972-20-GB   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004972-20-FI   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Georgia;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004972-20-DE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Georgia;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004972-20-CZ   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Georgia;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004972-20-BG   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Georgia;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004972-20-AT   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Georgia;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-004701-11-BG   Argentina;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Montenegro;Poland;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-004700-19-BG   Belarus;Brazil;Bulgaria;Canada;France;Germany;Greece;Italy;Kuwait;Lebanon;Lithuania;Mexico;Moldova, Republic of;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Thailand;Tunisia;Turkey;Ukraine;United States;
      -   Phase 3   EUCTR2019-004972-20-BE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Georgia;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
   Merck KGaA
      2017   Phase 2   EUCTR2016-001448-21-SK   Bulgaria;Croatia;Czech Republic;Czechia;Poland;Russian Federation;Serbia;Slovakia;Spain;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-001448-21-PL   Bulgaria;Croatia;Czech Republic;Poland;Russian Federation;Serbia;Slovakia;Spain;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-001448-21-ES   Bulgaria;Croatia;Czech Republic;Poland;Russian Federation;Serbia;Slovakia;Spain;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-001448-21-CZ   Bulgaria;Croatia;Czech Republic;Poland;Russian Federation;Serbia;Slovakia;Spain;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-001448-21-BG   Bulgaria;Croatia;Czech Republic;Poland;Russian Federation;Serbia;Slovakia;Spain;Turkey;Ukraine;United States;
MABCAMPATH 10 mg/ml concentrado para solución para perfusión   
   Genzyme Corporation
      2010   Phase 3   EUCTR2009-010788-18-ES   Austria;Belgium;Czech Republic;Denmark;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;
MANTADAN*20CPR   
   FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR
      2011   -   EUCTR2010-023678-38-IT   Italy;
MAVENCLAD - 10 MG - COMPRESSA - USO ORALE - BLISTER (AL/AL) - 6 COMPRESSE   
   MERCK KGAA
      2021   Phase 4   EUCTR2020-003995-42-IT   Australia;Canada;Czech Republic;Finland;Germany;Hungary;Israel;Italy;Poland;
      2021   Phase 4   EUCTR2020-003874-30-IT   Austria;Czechia;Denmark;France;Hungary;Italy;Netherlands;Poland;Slovakia;Spain;
MAVENCLAD 10 mg tablets   
   Westfälische Wilhelms-Universität Münster c/o Universitätsklinikum Münster, Geschäftsbereich Recht u. Drittmittel
      2019   Phase 4   EUCTR2018-004557-24-DE   Germany;
MBP peptide   
   Centrum Neurologii Krzysztof Selmaj
      2016   Phase 2   EUCTR2016-002180-33-PL   Poland;
MBP8298   
   BioMS Technology Corp.
      2007   Phase 3   NCT00468611   United States;
MBP8298 Synthetic Peptide   
   BioMS Technology Corp
      2007   -   EUCTR2004-002571-16-GB   Denmark;Estonia;Finland;Latvia;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2004-002571-16-NL   Denmark;Estonia;Finland;Latvia;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2004-002571-16-LV   Denmark;Estonia;Finland;Latvia;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2004-002571-16-LT   Denmark;Estonia;Finland;Latvia;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2004-002571-16-FI   Denmark;Estonia;Finland;Latvia;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2004-002571-16-ES   Denmark;Estonia;Finland;Latvia;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2004-002571-16-EE   Denmark;Estonia;Finland;Latvia;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2004-002571-16-DK   Denmark;Estonia;Finland;Latvia;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
      2005   -   EUCTR2004-002571-16-SE   Denmark;Estonia;Finland;Latvia;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
   BioMS Technology Corp.
      2006   Phase 2   EUCTR2006-001947-70-SK   Slovakia;
MD1003   
   MEDDAY PHARMACEUTICALS
      2017   Phase 3   EUCTR2016-000700-29-IT   Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States;
   MEDDAY PHARMACEUTICALS SA
      2018   Phase 3   EUCTR2016-000700-29-PL   Australia;Belgium;Canada;Czech Republic;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-000700-29-HU   Australia;Belgium;Canada;Czech Republic;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-000700-29-BE   Australia;Belgium;Canada;Czech Republic;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000700-29-SE   Australia;Belgium;Canada;Czech Republic;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000700-29-ES   Belgium;Canada;Czech Republic;Germany;Hungary;Italy;Poland;Spain;Sweden;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000700-29-DE   Australia;Belgium;Canada;Czech Republic;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-000700-29-CZ   Australia;Belgium;Canada;Czech Republic;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States;
   MEDDAY Pharmaceuticals SA
      2014   Phase 3   EUCTR2013-002112-27-GB   France;United Kingdom;
   MEDDAY SAS
      -   -   EUCTR2013-002113-35-FR   France;
      -   -   EUCTR2013-002112-27-FR   France;
MD1003 100mg capsule   
   MedDay Pharmaceuticals SA
      2016   Phase 3   NCT02936037   Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Turkey;United Kingdom;United States;
      2013   Phase 3   NCT02220933   France;
      2013   Phase 3   NCT02220244   France;United Kingdom;
MEDI-551   
   MedImmune LLC
      2018   Phase 2;Phase 3   EUCTR2014-000253-36-NL   Australia;Bulgaria;Canada;China;Colombia;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;India;Israel;Japan;Korea, Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;Ukraine;United States;
      2017   Phase 2;Phase 3   EUCTR2014-000253-36-HU   Australia;Bulgaria;Canada;Colombia;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;Israel;Japan;Korea, Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;Ukraine;United States;
      2017   Phase 2;Phase 3   EUCTR2014-000253-36-GR   Australia;Bulgaria;Canada;Colombia;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;Israel;Japan;Korea, Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;Ukraine;United States;
      2015   Phase 2;Phase 3   EUCTR2014-000253-36-ES   Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;Israel;Japan;Korea, Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Russian Federation;South Africa;Spain;Taiwan;Thailand;Turkey;Ukraine;United States;
      2015   Phase 2;Phase 3   EUCTR2014-000253-36-DE   Australia;Bulgaria;Canada;Colombia;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;Israel;Japan;Korea, Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;Ukraine;United States;
      2015   Phase 2;Phase 3   EUCTR2014-000253-36-BG   Australia;Bulgaria;Canada;Colombia;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;Israel;Japan;Korea, Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;Ukraine;United States;
      2014   Phase 2;Phase 3   EUCTR2014-000253-36-PL   Australia;Bulgaria;Canada;Colombia;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;Israel;Japan;Korea, Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;Ukraine;United States;
      2014   Phase 2;Phase 3   EUCTR2014-000253-36-EE   Australia;Bulgaria;Canada;Colombia;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;Israel;Japan;Korea, Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;Ukraine;United States;
      2014   Phase 2;Phase 3   EUCTR2014-000253-36-CZ   Australia;Bulgaria;Canada;Colombia;Czech Republic;Estonia;Germany;Greece;Hong Kong;Hungary;Israel;Japan;Korea, Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;Ukraine;United States;
      2012   -   EUCTR2011-005475-16-GB   Austria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
MEDI-551 100 MG-IV   
   MedImmune LLC
      2012   Phase 1   NCT01585766   Czech Republic;Poland;Spain;Ukraine;United Kingdom;United States;
MEDI-551 30 MG-IV   
   MedImmune LLC
      2012   Phase 1   NCT01585766   Czech Republic;Poland;Spain;Ukraine;United Kingdom;United States;
MEDI-551 300 MG-SC   
   MedImmune LLC
      2012   Phase 1   NCT01585766   Czech Republic;Poland;Spain;Ukraine;United Kingdom;United States;
MEDI-551 60 MG-SC   
   MedImmune LLC
      2012   Phase 1   NCT01585766   Czech Republic;Poland;Spain;Ukraine;United Kingdom;United States;
MEDI-551 600 MG-IV   
   MedImmune LLC
      2012   Phase 1   NCT01585766   Czech Republic;Poland;Spain;Ukraine;United Kingdom;United States;
METHYLPHENIDATE HYDROCHLORIDE   
   Medizinische Universität Wien
      2012   -   EUCTR2012-003418-15-AT   Austria;
METHYLPREDNISOLONE SODIUM HEMISUCCINATE   
   Servicio de Neurología, HU. Germans Trias i Pujol
      2012   Phase 4   EUCTR2012-001965-34-ES   Spain;
METHYLPREDNISOLONE SODIUM SUCCINATE   
   Danish Multiple Sclerosis Research Centre
      2009   Phase 2   EUCTR2009-011516-37-DK   Denmark;
   Department of Clinical Neuroscience, Karolinska Institutet
      2020   Phase 2   EUCTR2018-000620-34-DE   Germany;Sweden;
      2018   Phase 2   EUCTR2018-000620-34-SE   Sweden;
   Enceladus Pharmaceuticals BV
      2010   -   EUCTR2009-013884-21-PL   Belgium;Germany;Poland;
      2009   Phase 2   EUCTR2009-013884-21-BE   Belgium;Germany;Poland;
      2009   -   EUCTR2009-013884-21-DE   Belgium;Germany;Poland;
MIS416   
   Innate Immunotherapeutics
      2014   Phase 2   NCT02228213   Australia;New Zealand;
      2010   Phase 1/Phase 2   NCT01191996   New Zealand;
MK0812   
   Merck Sharp & Dohme Corp.
      2004   Phase 2   NCT00239655   Canada;Finland;Germany;United Kingdom;United States;
MLN1202   
   Millennium Pharmaceuticals, Inc.
      2006   Phase 2   EUCTR2004-002567-24-GB   Czech Republic;Hungary;United Kingdom;
      2005   Phase 2   NCT01199640   -
      2005   -   EUCTR2004-002567-24-HU   Czech Republic;Hungary;United Kingdom;
      2005   -   EUCTR2004-002567-24-CZ   Czech Republic;Hungary;United Kingdom;
MOG peptide   
   Centrum Neurologii Krzysztof Selmaj
      2016   Phase 2   EUCTR2016-002180-33-PL   Poland;
MOR103   
   MorphoSys AG
      2012   Phase 1/Phase 2   NCT01517282   Germany;Poland;United Kingdom;
MRI   
   University Hospital, Strasbourg, France
      2019   Phase 2   NCT03910738   France;
MRI contrast-enhancing preparations   
   Sanofi
      2021   Phase 2   NCT04879628   Bulgaria;Canada;Czechia;France;Germany;Spain;Turkey;Ukraine;United States;
MRNA COVID-19 vaccine   
   Novartis Pharmaceuticals
      2021   Phase 4   NCT04878211   United States;
MSC2015   
   SALK - Gemeinnützige Salzburger Landeskliniken Betriebsges. m.b.H., Christian-Doppler-Klinik, UK für Neurologie der PMU
      -   -   EUCTR2015-000137-78-AT   Austria;
MSC2304479A   
   Merck KGaA
      2013   Phase 2   EUCTR2013-002916-28-LV   Latvia;Russian Federation;
MSC2304480A   
   Merck KGaA
      2013   Phase 2   EUCTR2013-002916-28-LV   Latvia;Russian Federation;
MSC2304481A   
   Merck KGaA
      2013   Phase 2   EUCTR2013-002916-28-LV   Latvia;Russian Federation;
MSC2304482A   
   Merck KGaA
      2013   Phase 2   EUCTR2013-002916-28-LV   Latvia;Russian Federation;
MSC2358825A   
   Merck KGaA
      2013   Phase 2   EUCTR2013-002916-28-LV   Latvia;Russian Federation;
MSC2364447C   
   MERCK HEALTHCARE KGaA
      2020   Phase 3   EUCTR2019-004980-36-IT   Belarus;Brazil;Bulgaria;Canada;France;Germany;Greece;India;Italy;Kuwait;Latvia;Lithuania;Malaysia;Mexico;Moldova, Republic of;Norway;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;Tunisia;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2019-004972-20-IT   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Georgia;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
   Merck Healthcare KGaA
      2021   Phase 3   EUCTR2019-004980-36-SI   Belarus;Brazil;Bulgaria;Canada;France;Germany;Greece;India;Italy;Kuwait;Latvia;Lithuania;Malaysia;Mexico;Moldova, Republic of;Norway;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;Tunisia;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2019-004980-36-SK   Belarus;Brazil;Bulgaria;Canada;France;Germany;Greece;India;Italy;Kuwait;Latvia;Lithuania;Malaysia;Mexico;Moldova, Republic of;Norway;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;Tunisia;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2019-004980-36-PT   Belarus;Brazil;Bulgaria;Canada;France;Germany;Greece;India;Italy;Kuwait;Latvia;Lithuania;Malaysia;Mexico;Moldova, Republic of;Norway;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;Tunisia;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2019-004980-36-NO   Belarus;Brazil;Bulgaria;Canada;France;Germany;Greece;India;Italy;Kuwait;Latvia;Lithuania;Malaysia;Mexico;Moldova, Republic of;Norway;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;Tunisia;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2019-004980-36-LV   Belarus;Brazil;Bulgaria;Canada;France;Germany;Greece;India;Italy;Kuwait;Latvia;Lithuania;Malaysia;Mexico;Moldova, Republic of;Norway;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;Tunisia;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2019-004980-36-LT   Belarus;Brazil;Bulgaria;Canada;France;Germany;Greece;India;Italy;Kuwait;Latvia;Lithuania;Malaysia;Mexico;Moldova, Republic of;Norway;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;Tunisia;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2019-004980-36-GR   Belarus;Brazil;Bulgaria;Canada;France;Germany;Greece;India;Italy;Kuwait;Latvia;Lithuania;Malaysia;Mexico;Moldova, Republic of;Norway;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;Tunisia;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2019-004980-36-DE   Belarus;Brazil;Bulgaria;Canada;France;Germany;Greece;India;Italy;Kuwait;Latvia;Lithuania;Malaysia;Mexico;Moldova, Republic of;Norway;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;Tunisia;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2019-004980-36-BG   Belarus;Brazil;Bulgaria;Canada;France;Germany;Greece;India;Italy;Kuwait;Latvia;Lithuania;Malaysia;Mexico;Moldova, Republic of;Norway;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;Tunisia;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2019-004972-20-HU   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Georgia;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004972-20-GB   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Georgia;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004972-20-FI   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Georgia;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004972-20-DE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Georgia;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004972-20-CZ   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Georgia;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004972-20-BG   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Georgia;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004972-20-AT   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Georgia;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-004701-11-BG   Argentina;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Montenegro;Poland;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-004700-19-BG   Belarus;Brazil;Bulgaria;Canada;France;Germany;Greece;Italy;Kuwait;Lebanon;Lithuania;Mexico;Moldova, Republic of;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Thailand;Tunisia;Turkey;Ukraine;United States;
      -   Phase 3   EUCTR2019-004972-20-BE   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Georgia;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
MSC2430913A or ONO-4641 (to be used as synonyms)   
   Merck KGaA
      2014   Phase 3   EUCTR2013-002351-15-AT   Argentina;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Jordan;Latvia;Lebanon;Lithuania;Mexico;Morocco;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2014   -   EUCTR2013-003126-83-HU   Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2014   -   EUCTR2013-003126-83-GR   Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2014   -   EUCTR2013-003126-83-ES   Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2014   -   EUCTR2013-003126-83-DE   Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2014   -   EUCTR2013-003126-83-BG   Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Georgia;Germany;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2014   -   EUCTR2013-002351-15-PT   Argentina;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Jordan;Latvia;Lebanon;Lithuania;Mexico;Morocco;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2014   -   EUCTR2013-002351-15-LV   Argentina;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Jordan;Latvia;Lebanon;Lithuania;Mexico;Morocco;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2014   -   EUCTR2013-002351-15-HU   Argentina;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Jordan;Latvia;Lebanon;Lithuania;Mexico;Morocco;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2014   -   EUCTR2013-002351-15-ES   Argentina;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Jordan;Latvia;Lebanon;Lithuania;Mexico;Morocco;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2014   -   EUCTR2013-002351-15-EE   Argentina;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Jordan;Latvia;Lebanon;Lithuania;Mexico;Morocco;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2014   -   EUCTR2013-002351-15-BG   Argentina;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;Estonia;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Jordan;Latvia;Lebanon;Lithuania;Mexico;Morocco;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Tunisia;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
MSC2491529A   
   Merck KGaA
      2014   Phase 2   EUCTR2013-002283-25-GB   Bulgaria;Colombia;Croatia;Czech Republic;Finland;Greece;Hungary;Italy;Mexico;Poland;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2014   -   EUCTR2013-002283-25-PL   Bulgaria;Colombia;Croatia;Czech Republic;Finland;Greece;Hungary;Italy;Mexico;Poland;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2014   -   EUCTR2013-002283-25-GR   Bulgaria;Colombia;Croatia;Czech Republic;Finland;Greece;Hungary;Italy;Mexico;Poland;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2014   -   EUCTR2013-002283-25-ES   Bulgaria;Colombia;Croatia;Czech Republic;Finland;Greece;Hungary;Italy;Mexico;Poland;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2014   -   EUCTR2013-002283-25-BG   Bulgaria;Croatia;Czech Republic;Finland;Greece;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2013-002283-25-IT   Bulgaria;Colombia;Croatia;Czech Republic;Finland;Greece;Hungary;Italy;Mexico;Poland;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2013   -   EUCTR2013-002283-25-HU   Bulgaria;Colombia;Croatia;Czech Republic;Finland;Greece;Hungary;Italy;Mexico;Poland;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2013   -   EUCTR2013-002283-25-HR   Bulgaria;Colombia;Croatia;Czech Republic;Finland;Greece;Hungary;Italy;Mexico;Poland;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2013   -   EUCTR2013-002283-25-FI   Bulgaria;Colombia;Croatia;Czech Republic;Finland;Greece;Hungary;Italy;Mexico;Poland;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2013   -   EUCTR2013-002283-25-CZ   Bulgaria;Colombia;Croatia;Czech Republic;Finland;Greece;Hungary;Italy;Mexico;Poland;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
MSDMDs other than Betaseron (Interferon beta-1b, BAY86-5046)   
   Bayer
      2016   -   NCT02749396   Finland;
MSTC-001 (MS-STAT)   
   Imperial College London
      2007   Phase 2   EUCTR2006-006347-31-GB   United Kingdom;
MSmonitor, a self-management/education program with e-health interventions   
   Isala
      2021   -   NCT05242731   Netherlands;
MT-1303   
   MITSUBISHI PHARMA CORPORATION
      2013   -   EUCTR2012-002470-31-IT   Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;Hungary;Italy;Lithuania;Poland;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;
   Mitsubishi Tanabe Pharma Corporation
      2014   Phase 1   NCT02293967   United Kingdom;
   Mitsubishi Tanabe Pharma Corporation (MTPC)
      2013   Phase 2   EUCTR2012-002639-27-PL   Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;Germany;Hungary;Italy;Lithuania;Poland;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;
      2013   Phase 2   EUCTR2012-002639-27-LT   Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;Germany;Hungary;Italy;Lithuania;Poland;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;
      2013   Phase 2   EUCTR2012-002639-27-HU   Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;Germany;Hungary;Italy;Latvia;Lithuania;Poland;Russian Federation;Serbia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;
      2013   Phase 2   EUCTR2012-002639-27-GB   Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;Germany;Hungary;Italy;Latvia;Lithuania;Poland;Russian Federation;Serbia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;
      2013   Phase 2   EUCTR2012-002639-27-FI   Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;Germany;Hungary;Italy;Latvia;Lithuania;Poland;Russian Federation;Serbia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;
      2013   Phase 2   EUCTR2012-002639-27-ES   Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;Germany;Hungary;Italy;Latvia;Lithuania;Poland;Russian Federation;Serbia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;
      2013   Phase 2   EUCTR2012-002639-27-CZ   Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;Germany;Hungary;Italy;Latvia;Lithuania;Poland;Russian Federation;Serbia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;
      2013   Phase 2   EUCTR2012-002639-27-BG   Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;Germany;Hungary;Italy;Latvia;Lithuania;Poland;Russian Federation;Serbia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;
      2013   Phase 2   EUCTR2012-002639-27-BE   Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;Germany;Hungary;Italy;Lithuania;Poland;Russian Federation;Serbia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;
      2013   -   EUCTR2012-002470-31-LT   Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;Germany;Hungary;Italy;Lithuania;Poland;Russian Federation;Serbia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;
      2013   -   EUCTR2012-002470-31-FI   Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;Germany;Hungary;Italy;Latvia;Lithuania;Poland;Russian Federation;Serbia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;
      2013   -   EUCTR2012-002470-31-ES   Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;Germany;Hungary;Italy;Latvia;Lithuania;Poland;Russian Federation;Serbia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;
      2013   -   EUCTR2012-002470-31-BG   Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;Germany;Hungary;Italy;Latvia;Lithuania;Poland;Russian Federation;Serbia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;
      2013   -   EUCTR2012-002470-31-BE   Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;Germany;Hungary;Italy;Lithuania;Poland;Russian Federation;Serbia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;
      2012   -   EUCTR2012-002470-31-PL   Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;Germany;Hungary;Italy;Lithuania;Poland;Russian Federation;Serbia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;
      2012   -   EUCTR2012-002470-31-HU   Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;Germany;Hungary;Italy;Latvia;Lithuania;Poland;Russian Federation;Serbia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;
      2012   -   EUCTR2012-002470-31-GB   Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;Germany;Hungary;Italy;Latvia;Lithuania;Poland;Russian Federation;Serbia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;
      2012   -   EUCTR2012-002470-31-CZ   Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;Germany;Hungary;Italy;Latvia;Lithuania;Poland;Russian Federation;Serbia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;
MT-1303 [0.1]   
   MITSUBISHI TANABE PHARMA CORPORATION
      2013   Phase 2   EUCTR2012-002639-27-IT   Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;Germany;Hungary;Italy;Latvia;Lithuania;Poland;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;
MT-1303 [0.2]   
   MITSUBISHI TANABE PHARMA CORPORATION
      2013   Phase 2   EUCTR2012-002639-27-IT   Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;Germany;Hungary;Italy;Latvia;Lithuania;Poland;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;
MT-1303 [0.4]   
   MITSUBISHI TANABE PHARMA CORPORATION
      2013   Phase 2   EUCTR2012-002639-27-IT   Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;Germany;Hungary;Italy;Latvia;Lithuania;Poland;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;
MT-1303-FormA   
   Mitsubishi Tanabe Pharma Corporation
      2014   Phase 1   NCT02310048   United Kingdom;
MT-1303-FormB   
   Mitsubishi Tanabe Pharma Corporation
      2014   Phase 1   NCT02310048   United Kingdom;
MT-1303-High   
   Mitsubishi Tanabe Pharma Corporation
      2014   Phase 1   NCT02193217   United Kingdom;
      2013   Phase 2   NCT01890655   Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;Germany;Hungary;Italy;Lithuania;Poland;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;
      2013   Phase 2   NCT01742052   Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;Germany;Hungary;Italy;Lithuania;Poland;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;
MT-1303-Low   
   Mitsubishi Tanabe Pharma Corporation
      2014   Phase 1   NCT02193217   United Kingdom;
      2013   Phase 2   NCT01890655   Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;Germany;Hungary;Italy;Lithuania;Poland;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;
      2013   Phase 2   NCT01742052   Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;Germany;Hungary;Italy;Lithuania;Poland;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;
MT-1303-Middle   
   Mitsubishi Tanabe Pharma Corporation
      2013   Phase 2   NCT01890655   Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;Germany;Hungary;Italy;Lithuania;Poland;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom;
      2013   Phase 2   NCT01742052   Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;Germany;Hungary;Italy;Lithuania;Poland;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;
MabCampath ®   
   Genzyme Corporation
      2010   Phase 3   EUCTR2009-010788-18-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2009-010788-18-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2009   Phase 3   EUCTR2009-010788-18-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2008   Phase 3   EUCTR2007-001162-32-FR   Austria;Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2008   Phase 3   EUCTR2007-001162-32-ES   Austria;Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2008   Phase 3   EUCTR2007-001162-32-CZ   Austria;Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2008   Phase 3   EUCTR2007-001162-32-BE   Austria;Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2008   Phase 3   EUCTR2007-001161-14-FR   Czech Republic;France;Germany;Poland;Sweden;United Kingdom;
      2008   -   EUCTR2007-001162-32-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;France;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2008   -   EUCTR2007-001162-32-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;France;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2008   -   EUCTR2007-001162-32-NL   Austria;Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-001162-32-DK   Argentina;Australia;Austria;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;France;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2008   -   EUCTR2007-001162-32-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;France;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2008   -   EUCTR2007-001162-32-AT   Austria;Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-001161-14-SE   Argentina;Australia;Brazil;Croatia;Czech Republic;France;Germany;Mexico;Poland;Russian Federation;Serbia;Sweden;Ukraine;United Kingdom;
      2008   -   EUCTR2007-001161-14-PL   Argentina;Australia;Brazil;Croatia;Czech Republic;France;Germany;Mexico;Poland;Russian Federation;Serbia;Sweden;Ukraine;United Kingdom;
      2008   -   EUCTR2007-001161-14-DE   Argentina;Australia;Brazil;Croatia;Czech Republic;France;Germany;Mexico;Poland;Russian Federation;Serbia;Sweden;Ukraine;United Kingdom;
      2007   Phase 3   EUCTR2007-001162-32-GB   Austria;Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-001161-14-GB   Czech Republic;France;Germany;Poland;Sweden;United Kingdom;
   R&D Addenbrookes Hospital
      2008   Phase 2   EUCTR2005-002305-23-GB   United Kingdom;
MabCampath-1h   
   University of British Columbia
      2011   Phase 3   NCT01307332   Canada;
MabCampath®   
   Genzyme Corporation
      2009   Phase 3   EUCTR2009-010788-18-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2008   -   EUCTR2007-001161-14-PL   Argentina;Australia;Brazil;Croatia;Czech Republic;France;Germany;Mexico;Poland;Russian Federation;Serbia;Sweden;Ukraine;United Kingdom;
      2008   -   EUCTR2007-001161-14-CZ   Argentina;Australia;Brazil;Croatia;Czech Republic;France;Germany;Mexico;Poland;Russian Federation;Serbia;Sweden;Ukraine;United Kingdom;
MabThera (Rituximab)   
   Odense University Hospital
      2013   Phase 2   EUCTR2012-004436-36-DK   Denmark;
Mabthera or biosimilar rituximab product   
   Medical University of Vienna - Department of Neurology
      2018   Phase 2   EUCTR2017-000426-35-AT   Austria;
Mabthera®   
   Västerbottens Läns Landsting
      2014   Phase 2   EUCTR2013-002378-26-SE   Sweden;
Magnetic Resonance Imaging   
   University of Nottingham
      2017   -   NCT02481882   United Kingdom;
Maltodextrin   
   Medical University of Vienna
      2012   Phase 2   NCT01879202   Austria;
Maltodextrin fiber supplement   
   University of Iowa
      2010   Phase 1   NCT01381354   United States;
Mangafodipir (Teslascan)   
   National Institute of Neurological Disorders and Stroke (NINDS)
      2013   Phase 1   NCT01326715   United States;
Mannitol   
   Department of Neurology and Neurological Science, Tokyo Medical and Dental University
      2021   -   JPRN-UMIN000043910   Japan;
Marijuana   
   Colorado State University
      2016   -   NCT02898974   United States;
Masitinb mesylate   
   AB Science
      2015   Phase 3   EUCTR2012-003735-32-GR   Argentina;Belgium;Brazil;Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;Mexico;Slovakia;Spain;United Kingdom;
      2013   Phase 3   EUCTR2010-021219-17-GR   Bulgaria;Germany;Greece;Poland;Slovakia;Spain;Turkey;
      2013   -   EUCTR2010-021219-17-PL   Czech Republic;France;Germany;Greece;Poland;Romania;Slovakia;Spain;
      2011   Phase 3   EUCTR2010-021219-17-DE   Argentina;Bosnia and Herzegovina;Brazil;Bulgaria;France;Germany;Greece;Hungary;Italy;Mexico;Morocco;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Tunisia;Ukraine;United Kingdom;United States;
Masitinib   
   AB Science
      2011   Phase 3   NCT01433497   Bulgaria;France;Germany;Greece;Poland;Romania;Spain;United States;
      2005   Phase 2   NCT01450488   -
Masitinib mesilate   
   AB Science
      2022   Phase 3   EUCTR2021-000639-30-ES   Bulgaria;Canada;Finland;France;Germany;Greece;Hungary;Israel;Italy;Poland;Portugal;Russian Federation;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
Masitinib mesylate   
   AB Science
      2015   Phase 3   EUCTR2012-003735-32-SK   Argentina;Belgium;Brazil;Bulgaria;Canada;Colombia;Germany;Greece;Italy;Mexico;Slovakia;Spain;Switzerland;United Kingdom;
      2015   Phase 3   EUCTR2012-003735-32-GR   Argentina;Belgium;Brazil;Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;Mexico;Slovakia;Spain;United Kingdom;
      2015   Phase 3   EUCTR2010-021219-17-BG   Argentina;Bosnia and Herzegovina;Brazil;Bulgaria;France;Germany;Greece;Hungary;Italy;Mexico;Morocco;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Tunisia;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2010-021219-17-GR   Bulgaria;Germany;Greece;Poland;Slovakia;Spain;Turkey;
      2013   -   EUCTR2010-021219-17-PL   Czech Republic;France;Germany;Greece;Poland;Romania;Slovakia;Spain;
      2012   Phase 3   EUCTR2010-021219-17-SK   Argentina;Bosnia and Herzegovina;Brazil;Bulgaria;France;Germany;Greece;Hungary;Italy;Mexico;Morocco;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Tunisia;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-021219-17-ES   Bulgaria;Czech Republic;France;Germany;Greece;Poland;Romania;Slovakia;Spain;United States;
      2011   Phase 3   EUCTR2010-021219-17-DE   Argentina;Bosnia and Herzegovina;Brazil;Bulgaria;France;Germany;Greece;Hungary;Italy;Mexico;Morocco;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Tunisia;Ukraine;United Kingdom;United States;
Mastinib   
   AB Science
      2015   Phase 3   EUCTR2012-003735-32-SK   Argentina;Belgium;Brazil;Bulgaria;Canada;Colombia;Germany;Greece;Italy;Mexico;Slovakia;Spain;Switzerland;United Kingdom;
      2015   Phase 3   EUCTR2012-003735-32-GR   Argentina;Belgium;Brazil;Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;Mexico;Slovakia;Spain;United Kingdom;
      2013   Phase 3   EUCTR2010-021219-17-GR   Bulgaria;Germany;Greece;Poland;Slovakia;Spain;Turkey;
      2013   -   EUCTR2010-021219-17-PL   Czech Republic;France;Germany;Greece;Poland;Romania;Slovakia;Spain;
      2012   Phase 3   EUCTR2010-021219-17-SK   Argentina;Bosnia and Herzegovina;Brazil;Bulgaria;France;Germany;Greece;Hungary;Italy;Mexico;Morocco;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Tunisia;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-021219-17-DE   Argentina;Bosnia and Herzegovina;Brazil;Bulgaria;France;Germany;Greece;Hungary;Italy;Mexico;Morocco;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Tunisia;Ukraine;United Kingdom;United States;
Mavenclad   
   Helse Bergen HF, Haukeland University Hospital
      2019   Phase 3   EUCTR2017-001362-25-NL   Denmark;Netherlands;
      2018   Phase 3   EUCTR2017-001362-25-DK   Denmark;Netherlands;
   Merck Healthcare KGaA
      2021   Phase 4   EUCTR2020-003995-42-HU   Australia;Canada;Czech Republic;Finland;Germany;Hungary;Israel;
      2021   Phase 4   EUCTR2020-003995-42-CZ   Australia;Canada;Czech Republic;Finland;Germany;Hungary;Israel;
      2021   Phase 4   EUCTR2020-003874-30-HU   Hungary;
      2021   Phase 4   EUCTR2020-003874-30-DK   Denmark;Hungary;
      2021   Phase 4   EUCTR2020-003874-30-CZ   Czech Republic;Denmark;Hungary;Italy;
      2020   Phase 4   EUCTR2020-003995-42-FI   Australia;Canada;Finland;Germany;Israel;
      2020   Phase 4   EUCTR2020-003995-42-DE   Australia;Canada;Czech Republic;Finland;Germany;Hungary;Israel;Poland;
   Turku PET centre
      2019   Phase 4   EUCTR2019-001960-31-FI   Finland;
Mavenclad tabletter   
   Department of Neurology, Division of Clinical Neuroscience, Oslo University Hospital
      2019   Phase 3   EUCTR2019-001505-24-NO   Norway;
Mavenclad®   
   MERCK KGAA
      2018   Phase 4   EUCTR2017-002632-17-IT   Australia;Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Greece;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2018   Phase 4   EUCTR2017-002631-42-IT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Norway;Poland;Spain;Sweden;Switzerland;United Kingdom;
   Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
      2021   Phase 4   NCT04783935   Australia;Austria;Canada;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;
      2021   Phase 4   NCT04776213   Austria;Czechia;Denmark;France;Hungary;Italy;Netherlands;Poland;Slovakia;Spain;
   Merck KGaA
      2018   Phase 4   EUCTR2017-002632-17-SK   Australia;Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Greece;Hungary;Italy;Lithuania;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2018   Phase 4   EUCTR2017-002632-17-SE   Australia;Austria;Belgium;Czech Republic;Denmark;Finland;France;Greece;Hungary;Italy;Lithuania;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2018   Phase 4   EUCTR2017-002632-17-PT   Australia;Austria;Belgium;Czech Republic;Denmark;Finland;France;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;Switzerland;United Kingdom;
      2018   Phase 4   EUCTR2017-002632-17-NL   Australia;Austria;Belgium;Czech Republic;Denmark;Finland;France;Greece;Hungary;Italy;Lithuania;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2018   Phase 4   EUCTR2017-002632-17-LT   Australia;Austria;Belgium;Czech Republic;Denmark;Finland;France;Greece;Hungary;Italy;Lithuania;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2018   Phase 4   EUCTR2017-002632-17-HU   Australia;Austria;Belgium;Czech Republic;Denmark;Finland;France;Greece;Hungary;Ireland;Israel;Italy;Lithuania;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;Switzerland;United Kingdom;
      2018   Phase 4   EUCTR2017-002632-17-GR   Australia;Austria;Belgium;Czech Republic;Denmark;Finland;France;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;Switzerland;United Kingdom;
      2018   Phase 4   EUCTR2017-002632-17-GB   Austria;Belgium;Czech Republic;Denmark;Finland;France;Greece;Hungary;Italy;Lithuania;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2018   Phase 4   EUCTR2017-002632-17-FR   Australia;Austria;Belgium;Czech Republic;Denmark;Finland;France;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;Switzerland;United Kingdom;
      2018   Phase 4   EUCTR2017-002632-17-FI   Australia;Austria;Belgium;Czech Republic;Denmark;Finland;France;Greece;Hungary;Italy;Lithuania;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2018   Phase 4   EUCTR2017-002632-17-ES   Australia;Austria;Belgium;Czech Republic;Denmark;Finland;France;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;Switzerland;United Kingdom;
      2018   Phase 4   EUCTR2017-002632-17-DK   Australia;Austria;Belgium;Czech Republic;Denmark;Finland;France;Greece;Hungary;Italy;Lithuania;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2018   Phase 4   EUCTR2017-002632-17-CZ   Australia;Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Greece;Hungary;Italy;Lithuania;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2018   Phase 4   EUCTR2017-002632-17-BE   Australia;Austria;Belgium;Czech Republic;Denmark;Finland;France;Greece;Hungary;Italy;Lithuania;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2018   Phase 4   EUCTR2017-002632-17-AT   Australia;Austria;Belgium;Czech Republic;Denmark;Finland;France;Greece;Hungary;Italy;Lithuania;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2018   Phase 4   EUCTR2017-002631-42-SE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Norway;Poland;Spain;Sweden;Switzerland;United Kingdom;
      2018   Phase 4   EUCTR2017-002631-42-HU   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Norway;Spain;Sweden;Switzerland;United Kingdom;
      2018   Phase 4   EUCTR2017-002631-42-GB   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Norway;Poland;Spain;Sweden;Switzerland;United Kingdom;
      2018   Phase 4   EUCTR2017-002631-42-FR   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Norway;Spain;Sweden;Switzerland;United Kingdom;
      2018   Phase 4   EUCTR2017-002631-42-FI   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Norway;Spain;Sweden;Switzerland;United Kingdom;
      2018   Phase 4   EUCTR2017-002631-42-CZ   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Norway;Spain;Sweden;Switzerland;United Kingdom;
      2018   Phase 4   EUCTR2017-002631-42-BE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Norway;Poland;Spain;Sweden;Switzerland;United Kingdom;
      2018   Phase 4   EUCTR2017-002631-42-AT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Israel;Italy;Netherlands;Norway;Poland;Spain;Sweden;Switzerland;United Kingdom;
   Merck KGaA, Darmstadt, Germany
      2018   Phase 4   NCT03369665   Austria;Belgium;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Lithuania;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2018   Phase 4   NCT03364036   Australia;Austria;Belgium;Canada;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;
Mayzent   
   Novartis Farmacéutica S.A.
      2021   Phase 3   EUCTR2020-002700-39-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Novartis Pharma AG
      2021   Phase 3   EUCTR2020-002700-39-SK   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-002700-39-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-002700-39-LV   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-002700-39-LT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-002700-39-HR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-002700-39-FR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-002700-39-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-002700-39-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2020-002700-39-EE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2020-002700-39-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Novartis Pharmaceuticals
      2020   -   NCT04593927   Japan;
   Robert Zivadinov, MD, PhD
      2021   Phase 4   NCT04925557   United States;
Mayzent 0,25 mg Filmtabletten   
   Novartis Pharma GmbH
      2021   Phase 4   EUCTR2020-005752-38-DE   Germany;
Mayzent 0.25 mg fi   
   Novartis Pharma AG
      2021   Phase 3   EUCTR2020-002700-39-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Mayzent 2 mg Filmtabletten   
   Novartis Pharma GmbH
      2021   Phase 4   EUCTR2020-005752-38-DE   Germany;
Mayzent 2 mg film-coated tablets   
   Novartis Pharma AG
      2021   Phase 3   EUCTR2020-002700-39-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Medical Marijuana   
   Colorado State University
      2017   Phase 2/Phase 3   NCT03172741   -
Medication Event Monitoring System (MEMS)   
   Biogen
      2015   Phase 4   NCT02343159   United States;
Medrol   
   Scleroseklinikken, Rigshospitalet
      2011   -   EUCTR2010-024561-43-DK   Denmark;
Megadose oral methylprednisolone   
   Fred Lublin
      2003   Phase 3   NCT00418145   United States;
Melatonin   
   Isfahan University of Medical Sciences
      2012   Phase 2   NCT01718678   Iran, Islamic Republic of;
   Providence Health & Services
      2018   Early Phase 1   NCT03498131   United States;
   Tehran University of Medical Sciences
      2012   -   NCT02463318   Iran, Islamic Republic of;
      2010   Phase 2   NCT01279876   Iran, Islamic Republic of;
   University of California, San Francisco
      2019   -   NCT04035889   United States;
Melphalan   
   Fred Hutchinson Cancer Research Center
      2008   Phase 2   NCT00716066   United States;
Memantine   
   AZ. OSPEDALIERA GARIBALDI, S.LUIGI CURRO , ASCOLI TOMASELLI
      2007   -   EUCTR2007-000503-15-IT   Italy;
   Clinica Universidad de Navarra, Universidad de Navarra
      2007   Phase 2   NCT00638833   Spain;
   Hospices Civils de Lyon
      2012   Phase 2   NCT01744444   France;
   OSPEDALE S. RAFFAELE
      2008   Phase 2   EUCTR2008-000490-37-IT   Italy;
   Oregon Health and Science University
      2004   Phase 2/Phase 3   NCT00300716   United States;
   University Hospital, Caen
      2005   Phase 3   NCT01074619   France;
   University of Rochester
      2006   Phase 4   NCT00638027   United States;
Meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent)   
   Biogen
      2015   Phase 2   NCT02097849   United States;
Menitorix   
   R & D, Cambridge University Hospitals
      2009   -   EUCTR2009-011523-31-GB   United Kingdom;
Mesenchymal Stem Cells   
   Ottawa Hospital Research Institute
      2015   Phase 2   NCT02239393   Canada;
Mesenchymal Stem Cells (MSC)   
   Hadassah Medical Organization
      2013   Phase 1/Phase 2   NCT04823000   -
Mesenchymal stem cells   
   Dimitrios Karussis
      2015   Phase 2   NCT02166021   Israel;
   Imperial College London
      2013   Phase 1/Phase 2   NCT01606215   United Kingdom;
   University Hospital, Toulouse
      2015   Phase 1/Phase 2   NCT02403947   France;
Mesenchymal stem cells (MSCs)   
   Prof. Per Soelberg Sørensen
      2012   Phase 2   EUCTR2012-000518-13-DK   Denmark;
Mesenchymal stem/stromal cells   
   Prof. Per Soelberg Sørensen
      2012   Phase 2   EUCTR2012-000518-13-DK   Denmark;
Mesna   
   Northwestern University
      2019   Phase 2/Phase 3   NCT03829566   United States;
      2017   Phase 3   NCT03342638   United States;
Metabolic fatigue   
   Centre Hospitalier Universitaire de Saint Etienne
      2020   Phase 2   NCT03983720   France;
Metex   
   Universitätsklinikum Heidelberg
      2006   Phase 3   EUCTR2004-004403-37-DE   Germany;
Metformin   
   The Hospital for Sick Children
      2020   Phase 1/Phase 2   NCT04121468   Canada;
Methelphenidate   
   Kessler Foundation
      2014   Phase 2   NCT02286557   -
Methotrexat   
   Universitätsklinikum Heidelberg
      2006   Phase 3   EUCTR2004-004403-37-DE   Germany;
Methotrexate   
   Biogen Idec
      2003   Phase 4   NCT00112034   United States;
   Heidelberg University
      2006   Phase 3   NCT00344253   Germany;
   MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute
      2002   Phase 4   NCT00037115   United States;
      2001   Phase 4   NCT00037102   United States;
Methyl B12   
   University of Iowa
      2010   Phase 1   NCT01381354   United States;
Methyl Prednisolonate   
   University Hospital Muenster
      2018   -   NCT04450030   Germany;
Methyl folate   
   University of Iowa
      2010   Phase 1   NCT01381354   United States;
Methyloprednisolone   
   Genentech, Inc.
      2016   Phase 3   NCT02688985   Canada;Germany;Sweden;United States;
Methylphenidate   
   Johns Hopkins University
      2017   Phase 3   NCT03185065   United States;
   Oregon Health and Science University
      2013   Phase 2/Phase 3   NCT01896700   United States;
Methylphenidate modified release   
   Medical University of Vienna
      2012   Phase 2   NCT01879202   Austria;
   Medizinische Universität Wien
      2012   -   EUCTR2012-003418-15-AT   Austria;
Methylprednisolon-21-hydrogensuccinat, Natriumsalz   
   IFSgGmbH, Institute for clinical research
      2006   -   EUCTR2005-005592-14-DE   Germany;
Methylprednisolone   
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2008   -   EUCTR2007-002179-15-FR   France;
   Beijing Tongren Hospital
      2020   -   NCT04601142   China;
   Biogen
      2010   Phase 2   NCT01071083   Germany;Spain;United States;
   Biogen Idec
      2003   Phase 4   NCT00493116   Australia;New Zealand;
      2003   Phase 4   NCT00492466   Finland;
   Galapagos NV
      2009   Phase 2   NCT01039103   Belgium;Germany;Poland;
   Genzyme, a Sanofi Company
      2017   Phase 3   NCT03368664   Austria;Belgium;Bulgaria;Czechia;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;
      2015   Phase 1   NCT02583594   Spain;
      2014   Phase 4   NCT02205489   Belgium;France;Netherlands;Spain;
   Germans Trias i Pujol Hospital
      2008   Phase 4   NCT00753792   Spain;
   Hoffmann-La Roche
      2020   Phase 3   NCT04548999   Argentina;Belgium;Brazil;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Mexico;Peru;Poland;Portugal;Puerto Rico;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   NCT04544436   Argentina;Australia;Belgium;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
   IFSgGmbH, Institute for clinical research
      2006   -   EUCTR2005-005592-14-DE   Germany;
   Jena University Hospital
      2020   -   NCT04832269   Germany;
   Merck KGaA, Darmstadt, Germany
      2018   Phase 2   NCT03387046   Germany;Italy;
   MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute
      2002   Phase 4   NCT00037115   United States;
   National Eye Institute (NEI)
      1988   Phase 3   NCT00000146   United States;
      1988   -   NCT00000147   United States;
   National Institute of Neurological Disorders and Stroke (NINDS)
      2016   Phase 2   NCT02784210   United States;
   Neurologique Foundation, Inc.
      2009   Phase 2/Phase 3   NCT00947895   United States;
   Northwestern Memorial Hospital
      2001   Phase 1   NCT00017628   United States;
   Northwestern University
      2019   Phase 2/Phase 3   NCT03829566   United States;
      2017   Phase 3   NCT03342638   United States;
   Rigshospitalet, Denmark
      2021   Phase 3   NCT04688788   Denmark;
      2011   Phase 2   NCT01305837   Denmark;
   Stanford University
      2014   Phase 1   NCT02087813   United States;
   Sykehuset Innlandet HF
      2009   -   NCT00764413   Norway;
   Tomas Olsson
      2018   Phase 2   NCT03674099   Denmark;Germany;Norway;Sweden;
   University Hospital, Clermont-Ferrand
      2016   Phase 4   NCT02769689   France;
   University of Southern California
      2009   Phase 1   NCT01049451   United States;
   University of Texas Southwestern Medical Center
      2013   Phase 2   NCT01710228   United States;
Methylprednisolone (drug)   
   University Hospital, Bordeaux
      2005   Phase 3   NCT00241254   France;
Methylprednisolone 1250 mg/24h x3 days   
   Germans Trias i Pujol Hospital
      2013   Phase 4   NCT01986998   Spain;
Methylprednisolone IV   
   Centre Hospitalier de PAU
      2015   Phase 2   NCT02545959   France;
   Hoffmann-La Roche
      2022   Phase 3   NCT05232825   Brazil;Canada;Czechia;Italy;Poland;Russian Federation;Spain;Turkey;Ukraine;United States;
   Rennes University Hospital
      2008   Phase 3   NCT00984984   France;
Methylprednisolone PO   
   Rennes University Hospital
      2008   Phase 3   NCT00984984   France;
Methylprednisolone hemisuccinate   
   BBB-Therapeutics B.V.
      2013   Phase 1   NCT02048358   Netherlands;
Methylprednisolone succinate   
   Mazandaran University of Medical Sciences
      2021   Phase 2   NCT04979650   Iran, Islamic Republic of;
Metilprednisolone sodio succinato   
   NOVARTIS PHARMA AG
      2018   Phase 2   EUCTR2017-004702-17-IT   Austria;Bulgaria;Czech Republic;Czechia;Estonia;Germany;Italy;Latvia;Lithuania;Poland;Russian Federation;Spain;United States;
Microgynon   
   Novartis Pharma Services AG
      2012   -   EUCTR2011-006043-30-NL   Netherlands;
Microgynon®   
   Merck Healthcare KGaA, Darmstadt Germany, an affiliate of Merck KGaA, Darmstadt, Germany
      2019   Phase 1   NCT04086225   Germany;Poland;
   Merck KGaA, Darmstadt, Germany
      2019   Phase 1   NCT03745144   Germany;Poland;
Micropirin   
   Biogen Idec Research Limited
      2014   -   EUCTR2013-001895-40-IE   Ireland;United Kingdom;
Midazolam   
   Biogen
      2011   Phase 3   NCT01462318   Czech Republic;Hungary;Poland;Russian Federation;United States;
   Johns Hopkins University
      2018   Phase 1/Phase 2   NCT03500289   United States;
Mild dose cannabis   
   University of California, Davis
      2009   Phase 1/Phase 2   NCT01037088   United States;
Mineral boost (magnesium)   
   University of Iowa
      2010   Phase 1   NCT01381354   United States;
Minocycline   
   Dr. Luanne Metz
      2009   Phase 3   NCT00666887   Canada;
   Merck KGaA
      2006   Phase 2   NCT01134627   Denmark;
   University of Calgary
      2020   Phase 3   NCT04291456   Canada;
      2010   Phase 2   NCT01073813   Canada;
Minocycline 100 mg Film-coated Tablets   
   E. Merck AB
      2005   -   EUCTR2005-004289-18-DK   Denmark;Finland;Sweden;
   Merck AB
      2006   -   EUCTR2005-004289-18-SE   Finland;Sweden;
      2006   -   EUCTR2005-004289-18-FI   Finland;Sweden;
Minocycline Hydrochloride   
   E. Merck AB
      2005   -   EUCTR2005-004289-18-DK   Denmark;Finland;Sweden;
   Merck AB
      2006   -   EUCTR2005-004289-18-SE   Finland;Sweden;
      2006   -   EUCTR2005-004289-18-FI   Finland;Sweden;
Mirabegron   
   Theodore R. Brown, MD MPH
      2014   Phase 4   NCT02086188   United States;
Mitoquinone   
   Oregon Health and Science University
      2018   Phase 1/Phase 2   NCT03166800   United States;
Mitoxantrone   
   AZIENDA OSPEDALIERA UNIVERSITARIA DELLA SECONDA UNIVERSITA` DEGLI STUDI DI NAPOLI
      2009   -   EUCTR2009-010661-23-IT   Italy;
   Fundación Española de Esclerosis Múltiple (FEDEM)
      2006   -   EUCTR2004-001286-17-PT   Portugal;
   OSPEDALE S. RAFFAELE
      2004   -   EUCTR2004-001601-10-IT   France;Italy;
   Queen Mary, University of London
      2009   -   EUCTR2008-000256-26-GB   United Kingdom;
   Rennes University Hospital
      2010   Phase 3   NCT02937285   France;
      2010   -   NCT01065727   France;
      1999   Phase 2   NCT00219908   France;Italy;
   State University of New York at Buffalo
      2001   Phase 4   NCT00304291   United States;
   The Walton Centre for Neurology and Neurosurgery
      2005   Phase 4   EUCTR2004-004903-39-GB   United Kingdom;
   University Medical Center Hamburg Eppendorf
      2007   -   EUCTR2007-001962-34-DE   Germany;
   Wyeth is now a wholly owned subsidiary of Pfizer
      2005   Phase 3   NCT00146159   Germany;
   Xuanwu Hospital, Beijing
      2009   Phase 4   NCT02021825   China;
Modafinil   
   Johns Hopkins University
      2017   Phase 3   NCT03185065   United States;
   Kessler Foundation
      2003   -   NCT00142402   United States;
   University of Michigan
      2018   Phase 4   NCT03621761   United States;
Moderna mRNA-1273   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 2   NCT05000216   United States;
Monoclonal antibody M-T412   
   National Center for Research Resources (NCRR)
      1995   Phase 1   NCT00004816   -
Monomethyl fumarate   
   Banner Life Sciences LLC
      2021   -   NCT04925778   -
      2017   Phase 1   NCT04570670   -
Montelukast   
   Biogen
      2015   Phase 4   NCT02410278   United States;
Most recent vaccine to seasonal influenza   
   Heinrich-Heine University, Duesseldorf
      2020   -   NCT05019248   Germany;
Multiferon   
   Dansk Multipel Sclerose Center
      2010   -   EUCTR2009-016824-29-DK   Denmark;
Multiple (4 autologous subcutaneous T cell vaccinations with T cell lines reactive to nine myelin peptides)   
   Hadassah Medical Organization
      2002   Phase 1/Phase 2   NCT01448252   Israel;
Mutagrip   
   sanofi-aventis recherche & developpement
      2011   -   EUCTR2011-001160-21-DE   Austria;Canada;Germany;Russian Federation;Ukraine;
      2011   -   EUCTR2011-001160-21-AT   Austria;Canada;Germany;Russian Federation;Ukraine;
MyBETAapp   
   Bayer
      2017   -   NCT03134573   Germany;
Mycophenolate Mofetil (CellCept)   
   University of Texas Southwestern Medical Center
      2006   Phase 2   NCT00324506   United States;
Mycophenolate Mofetil (cellcept)   
   University of Texas Southwestern Medical Center
      2004   Phase 2/Phase 3   NCT00223301   United States;
Mycophenolate mofetil   
   Kobe University Hospital
      2018   -   JPRN-UMIN000031135   Japan;
   Sekiguchi Kenji
      2018   Phase 2   JPRN-jRCTs051180080   Japan;
   Shandong University Qilu Hospital
      2021   Phase 4   ChiCTR2100043013   China;
   The Ophthalmology Department of the Chinese Peoples Liberation Army Hospital
      2019   Phase 4   ChiCTR1900025744   China;
      2014   -   ChiCTR-ICR-15007177   China;
   The third affiliated hospital,Sun Yat-sen university
      2016   -   ChiCTR-OPB-16007730   China;
   Third Affiliated Hospital, Sun Yat-Sen University
      2016   Phase 4   NCT02809079   -
Mycophenolate mofetil (Cellcept)   
   Aaron Boster
      2006   Phase 0   NCT00618527   United States;
Mycophenolate mofetil (MMF)   
   Hoffmann-La Roche
      2021   Phase 3   NCT04660539   Bulgaria;Canada;Croatia;Germany;Hungary;Italy;Japan;Korea, Republic of;Malaysia;Poland;Puerto Rico;Romania;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Méthylprednisolone Mylan   
   Centre Hospitalier de Pau
      2015   Phase 2   EUCTR2014-005493-11-FR   France;
N acetylcysteine   
   University of Iowa
      2010   Phase 1   NCT01381354   United States;
N-acetyl Cysteine   
   Thomas Jefferson University
      2017   -   NCT03032601   United States;
N-acetyl cysteine   
   Emmanuelle Waubant
      2021   Phase 2   NCT05122559   -
   University of California, San Francisco
      2016   Phase 2   NCT02804594   United States;
N-acetylcysteine   
   ISTITUTO C. MONDINO
      2007   -   EUCTR2008-000955-90-IT   Italy;
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine   
N. MENINGITIDIS GROUP W135 OLIGOSACCHARIDE CONJUGATED CRM197   
   ALEXION PHARMACEUTICALS INCORPORATED
      2020   Phase 2;Phase 3   EUCTR2019-001829-26-IT   Canada;Germany;Italy;Japan;Korea, Republic of;Spain;United States;
N.A.   
   Genzyme Corporation
      2010   Phase 3   EUCTR2009-010788-18-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2009   Phase 3   EUCTR2009-010788-18-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2009   Phase 3   EUCTR2009-010788-18-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
N02BG10   
   JOSE MANUEL GARCIA DOMINGUEZ
      2013   -   EUCTR2011-000985-36-ES   Spain;
N03AX12   
   HOSPICES CIVILS DE LYON
      2015   Phase 2   EUCTR2014-005548-17-FR   France;
N06DX01   
   HOSPICES CIVILS DE LYON
      2015   Phase 2   EUCTR2014-005548-17-FR   France;
NBI-5788   
   Neurocrine Biosciences
      2003   Phase 2   NCT00079495   -
NBT-NM108 (60 g/day)   
   Suhayl Dhib-Jalbut, MD
      2021   Phase 1/Phase 2   NCT04574024   United States;
NEUPOGEN   
   OSPEDALE S. RAFFAELE
      2007   Phase 2   EUCTR2007-000586-38-IT   Italy;
NEUROASPIS PLP10®   
   PALUPA Medical Ltd
      2016   Phase 3   EUCTR2015-003147-19-GR   Greece;
NEURONTIN   
   HOSPICES CIVILS DE LYON
      2015   Phase 2   EUCTR2014-005548-17-FR   France;
NIRS after bosentan administration   
   Universitair Ziekenhuis Brussel
      2014   -   NCT02389426   Belgium;
NIRS baseline   
   Universitair Ziekenhuis Brussel
      2014   -   NCT02389426   Belgium;
NO   
   Carol Davila University of Medicine and Pharmacy
      2012   -   NCT03001284   -
NOVANTRONE*INF 2MG/ML 5ML   
   OSPEDALE S. RAFFAELE
      2004   -   EUCTR2004-001601-10-IT   France;Italy;
NOVATREX   
   CHU de Rennes
      2018   Phase 3   EUCTR2018-001292-21-FR   France;
NPB-01   
   Nihon Pharmaceutical Co., Ltd
      2013   Phase 2   NCT01845584   Japan;
NT-KO-003   
   Neurotec Pharma
      2011   Phase 2   NCT01428726   Germany;Spain;
NU100   
   NURON BIOTECH INC.
      2012   -   EUCTR2011-002683-24-IT   Belarus;Bulgaria;Hungary;Italy;Russian Federation;Spain;
   Nuron Biotech Inc.
      2011   Phase 3   NCT01464905   Belarus;Bulgaria;Croatia;Georgia;Hungary;India;Italy;Lebanon;Poland;Russian Federation;Serbia;Spain;Ukraine;
   Nuron Biotech, Inc.
      2012   -   EUCTR2011-002683-24-HU   Belarus;Bulgaria;Croatia;Georgia;Hungary;Italy;Lebanon;Poland;Russian Federation;Spain;Ukraine;
      2012   -   EUCTR2011-002683-24-ES   Belarus;Bulgaria;Croatia;Georgia;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine;
      2012   -   EUCTR2011-002683-24-BG   Belarus;Bulgaria;Croatia;Georgia;Hungary;Italy;Lebanon;Poland;Russian Federation;Spain;Ukraine;
NVF233   
   Novartis Farma S.p.A.
      2012   -   EUCTR2010-023023-19-DE   Germany;Italy;
Na18F   
   AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA
      2016   Phase 2   EUCTR2015-001202-34-IT   Italy;
Nabilone   
   University of Manitoba
      2007   Phase 4   NCT00480181   Canada;
Nabiximols   
   GW Pharmaceuticals Ltd.
      2021   Phase 3   NCT04984278   -
      2020   Phase 3   NCT04657666   Czechia;Poland;
      2020   Phase 3   NCT04203498   Czechia;Poland;United States;
Nabiximols - Sativex   
   GW Pharma Limited
      2022   Phase 3   EUCTR2020-004306-58-LT   Bulgaria;Canada;Hungary;Italy;Lithuania;Spain;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003271-18-ES   Australia;Belgium;Czech Republic;Czechia;Poland;Spain;Sweden;United Kingdom;
      2021   Phase 3   EUCTR2020-003271-18-CZ   Australia;Belgium;Czech Republic;Czechia;Poland;Spain;Sweden;United Kingdom;
      2021   Phase 3   EUCTR2019-002625-29-CZ   Czech Republic;Czechia;Poland;United Kingdom;
      2020   Phase 3   EUCTR2019-002625-29-PL   Czech Republic;Czechia;Poland;United Kingdom;
Naltrexone   
   OSPEDALE S. RAFFAELE
      2006   -   EUCTR2005-005679-13-IT   Italy;
   University of California, San Francisco
      2007   Phase 3   NCT00501696   United States;
Namisol   
   Echo Pharmaceuticals B.V.
      2011   -   EUCTR2010-022033-28-NL   Netherlands;
Nanocort   
   Enceladus Pharmaceuticals BV
      2010   -   EUCTR2009-013884-21-PL   Belgium;Germany;Poland;
      2009   Phase 2   EUCTR2009-013884-21-BE   Belgium;Germany;Poland;
      2009   -   EUCTR2009-013884-21-DE   Belgium;Germany;Poland;
Nanocurcumin   
   Tabriz University of Medical Sciences
      2016   Phase 2   NCT03150966   Iran, Islamic Republic of;
Naproxen   
   Biogen
      2013   Phase 3   NCT01939002   United States;
Natalizumab   
   Amir Hadi Maghzi
      2022   Phase 3   JPRN-jRCT2051210146   Japan;
   Amsterdam University Medical Center
      2019   Phase 4   EUCTR2019-002566-13-NL   Netherlands;
   BIOGEN IDEC LTD
      2010   -   EUCTR2009-015556-15-IT   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-004061-41-IT   Australia;Austria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;New Zealand;Spain;Sweden;Switzerland;Turkey;United Kingdom;
   Biogen
      2022   Phase 3   NCT05265728   -
      2019   -   NCT05236777   Czechia;
      2018   Phase 3   NCT03689972   Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;United Kingdom;United States;
      2015   -   NCT02677077   Belgium;Czech Republic;Czechia;
      2015   -   NCT02386566   Switzerland;
      2014   Phase 4   NCT02342704   Australia;Czech Republic;Czechia;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
      2014   Phase 4   NCT02241785   Germany;United States;
      2014   Phase 2   NCT02142192   Belgium;Denmark;Germany;Italy;
      2014   -   NCT02159573   United States;
      2014   -   NCT02137109   -
      2013   Phase 1   NCT01884935   Italy;
      2013   -   NCT04832399   Portugal;
      2012   -   NCT01485003   United States;
      2011   Phase 3   NCT01416181   Belgium;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Ireland;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   -   NCT01943526   Ireland;
      2010   Phase 2   NCT01416155   China;Japan;
      2010   Phase 2   NCT01071083   Germany;Spain;United States;
      2010   -   NCT01070836   Puerto Rico;United States;
      2009   -   NCT00884481   Austria;Denmark;Norway;Sweden;United States;
      2007   -   NCT00493298   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Italy;Mexico;Netherlands;Norway;Portugal;Slovakia;Spain;Switzerland;United Kingdom;
      2006   Phase 3   NCT00297232   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Netherlands;New Zealand;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2001   Phase 3   NCT00027300   Belgium;Canada;Czech Republic;France;Germany;Netherlands;United Kingdom;United States;
   Biogen Idec
      2008   Phase 4   NCT00744679   United States;
      2007   Phase 1   NCT00559702   United States;
      2003   Phase 3   NCT00276172   United States;
      2003   Phase 2   NCT00097760   -
      2002   Phase 3   NCT00030966   Austria;Belgium;France;Germany;Israel;Italy;United States;
   Biogen Idec GmbH
      2005   -   EUCTR2004-004130-14-AT   Austria;
   Biogen Idec International GmbH
      2010   Phase 4   EUCTR2009-009503-19-BE   Belgium;
   Biogen Idec Ltd.
      2004   -   EUCTR2004-000047-18-SE   Sweden;
   Claudio Gobbi
      2010   Phase 4   NCT01144052   Switzerland;
   Multiple Sclerosis Center of Northeastern New York
      2021   -   NCT04964700   United States;
   Nantes University Hospital
      2021   -   NCT04777539   France;
   Northwestern University
      2013   Phase 2   EUCTR2012-004165-41-GB   United Kingdom;United States;
   Rennes University Hospital
      2010   -   NCT01065727   France;
   Rigshospitalet, Denmark
      2010   Phase 2   NCT01077466   Denmark;
   State University of New York at Buffalo
      2015   Phase 4   NCT03046251   United States;
   University Hospital Muenster
      2014   Phase 4   NCT02325440   Germany;
   University Hospital, Toulouse
      2009   Phase 4   NCT00942214   France;
   University at Buffalo
      2012   Phase 4   NCT02775110   United States;
   VU University Medical Center
      2016   Phase 4   NCT03516526   Netherlands;
Natalizumab (BG00002)   
   Biogen
      2010   Phase 2/Phase 3   NCT01440101   China;Japan;
Natalizumab (NTZ)   
   University Hospital, Clermont-Ferrand
      2016   Phase 4   NCT02769689   France;
Natalizumab (Tysabri)   
   Cornerstone Health Care, PA
      2012   Phase 4   NCT01591551   United States;
Natalizumab 300 MG in 15 ML Injection   
   Vanderbilt University Medical Center
      2022   Phase 4   NCT05177718   United States;
Natalizumab IV   
   Biogen
      2011   Phase 2   NCT01405820   Belgium;France;Germany;Italy;Spain;
Natalizumab Injection [Tysabri]   
   University Hospital, Caen
      2020   -   NCT04580381   France;
Natalizumab SC   
   Biogen
      2011   Phase 2   NCT01405820   Belgium;France;Germany;Italy;Spain;
Natalizumab for IV Infusion   
   Biogen Idec Limited
      2011   -   EUCTR2010-024000-10-ES   Belgium;Germany;Italy;Spain;
      2011   -   EUCTR2010-024000-10-DE   Belgium;Germany;Italy;Spain;
      2011   -   EUCTR2010-024000-10-BE   Belgium;Germany;Italy;Spain;
Natalizumab for Subcutaneous Injection   
   Biogen Idec Limited
      2011   -   EUCTR2010-024000-10-ES   Belgium;Germany;Italy;Spain;
      2011   -   EUCTR2010-024000-10-DE   Belgium;Germany;Italy;Spain;
      2011   -   EUCTR2010-024000-10-BE   Belgium;Germany;Italy;Spain;
   Biogen Idec Research Limited
      2014   Phase 2   EUCTR2014-000917-30-DE   Belgium;Denmark;Germany;Italy;
      2014   -   EUCTR2014-000917-30-IT   Belgium;Denmark;Italy;
      2014   -   EUCTR2014-000917-30-DK   Belgium;Denmark;Italy;
      2014   -   EUCTR2014-000917-30-BE   Belgium;Denmark;Italy;
Natalizumab treatment   
   Biogen Idec
      2007   Phase 0   NCT00424788   United States;
Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection   
   University Hospital, Strasbourg, France
      2019   Phase 2   NCT03910738   France;
NeoRecormon   
   Danish Multiple Sclerosis Research Centre
      2009   Phase 2   EUCTR2009-011516-37-DK   Denmark;
Neorecormon   
   Walton Centre for Neurology and Neurosurgery
      2008   -   EUCTR2008-005125-11-GB   United Kingdom;
Neramexane mesylate   
   Merz Pharmaceuticals GmbH
      2009   Phase 2   NCT00799942   United Kingdom;
Nerispirdine (HP184)   
   Sanofi
      2008   Phase 2   NCT00811902   Canada;Finland;France;Germany;Norway;Spain;United States;
      2008   Phase 2   NCT00772525   United States;
Nerispirdine hydrochloride   
   sanofi-aventis Recherche & Développement
      2009   Phase 2   EUCTR2008-001999-67-FR   Finland;France;Germany;Spain;
      2009   Phase 2   EUCTR2008-001999-67-ES   Finland;France;Germany;Spain;
      2009   -   EUCTR2008-001999-67-FI   Finland;France;Germany;Spain;
      2009   -   EUCTR2008-001999-67-DE   Finland;France;Germany;Spain;
Neupogen   
   Uppsala l?ns landsting
      2011   -   EUCTR2010-023560-40-SE   Brazil;Canada;Sweden;United States;
NeuroVax   
   Immune Response BioPharma, Inc.
      2020   Phase 2/Phase 3   NCT02057159   United States;
      2020   Phase 2   NCT02149706   United States;
      2020   Phase 1   NCT02200718   United States;
NeuroVax 300ug/mL Dose for IM Injection   
   The Immune Response Corporation
      2007   Phase 2   EUCTR2006-003384-30-SK   Slovakia;
Neuromuscular electrical stimulation delivered using the electrical therapy device EMPI 300 PV   
   University of Iowa
      2010   Phase 1   NCT01381354   United States;
Neurontin 300 mg hard capsule   
   Charité University Medicine Berlin
      2010   Phase 4   EUCTR2008-005167-33-DE   Germany;
New Formulation of rebif - human interferon beta-1a   
   EMD Serono
      2006   Phase 3   NCT00428584   United States;
Niacinamide   
   University of Iowa
      2010   Phase 1   NCT01381354   United States;
Nicotine dependence   
   University of Jordan
      2021   -   NCT05046535   -
Nintendo Wii Fit Balance Board   
   University Hospital of Ferrara
      2014   -   NCT02287948   Italy;
Nitrofurantoin   
   University College London
      2010   Phase 4   EUCTR2009-017939-18-GB   United Kingdom;
Nivolumab   
   Alliance Foundation Trials, LLC.
      2019   Phase 1   NCT03656627   United States;
   National Cancer Institute (NCI)
      2019   Phase 1   NCT03816345   Canada;United States;
Nomegestrol   
   OSPEDALI CIVILI DI LIONE
      2007   -   EUCTR2006-005460-30-IT   Italy;
Nomegestrol acetate   
   Hospices Civils de Lyon
      2005   Phase 3   NCT00127075   France;
Non applicabile   
   MERCK HEALTHCARE KGaA
      2020   Phase 3   EUCTR2019-004980-36-IT   Belarus;Brazil;Bulgaria;Canada;France;Germany;Greece;India;Italy;Kuwait;Latvia;Lithuania;Malaysia;Mexico;Moldova, Republic of;Norway;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Saudi Arabia;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;Tunisia;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2019-004972-20-IT   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Georgia;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
Non-pegylated interferon   
   Biogen
      2015   Phase 2   NCT02097849   United States;
Norethindrone   
   University of California, Los Angeles
      2011   Phase 2   NCT01466114   United States;
Normal Saline for Injection   
   University of Manitoba
      2013   Phase 2   NCT01911377   Canada;
Normal saline   
   Mazandaran University of Medical Sciences
      2021   Phase 2   NCT04979650   Iran, Islamic Republic of;
Novartis Pharmaceuticals Corporation   
   Universitätsklinikum Hamburg-Eppendorf
      2013   -   NCT03216915   Germany;
NurOwn (MSC-NTF cells)   
   Brainstorm-Cell Therapeutics
      2019   Phase 2   NCT03799718   United States;
OCH-NCNP1   
   National Center of Neurology and Psychiatry, Japan
      2019   Phase 2   NCT04211740   Japan;
OCR   
   Hoffmann-La Roche
      2015   Phase 3   NCT02545868   Canada;United States;
OMB 157   
   NOVARTIS PHARMA SERVICES AG
      2017   Phase 3   EUCTR2015-005419-33-IT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Egypt;Finland;France;Germany;Hungary;India;Italy;Latvia;Lebanon;Lithuania;Mexico;Peru;Portugal;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Arab Emirates;United Kingdom;United States;
OMB157   
   NOVARTIS PHARMA AG
      2018   Phase 2   EUCTR2017-004702-17-IT   Austria;Bulgaria;Czech Republic;Czechia;Estonia;Germany;Italy;Latvia;Lithuania;Poland;Russian Federation;Spain;United States;
   NOVARTIS PHARMA SERVICES AG
      2021   Phase 3   EUCTR2020-002700-39-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005418-31-IT   Argentina;Australia;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
   Novartis Farmacéutica S.A.
      2021   Phase 3   EUCTR2020-002700-39-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001341-40-ES   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Lebanon;Mexico;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Slovakia;Spain;Switzerland;Turkey;United Kingdom;United States;
   Novartis Farmacéutica, S.A
      2019   Phase 3   EUCTR2017-004703-51-ES   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
   Novartis Farmacéutica, S.A.
      2018   Phase 2   EUCTR2017-004702-17-ES   Austria;Bulgaria;Czech Republic;Estonia;Germany;Italy;Latvia;Lithuania;Poland;Russian Federation;Spain;United States;
      2016   Phase 3   EUCTR2015-005419-33-ES   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Egypt;Finland;France;Germany;Hungary;India;Latvia;Lebanon;Mexico;Peru;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Arab Emirates;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005418-31-ES   Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Kuwait;Mexico;Netherlands;Poland;Russian Federation;Saudi Arabia;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
   Novartis Pharma Services AG
      2016   Phase 3   EUCTR2015-005419-33-SK   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Germany;Hungary;India;Latvia;Lithuania;Mexico;Peru;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005419-33-GB   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Germany;Hungary;India;Latvia;Lithuania;Mexico;Peru;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
   Novartis Pharma AG
      2021   Phase 3   EUCTR2020-004505-32-FR   France;Germany;
      2021   Phase 3   EUCTR2020-004505-32-DE   France;Germany;Italy;Spain;
      2021   Phase 3   EUCTR2020-002700-39-SK   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-002700-39-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-002700-39-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-002700-39-LV   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-002700-39-LT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-002700-39-HR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-002700-39-FR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-002700-39-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-002700-39-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-001341-40-SI   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Estonia;Germany;Greece;Hungary;Italy;Latvia;Lebanon;Mexico;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Slovakia;Slovenia;Spain;Switzerland;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-001341-40-PL   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Italy;Lebanon;Mexico;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Slovakia;Slovenia;Spain;Switzerland;Turkey;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-001341-40-LV   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Estonia;Germany;Greece;Hungary;Italy;Latvia;Lebanon;Mexico;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Slovakia;Slovenia;Spain;Switzerland;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001341-40-PT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Italy;Lebanon;Mexico;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Slovakia;Spain;Switzerland;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001341-40-IT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Italy;Lebanon;Mexico;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Slovakia;Spain;Switzerland;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001341-40-HU   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Italy;Latvia;Lebanon;Mexico;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Slovakia;Slovenia;Spain;Switzerland;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001341-40-GR   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Italy;Latvia;Lebanon;Mexico;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Slovakia;Slovenia;Spain;Switzerland;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001341-40-DE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Italy;Latvia;Lebanon;Mexico;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Slovakia;Slovenia;Spain;Switzerland;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001341-40-CZ   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Lebanon;Mexico;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Slovakia;Spain;Switzerland;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001341-40-BG   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Italy;Latvia;Lebanon;Mexico;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Slovakia;Slovenia;Spain;Switzerland;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001341-40-BE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Italy;Latvia;Lebanon;Mexico;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Slovakia;Slovenia;Spain;Switzerland;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001341-40-AT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Italy;Latvia;Lebanon;Mexico;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Slovakia;Slovenia;Spain;Switzerland;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004703-51-PT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004703-51-NL   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004703-51-LV   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004703-51-LT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004703-51-HR   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004703-51-GR   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004703-51-GB   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004703-51-FR   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004703-51-FI   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004703-51-DK   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004703-51-DE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004703-51-CZ   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004703-51-BE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2019   Phase 2   EUCTR2017-004702-17-PL   Austria;Bulgaria;Czech Republic;Estonia;Germany;Italy;Latvia;Lithuania;Poland;Russian Federation;Spain;United States;
      2018   Phase 3   EUCTR2017-004703-51-SK   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004703-51-SE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004703-51-HU   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004703-51-AT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-004702-17-LV   Austria;Bulgaria;Czech Republic;Estonia;Germany;Italy;Latvia;Lithuania;Poland;Russian Federation;Spain;United States;
      2018   Phase 2   EUCTR2017-004702-17-LT   Austria;Bulgaria;Czech Republic;Estonia;Germany;Italy;Latvia;Lithuania;Poland;Russian Federation;Spain;United States;
      2018   Phase 2   EUCTR2017-004702-17-EE   Austria;Bulgaria;Czech Republic;Estonia;Germany;Italy;Latvia;Lithuania;Poland;Russian Federation;Spain;United States;
      2018   Phase 2   EUCTR2017-004702-17-CZ   Austria;Bulgaria;Czech Republic;Estonia;Germany;Italy;Latvia;Lithuania;Poland;Russian Federation;Spain;United States;
      2018   Phase 2   EUCTR2017-004702-17-BG   Austria;Bulgaria;Czech Republic;Estonia;Germany;Italy;Latvia;Lithuania;Poland;Russian Federation;Spain;United States;
      2018   Phase 2   EUCTR2017-004702-17-AT   Austria;Bulgaria;Czech Republic;Estonia;Germany;Italy;Latvia;Lithuania;Poland;Russian Federation;Spain;United States;
      2017   Phase 3   EUCTR2015-005418-31-FR   Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Croatia;Czech Republic;Denmark;Estonia;European Union;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Kuwait;Mexico;Netherlands;Poland;Russian Federation;Saudi Arabia;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005419-33-FR   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Egypt;European Union;Finland;France;Germany;Hungary;India;Latvia;Lebanon;Lithuania;Mexico;Peru;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Arab Emirates;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005419-33-BE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Egypt;Finland;France;Germany;Hungary;India;Latvia;Lebanon;Lithuania;Mexico;Peru;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Arab Emirates;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005418-31-HU   Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Kuwait;Mexico;Netherlands;Poland;Russian Federation;Saudi Arabia;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005418-31-GR   Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Kuwait;Mexico;Netherlands;Poland;Russian Federation;Saudi Arabia;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005418-31-BE   Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Kuwait;Mexico;Netherlands;Poland;Russian Federation;Saudi Arabia;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
      -   Phase 3   EUCTR2020-002700-39-EE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2020-002700-39-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Novartis Pharma Services AG
      2017   Phase 3   EUCTR2015-005419-33-HR   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Germany;Hungary;India;Latvia;Lithuania;Mexico;Peru;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005419-33-BG   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Germany;Hungary;India;Latvia;Lithuania;Mexico;Peru;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005418-31-NL   Argentina;Australia;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005418-31-CZ   Argentina;Australia;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Germany;Greece;Hungary;India;Israel;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005419-33-LV   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Egypt;Finland;France;Germany;Hungary;India;Latvia;Lebanon;Lithuania;Mexico;Peru;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Arab Emirates;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005419-33-LT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Germany;Hungary;India;Latvia;Lithuania;Mexico;Peru;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005419-33-HU   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Germany;Hungary;India;Latvia;Lithuania;Mexico;Peru;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005419-33-FI   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Germany;Hungary;India;Latvia;Lithuania;Mexico;Peru;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005418-31-SK   Argentina;Australia;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005418-31-SE   Argentina;Australia;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005418-31-PL   Argentina;Australia;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005418-31-HR   Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Croatia;Czech Republic;Denmark;Estonia;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Kuwait;Mexico;Netherlands;Poland;Russian Federation;Saudi Arabia;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005418-31-GB   Argentina;Australia;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005418-31-EE   Argentina;Australia;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005418-31-DK   Argentina;Australia;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005418-31-BG   Argentina;Australia;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
OMB157G   
   Novartis Pharma Services AG
      2017   Phase 3   EUCTR2015-005419-33-CZ   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Germany;Hungary;India;Latvia;Lithuania;Mexico;Peru;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005419-33-PT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Egypt;Finland;France;Germany;Hungary;India;Italy;Latvia;Lebanon;Lithuania;Mexico;Peru;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Arab Emirates;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005419-33-DE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Germany;Hungary;India;Latvia;Lithuania;Mexico;Peru;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005419-33-AT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Germany;Hungary;India;Latvia;Lithuania;Mexico;Peru;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-005418-31-DE   Argentina;Australia;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
   Novartis Pharma Vertriebs GmbH
      2021   Phase 4   EUCTR2021-000307-20-DE   Germany;
ONO-4641   
   EMD Serono
      2010   Phase 2   NCT01226745   Belgium;Canada;Czech Republic;Germany;Greece;Japan;Poland;Russian Federation;Spain;Ukraine;United States;
   ONO Pharmaceutical Co., Ltd.
      2011   -   EUCTR2010-018705-11-GR   Belgium;Canada;Czech Republic;Germany;Greece;Japan;Russian Federation;Spain;Ukraine;United States;
      2010   Phase 2   EUCTR2009-014339-19-ES   Czech Republic;Germany;Greece;Spain;
      2010   -   EUCTR2010-018705-11-ES   Belgium;Czech Republic;Germany;Greece;Spain;
      2010   -   EUCTR2009-014339-19-GR   Czech Republic;Germany;Greece;Spain;
      2010   -   EUCTR2009-014339-19-DE   Canada;Czech Republic;Germany;Greece;Japan;Russian Federation;Spain;Ukraine;United States;
      2010   -   EUCTR2009-014339-19-CZ   Czech Republic;Germany;Greece;Spain;
   Ono Pharma USA Inc
      2010   Phase 2   NCT01081782   Belgium;Canada;Czech Republic;Germany;Greece;Japan;Poland;Russian Federation;Spain;Ukraine;United States;
ONO-4641/ MSC2430913A   
   Merck KGaA
      -   -   EUCTR2010-018705-11-DE   Belgium;Canada;Czech Republic;Germany;Greece;Japan;Russian Federation;Spain;Ukraine;United States;
ONO-4641/MSC2430913A   
   Merck KGaA
      2010   -   EUCTR2010-018705-11-CZ   Belgium;Canada;Czech Republic;Germany;Greece;Japan;Russian Federation;Spain;Ukraine;United States;
   Merck Serono S.A. - Geneva
      2010   -   EUCTR2010-018705-11-BE   Belgium;Canada;Czech Republic;Germany;Greece;Japan;Russian Federation;Spain;Ukraine;United States;
ORY2001   
   Oryzon Genomics S. A
      2017   Phase 2   EUCTR2017-002838-23-ES   Spain;
OS440   
   Osmotica Pharmaceutical US LLC
      2018   Phase 3   EUCTR2017-004101-40-PL   Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Moldova, Republic of;Poland;Russian Federation;Serbia;Ukraine;United States;
      2018   Phase 3   EUCTR2017-004101-40-HR   Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Moldova, Republic of;Poland;Russian Federation;Serbia;Ukraine;United States;
      2018   Phase 3   EUCTR2017-004101-40-BG   Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Moldova, Republic of;Poland;Russian Federation;Serbia;Ukraine;United States;
      2018   Phase 3   EUCTR2017-004100-22-PL   Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Moldova, Republic of;Poland;Russian Federation;Serbia;Ukraine;United States;
      2018   Phase 3   EUCTR2017-004100-22-HR   Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Moldova, Republic of;Poland;Russian Federation;Serbia;Ukraine;United States;
      2018   Phase 3   EUCTR2017-004100-22-BG   Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Moldova, Republic of;Poland;Russian Federation;Serbia;Ukraine;United States;
Oclelizumab   
   Hoffman La Roche Ltd
      2008   Phase 2   EUCTR2007-006338-32-BG   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Mexico;Netherlands;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
Ocrelizumab   
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2018   Phase 3   EUCTR2017-004158-40-FR   France;
   Assistance Publique - Hôpitaux de Paris
      2018   Phase 3   NCT03691077   France;
   Brigham and Women's Hospital
      2021   -   NCT05131984   United States;
   Claudio Gobbi
      2020   -   NCT04640818   Switzerland;
   Dr Recai Turkoglu
      2021   -   NCT04874597   Turkey;
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 3   EUCTR2020-005448-48-IT   Brazil;Czechia;France;Italy;Spain;
      2021   Phase 3   EUCTR2020-004128-41-IT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000893-69-IT   Argentina;Australia;Belgium;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-001511-73-IT   Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Colombia;Croatia;Egypt;France;Georgia;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 2   EUCTR2016-002667-34-IT   Italy;Poland;United States;
   F. Hoffman-La Roche Ltd
      2008   Phase 2   EUCTR2007-006338-32-DE   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Mexico;Netherlands;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
   F. Hoffmann - La Roche
      2010   -   EUCTR2010-020338-25-IT   Austria;Belgium;Bulgaria;Czech Republic;Denmark;Finland;Greece;Hungary;Italy;Lithuania;Portugal;Spain;United Kingdom;
   F.Hoffmann-La Roche
      2012   Phase 3   EUCTR2010-020315-36-CZ   Argentina;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;France;Germany;Ireland;Italy;Mexico;Peru;Russian Federation;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020338-25-BG   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020315-36-SK   Argentina;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;France;Germany;Ireland;Italy;Mexico;Peru;Russian Federation;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020315-36-SE   Argentina;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;France;Germany;Ireland;Italy;Mexico;Peru;Russian Federation;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020315-36-IE   Argentina;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;France;Germany;Ireland;Italy;Mexico;Peru;Russian Federation;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020315-36-GB   Argentina;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;France;Germany;Ireland;Italy;Mexico;Peru;Russian Federation;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020315-36-FR   Argentina;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;France;Germany;Ireland;Italy;Mexico;Peru;Russian Federation;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020315-36-DE   Argentina;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;France;Germany;Ireland;Italy;Mexico;Peru;Russian Federation;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020315-36-BG   Argentina;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;France;Germany;Ireland;Italy;Mexico;Peru;Russian Federation;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020315-36-BE   Argentina;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;France;Germany;Ireland;Italy;Mexico;Peru;Russian Federation;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-020338-25-DK   Austria;Belgium;Bulgaria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Italy;Lithuania;Netherlands;Portugal;Spain;United Kingdom;
      2011   -   EUCTR2010-020337-99-ES   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-020315-36-ES   Argentina;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;Colombia;Croatia;Ireland;Italy;Mexico;Peru;Russian Federation;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020337-99-FI   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;United Kingdom;United States;
      2010   -   EUCTR2010-020338-25-HU   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2010-020338-25-ES   Austria;Belgium;Bulgaria;Czech Republic;Denmark;Finland;Greece;Hungary;Italy;Lithuania;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-020337-99-HU   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
   F.Hoffmann-La Roche Ltd.
      2008   -   EUCTR2007-006338-32-IT   Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Mexico;Netherlands;Russian Federation;Spain;Switzerland;Ukraine;United Kingdom;United States;
   Genentech, Inc.
      2020   Phase 4   NCT04377555   Kenya;Puerto Rico;United States;
      2016   Phase 3   NCT02688985   Canada;Germany;Sweden;United States;
      2016   Phase 3   NCT02637856   Canada;United States;
      2016   -   NCT02807285   United States;
      2008   Phase 2   NCT00676715   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Mexico;Netherlands;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
   Georgia State University
      2021   Phase 4   NCT04387734   United States;
   Haukeland University Hospital
      2020   Phase 3   NCT04578639   Norway;
   Helse Bergen HF, Haukeland University Hospital
      2022   Phase 3   EUCTR2020-001205-23-SE   Sweden;
      2018   Phase 3   EUCTR2017-001362-25-DK   Denmark;Netherlands;
   Hoffman La Roche Ltd
      2008   Phase 2   EUCTR2007-006338-32-GB   Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Mexico;Netherlands;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2008   Phase 2   EUCTR2007-006338-32-FR   Belgium;Bulgaria;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Slovakia;Spain;United Kingdom;
      2008   Phase 2   EUCTR2007-006338-32-ES   Belgium;Bulgaria;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Slovakia;Spain;United Kingdom;
      2008   Phase 2   EUCTR2007-006338-32-DK   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Mexico;Netherlands;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2008   Phase 2   EUCTR2007-006338-32-CZ   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Mexico;Netherlands;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2008   Phase 2   EUCTR2007-006338-32-BG   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Mexico;Netherlands;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2008   Phase 2   EUCTR2007-006338-32-BE   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Mexico;Netherlands;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2008   -   EUCTR2007-006338-32-NL   Belgium;Bulgaria;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-006338-32-FI   Belgium;Bulgaria;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;United Kingdom;
   Hoffmann-La Roche
      2022   Phase 4   NCT05208840   Russian Federation;
      2022   Phase 4   NCT04998812   Canada;France;Germany;Italy;Spain;Switzerland;United Kingdom;United States;
      2022   Phase 3   NCT05269004   -
      2022   Phase 3   NCT05123703   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;Germany;Greece;Hungary;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 4   NCT04998851   Australia;Canada;France;Germany;Italy;Spain;Switzerland;United Kingdom;United States;
      2020   Phase 3   NCT04548999   Argentina;Belgium;Brazil;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Mexico;Peru;Poland;Portugal;Puerto Rico;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   NCT04544449   Argentina;Australia;Austria;Belgium;Brazil;Canada;Colombia;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Puerto Rico;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   NCT04544436   Argentina;Australia;Belgium;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 2   NCT04075266   Italy;Poland;United States;
      2019   Phase 3   NCT04035005   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Colombia;Croatia;Egypt;France;Georgia;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 1   NCT03972306   Canada;United States;
      2018   Phase 4   NCT03589105   France;
      2018   Phase 3   NCT03599245   Argentina;Belgium;Brazil;Bulgaria;Canada;Croatia;Czechia;Denmark;Estonia;Finland;France;Hungary;Ireland;Italy;Kuwait;Mexico;Netherlands;Norway;Poland;Portugal;Slovakia;Slovenia;Spain;Sweden;Turkey;United Kingdom;
      2018   Phase 3   NCT03523858   Algeria;Bosnia and Herzegovina;Brazil;Canada;Colombia;Costa Rica;Czechia;Denmark;Egypt;France;Germany;Guatemala;Hungary;Ireland;Italy;Lebanon;Mexico;Morocco;Netherlands;Panama;Poland;Russian Federation;Saudi Arabia;Spain;United Arab Emirates;United States;
      2018   -   NCT03593590   Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Dominican Republic;Egypt;Israel;Italy;Kuwait;Montenegro;Netherlands;Panama;Paraguay;Poland;Portugal;Qatar;Romania;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Turkey;United Arab Emirates;United Kingdom;
      2017   Phase 3   NCT03085810   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;Finland;France;Germany;Hungary;Italy;Kuwait;Lebanon;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2016   Phase 3   NCT02861014   Australia;Belgium;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Hong Kong;Ireland;Italy;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2011   Phase 3   NCT01412333   Argentina;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;France;Germany;Ireland;Italy;Mexico;Morocco;Norway;Poland;Russian Federation;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   NCT01247324   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Czechia;Estonia;Finland;France;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2011   Phase 3   NCT01194570   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;Uruguay;
   Hospital Italiano de Buenos Aires
      2019   -   NCT03784547   Argentina;
   Johns Hopkins University
      2020   Phase 4   NCT04261790   United States;
      2019   Phase 4   NCT03853746   United States;
      2019   -   NCT03873389   United States;
   NYU Langone Health
      2020   -   NCT04855617   United States;
   National Institute of Allergy and Infectious Diseases (NIAID)
      2022   Phase 4   NCT05285891   -
   Novartis Pharmaceuticals
      2022   -   NCT05266469   -
      2021   -   NCT04676555   Australia;United Kingdom;United States;
   Rigshospitalet, Denmark
      2021   Phase 3   NCT04688788   Denmark;
   Sheffield Teaching Hospitals
      2020   Phase 3   EUCTR2019-001549-42-GB   United Kingdom;
   University at Buffalo
      2017   -   NCT03025269   United States;
   University of California, San Francisco
      2020   Phase 4   NCT04466150   United States;
      2020   -   NCT04387110   United States;
   University of Chicago
      2017   -   NCT03344094   United States;
   University of Colorado, Denver
      2017   Phase 3   NCT02980042   United States;
   University of Michigan
      2020   -   NCT04459988   United States;
   University of South Florida
      2018   -   NCT03562975   United States;
   Universitätsklinikum Hamburg-Eppendorf
      2021   Phase 2   NCT04971005   Germany;
   VU medical center
      2022   Phase 4   EUCTR2021-004791-34-NL   Netherlands;
   Wayne State University
      2020   -   NCT04458688   -
   Yale University
      2022   Phase 4   NCT04877457   United States;
Ocrelizumab (CinnaGen, Iran)   
   Cinnagen
      2019   Phase 3   NCT04966338   Iran, Islamic Republic of;
Ocrelizumab (Roche, Switzerland)   
   Cinnagen
      2019   Phase 3   NCT04966338   Iran, Islamic Republic of;
Ocrelizumab 300mg /10ml   
   F.Hoffmann-La Roche
      2012   Phase 3   EUCTR2010-020337-99-NL   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
Ocrelizumab 300mg/10 ml   
   F.Hoffmann-La Roche
      2011   Phase 3   EUCTR2010-020338-25-DE   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
Ocrelizumab 300mg/10ml   
   F.Hoffmann-La Roche
      2013   Phase 3   EUCTR2010-020338-25-NL   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020338-25-PT   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020338-25-PL   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020338-25-GR   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020338-25-CZ   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020338-25-BE   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020338-25-AT   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020337-99-SK   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020337-99-PT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020337-99-PL   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020337-99-LT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020337-99-GB   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020337-99-DE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020337-99-CZ   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020337-99-BG   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020337-99-BE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020337-99-AT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020338-25-LT   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020338-25-GB   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020338-25-FI   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020337-99-LV   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020337-99-EE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
   GENENTECH Inc.
      2016   Phase 3   EUCTR2015-004616-37-SE   Germany;Sweden;Switzerland;United States;
      2016   Phase 3   EUCTR2015-004616-37-DE   Germany;Sweden;Switzerland;United States;
Ocrelizumab Dose 1   
   Genentech, Inc.
      2018   Phase 3   NCT03606460   United States;
Ocrelizumab Dose 2 and Dose 3   
   Genentech, Inc.
      2018   Phase 3   NCT03606460   United States;
Ocrelizumab IV   
   Hoffmann-La Roche
      2022   Phase 3   NCT05232825   Brazil;Canada;Czechia;Italy;Poland;Russian Federation;Spain;Turkey;Ukraine;United States;
Ocrelizumab SC   
   Hoffmann-La Roche
      2022   Phase 3   NCT05232825   Brazil;Canada;Czechia;Italy;Poland;Russian Federation;Spain;Turkey;Ukraine;United States;
Ocrelizumab at home   
   University of Colorado, Denver
      2021   Phase 4   NCT04650321   United States;
Ocrevus   
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2018   Phase 3   EUCTR2017-004158-40-FR   France;
   Danish Multiple Sclerosis Center, Rigshospitalet
      2020   Phase 3   EUCTR2020-002981-15-DK   Denmark;
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 3   EUCTR2020-005448-48-IT   Brazil;Czechia;France;Italy;Spain;
      2021   Phase 3   EUCTR2020-004128-41-IT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000894-26-IT   Argentina;Belgium;Brazil;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000893-69-IT   Argentina;Australia;Belgium;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-001511-73-IT   Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Colombia;Croatia;Egypt;France;Georgia;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 2   EUCTR2016-002667-34-IT   Italy;Poland;United States;
   F. Hoffman-La Roche Ltd
      2008   Phase 2   EUCTR2007-006338-32-DE   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Mexico;Netherlands;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
   F. Hoffmann-La Roche Ltd
      2022   Phase 3   EUCTR2020-005448-48-CZ   Australia;Brazil;Canada;Czech Republic;Czechia;France;Italy;New Zealand;Poland;Russian Federation;Spain;Turkey;Ukraine;United States;
      2022   Phase 3   EUCTR2020-004128-41-BG   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 4   EUCTR2021-000063-79-ES   Australia;Canada;France;Germany;Italy;Spain;Switzerland;United Kingdom;United States;
      2021   Phase 4   EUCTR2021-000062-14-ES   Australia;Canada;France;Germany;Italy;Spain;Switzerland;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-005448-48-PL   Australia;Brazil;Canada;Czechia;France;Italy;New Zealand;Poland;Russian Federation;Spain;Turkey;Ukraine;United States;
      2021   Phase 3   EUCTR2020-004128-41-PL   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004128-41-NL   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004128-41-HU   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004128-41-GR   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-004128-41-BE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000894-26-GR   Argentina;Belgium;Brazil;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000894-26-DK   Argentina;Belgium;Brazil;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000894-26-BG   Argentina;Belgium;Brazil;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000893-69-GR   Argentina;Australia;Belgium;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000893-69-DK   Argentina;Australia;Belgium;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-003919-53-PT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-003919-53-HU   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-003919-53-GR   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-003919-53-DK   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-003919-53-DE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-003919-53-BG   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-003919-53-AT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2017-004886-29-SK   Argentina;Belgium;Brazil;Bulgaria;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Hungary;Ireland;Italy;Mexico;Netherlands;Norway;Poland;Portugal;Slovakia;Slovenia;Spain;Sweden;Turkey;United Kingdom;
      2021   Phase 3   EUCTR2017-004886-29-SI   Argentina;Belgium;Brazil;Czech Republic;Denmark;Estonia;Finland;France;Ireland;Mexico;Netherlands;Poland;Portugal;Slovenia;Spain;Sweden;Turkey;United Kingdom;
      2021   Phase 3   EUCTR2017-004886-29-PT   Argentina;Belgium;Brazil;Bulgaria;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Hungary;Ireland;Italy;Mexico;Netherlands;Norway;Poland;Portugal;Slovakia;Slovenia;Spain;Sweden;Turkey;United Kingdom;
      2021   Phase 3   EUCTR2017-004886-29-PL   Argentina;Belgium;Brazil;Bulgaria;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Ireland;Italy;Mexico;Netherlands;Norway;Poland;Portugal;Slovenia;Spain;Sweden;Turkey;United Kingdom;
      2021   Phase 3   EUCTR2017-004886-29-HU   Argentina;Belgium;Brazil;Bulgaria;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Hungary;Ireland;Italy;Mexico;Netherlands;Norway;Poland;Portugal;Slovakia;Slovenia;Spain;Sweden;Turkey;United Kingdom;
      2021   Phase 3   EUCTR2017-004886-29-HR   Argentina;Belgium;Brazil;Bulgaria;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Hungary;Ireland;Italy;Mexico;Netherlands;Norway;Poland;Portugal;Slovakia;Slovenia;Spain;Sweden;Turkey;United Kingdom;
      2021   Phase 3   EUCTR2017-004886-29-BG   Argentina;Belgium;Brazil;Bulgaria;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Hungary;Ireland;Italy;Mexico;Netherlands;Norway;Poland;Portugal;Slovakia;Slovenia;Spain;Sweden;Turkey;United Kingdom;
      2021   Phase 3   EUCTR2017-004886-29-BE   Argentina;Belgium;Brazil;Bulgaria;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Hungary;Ireland;Italy;Mexico;Netherlands;Norway;Poland;Portugal;Slovakia;Slovenia;Spain;Sweden;Turkey;United Kingdom;
      2020   Phase 3   EUCTR2020-000894-26-PT   Argentina;Belgium;Brazil;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000894-26-HU   Argentina;Belgium;Brazil;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000894-26-GB   Argentina;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000894-26-FR   Argentina;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000894-26-DE   Argentina;Belgium;Brazil;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000893-69-PT   Argentina;Australia;Belgium;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000893-69-PL   Argentina;Australia;Belgium;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000893-69-NL   Argentina;Australia;Belgium;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000893-69-HU   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000893-69-GB   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000893-69-DE   Argentina;Australia;Belgium;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000893-69-BE   Argentina;Australia;Belgium;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-003919-53-GB   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-001511-73-RO   Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Colombia;Croatia;Egypt;France;Georgia;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-001511-73-PT   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Colombia;Croatia;Egypt;France;Georgia;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-001511-73-IE   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Colombia;Croatia;Egypt;France;Georgia;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-001511-73-DE   Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Colombia;Croatia;Egypt;France;Georgia;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2017-001313-93-DE   Algeria;Bosnia and Herzegovina;Brazil;Canada;Colombia;Costa Rica;Czech Republic;Czechia;Denmark;Egypt;France;Germany;Guatemala;Hungary;Ireland;Italy;Lebanon;Mexico;Morocco;Netherlands;Panama;Poland;Russian Federation;Spain;United Arab Emirates;
      2020   Phase 2   EUCTR2016-002667-34-PL   Italy;Poland;United States;
      2019   Phase 3   EUCTR2018-001511-73-PL   Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Colombia;Croatia;Egypt;France;Georgia;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-001511-73-HU   Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Colombia;Croatia;Egypt;France;Georgia;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-001511-73-HR   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Colombia;Croatia;Egypt;France;Georgia;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-001511-73-GB   Bulgaria;Croatia;Germany;Hungary;Ireland;Poland;Portugal;Spain;United Kingdom;
      2019   Phase 3   EUCTR2018-001511-73-ES   Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Colombia;Croatia;Egypt;France;Georgia;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-001511-73-BG   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Colombia;Croatia;Egypt;France;Georgia;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004886-29-IE   Argentina;Belgium;Brazil;Bulgaria;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Ireland;Italy;Mexico;Netherlands;Norway;Poland;Portugal;Slovenia;Spain;Sweden;Turkey;United Kingdom;
      2018   Phase 3   EUCTR2017-004886-29-SE   Argentina;Belgium;Brazil;Bulgaria;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Hungary;Ireland;Italy;Mexico;Netherlands;Norway;Poland;Portugal;Slovakia;Slovenia;Spain;Sweden;Turkey;United Kingdom;
      2018   Phase 3   EUCTR2017-004886-29-NL   Argentina;Belgium;Brazil;Bulgaria;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Hungary;Ireland;Italy;Mexico;Netherlands;Norway;Poland;Portugal;Slovakia;Slovenia;Spain;Sweden;Turkey;United Kingdom;
      2018   Phase 3   EUCTR2017-004886-29-GB   Czech Republic;Denmark;Estonia;Finland;France;Ireland;Netherlands;Spain;Sweden;United Kingdom;
      2018   Phase 3   EUCTR2017-004886-29-FI   Czech Republic;Denmark;Estonia;Finland;France;Ireland;Italy;Netherlands;Norway;Spain;Sweden;Turkey;United Kingdom;
      2018   Phase 3   EUCTR2017-004886-29-EE   Czech Republic;Denmark;Estonia;Finland;France;Ireland;Italy;Netherlands;Norway;Spain;Sweden;Turkey;United Kingdom;
      2018   Phase 3   EUCTR2017-004886-29-DK   Argentina;Belgium;Brazil;Bulgaria;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Hungary;Ireland;Italy;Mexico;Netherlands;Norway;Poland;Portugal;Slovakia;Slovenia;Spain;Sweden;Turkey;United Kingdom;
      2018   Phase 3   EUCTR2017-004886-29-CZ   Argentina;Belgium;Brazil;Bulgaria;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Hungary;Ireland;Italy;Mexico;Netherlands;Norway;Poland;Portugal;Slovakia;Slovenia;Spain;Sweden;Turkey;United Kingdom;
      2018   Phase 3   EUCTR2017-001313-93-PL   Algeria;Bosnia and Herzegovina;Brazil;Canada;Colombia;Costa Rica;Czech Republic;Czechia;Denmark;Egypt;France;Germany;Guatemala;Hungary;Ireland;Italy;Lebanon;Mexico;Morocco;Netherlands;Panama;Poland;Russian Federation;Spain;United Arab Emirates;
      2018   Phase 3   EUCTR2017-001313-93-IE   Algeria;Bosnia and Herzegovina;Brazil;Canada;Colombia;Costa Rica;Czech Republic;Czechia;Denmark;Egypt;France;Germany;Guatemala;Hungary;Ireland;Italy;Lebanon;Mexico;Morocco;Netherlands;Panama;Poland;Russian Federation;Spain;United Arab Emirates;
      2018   Phase 3   EUCTR2017-001313-93-DK   Algeria;Bosnia and Herzegovina;Brazil;Canada;Colombia;Costa Rica;Czech Republic;Czechia;Denmark;Egypt;France;Germany;Guatemala;Hungary;Ireland;Italy;Lebanon;Mexico;Morocco;Netherlands;Panama;Poland;Russian Federation;Spain;United Arab Emirates;
      2018   Phase 3   EUCTR2017-001313-93-CZ   Algeria;Bosnia and Herzegovina;Brazil;Canada;Colombia;Costa Rica;Czech Republic;Czechia;Denmark;Egypt;France;Germany;Guatemala;Hungary;Ireland;Italy;Lebanon;Mexico;Morocco;Netherlands;Panama;Poland;Russian Federation;Spain;United Arab Emirates;
      2017   Phase 3   EUCTR2016-002937-31-SK   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Hungary;Italy;Kuwait;Lebanon;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002937-31-SI   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Hungary;Italy;Kuwait;Lebanon;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002937-31-SE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Hungary;Italy;Kuwait;Lebanon;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002937-31-PT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;Finland;France;Germany;Hungary;Italy;Kuwait;Lebanon;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002937-31-NO   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Hungary;Italy;Kuwait;Lebanon;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002937-31-NL   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Hungary;Italy;Kuwait;Lebanon;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002937-31-HU   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Hungary;Italy;Kuwait;Lebanon;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002937-31-HR   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Hungary;Italy;Kuwait;Lebanon;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002937-31-GB   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Hungary;Italy;Kuwait;Lebanon;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002937-31-DK   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Hungary;Italy;Kuwait;Lebanon;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002937-31-DE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;Finland;France;Germany;Hungary;Italy;Kuwait;Lebanon;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002937-31-BG   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Hungary;Italy;Kuwait;Lebanon;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002937-31-BE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Hungary;Italy;Kuwait;Lebanon;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002937-31-AT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Hungary;Italy;Kuwait;Lebanon;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      -   Phase 4   EUCTR2021-000063-79-DE   Canada;France;Germany;Italy;Spain;Switzerland;United Kingdom;United States;
      -   Phase 3   EUCTR2020-004128-41-FR   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2020-004128-41-DK   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2020-004128-41-AT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
   F.Hoffmann-La Roche
      2013   Phase 3   EUCTR2010-020338-25-NL   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2012   Phase 3   EUCTR2010-020315-36-CZ   Argentina;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;France;Germany;Ireland;Italy;Mexico;Peru;Russian Federation;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020338-25-PL   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020338-25-GR   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020338-25-DE   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020338-25-CZ   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020338-25-BE   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020338-25-AT   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020337-99-SK   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020337-99-PT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020337-99-PL   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020337-99-LT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020337-99-GB   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020337-99-DE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020337-99-CZ   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020337-99-BG   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020337-99-BE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020337-99-AT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020315-36-SK   Argentina;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;France;Germany;Ireland;Italy;Mexico;Peru;Russian Federation;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020315-36-SE   Argentina;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;France;Germany;Ireland;Italy;Mexico;Peru;Russian Federation;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020315-36-IE   Argentina;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;France;Germany;Ireland;Italy;Mexico;Peru;Russian Federation;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020315-36-GB   Argentina;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;France;Germany;Ireland;Italy;Mexico;Peru;Russian Federation;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020315-36-DE   Argentina;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;France;Germany;Ireland;Italy;Mexico;Peru;Russian Federation;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020315-36-BG   Argentina;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;France;Germany;Ireland;Italy;Mexico;Peru;Russian Federation;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020338-25-LT   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020338-25-GB   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020338-25-FI   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020337-99-EE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
   GENENTECH Inc.
      2016   Phase 3   EUCTR2015-004616-37-SE   Germany;Sweden;Switzerland;United States;
      2016   Phase 3   EUCTR2015-004616-37-DE   Germany;Sweden;Switzerland;United States;
   Helse Bergen HF, Haukeland University Hospital
      2022   Phase 3   EUCTR2020-001205-23-SE   Sweden;
      2019   Phase 3   EUCTR2017-001362-25-NL   Denmark;Netherlands;
      2018   Phase 3   EUCTR2017-001362-25-DK   Denmark;Netherlands;
   Hoffman La Roche Ltd
      2008   Phase 2   EUCTR2007-006338-32-SK   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Mexico;Netherlands;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2008   Phase 2   EUCTR2007-006338-32-GB   Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Mexico;Netherlands;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2008   Phase 2   EUCTR2007-006338-32-DK   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Mexico;Netherlands;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2008   Phase 2   EUCTR2007-006338-32-CZ   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Mexico;Netherlands;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2008   Phase 2   EUCTR2007-006338-32-BG   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Mexico;Netherlands;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2008   Phase 2   EUCTR2007-006338-32-BE   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Mexico;Netherlands;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
   Kessler Foundation
      2021   -   NCT04448977   United States;
   Robert Zivadinov, MD, PhD
      2021   Phase 4   NCT04925557   United States;
   Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-005448-48-ES   Brazil;Czechia;France;Italy;Spain;
   University Medical Centre Hamburg-Eppendorf
      2020   Phase 2   EUCTR2016-001166-29-DE   Germany;
   VU medical center
      2022   Phase 4   EUCTR2021-004791-34-NL   Netherlands;
Ocrevus 300 mg, solution à diluer pour perfusion   
   ROCHE
      2018   Phase 4   EUCTR2018-000780-91-FR   France;
Ocrrelizumab   
   F. Hoffman-La Roche Ltd
      2008   Phase 2   EUCTR2007-006338-32-DE   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Mexico;Netherlands;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
Octagam   
   Octapharma AG
      2009   -   EUCTR2008-004579-22-DE   Austria;Germany;
      2008   -   EUCTR2008-004579-22-AT   Austria;
Octagam 50 mg/ml   
   Octapharma AG
      2015   Phase 3   EUCTR2012-005086-12-PL   Austria;Bulgaria;Germany;Hungary;Poland;Russian Federation;Serbia;Ukraine;
      2013   -   EUCTR2012-005086-12-HU   Austria;Bulgaria;Germany;Hungary;Poland;Russian Federation;
      2013   -   EUCTR2012-005086-12-DE   Austria;Bulgaria;Germany;Hungary;Poland;Russian Federation;
      2013   -   EUCTR2012-005086-12-BG   Austria;Bulgaria;Germany;Hungary;Poland;Russian Federation;
      2013   -   EUCTR2012-005086-12-AT   Austria;Bulgaria;Germany;Hungary;Poland;Russian Federation;
Ocufolin   
   University of Miami
      2007   -   NCT03135327   United States;
Ofatumumab   
   Brigham and Women's Hospital
      2020   Phase 3   NCT04510220   United States;
   Genmab A/S
      2008   Phase 2   EUCTR2007-004223-38-DE   Belgium;Czech Republic;Denmark;Germany;Sweden;United Kingdom;
      2008   -   EUCTR2007-004223-38-BE   Belgium;Czech Republic;Denmark;Germany;Sweden;United Kingdom;
   GlaxoSmithKline
      2011   Phase 2   NCT01457924   Bulgaria;Canada;Czech Republic;Czechia;Denmark;Germany;Italy;Netherlands;Norway;Russian Federation;Spain;United States;
      2008   -   EUCTR2007-004223-38-DK   Czech Republic;Denmark;Germany;Sweden;United Kingdom;
   GlaxoSmithKline AB
      2008   -   EUCTR2007-004223-38-SE   Czech Republic;Denmark;Germany;Sweden;United Kingdom;
   GlaxoSmithKline UK
      2009   Phase 2   EUCTR2007-004223-38-GB   Belgium;Czech Republic;Denmark;Germany;Sweden;United Kingdom;
   GlaxoSmithKline s.r.o.
      2008   -   EUCTR2007-004223-38-CZ   Czech Republic;Denmark;Germany;Sweden;United Kingdom;
   NOVARTIS PHARMA SERVICES AG
      2021   Phase 3   EUCTR2020-002700-39-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005419-33-IT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Egypt;Finland;France;Germany;Hungary;India;Italy;Latvia;Lebanon;Lithuania;Mexico;Peru;Portugal;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Arab Emirates;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005418-31-IT   Argentina;Australia;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
   Novartis Pharma K.K.
      2018   Phase 2   JPRN-JapicCTI-173711   Japan, Russia;
   Novartis Pharmaceuticals
      2022   Phase 4   NCT05090371   United States;
      2022   Phase 4   NCT05084638   United States;
      2022   -   NCT05285904   -
      2022   -   NCT05266469   -
      2022   -   NCT05090033   -
      2021   Phase 4   NCT04878211   United States;
      2021   Phase 4   NCT04869358   Germany;
      2021   Phase 4   NCT04667117   United States;
      2021   Phase 3   NCT04926818   Australia;Austria;Belgium;France;Germany;India;Latvia;Mexico;Poland;Portugal;Russian Federation;Slovakia;Spain;Turkey;United States;
      2021   Phase 3   NCT04788615   France;Germany;Spain;United Kingdom;
      2021   -   NCT04847596   Puerto Rico;United States;
      2021   -   NCT04676555   Australia;United Kingdom;United States;
      2020   Phase 3   NCT04486716   Puerto Rico;United States;
      2020   Phase 3   NCT04353492   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czechia;Estonia;Germany;Greece;Hungary;Italy;Latvia;Lebanon;Mexico;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Slovakia;Slovenia;Spain;Switzerland;Turkey;United Kingdom;United States;
      2018   Phase 3   NCT03650114   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2018   Phase 2   NCT03249714   Japan;Russian Federation;
   University of Southern California
      2022   -   NCT05171972   United States;
Ofatumumab 100   
   GlaxoSmithKline
      2008   Phase 2   NCT00640328   Belgium;Czech Republic;Denmark;Former Serbia and Montenegro;Germany;Poland;Serbia;Sweden;United Kingdom;
Ofatumumab 300   
   GlaxoSmithKline
      2008   Phase 2   NCT00640328   Belgium;Czech Republic;Denmark;Former Serbia and Montenegro;Germany;Poland;Serbia;Sweden;United Kingdom;
Ofatumumab 700   
   GlaxoSmithKline
      2008   Phase 2   NCT00640328   Belgium;Czech Republic;Denmark;Former Serbia and Montenegro;Germany;Poland;Serbia;Sweden;United Kingdom;
Ofatumumab subcutaneous injection   
   Novartis Pharmaceuticals
      2016   Phase 3   NCT02792231   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czechia;Finland;France;Germany;Hungary;India;Italy;Latvia;Lithuania;Mexico;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2016   Phase 3   NCT02792218   Argentina;Australia;Belgium;Bulgaria;Canada;Croatia;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Puerto Rico;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
Oleovit D3 14.400 IU/ml oral drops, solution   
   University medical centre Maribor
      2017   Phase 4   EUCTR2017-004846-31-SI   Slovenia;
Olesoxime (TRO19622)   
   Hoffmann-La Roche
      2013   Phase 1   NCT01808885   France;
Olive oil   
   Terry L. Wahls
      2022   -   NCT05007483   United States;
Omega 3 fatty acids   
   University of Iowa
      2010   Phase 1   NCT01381354   United States;
Omeprazole   
   Biogen
      2011   Phase 3   NCT01462318   Czech Republic;Hungary;Poland;Russian Federation;United States;
OnabotulinumtoxinA   
   Allergan
      2012   Phase 3   NCT01600716   Belgium;Canada;Czech Republic;Czechia;France;Poland;Portugal;Russian Federation;United States;
Opicinumab   
   BIOGEN IDEC RESEARCH LIMITED
      2019   Phase 2   EUCTR2017-001224-22-IT   Australia;Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
   Biogen Idec Research Limited
      2018   Phase 2   EUCTR2017-001224-22-PL   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-001224-22-NL   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-001224-22-DE   Australia;Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-001224-22-BE   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2017   Phase 2   EUCTR2017-001224-22-HU   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2017   Phase 2   EUCTR2017-001224-22-GB   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2017   Phase 2   EUCTR2017-001224-22-ES   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
      2017   Phase 2   EUCTR2017-001224-22-CZ   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
Optical coherence tomography (OCT)   
   Medical University of Vienna
      2018   -   NCT03401879   Austria;
Optical coherence tomography angiography (OCTA)   
   Medical University of Vienna
      2018   -   NCT03401879   Austria;
Oral Methylprednisolone 625 mg/24h x3 days   
   Germans Trias i Pujol Hospital
      2013   Phase 4   NCT01986998   Spain;
Oral THC   
   University of California, Davis
      2004   Phase 1/Phase 2   NCT00682929   United States;
Oral corticosteroids   
   Hoffmann-La Roche
      2021   Phase 3   NCT04660539   Bulgaria;Canada;Croatia;Germany;Hungary;Italy;Japan;Korea, Republic of;Malaysia;Poland;Puerto Rico;Romania;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Oral lipoic acid (LA)   
   Oregon Health and Science University
      2005   Phase 1   NCT00676156   United States;
Orelabrutinib   
   Beijing InnoCare Pharma Tech Co., Ltd.
      2021   Phase 2   NCT04711148   China;Poland;Ukraine;United States;
   Peking Union Medical College Hospital
      2022   -   NCT05284175   China;
Other H1 antagonist   
   Genzyme, a Sanofi Company
      2017   Phase 3   NCT03368664   Austria;Belgium;Bulgaria;Czechia;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;
Other analgesics and antipyretics   
   GW PHARMA LTD
      2008   -   EUCTR2006-005910-11-IT   Germany;Italy;Spain;United Kingdom;
Other disease-modifying therapy   
   Novartis Pharmaceuticals
      2011   -   NCT01442194   Argentina;Australia;Canada;Chile;Mexico;Puerto Rico;United States;
Other nervous system drugs   
   NOVARTIS FARMA
      2011   -   EUCTR2011-000770-60-IT   Italy;
Ovastat 1000   
   medac Gesellschaft für klinische Spezialpräparate mbH
      2007   -   EUCTR2006-002856-14-DE   Germany;
Ovastat 5000   
   medac Gesellschaft für klinische Spezialpräparate mbH
      2007   -   EUCTR2006-002856-14-DE   Germany;
Oxcarbazepine   
   Queen Mary University London
      2014   Phase 2   EUCTR2013-002419-87-GB   United Kingdom;
   Queen Mary University of London
      2014   Phase 2   NCT02104661   United Kingdom;
Oxybutynin Hydrochloride   
   Astellas Pharma Inc
      2008   Phase 4   NCT00629642   Australia;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;
Ozanimod   
   Celgene
      2014   Phase 3   NCT02294058   Argentina;Austria;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Czechia;Estonia;Georgia;Germany;Hungary;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2013   Phase 3   NCT02047734   Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Georgia;Greece;Hungary;Italy;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
   Celgene International II Sàrl (CIS II)
      2015   Phase 3   EUCTR2015-002500-91-HU   Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Croatia;Estonia;Georgia;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Moldova, Republic of;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-002500-91-GB   Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Croatia;Estonia;Georgia;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-002500-91-BE   Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Croatia;Estonia;Georgia;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Moldova, Republic of;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002320-27-PL   Austria;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Estonia;Georgia;Germany;Hungary;Latvia;Lithuania;Moldova, Republic of;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002320-27-LV   Austria;Belarus;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Georgia;Germany;Hungary;Latvia;Lithuania;Moldova, Republic of;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002320-27-LT   Austria;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Estonia;Georgia;Germany;Hungary;Latvia;Lithuania;Moldova, Republic of;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002320-27-HU   Austria;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Estonia;Georgia;Germany;Hungary;Latvia;Lithuania;Moldova, Republic of;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002320-27-HR   Austria;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Estonia;Georgia;Germany;Hungary;Latvia;Lithuania;Moldova, Republic of;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002320-27-GB   Argentina;Austria;Belarus;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;Georgia;Germany;Hungary;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002320-27-BG   Austria;Belarus;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Georgia;Germany;Hungary;Latvia;Lithuania;Moldova, Republic of;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-002320-27-PT   Austria;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Estonia;Georgia;Germany;Hungary;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-002320-27-EE   Austria;Belarus;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Georgia;Germany;Hungary;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2013   Phase 2;Phase 3   EUCTR2012-002714-40-HU   Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Georgia;Greece;Hungary;Italy;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2013   Phase 2;Phase 3   EUCTR2012-002714-40-BG   Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Georgia;Greece;Hungary;Italy;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2013   Phase 2;Phase 3   EUCTR2012-002714-40-BE   Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Georgia;Greece;Hungary;Israel;Italy;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
   Receptos, Inc.
      2015   Phase 3   EUCTR2014-002320-27-SE   Argentina;Austria;Belarus;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;Georgia;Germany;Hungary;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002320-27-NL   Argentina;Austria;Belarus;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;Georgia;Germany;Hungary;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002320-27-ES   Argentina;Austria;Belarus;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;Georgia;Germany;Hungary;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2015   -   EUCTR2015-002500-91-ES   Argentina;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Colombia;Croatia;Estonia;Georgia;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
Ozanimod HCI   
   Celgene International II Sàrl (CIS II)
      2016   Phase 3   EUCTR2015-002500-91-PT   Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Croatia;Estonia;Georgia;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Moldova, Republic of;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-002500-91-GR   Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Croatia;Estonia;Georgia;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Moldova, Republic of;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
Ozanimod HCL   
   CELGENE INTERNATIONAL II SàRL
      2016   Phase 3   EUCTR2015-002500-91-IT   Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Croatia;Estonia;Georgia;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
Ozanimod HCl   
   Celgene International II Sàrl (CIS II)
      2017   Phase 3   EUCTR2015-002500-91-SE   Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Croatia;Estonia;Georgia;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Moldova, Republic of;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-002500-91-SK   Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Croatia;Estonia;Georgia;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Moldova, Republic of;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-002500-91-PL   Argentina;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Colombia;Croatia;Estonia;Georgia;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-002500-91-LV   Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Croatia;Estonia;Georgia;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Moldova, Republic of;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-002500-91-LT   Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Croatia;Estonia;Georgia;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Moldova, Republic of;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-002500-91-HR   Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Croatia;Estonia;Georgia;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Moldova, Republic of;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-002500-91-EE   Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Croatia;Estonia;Georgia;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Moldova, Republic of;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-002500-91-BG   Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Croatia;Estonia;Georgia;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Moldova, Republic of;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
Ozanimod hydrochloride   
   Celgene International II Sàrl
      2016   Phase 1   EUCTR2016-003073-18-GB   United Kingdom;
PAT   
   University of Ottawa
      2020   -   NCT04267185   Canada;
PB006   
   Polpharma Biologics S.A.
      2019   Phase 3   EUCTR2018-004751-20-PL   Belarus;Croatia;Georgia;Moldova, Republic of;Poland;Serbia;Ukraine;
      2019   Phase 3   EUCTR2018-004751-20-HR   Belarus;Croatia;Georgia;Moldova, Republic of;Poland;Serbia;Ukraine;
PEG-liposomal Prednisolone Sodium Phosphate   
   Enceladus Pharmaceuticals BV
      2010   -   EUCTR2009-013884-21-PL   Belgium;Germany;Poland;
      2009   Phase 2   EUCTR2009-013884-21-BE   Belgium;Germany;Poland;
      2009   -   EUCTR2009-013884-21-DE   Belgium;Germany;Poland;
PEG-liposomal prednisolone sodium phosphate   
   Galapagos NV
      2009   Phase 2   NCT01039103   Belgium;Germany;Poland;
PEGINTERFERONE BETA-1A   
   BIOGEN IDEC RESEARCH LIMITED
      2019   Phase 3   EUCTR2018-003008-38-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
PEGINTERFERONE LAMBDA-1A   
   BIOGEN IDEC RESEARCH LIMITED
      2019   Phase 3   EUCTR2018-003008-38-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
PEGylated Intereron Beta-1a   
   Biogen Idec Limited
      2012   Phase 3   EUCTR2010-024477-39-GR   Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;India;Latvia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2012   Phase 3   EUCTR2010-024477-39-GB   Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;India;Latvia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2010-024477-39-CZ   Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;India;Latvia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-024477-39-DE   Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;India;Latvia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-024477-39-BG   Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;India;Latvia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-024477-39-LV   Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;India;Latvia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-024477-39-EE   Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;India;Latvia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-024477-39-BE   Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;India;Latvia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
PEGylated Interferon Beta-1a   
   BIOGEN IDEC RESEARCH LIMITED
      2019   Phase 3   EUCTR2018-003008-38-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
   Biogen Idec LTD
      2009   -   EUCTR2008-006333-27-LV   Belgium;Bulgaria;Czech Republic;Estonia;Germany;Greece;Latvia;Netherlands;Spain;United Kingdom;
   Biogen Idec Limited
      2012   Phase 3   EUCTR2010-024477-39-GR   Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;India;Latvia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2012   Phase 3   EUCTR2010-024477-39-GB   Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;India;Latvia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2010-024477-39-CZ   Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;India;Latvia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-024477-39-DE   Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;India;Latvia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-024477-39-BG   Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;India;Latvia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-024477-39-LV   Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;India;Latvia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-024477-39-EE   Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;India;Latvia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-024477-39-BE   Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Germany;Greece;India;Latvia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2008-006333-27-GR   Belgium;Bulgaria;Czech Republic;Estonia;Germany;Greece;Latvia;Netherlands;Spain;United Kingdom;
      2010   -   EUCTR2008-006333-27-CZ   Belarus;Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;India;Kazakhstan;Latvia;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Turkey;Ukraine;United Kingdom;United States;
      2009   Phase 3   EUCTR2008-006333-27-GB   Belarus;Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;India;Kazakhstan;Latvia;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Turkey;Ukraine;United Kingdom;United States;
      2009   -   EUCTR2008-006333-27-NL   Belarus;Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;India;Kazakhstan;Latvia;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Turkey;Ukraine;United Kingdom;United States;
      2009   -   EUCTR2008-006333-27-EE   Belarus;Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;India;Kazakhstan;Latvia;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Turkey;Ukraine;United Kingdom;United States;
      2009   -   EUCTR2008-006333-27-BG   Belarus;Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;India;Kazakhstan;Latvia;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Turkey;Ukraine;United Kingdom;United States;
      2009   -   EUCTR2008-006333-27-BE   Belarus;Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;India;Kazakhstan;Latvia;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Turkey;Ukraine;United Kingdom;United States;
      -   -   EUCTR2008-006333-27-DE   Belarus;Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;India;Kazakhstan;Latvia;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Turkey;Ukraine;United Kingdom;United States;
   Biogen Idec Research Limited
      2020   Phase 3   EUCTR2018-003008-38-DE   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-003008-38-SK   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-003008-38-PT   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-003008-38-HU   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-003008-38-HR   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-003008-38-GR   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-003008-38-ES   Argentina;Belgium;Brazil;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;
      2019   Phase 3   EUCTR2018-003008-38-CZ   Argentina;Belgium;Brazil;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;
      2019   Phase 3   EUCTR2018-003008-38-BG   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-003008-38-BE   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-000516-22-PT   Bulgaria;Colombia;Croatia;Estonia;Greece;Hungary;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Taiwan;Thailand;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-000516-22-HU   Bulgaria;Colombia;Croatia;Estonia;Greece;Hungary;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Taiwan;Thailand;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-000516-22-EE   Bulgaria;Colombia;Croatia;Estonia;Greece;Hungary;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Taiwan;Thailand;Tunisia;Turkey;United States;
      -   Phase 3   EUCTR2018-003008-38-FR   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
PET with 11C-Flumazenil   
   Assistance Publique - Hôpitaux de Paris
      2013   -   NCT01651520   France;
PET-MRI with [18F]-Florbetaben and PET-MRI with [18F]-DPA-714   
   Assistance Publique - Hôpitaux de Paris
      2022   -   NCT05147532   -
PF-06342674   
   Pfizer
      2014   Phase 1   NCT02045732   United States;
PHENYLCYCLOPROPYLAMINE DERIVATIVES AND DUAL LSD1/MAO-B (LYSINE-SPECIFIC DEMETHYLASE 1 AND MONOAMINE OXIDASE-B) INHIBITOR   
   Oryzon Genomics S. A
      2017   Phase 2   EUCTR2017-002838-23-ES   Spain;
PI-2301   
   PEPTIMMUNE Inc
      2008   -   EUCTR2007-007759-15-HU   Hungary;
   Peptimmune Inc.
      2010   Phase 2   EUCTR2009-012716-40-SK   Bulgaria;Czech Republic;Estonia;France;Germany;Poland;Slovakia;
      2010   Phase 2   EUCTR2009-012716-40-DE   Bulgaria;Czech Republic;Estonia;France;Germany;Poland;Slovakia;
      2010   -   EUCTR2009-012716-40-PL   Bulgaria;Czech Republic;Estonia;France;Germany;Poland;
      2010   -   EUCTR2009-012716-40-FR   Bulgaria;Czech Republic;Estonia;France;Germany;Poland;
      2010   -   EUCTR2009-012716-40-CZ   Bulgaria;Czech Republic;Estonia;France;Germany;Poland;
      2010   -   EUCTR2009-012716-40-BG   Bulgaria;Czech Republic;Estonia;France;Germany;Poland;
      2009   -   EUCTR2009-012716-40-EE   Bulgaria;Czech Republic;Estonia;France;Germany;Poland;
PIPE-307   
   Pipeline Therapeutics, Inc.
      2021   Phase 1   NCT04941781   United Kingdom;
      2021   Phase 1   NCT04725175   Australia;
PL 04515/0127   
   Queen Mary, University of London
      2009   -   EUCTR2008-000256-26-GB   United Kingdom;
PL 12762/0049   
   University College London
      2010   Phase 4   EUCTR2009-017939-18-GB   United Kingdom;
PLEDIGRY   
   CHU de Rennes
      2018   Phase 3   EUCTR2018-001292-21-FR   France;
PLEGRIDY - 125 MCG - SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - PENNA PRERIEMPITA - 0,5 ML - 6 PENNE PRERIEMPITE   
   BIOGEN IDEC ITALIA S.R.L.
      2015   Phase 4   EUCTR2015-002201-11-IT   Italy;
PLP peptide   
   Centrum Neurologii Krzysztof Selmaj
      2016   Phase 2   EUCTR2016-002180-33-PL   Poland;
PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE (13-VALENT, ADSORBED)   
   ALEXION PHARMACEUTICALS INCORPORATED
      2020   Phase 2;Phase 3   EUCTR2019-001829-26-IT   Canada;Germany;Italy;Japan;Korea, Republic of;Spain;United States;
PNU-215062 sodium salt   
   Teva Pharmaceutical Industries Ltd
      2006   Phase 2   EUCTR2005-004334-41-ES   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
      2005   Phase 2   EUCTR2004-003943-28-GB   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
      2005   Phase 2   EUCTR2004-003943-28-ES   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-003943-28-HU   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-003943-28-DE   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-003943-28-CZ   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom;
PO   
   Actelion Pharmaceuticals Ltd.
      2018   Phase 3   EUCTR2016-004719-10-PT   Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-004719-10-GR   Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-004719-10-GB   Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-004719-10-FI   Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-004719-10-CZ   Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2016-004719-10-BG   Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-004719-10-SE   Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-004719-10-PL   Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-004719-10-LT   Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
PRD806998   
   Biogen Idec Research Limited
      2013   Phase 2   EUCTR2011-006262-40-NL   Canada;Czech Republic;France;Hungary;Italy;Netherlands;Poland;Russian Federation;Serbia;Spain;United Kingdom;United States;
PRN2246   
   GENZYME CORPORATION
      2020   Phase 3   EUCTR2020-000647-30-IT   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lithuania;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000645-14-IT   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Latvia;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000637-41-IT   Austria;Belarus;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Hong Kong;Italy;Japan;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United States;
   Genzyme Corporation
      2021   Phase 3   EUCTR2020-000647-30-PT   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lithuania;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000645-14-PT   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Latvia;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000645-14-NL   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Latvia;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000645-14-HU   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Latvia;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000645-14-HR   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Latvia;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000645-14-DE   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Latvia;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000645-14-BE   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Latvia;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000644-55-DE   Argentina;Belgium;Brazil;Canada;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Latvia;Netherlands;Norway;Portugal;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000637-41-AT   Austria;Belarus;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Hong Kong;Italy;Japan;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2020-000647-30-PL   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lithuania;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000647-30-NL   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lithuania;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000647-30-LT   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lithuania;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000647-30-GR   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lithuania;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000647-30-GB   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;China;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lithuania;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000647-30-FI   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lithuania;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000647-30-DK   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lithuania;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000647-30-DE   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lithuania;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000647-30-CZ   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lithuania;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000647-30-BG   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lithuania;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000645-14-GR   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Latvia;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000645-14-GB   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Latvia;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000645-14-FR   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Latvia;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000645-14-EE   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Latvia;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000645-14-DK   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Latvia;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000645-14-CZ   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Latvia;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000645-14-BG   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Latvia;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000644-55-SK   Argentina;Belgium;Brazil;Canada;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Latvia;Netherlands;Norway;Portugal;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000644-55-PT   Argentina;Belgium;Brazil;Canada;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Latvia;Netherlands;Norway;Portugal;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000644-55-NL   Argentina;Belgium;Brazil;Canada;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Latvia;Netherlands;Norway;Portugal;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000644-55-LV   Argentina;Belgium;Brazil;Canada;Chile;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Latvia;Netherlands;Norway;Portugal;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000644-55-HU   Argentina;Belgium;Brazil;Canada;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Latvia;Netherlands;Norway;Portugal;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000644-55-GR   Argentina;Belgium;Brazil;Canada;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Latvia;Netherlands;Norway;Portugal;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000644-55-GB   Argentina;Belgium;Brazil;Canada;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Latvia;Netherlands;Norway;Portugal;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000644-55-FR   Argentina;Belgium;Brazil;Canada;Chile;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Latvia;Netherlands;Norway;Portugal;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000644-55-CZ   Argentina;Belgium;Brazil;Canada;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Latvia;Netherlands;Norway;Portugal;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000637-41-SE   Austria;Belarus;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Hong Kong;Italy;Japan;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2020-000637-41-PL   Austria;Belarus;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Hong Kong;Italy;Japan;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2020-000637-41-LT   Austria;Belarus;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Hong Kong;Italy;Japan;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2020-000637-41-FI   Austria;Belarus;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Hong Kong;Italy;Japan;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2020-000637-41-DK   Austria;Belarus;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Hong Kong;Italy;Japan;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2020-000637-41-DE   Austria;Belarus;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Hong Kong;Italy;Japan;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2020-000637-41-CZ   Austria;Belarus;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Hong Kong;Italy;Japan;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2020-000637-41-BG   Austria;Belarus;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Hong Kong;Italy;Japan;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United States;
      2019   Phase 2   EUCTR2018-004731-76-SK   Canada;Czech Republic;Estonia;France;Netherlands;Russian Federation;Slovakia;Spain;Ukraine;United States;
      2019   Phase 2   EUCTR2018-004731-76-NL   Canada;Czech Republic;Czechia;Estonia;France;Netherlands;Russian Federation;Slovakia;Spain;Ukraine;United States;
      2019   Phase 2   EUCTR2018-004731-76-ES   Canada;Czech Republic;Estonia;France;Netherlands;Russian Federation;Slovakia;Spain;Ukraine;United States;
      2019   Phase 2   EUCTR2018-004731-76-EE   Canada;Czech Republic;Czechia;Estonia;France;Netherlands;Russian Federation;Slovakia;Spain;Ukraine;United States;
      2019   Phase 2   EUCTR2018-004731-76-CZ   Canada;Czech Republic;Estonia;France;Netherlands;Russian Federation;Slovakia;Spain;Ukraine;United States;
      2019   Phase 2   EUCTR2018-003927-12-SK   Canada;Czech Republic;Estonia;France;Netherlands;Norway;Russian Federation;Slovakia;Spain;Sweden;Ukraine;United States;
      2019   Phase 2   EUCTR2018-003927-12-SE   Canada;Czech Republic;Estonia;France;Netherlands;Norway;Russian Federation;Slovakia;Spain;Sweden;Ukraine;United States;
      2019   Phase 2   EUCTR2018-003927-12-NL   Canada;Czech Republic;Estonia;France;Netherlands;Norway;Russian Federation;Slovakia;Spain;Sweden;Ukraine;United States;
      2019   Phase 2   EUCTR2018-003927-12-ES   Canada;Czech Republic;Estonia;France;Netherlands;Norway;Russian Federation;Slovakia;Spain;Sweden;Ukraine;United States;
      2019   Phase 2   EUCTR2018-003927-12-EE   Canada;Czech Republic;Estonia;France;Netherlands;Norway;Russian Federation;Slovakia;Spain;Sweden;Ukraine;United States;
PTL201   
   PhytoTech Therapeutics, Ltd.
      2018   Phase 2   NCT03005119   Israel;
Paired associative stimulation (PAS)   
   Shirley Ryan AbilityLab
      2017   -   NCT03723434   United States;
Palifermin   
   Cambridge University Hospitals NHS Foundation Trust
      2012   Phase 1/Phase 2   NCT01712945   United Kingdom;
   Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
      2012   Phase 2   EUCTR2011-005606-30-GB   United Kingdom;
Pantoprazole   
   Merck KGaA
      2008   Phase 1   NCT00938366   -
Paracetamol   
   Genzyme, a Sanofi Company
      2017   Phase 3   NCT03368664   Austria;Belgium;Bulgaria;Czechia;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;
      2015   Phase 1   NCT02583594   Spain;
      2014   Phase 4   NCT02205489   Belgium;France;Netherlands;Spain;
   Rigshospitalet, Denmark
      2021   Phase 3   NCT04688788   Denmark;
Paracetamolo   
   NOVARTIS PHARMA AG
      2018   Phase 2   EUCTR2017-004702-17-IT   Austria;Bulgaria;Czech Republic;Czechia;Estonia;Germany;Italy;Latvia;Lithuania;Poland;Russian Federation;Spain;United States;
Paroxetine   
   University of Manitoba
      2006   Phase 3   NCT00291148   Canada;
Part A: 100 mg/mL GSK2618960   
   GlaxoSmithKline
      2013   Phase 1   NCT01808482   United Kingdom;
Part B: Dose of GSK2618960 decided from Part A   
   GlaxoSmithKline
      2013   Phase 1   NCT01808482   United Kingdom;
Part C: Dose of GSK2618960 decided from Part A and B   
   GlaxoSmithKline
      2013   Phase 1   NCT01808482   United Kingdom;
Peanut   
   Rocky Mountain MS Research Group, LLC
      2014   Phase 4   NCT02217982   United States;
Peginterferon beta-1a   
   Biogen
      2017   Phase 4   NCT03177083   Portugal;
      2016   Phase 4   NCT02587065   Italy;
      2016   Phase 4   NCT02568111   -
      2014   -   NCT02230969   Australia;Austria;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;Switzerland;United Kingdom;United States;
      2013   -   NCT01911767   Australia;Canada;France;Germany;Ireland;Italy;Poland;Spain;United Kingdom;United States;
      2011   Phase 3   NCT01332019   Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;India;Latvia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
   Biogen Idec
      2014   Phase 1   NCT02269930   United States;
Peginterferone beta 1a   
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-004505-32-IT   France;Germany;Italy;Spain;
Pegylated interferon beta-1a   
   Cinnagen
      2017   Phase 3   NCT05242133   Iran, Islamic Republic of;
Pending   
   JOSE MANUEL GARCIA DOMINGUEZ
      2013   -   EUCTR2011-000985-36-ES   Spain;
Peripheral Blood Stem Cell Transplantation   
   Fred Hutchinson Cancer Research Center
      2008   Phase 2   NCT00716066   United States;
Peripheral blood stem cell transplantation   
   Fred Hutchinson Cancer Research Center
      1997   Phase 1   NCT00014755   United States;
Personalized extended interval dosing of natalizumab   
   VU University Medical Center
      2020   Phase 4   NCT04225312   Netherlands;
Phenytoin   
   University College, London
      2011   Phase 2   NCT01451593   United Kingdom;
Pioglitazone   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2017   Phase 1/Phase 2   NCT03109288   United States;
Pirfenidone   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2017   Phase 1/Phase 2   NCT03109288   United States;
Pixantrone   
   Fondation Charcot Stichting
      2009   Phase 1;Phase 2   EUCTR2007-003086-40-BE   Belgium;France;
      2008   -   EUCTR2007-003086-40-FR   France;
Placebo   
   Novartis Pharma K.K.
      2018   Phase 2   JPRN-JapicCTI-173711   Japan, Russia;
      2014   Phase 3   JPRN-JapicCTI-142447   -
      2013   Phase 2   JPRN-JapicCTI-132178   -
Plasma exchange   
   Biogen Idec
      2007   Phase 0   NCT00424788   United States;
Platelet transfusion   
   Region Skane
      2016   -   NCT02601131   Sweden;
Platform   
   Georgia State University
      2021   Phase 4   NCT04387734   United States;
Plegridy   
   BIOGEN IDEC RESEARCH LIMITED
      2019   Phase 3   EUCTR2018-003008-38-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
   Biogen Idec Research Limited
      2020   Phase 3   EUCTR2018-003008-38-DE   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-003008-38-SK   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-003008-38-PT   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-003008-38-HU   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-003008-38-HR   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-003008-38-GR   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-003008-38-ES   Argentina;Belgium;Brazil;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;
      2019   Phase 3   EUCTR2018-003008-38-CZ   Argentina;Belgium;Brazil;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Poland;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;
      2019   Phase 3   EUCTR2018-003008-38-BG   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-003008-38-BE   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-000516-22-PT   Bulgaria;Colombia;Croatia;Estonia;Greece;Hungary;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Taiwan;Thailand;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-000516-22-HU   Bulgaria;Colombia;Croatia;Estonia;Greece;Hungary;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Taiwan;Thailand;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-000516-22-EE   Bulgaria;Colombia;Croatia;Estonia;Greece;Hungary;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Taiwan;Thailand;Tunisia;Turkey;United States;
      -   Phase 3   EUCTR2018-003008-38-FR   Argentina;Australia;Belgium;Bulgaria;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Kuwait;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Tunisia;Turkey;United States;
   Holy Name Medical Center, Inc.
      2017   Phase 4   NCT03424733   United States;
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-004505-32-IT   France;Germany;Italy;Spain;
Plegridy (peginterferon beta-1a), Biogen Idec Ltd   
   Bayer
      2016   -   NCT02749396   Finland;
Plegridy 125 micrograms   
   Biogen Portugal
      2016   Phase 4   EUCTR2016-000434-21-PT   Portugal;
Plegridy 63 micrograms   
   Biogen Portugal
      2016   Phase 4   EUCTR2016-000434-21-PT   Portugal;
Pleneva TM BGC20-0134   
   BTG International Inc.
      2009   Phase 2   NCT01037907   Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;
Plovamer acetate   
   Merck KGaA
      2014   Phase 2   EUCTR2013-002283-25-GB   Bulgaria;Colombia;Croatia;Czech Republic;Finland;Greece;Hungary;Italy;Mexico;Poland;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2014   -   EUCTR2013-002283-25-PL   Bulgaria;Colombia;Croatia;Czech Republic;Finland;Greece;Hungary;Italy;Mexico;Poland;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2014   -   EUCTR2013-002283-25-GR   Bulgaria;Colombia;Croatia;Czech Republic;Finland;Greece;Hungary;Italy;Mexico;Poland;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2014   -   EUCTR2013-002283-25-ES   Bulgaria;Colombia;Croatia;Czech Republic;Finland;Greece;Hungary;Italy;Mexico;Poland;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2014   -   EUCTR2013-002283-25-BG   Bulgaria;Croatia;Czech Republic;Finland;Greece;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
      2013   -   EUCTR2013-002283-25-IT   Bulgaria;Colombia;Croatia;Czech Republic;Finland;Greece;Hungary;Italy;Mexico;Poland;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2013   -   EUCTR2013-002283-25-HU   Bulgaria;Colombia;Croatia;Czech Republic;Finland;Greece;Hungary;Italy;Mexico;Poland;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2013   -   EUCTR2013-002283-25-HR   Bulgaria;Colombia;Croatia;Czech Republic;Finland;Greece;Hungary;Italy;Mexico;Poland;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2013   -   EUCTR2013-002283-25-FI   Bulgaria;Colombia;Croatia;Czech Republic;Finland;Greece;Hungary;Italy;Mexico;Poland;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
      2013   -   EUCTR2013-002283-25-CZ   Bulgaria;Colombia;Croatia;Czech Republic;Finland;Greece;Hungary;Italy;Mexico;Poland;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
Plovamer acetate 0.5 milligram (mg)   
   EMD Serono
      2013   Phase 2   NCT01963611   Bulgaria;Croatia;Czech Republic;Finland;Germany;Greece;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
Pneumococcal polysaccharide vaccine   
   Celgene
      2021   Phase 3   NCT05028634   Germany;United States;
Pneumovax II   
   R & D, Cambridge University Hospitals
      2009   -   EUCTR2009-011523-31-GB   United Kingdom;
Polyphenon E   
   Louisiana State University Health Sciences Center in New Orleans
      2011   Phase 2   NCT01451723   United States;
      2009   Phase 1   NCT00836719   United States;
Ponesimod   
   ACTELION Pharmaceuticals Ltd
      2010   Phase 2   EUCTR2009-011470-15-HU   Australia;Austria;Bulgaria;Canada;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
   Actelion
      2017   Phase 3   NCT03232073   Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czechia;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 3   NCT02907177   Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Mexico;Norway;Poland;Portugal;Russian Federation;Spain;Switzerland;United Kingdom;United States;
      2015   Phase 3   NCT02425644   Argentina;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2010   Phase 2   NCT01093326   Austria;Bulgaria;Canada;Czech Republic;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
Pravastatin   
   Nantes University Hospital
      2004   Phase 3   NCT00200655   France;
Prebiotics (Prebiotin Prebiotic Fiber Stick Pac)   
   Columbia University
      2020   -   NCT04038541   United States;
Prednisolone   
   Genzyme, a Sanofi Company
      2017   Phase 3   NCT03368664   Austria;Belgium;Bulgaria;Czechia;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;
   Tohoku University Hospital
      2013   Phase 1,2   JPRN-UMIN000010094   Japan;
Prednisone   
   Claudio Gobbi
      2011   Phase 4   NCT01411514   Switzerland;
   Fred Hutchinson Cancer Research Center
      2008   Phase 2   NCT00716066   United States;
      1997   Phase 1   NCT00014755   United States;
   Holy Name Medical Center, Inc.
      2017   Phase 4   NCT03424733   United States;
   National Eye Institute (NEI)
      1988   Phase 3   NCT00000146   United States;
      1988   -   NCT00000147   United States;
   National Institute of Neurological Disorders and Stroke (NINDS)
      2016   Phase 2   NCT02784210   United States;
   Teva Pharmaceutical Industries
      2005   Phase 4   NCT00203047   Canada;United States;
   Third Affiliated Hospital, Sun Yat-Sen University
      2016   Phase 4   NCT02809079   -
Pregabalin   
   Pfizer Japan Inc.
      2010   Phase 3   JPRN-JapicCTI-101335   -
   Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
      2010   Phase 3   NCT01202227   Japan;
   University of Manitoba
      2006   Phase 3   NCT00291148   Canada;
Prepulsid   
   Department of Neurology UMCG
      2006   -   EUCTR2006-004318-42-NL   Netherlands;
Prevenar 13   
   ALEXION PHARMACEUTICALS INCORPORATED
      2020   Phase 2;Phase 3   EUCTR2019-001829-26-IT   Canada;Germany;Italy;Japan;Korea, Republic of;Spain;United States;
Probiotics (Visbiome®)   
   Columbia University
      2020   -   NCT04038541   United States;
Prohance (Gadoteridol)   
   University of Nottingham
      2017   -   NCT02481882   United Kingdom;
Prolonged-release Fampridine   
   University of Zurich
      2012   Phase 2   NCT01576354   Switzerland;
Prophylactic vaccine (tetanus, diphtheria, pertussis, poliomyelitis, influenza, hepatitis A, hepatitis B, tick-borne encephalitis, meningococcal, pneumococcal)   
   Dr. med. Micha Loebermann
      2009   -   NCT02275741   Germany;
Provigil   
   Sheba Medical Center
      2005   -   NCT00220506   Israel;
Provigil (modafinil)   
   Institute for Clinical Research
      2003   -   NCT00210301   United States;
Pure ECGC capsules   
   Louisiana State University Health Sciences Center in New Orleans
      2015   Phase 2   NCT02011451   United States;
Quadrivalent influenza vaccine   
   Novartis Pharmaceuticals
      2021   Phase 4   NCT04667117   United States;
Quality of life   
   University Hospital, Strasbourg, France
      2019   Phase 2   NCT03910738   France;
Quinidina sulfato   
   Avanir Pharmaceuticals, Inc.
      2011   Phase 2   EUCTR2011-002178-22-ES   Argentina;Bulgaria;Czech Republic;Poland;Spain;United Kingdom;United States;
Quinidine Sulfate   
   Avanir Pharmaceuticals, Inc.
      2012   Phase 2   EUCTR2011-002178-22-GB   Argentina;Bulgaria;Czech Republic;Germany;Poland;Spain;United Kingdom;United States;
      2012   -   EUCTR2011-002178-22-PL   Argentina;Bulgaria;Czech Republic;Germany;Poland;Spain;United Kingdom;United States;
      2012   -   EUCTR2011-002178-22-CZ   Argentina;Bulgaria;Czech Republic;Germany;Poland;Spain;United Kingdom;United States;
R lipoic acid   
   Oregon Health and Science University
      2005   Phase 1   NCT00676156   United States;
RABBIT HUMAN T LYMPHOCYTE IMMUNOGLOBULIN   
   Uppsala l?ns landsting
      2011   -   EUCTR2010-023560-40-SE   Brazil;Canada;Sweden;United States;
RAS   
   The Cleveland Clinic
      2014   -   NCT02065284   United States;
RATG   
   Northwestern University
      2019   Phase 2/Phase 3   NCT03829566   United States;
      2017   Phase 3   NCT03342638   United States;
RC18   
   RemeGen Co., Ltd.
      2021   Phase 2   NCT04625153   China;
      2018   Phase 3   NCT03330418   China;
REBIF - 44 MCG(12 MILIONI UI) -SOLUZ INIETTABILE- USO SOTTOCUTANEO-PENNA PRERIEMPITA 0.5 ML (24 MILIONI UI/ML)12 PENNE PRERIEMPITE   
   OSPEDALE SAN RAFFAELE
      2018   Phase 4   EUCTR2016-004819-12-IT   Italy;
REBIF 44 microgramos solución inyectable   
   Merck Serono International, a branch of Laboratoires Serono SA an affiliate of Merck KGaA, Darmstadt
      2009   Phase 3   EUCTR2008-004954-34-ES   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Greece;Italy;Latvia;Poland;Portugal;Slovakia;Spain;
   Merck Serono S.A. - Geneva, an affiliate of Merck KGaA Darmstadt, Germany
      2006   -   EUCTR2006-002982-38-ES   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Italy;Lithuania;Portugal;Spain;
   sanofi-aventis recherche et development
      2009   -   EUCTR2008-006226-34-ES   Belgium;Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
REBIF 44 microgramos solución inyectable en jeringa precargada   
   Biogen Idec Limited
      2010   -   EUCTR2009-015556-15-ES   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
REBIF SC 12SIR 12000000UI44MCG   
   Universita di Firenze
      2006   -   EUCTR2006-004937-13-IT   Italy;
REBIF SC 12SIR 6000000UI 22MCG   
   Universita di Firenze
      2006   -   EUCTR2006-004937-13-IT   Italy;
REBIF*SC 12SIR 12000000UI44MCG   
   MERCK SERONO INTERNATIONAL SA
      2008   -   EUCTR2006-003366-33-IT   Italy;Spain;
   MERCK SERONO SA
      2009   -   EUCTR2008-004954-34-IT   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Greece;Italy;Latvia;Poland;Portugal;Spain;
      2009   -   EUCTR2008-003706-33-IT   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Greece;Italy;Norway;Portugal;Spain;Sweden;United Kingdom;
   OSPEDALE S. RAFFAELE
      2004   -   EUCTR2004-001601-10-IT   France;Italy;
REBIF*SC 12SIR 6000000UI 22MCG   
   BIOGEN IDEC LTD
      2010   -   EUCTR2009-015556-15-IT   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
RECOMBINANT INTERFERON BE   
   Novartis Pharma GmbH
      2021   Phase 4   EUCTR2020-005752-38-DE   Germany;
RECOMBINANT INTERFERON BETA-1B   
   Bayer AG
      2018   Phase 4   EUCTR2017-001176-31-PT   Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Norway;Poland;Portugal;Slovenia;Spain;Sweden;Switzerland;United Kingdom;
      2017   Phase 4   EUCTR2017-001176-31-GB   Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Norway;Poland;Portugal;Slovenia;Spain;Sweden;Switzerland;United Kingdom;
      2017   Phase 4   EUCTR2017-001176-31-FR   Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Norway;Poland;Portugal;Slovenia;Spain;Sweden;Switzerland;United Kingdom;
      2017   Phase 4   EUCTR2017-001176-31-FI   Austria;Belgium;Canada;Czech Republic;Denmark;Finland;Germany;Hungary;Israel;Italy;Norway;Poland;Portugal;Slovenia;Spain;Sweden;Switzerland;United Kingdom;
      2017   Phase 4   EUCTR2017-001176-31-ES   Austria;Belgium;Canada;Czech Republic;Denmark;Finland;Germany;Hungary;Israel;Italy;Norway;Poland;Portugal;Slovenia;Spain;Sweden;Switzerland;United Kingdom;
      2017   Phase 4   EUCTR2017-001176-31-DK   Austria;Belgium;Canada;Czech Republic;Denmark;Finland;Germany;Hungary;Israel;Italy;Norway;Poland;Portugal;Slovenia;Spain;Sweden;Switzerland;United Kingdom;
      2017   Phase 4   EUCTR2017-001176-31-CZ   Austria;Belgium;Canada;Czech Republic;Denmark;Finland;Germany;Hungary;Israel;Italy;Norway;Poland;Portugal;Slovenia;Spain;Sweden;Switzerland;United Kingdom;
      2017   Phase 4   EUCTR2017-001176-31-AT   Austria;Belgium;Canada;Czech Republic;Denmark;Finland;Germany;Hungary;Israel;Italy;Norway;Poland;Portugal;Slovenia;Spain;Sweden;Switzerland;United Kingdom;
RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NHBA FUSION PROTEIN   
   ALEXION PHARMACEUTICALS INCORPORATED
      2020   Phase 2;Phase 3   EUCTR2019-001829-26-IT   Canada;Germany;Italy;Japan;Korea, Republic of;Spain;United States;
REVAXIS   
   R & D, Cambridge University Hospitals
      2009   -   EUCTR2009-011523-31-GB   United Kingdom;
RG2077 (CTLA4-IgG4m)   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2003   Phase 1   NCT00076934   United States;
RHB-104   
   RedHill Biopharma Limited
      2013   Phase 2   NCT01717664   Israel;
RHIgM22   
   Acorda Therapeutics
      2015   Phase 1   NCT02398461   United States;
      2013   Phase 1   NCT01803867   United States;
RHuPH20   
   Hoffmann-La Roche
      2019   Phase 1   NCT03972306   Canada;United States;
RIPK1 inhibitor   
   Sanofi
      2021   Phase 1   NCT04982991   United Kingdom;
RNF   
   Merck KGaA
      2008   Phase 3   NCT00813709   Argentina;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Germany;Greece;Israel;Italy;Latvia;Lebanon;Morocco;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Turkey;
      2006   Phase 3   NCT00404352   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Israel;Italy;Latvia;Lebanon;Morocco;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Slovakia;Spain;Switzerland;Turkey;
RNS60   
   University Hospital Zürich
      2014   Phase 2   EUCTR2014-000221-20-AT   Austria;Switzerland;
RNS60 125 ml   
   Revalesio Corporation
      2013   Phase 2   NCT01714089   United States;
RNS60 250 ml   
   Revalesio Corporation
      2013   Phase 2   NCT01714089   United States;
RO0506997   
   F. Hoffmann-La Roche Ltd
      2007   Phase 2   EUCTR2004-004519-43-SK   Czech Republic;Germany;Slovakia;Spain;United Kingdom;
      2007   -   EUCTR2004-004519-43-GB   Czech Republic;Germany;Spain;United Kingdom;
      2007   -   EUCTR2004-004519-43-DE   Czech Republic;Germany;Spain;United Kingdom;
      2005   -   EUCTR2004-004519-43-CZ   Czech Republic;Germany;Spain;United Kingdom;
RO4964913   
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 3   EUCTR2020-005448-48-IT   Brazil;Czechia;France;Italy;Spain;
      2018   Phase 3;Phase 4   EUCTR2017-004886-29-IT   Belgium;Bulgaria;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Hungary;Ireland;Italy;Netherlands;Norway;Poland;Portugal;Slovakia;Slovenia;Spain;Sweden;Turkey;United Kingdom;
   F. Hoffmann-La Roche Ltd
      2022   Phase 3   EUCTR2020-005448-48-CZ   Australia;Brazil;Canada;Czech Republic;Czechia;France;Italy;New Zealand;Poland;Russian Federation;Spain;Turkey;Ukraine;United States;
      2021   Phase 3   EUCTR2020-005448-48-PL   Australia;Brazil;Canada;Czechia;France;Italy;New Zealand;Poland;Russian Federation;Spain;Turkey;Ukraine;United States;
      2021   Phase 3   EUCTR2019-003919-53-PT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-003919-53-HU   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-003919-53-GR   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-003919-53-DK   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-003919-53-DE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-003919-53-BG   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-003919-53-AT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2017-004886-29-SI   Argentina;Belgium;Brazil;Czech Republic;Denmark;Estonia;Finland;France;Ireland;Mexico;Netherlands;Poland;Portugal;Slovenia;Spain;Sweden;Turkey;United Kingdom;
      2021   Phase 3   EUCTR2017-004886-29-PT   Argentina;Belgium;Brazil;Bulgaria;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Hungary;Ireland;Italy;Mexico;Netherlands;Norway;Poland;Portugal;Slovakia;Slovenia;Spain;Sweden;Turkey;United Kingdom;
      2021   Phase 3   EUCTR2017-004886-29-PL   Argentina;Belgium;Brazil;Bulgaria;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Ireland;Italy;Mexico;Netherlands;Norway;Poland;Portugal;Slovenia;Spain;Sweden;Turkey;United Kingdom;
      2021   Phase 3   EUCTR2017-004886-29-HU   Argentina;Belgium;Brazil;Bulgaria;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Hungary;Ireland;Italy;Mexico;Netherlands;Norway;Poland;Portugal;Slovakia;Slovenia;Spain;Sweden;Turkey;United Kingdom;
      2021   Phase 3   EUCTR2017-004886-29-HR   Argentina;Belgium;Brazil;Bulgaria;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Hungary;Ireland;Italy;Mexico;Netherlands;Norway;Poland;Portugal;Slovakia;Slovenia;Spain;Sweden;Turkey;United Kingdom;
      2021   Phase 3   EUCTR2017-004886-29-BG   Argentina;Belgium;Brazil;Bulgaria;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Hungary;Ireland;Italy;Mexico;Netherlands;Norway;Poland;Portugal;Slovakia;Slovenia;Spain;Sweden;Turkey;United Kingdom;
      2021   Phase 3   EUCTR2017-004886-29-BE   Argentina;Belgium;Brazil;Bulgaria;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Hungary;Ireland;Italy;Mexico;Netherlands;Norway;Poland;Portugal;Slovakia;Slovenia;Spain;Sweden;Turkey;United Kingdom;
      2020   Phase 3   EUCTR2019-003919-53-GB   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2017-001313-93-DE   Algeria;Bosnia and Herzegovina;Brazil;Canada;Colombia;Costa Rica;Czech Republic;Czechia;Denmark;Egypt;France;Germany;Guatemala;Hungary;Ireland;Italy;Lebanon;Mexico;Morocco;Netherlands;Panama;Poland;Russian Federation;Spain;United Arab Emirates;
      2019   Phase 3   EUCTR2017-004886-29-IE   Argentina;Belgium;Brazil;Bulgaria;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Ireland;Italy;Mexico;Netherlands;Norway;Poland;Portugal;Slovenia;Spain;Sweden;Turkey;United Kingdom;
      2018   Phase 3   EUCTR2017-004886-29-SE   Argentina;Belgium;Brazil;Bulgaria;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Hungary;Ireland;Italy;Mexico;Netherlands;Norway;Poland;Portugal;Slovakia;Slovenia;Spain;Sweden;Turkey;United Kingdom;
      2018   Phase 3   EUCTR2017-004886-29-NL   Argentina;Belgium;Brazil;Bulgaria;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Hungary;Ireland;Italy;Mexico;Netherlands;Norway;Poland;Portugal;Slovakia;Slovenia;Spain;Sweden;Turkey;United Kingdom;
      2018   Phase 3   EUCTR2017-004886-29-GB   Czech Republic;Denmark;Estonia;Finland;France;Ireland;Netherlands;Spain;Sweden;United Kingdom;
      2018   Phase 3   EUCTR2017-004886-29-FR   Czech Republic;Denmark;Estonia;Finland;France;Ireland;Italy;Netherlands;Norway;Spain;Sweden;Turkey;United Kingdom;
      2018   Phase 3   EUCTR2017-004886-29-FI   Czech Republic;Denmark;Estonia;Finland;France;Ireland;Italy;Netherlands;Norway;Spain;Sweden;Turkey;United Kingdom;
      2018   Phase 3   EUCTR2017-004886-29-EE   Czech Republic;Denmark;Estonia;Finland;France;Ireland;Italy;Netherlands;Norway;Spain;Sweden;Turkey;United Kingdom;
      2018   Phase 3   EUCTR2017-004886-29-DK   Argentina;Belgium;Brazil;Bulgaria;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Hungary;Ireland;Italy;Mexico;Netherlands;Norway;Poland;Portugal;Slovakia;Slovenia;Spain;Sweden;Turkey;United Kingdom;
      2018   Phase 3   EUCTR2017-004886-29-CZ   Argentina;Belgium;Brazil;Bulgaria;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Hungary;Ireland;Italy;Mexico;Netherlands;Norway;Poland;Portugal;Slovakia;Slovenia;Spain;Sweden;Turkey;United Kingdom;
      2018   Phase 3   EUCTR2017-001313-93-PL   Algeria;Bosnia and Herzegovina;Brazil;Canada;Colombia;Costa Rica;Czech Republic;Czechia;Denmark;Egypt;France;Germany;Guatemala;Hungary;Ireland;Italy;Lebanon;Mexico;Morocco;Netherlands;Panama;Poland;Russian Federation;Spain;United Arab Emirates;
      2018   Phase 3   EUCTR2017-001313-93-IE   Algeria;Bosnia and Herzegovina;Brazil;Canada;Colombia;Costa Rica;Czech Republic;Czechia;Denmark;Egypt;France;Germany;Guatemala;Hungary;Ireland;Italy;Lebanon;Mexico;Morocco;Netherlands;Panama;Poland;Russian Federation;Spain;United Arab Emirates;
      2018   Phase 3   EUCTR2017-001313-93-HU   Algeria;Bosnia and Herzegovina;Brazil;Canada;Colombia;Costa Rica;Czech Republic;Denmark;Egypt;France;Guatemala;Hungary;Ireland;Italy;Kuwait;Lebanon;Mexico;Morocco;Netherlands;Panama;Poland;Russian Federation;Saudi Arabia;Spain;United Arab Emirates;
      2018   Phase 3   EUCTR2017-001313-93-DK   Algeria;Bosnia and Herzegovina;Brazil;Canada;Colombia;Costa Rica;Czech Republic;Czechia;Denmark;Egypt;France;Germany;Guatemala;Hungary;Ireland;Italy;Lebanon;Mexico;Morocco;Netherlands;Panama;Poland;Russian Federation;Spain;United Arab Emirates;
      2018   Phase 3   EUCTR2017-001313-93-CZ   Algeria;Bosnia and Herzegovina;Brazil;Canada;Colombia;Costa Rica;Czech Republic;Czechia;Denmark;Egypt;France;Germany;Guatemala;Hungary;Ireland;Italy;Lebanon;Mexico;Morocco;Netherlands;Panama;Poland;Russian Federation;Spain;United Arab Emirates;
   F.Hoffmann-La Roche
      2011   Phase 3   EUCTR2010-020315-36-FR   Argentina;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;France;Germany;Ireland;Italy;Mexico;Peru;Russian Federation;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-020338-25-DK   Austria;Belgium;Bulgaria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Italy;Lithuania;Netherlands;Portugal;Spain;United Kingdom;
      2011   -   EUCTR2010-020337-99-ES   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-020315-36-ES   Argentina;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;Colombia;Croatia;Ireland;Italy;Mexico;Peru;Russian Federation;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020337-99-FI   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;United Kingdom;United States;
      2010   -   EUCTR2010-020338-25-ES   Austria;Belgium;Bulgaria;Czech Republic;Denmark;Finland;Greece;Hungary;Italy;Lithuania;Portugal;Spain;United Kingdom;
      2010   -   EUCTR2010-020337-99-HU   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
   F.Hoffmann-La Roche Ltd.
      2008   -   EUCTR2007-006338-32-IT   Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Mexico;Netherlands;Russian Federation;Spain;Switzerland;Ukraine;United Kingdom;United States;
   Hoffman La Roche Ltd
      2008   Phase 2   EUCTR2007-006338-32-ES   Belgium;Bulgaria;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Slovakia;Spain;United Kingdom;
      2008   -   EUCTR2007-006338-32-NL   Belgium;Bulgaria;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-006338-32-FI   Belgium;Bulgaria;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;United Kingdom;
   ROCHE
      2018   Phase 4   EUCTR2018-000780-91-FR   France;
      2011   -   EUCTR2010-020337-99-IT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;New Zealand;Peru;Poland;Portugal;Russian Federation;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-020315-36-IT   Argentina;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;Colombia;Croatia;Ireland;Italy;Mexico;Peru;Russian Federation;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
   Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-005448-48-ES   Brazil;Czechia;France;Italy;Spain;
   Roche Farma S.A(Soc. Unipersonal) que realiza el ensayo en España y actúa como representante de F. Hoffmann-La Roche LTD
      2018   Phase 3   EUCTR2017-001313-93-ES   Algeria;Bosnia and Herzegovina;Brazil;Canada;Colombia;Costa Rica;Czech Republic;Denmark;Egypt;France;Guatemala;Hungary;Ireland;Italy;Kuwait;Lebanon;Mexico;Morocco;Netherlands;Panama;Poland;Russian Federation;Saudi Arabia;Spain;United Arab Emirates;
   Roche Farma SA (Soc unipersonal) que realiza el ensayo en España y que actúa como representante F.Hoffmann-La Roche Ltd
      2018   Phase 3   EUCTR2017-004886-29-ES   Czech Republic;Denmark;Estonia;Finland;France;Ireland;Italy;Netherlands;Norway;Spain;Sweden;Turkey;United Kingdom;
RO4964913 F07   
   F.Hoffmann-La Roche
      2012   Phase 3   EUCTR2010-020337-99-NL   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
RO4964913/F03   
   Hoffman La Roche Ltd
      2008   Phase 2   EUCTR2007-006338-32-FR   Belgium;Bulgaria;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Slovakia;Spain;United Kingdom;
RO4964913/F07   
   F. HOFFMANN - LA ROCHE LTD.
      2016   Phase 3   EUCTR2015-005597-38-IT   Belgium;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;
   F. Hoffman-La Roche Ltd
      2008   Phase 2   EUCTR2007-006338-32-DE   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Mexico;Netherlands;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
   F. Hoffmann-La Roche Ltd
      2016   Phase 3   EUCTR2015-005597-38-SE   Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2016   Phase 3   EUCTR2015-005597-38-NL   Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2016   Phase 3   EUCTR2015-005597-38-IE   Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2016   Phase 3   EUCTR2015-005597-38-GB   Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2016   Phase 3   EUCTR2015-005597-38-FR   Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2016   Phase 3   EUCTR2015-005597-38-FI   Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2016   Phase 3   EUCTR2015-005597-38-EE   Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2016   Phase 3   EUCTR2015-005597-38-DK   Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2016   Phase 3   EUCTR2015-005597-38-DE   Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2016   Phase 3   EUCTR2015-005597-38-CZ   Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2016   Phase 3   EUCTR2015-005597-38-BE   Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;
   F.Hoffmann-La Roche
      2012   Phase 3   EUCTR2010-020315-36-CZ   Argentina;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;France;Germany;Ireland;Italy;Mexico;Peru;Russian Federation;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020337-99-SK   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020337-99-PT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020337-99-PL   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020337-99-LT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020337-99-GB   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020337-99-DE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020337-99-CZ   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020337-99-BG   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020337-99-BE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020337-99-AT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020315-36-SK   Argentina;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;France;Germany;Ireland;Italy;Mexico;Peru;Russian Federation;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020315-36-SE   Argentina;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;France;Germany;Ireland;Italy;Mexico;Peru;Russian Federation;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020315-36-IE   Argentina;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;France;Germany;Ireland;Italy;Mexico;Peru;Russian Federation;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020315-36-GB   Argentina;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;France;Germany;Ireland;Italy;Mexico;Peru;Russian Federation;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020315-36-DE   Argentina;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;France;Germany;Ireland;Italy;Mexico;Peru;Russian Federation;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020315-36-BG   Argentina;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;France;Germany;Ireland;Italy;Mexico;Peru;Russian Federation;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020315-36-BE   Argentina;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;France;Germany;Ireland;Italy;Mexico;Peru;Russian Federation;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020337-99-LV   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020337-99-EE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
   GENENTECH Inc.
      2016   Phase 3   EUCTR2015-004616-37-SE   Germany;Sweden;Switzerland;United States;
      2016   Phase 3   EUCTR2015-004616-37-DE   Germany;Sweden;Switzerland;United States;
   Hoffman La Roche Ltd
      2008   Phase 2   EUCTR2007-006338-32-SK   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Mexico;Netherlands;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2008   Phase 2   EUCTR2007-006338-32-GB   Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Mexico;Netherlands;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2008   Phase 2   EUCTR2007-006338-32-DK   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Mexico;Netherlands;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2008   Phase 2   EUCTR2007-006338-32-CZ   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Mexico;Netherlands;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2008   Phase 2   EUCTR2007-006338-32-BG   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Mexico;Netherlands;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2008   Phase 2   EUCTR2007-006338-32-BE   Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Mexico;Netherlands;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
   Roche Farma S.A. que representa en España a F. Hoffmann-La Roche Ltd
      2016   Phase 3   EUCTR2015-005597-38-ES   Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;
RO4964913/F07-01   
   F. HOFFMANN - LA ROCHE LTD.
      2020   Phase 3   EUCTR2020-000894-26-IT   Argentina;Belgium;Brazil;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000893-69-IT   Argentina;Australia;Belgium;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-001511-73-IT   Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Colombia;Croatia;Egypt;France;Georgia;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 2   EUCTR2016-002667-34-IT   Italy;Poland;United States;
      2017   Phase 3   EUCTR2016-002937-31-IT   Austria;Belgium;Brazil;Bulgaria;Croatia;Denmark;Finland;France;Germany;Hungary;Italy;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
   F. Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-000894-26-GR   Argentina;Belgium;Brazil;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000894-26-DK   Argentina;Belgium;Brazil;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000894-26-BG   Argentina;Belgium;Brazil;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000893-69-GR   Argentina;Australia;Belgium;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000893-69-DK   Argentina;Australia;Belgium;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000894-26-PT   Argentina;Belgium;Brazil;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000894-26-HU   Argentina;Belgium;Brazil;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000894-26-GB   Argentina;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000894-26-FR   Argentina;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000894-26-DE   Argentina;Belgium;Brazil;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000893-69-PT   Argentina;Australia;Belgium;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000893-69-PL   Argentina;Australia;Belgium;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000893-69-NL   Argentina;Australia;Belgium;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000893-69-HU   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000893-69-GB   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000893-69-DE   Argentina;Australia;Belgium;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000893-69-BE   Argentina;Australia;Belgium;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-001511-73-RO   Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Colombia;Croatia;Egypt;France;Georgia;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-001511-73-PT   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Colombia;Croatia;Egypt;France;Georgia;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-001511-73-IE   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Colombia;Croatia;Egypt;France;Georgia;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2018-001511-73-DE   Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Colombia;Croatia;Egypt;France;Georgia;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2020   Phase 2   EUCTR2016-002667-34-PL   Italy;Poland;United States;
      2019   Phase 3   EUCTR2018-001511-73-PL   Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Colombia;Croatia;Egypt;France;Georgia;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-001511-73-HU   Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Colombia;Croatia;Egypt;France;Georgia;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-001511-73-HR   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Colombia;Croatia;Egypt;France;Georgia;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-001511-73-GB   Bulgaria;Croatia;Germany;Hungary;Ireland;Poland;Portugal;Spain;United Kingdom;
      2019   Phase 3   EUCTR2018-001511-73-ES   Australia;Austria;Belarus;Belgium;Brazil;Bulgaria;Canada;Colombia;Croatia;Egypt;France;Georgia;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-001511-73-BG   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Colombia;Croatia;Egypt;France;Georgia;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002937-31-SK   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Hungary;Italy;Kuwait;Lebanon;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002937-31-SI   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Hungary;Italy;Kuwait;Lebanon;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002937-31-SE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Hungary;Italy;Kuwait;Lebanon;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002937-31-PT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;Finland;France;Germany;Hungary;Italy;Kuwait;Lebanon;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002937-31-PL   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Hungary;Italy;Kuwait;Lebanon;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002937-31-NO   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Hungary;Italy;Kuwait;Lebanon;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002937-31-NL   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Hungary;Italy;Kuwait;Lebanon;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002937-31-HU   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Hungary;Italy;Kuwait;Lebanon;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002937-31-HR   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Hungary;Italy;Kuwait;Lebanon;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002937-31-GB   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Hungary;Italy;Kuwait;Lebanon;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002937-31-FR   Austria;Belgium;Brazil;Bulgaria;Croatia;Denmark;Finland;France;Germany;Hungary;Italy;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002937-31-DK   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Hungary;Italy;Kuwait;Lebanon;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002937-31-DE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;Finland;France;Germany;Hungary;Italy;Kuwait;Lebanon;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002937-31-BG   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Hungary;Italy;Kuwait;Lebanon;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002937-31-BE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Hungary;Italy;Kuwait;Lebanon;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002937-31-AT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Hungary;Italy;Kuwait;Lebanon;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
   Roche Farma S.A. (Soc.unipersonal)que realiza el ensayo en España y que actúa como representante de F.Hoffmann-La Roche
      2017   Phase 3   EUCTR2016-002937-31-ES   Austria;Belgium;Brazil;Bulgaria;Croatia;Denmark;Finland;France;Germany;Hungary;Italy;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
RO5333787   
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 3   EUCTR2021-001088-26-IT   Canada;France;Germany;India;Italy;Korea, Republic of;Turkey;United States;
      2021   Phase 3   EUCTR2020-003413-35-IT   Bulgaria;Canada;Croatia;Georgia;Germany;Hungary;Italy;Japan;Korea, Republic of;Malaysia;Poland;Romania;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   F. Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-003413-35-HU   Bulgaria;Canada;Croatia;Georgia;Germany;Hungary;Italy;Japan;Korea, Republic of;Malaysia;Poland;Romania;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003413-35-HR   Bulgaria;Canada;Croatia;Georgia;Germany;Hungary;Italy;Japan;Korea, Republic of;Malaysia;Poland;Romania;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003413-35-DE   Bulgaria;Canada;Croatia;Georgia;Germany;Hungary;Italy;Japan;Korea, Republic of;Malaysia;Poland;Romania;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003413-35-BG   Bulgaria;Canada;Croatia;Georgia;Germany;Hungary;Italy;Japan;Korea, Republic of;Malaysia;Poland;Romania;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2020-003413-35-PL   Bulgaria;Canada;Croatia;Georgia;Germany;Hungary;Italy;Japan;Korea, Republic of;Malaysia;Poland;Romania;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
RO7010939   
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 3   EUCTR2020-001168-28-IT   Bulgaria;Denmark;Finland;France;Italy;Netherlands;United States;
      2021   Phase 3   EUCTR2019-004857-10-IT   Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;United States;
   F. Hoffman-La Roche
      2021   Phase 3   EUCTR2020-001168-28-DK   Austria;Belgium;Brazil;Bulgaria;Canada;Denmark;France;Greece;India;Italy;Korea, Republic of;Mexico;Poland;Portugal;Russian Federation;Turkey;United Kingdom;United States;
   F. Hoffmann-La Roche Ltd
      2022   Phase 2   EUCTR2021-003772-14-HR   Croatia;Czechia;Egypt;Japan;Kenya;Morocco;Norway;Serbia;Slovakia;Slovenia;
      2021   Phase 3   EUCTR2020-001168-28-BG   Bulgaria;Finland;France;Netherlands;United States;
      2021   Phase 3   EUCTR2019-004857-10-PT   Finland;France;Germany;Netherlands;Portugal;United States;
      2021   Phase 3   EUCTR2019-004857-10-NL   Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;United States;
      2021   Phase 3   EUCTR2019-004857-10-HU   Finland;France;Germany;Hungary;Netherlands;Portugal;United States;
      2021   Phase 3   EUCTR2019-004857-10-DE   Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;United States;
      2020   Phase 3   EUCTR2019-004857-10-FI   Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;United States;
RPC-1063   
   Celgene
      2020   Phase 3   NCT04140305   Canada;Puerto Rico;United States;
RPC1063   
   CELGENE INTERNATIONAL II SàRL
      2016   Phase 3   EUCTR2015-002500-91-IT   Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Croatia;Estonia;Georgia;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
   Celgene
      2016   Phase 1   NCT02797015   United States;
      2015   Phase 3   NCT02576717   Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Croatia;Estonia;Georgia;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Moldova, Republic of;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2012   Phase 2/Phase 3   NCT01628393   Belgium;Bulgaria;Georgia;Greece;Hungary;Italy;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
   Celgene International II Sàrl (CIS II)
      2017   Phase 3   EUCTR2015-002500-91-SE   Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Croatia;Estonia;Georgia;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Moldova, Republic of;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-002500-91-SK   Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Croatia;Estonia;Georgia;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Moldova, Republic of;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-002500-91-PT   Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Croatia;Estonia;Georgia;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Moldova, Republic of;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-002500-91-PL   Argentina;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Colombia;Croatia;Estonia;Georgia;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-002500-91-LV   Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Croatia;Estonia;Georgia;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Moldova, Republic of;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-002500-91-LT   Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Croatia;Estonia;Georgia;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Moldova, Republic of;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-002500-91-HR   Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Croatia;Estonia;Georgia;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Moldova, Republic of;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-002500-91-EE   Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Croatia;Estonia;Georgia;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Moldova, Republic of;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-002500-91-BG   Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Croatia;Estonia;Georgia;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Moldova, Republic of;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-002500-91-HU   Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Croatia;Estonia;Georgia;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Moldova, Republic of;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-002500-91-GR   Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Croatia;Estonia;Georgia;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Moldova, Republic of;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-002500-91-GB   Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Croatia;Estonia;Georgia;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-002500-91-BE   Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Croatia;Estonia;Georgia;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Moldova, Republic of;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002320-27-PL   Austria;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Estonia;Georgia;Germany;Hungary;Latvia;Lithuania;Moldova, Republic of;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002320-27-LV   Austria;Belarus;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Georgia;Germany;Hungary;Latvia;Lithuania;Moldova, Republic of;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002320-27-LT   Austria;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Estonia;Georgia;Germany;Hungary;Latvia;Lithuania;Moldova, Republic of;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002320-27-HU   Austria;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Estonia;Georgia;Germany;Hungary;Latvia;Lithuania;Moldova, Republic of;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002320-27-HR   Austria;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Estonia;Georgia;Germany;Hungary;Latvia;Lithuania;Moldova, Republic of;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002320-27-GB   Argentina;Austria;Belarus;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;Georgia;Germany;Hungary;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002320-27-BG   Austria;Belarus;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Georgia;Germany;Hungary;Latvia;Lithuania;Moldova, Republic of;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-002320-27-PT   Austria;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Estonia;Georgia;Germany;Hungary;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2014-002320-27-EE   Austria;Belarus;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Georgia;Germany;Hungary;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2014   Phase 2;Phase 3   EUCTR2012-002714-40-SK   Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Georgia;Greece;Hungary;Italy;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2014   Phase 2;Phase 3   EUCTR2012-002714-40-GB   Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Georgia;Greece;Hungary;Italy;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2013   Phase 2;Phase 3   EUCTR2012-002714-40-HU   Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Georgia;Greece;Hungary;Italy;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2013   Phase 2;Phase 3   EUCTR2012-002714-40-BG   Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Georgia;Greece;Hungary;Italy;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2013   Phase 2;Phase 3   EUCTR2012-002714-40-BE   Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Georgia;Greece;Hungary;Israel;Italy;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
   Receptos, Inc.
      2015   Phase 3   EUCTR2014-002320-27-SE   Argentina;Austria;Belarus;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;Georgia;Germany;Hungary;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002320-27-NL   Argentina;Austria;Belarus;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;Georgia;Germany;Hungary;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2015   Phase 3   EUCTR2014-002320-27-ES   Argentina;Austria;Belarus;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;Georgia;Germany;Hungary;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2015   -   EUCTR2015-002500-91-ES   Argentina;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Colombia;Croatia;Estonia;Georgia;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
      2014   Phase 2;Phase 3   EUCTR2012-002714-40-HR   Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Georgia;Greece;Hungary;Italy;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2013   Phase 2;Phase 3   EUCTR2012-002714-40-IT   Belgium;Bulgaria;Canada;Croatia;Georgia;Greece;Hungary;Israel;Italy;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2013   Phase 2;Phase 3   EUCTR2012-002714-40-GR   Belgium;Bulgaria;Canada;Croatia;Czech Republic;Georgia;Greece;Hungary;Israel;Italy;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2013   Phase 2;Phase 3   EUCTR2012-002714-40-ES   Belgium;Bulgaria;Canada;Croatia;Czech Republic;Georgia;Greece;Hungary;Israel;Italy;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States;
RTL1000 (recombinant T cell receptor ligand)   
   Artielle ImmunoTherapeutics
      2006   Phase 1   NCT00411723   United States;
RYAH-Medtech Inhaler   
   OMNI Medical Services, LLC
      2018   Phase 2   NCT03944447   United States;
Rabbit anti-human thymocyte immunoglobulin   
   Sheffield Teaching Hospitals
      2020   Phase 3   EUCTR2019-001549-42-GB   United Kingdom;
Radiation therapy   
   Baylor College of Medicine
      1999   Phase 2   NCT00040482   United States;
Ralenova   
   University Medical Center Hamburg Eppendorf
      2007   -   EUCTR2007-001962-34-DE   Germany;
Raltegravir   
   Queen Mary University of London
      2013   Phase 2   NCT01767701   United Kingdom;
      2013   -   EUCTR2012-004847-61-GB   United Kingdom;
Ramatroban   
   Iou hospital
      2008   -   JPRN-UMIN000002725   Japan;
Ranitidine   
   Genzyme, a Sanofi Company
      2017   Phase 3   NCT03368664   Austria;Belgium;Bulgaria;Czechia;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;
      2014   Phase 4   NCT02205489   Belgium;France;Netherlands;Spain;
Raptiva 100 mg/ml powder and solvent for solution for injection   
   Merck Serono International S.A.
      2009   -   EUCTR2007-001377-28-PT   Austria;France;Germany;Netherlands;Portugal;
      2008   -   EUCTR2007-001377-28-NL   Austria;France;Germany;Netherlands;Portugal;
      2008   -   EUCTR2007-001377-28-FR   Austria;France;Germany;Netherlands;Portugal;
      2008   -   EUCTR2007-001377-28-DE   Austria;France;Germany;Netherlands;Portugal;
      2008   -   EUCTR2007-001377-28-AT   Austria;France;Germany;Netherlands;Portugal;
Ravulizumab   
   ALEXION PHARMACEUTICALS INCORPORATED
      2020   Phase 3   EUCTR2019-003352-37-IT   Australia;Austria;Canada;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
   Alexion Pharmaceuticals
      2019   Phase 3   NCT04201262   Australia;Austria;Canada;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
Rebif   
   Bayer
      2006   Phase 4   NCT00317941   France;
   Biogen Idec
      2014   Phase 1   NCT02269930   United States;
   Dansk Multipel Sclerose Center
      2010   -   EUCTR2009-016824-29-DK   Denmark;
   EMD Serono
      2010   Phase 4   NCT01085318   United States;
      2004   Phase 4   NCT00101959   United States;
   F.Hoffmann-La Roche
      2012   Phase 3   EUCTR2010-020337-99-NL   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2012   Phase 3   EUCTR2010-020315-36-CZ   Argentina;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;France;Germany;Ireland;Italy;Mexico;Peru;Russian Federation;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020337-99-SK   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020337-99-PT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020337-99-PL   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020337-99-LT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020337-99-GB   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020337-99-DE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020337-99-CZ   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020337-99-BG   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020337-99-BE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020337-99-AT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020315-36-SK   Argentina;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;France;Germany;Ireland;Italy;Mexico;Peru;Russian Federation;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020315-36-SE   Argentina;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;France;Germany;Ireland;Italy;Mexico;Peru;Russian Federation;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020315-36-IE   Argentina;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;France;Germany;Ireland;Italy;Mexico;Peru;Russian Federation;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020315-36-GB   Argentina;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;France;Germany;Ireland;Italy;Mexico;Peru;Russian Federation;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020315-36-FR   Argentina;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;France;Germany;Ireland;Italy;Mexico;Peru;Russian Federation;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020315-36-DE   Argentina;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;France;Germany;Ireland;Italy;Mexico;Peru;Russian Federation;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020315-36-BG   Argentina;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;France;Germany;Ireland;Italy;Mexico;Peru;Russian Federation;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020315-36-BE   Argentina;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;France;Germany;Ireland;Italy;Mexico;Peru;Russian Federation;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-020337-99-ES   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-020315-36-ES   Argentina;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;Colombia;Croatia;Ireland;Italy;Mexico;Peru;Russian Federation;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020337-99-LV   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020337-99-FI   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020337-99-EE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;Netherlands;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2010-020337-99-HU   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;New Zealand;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
   Genzyme Corporation
      2008   Phase 3   EUCTR2007-001162-32-FR   Austria;Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2008   Phase 3   EUCTR2007-001162-32-ES   Austria;Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2008   Phase 3   EUCTR2007-001162-32-CZ   Austria;Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2008   Phase 3   EUCTR2007-001162-32-BE   Austria;Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2008   Phase 3   EUCTR2007-001161-14-FR   Czech Republic;France;Germany;Poland;Sweden;United Kingdom;
      2008   -   EUCTR2007-001162-32-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;France;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2008   -   EUCTR2007-001162-32-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;France;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2008   -   EUCTR2007-001162-32-NL   Austria;Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-001162-32-DK   Argentina;Australia;Austria;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;France;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2008   -   EUCTR2007-001162-32-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;France;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2008   -   EUCTR2007-001162-32-AT   Austria;Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-001161-14-SE   Argentina;Australia;Brazil;Croatia;Czech Republic;France;Germany;Mexico;Poland;Russian Federation;Serbia;Sweden;Ukraine;United Kingdom;
      2008   -   EUCTR2007-001161-14-DE   Argentina;Australia;Brazil;Croatia;Czech Republic;France;Germany;Mexico;Poland;Russian Federation;Serbia;Sweden;Ukraine;United Kingdom;
      2007   Phase 3   EUCTR2007-001162-32-GB   Austria;Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-001161-14-GB   Czech Republic;France;Germany;Poland;Sweden;United Kingdom;
   IMS HEALTH GmbH & Co. OHG
      2016   -   NCT02823951   Canada;United States;
   Karolinska Institutet
      2017   Phase 4   EUCTR2017-002634-24-SE   Sweden;
      2017   Phase 4   EUCTR2016-003587-39-SE   Sweden;
   Medizinische Universität Innsbruck
      2014   Phase 4   EUCTR2012-005450-30-AT   Austria;Sweden;
      2014   -   EUCTR2012-005450-30-SE   Austria;Sweden;
   Merck KGaA
      2012   -   NCT01601119   United Kingdom;
      2009   Phase 2   NCT01198132   France;
   Merck KGaA, Darmstadt, Germany
      2017   -   NCT02949908   Germany;
      2014   Phase 4   NCT02254304   Germany;
   Merck Serono International SA
      2007   Phase 3   EUCTR2006-003037-32-ES   Estonia;Germany;Italy;Lithuania;Spain;
      2007   -   EUCTR2006-003037-32-LT   Estonia;Germany;Italy;Lithuania;Spain;
      2007   -   EUCTR2006-003037-32-EE   Estonia;Germany;Italy;Lithuania;Spain;
   Merck Serono International, a branch of Laboratoires Serono SA An affiliate of Merck KGaA
      2007   Phase 3   EUCTR2006-002982-38-SK   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Italy;Lithuania;Portugal;Slovakia;Spain;
      2007   -   EUCTR2006-002982-38-EE   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Italy;Lithuania;Portugal;Spain;
   Merck Serono International, a branch of Laboratoires Serono SA an affiliate of Merck KGaA, Darmstadt
      2009   -   EUCTR2008-004954-34-GR   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Greece;Italy;Latvia;Poland;Portugal;Spain;
   Merck Serono S.A. - Geneva
      2010   -   EUCTR2009-016087-37-GB   France;Ireland;Italy;Spain;United Kingdom;
      2009   -   EUCTR2009-016087-37-ES   France;Ireland;Italy;Spain;United Kingdom;
   Merck Serono S.A. - Geneva, an affiliate of Merck KGaA Darmstadt, Germany
      2007   -   EUCTR2006-002982-38-PT   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Italy;Lithuania;Portugal;Spain;
      2007   -   EUCTR2006-002982-38-DE   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Italy;Lithuania;Portugal;Spain;
      2006   -   EUCTR2006-002982-38-FI   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Italy;Lithuania;Portugal;Spain;
      2006   -   EUCTR2006-002982-38-CZ   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Italy;Lithuania;Portugal;Spain;
   Merck Serono S.A. - Geneva, an affiliate of Merck KGaA, Darmstadt, Germany
      2010   -   EUCTR2008-004954-34-AT   Argentina;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Germany;Greece;Israel;Italy;Latvia;Lebanon;Morocco;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Turkey;
      2009   Phase 3   EUCTR2008-004954-34-SK   Argentina;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Germany;Greece;Israel;Italy;Latvia;Lebanon;Morocco;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Turkey;
      2009   Phase 3   EUCTR2008-004954-34-PT   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Greece;Italy;Latvia;Poland;Portugal;Spain;
      2009   Phase 3   EUCTR2008-004954-34-BE   Argentina;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Germany;Greece;Israel;Italy;Latvia;Lebanon;Morocco;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Turkey;
      2009   -   EUCTR2008-004954-34-PL   Argentina;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Germany;Greece;Israel;Italy;Latvia;Lebanon;Morocco;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Turkey;
      2009   -   EUCTR2008-004954-34-LV   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Greece;Italy;Latvia;Poland;Portugal;Spain;
      2009   -   EUCTR2008-004954-34-FI   Argentina;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Germany;Greece;Israel;Italy;Latvia;Lebanon;Morocco;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Turkey;
      2009   -   EUCTR2008-004954-34-EE   Argentina;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Germany;Greece;Israel;Italy;Latvia;Lebanon;Morocco;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Turkey;
      2009   -   EUCTR2008-004954-34-DE   Argentina;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Germany;Greece;Israel;Italy;Latvia;Lebanon;Morocco;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Turkey;
      2009   -   EUCTR2008-004954-34-BG   Argentina;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Germany;Greece;Israel;Italy;Latvia;Lebanon;Morocco;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Turkey;
      2008   -   EUCTR2008-004954-34-CZ   Argentina;Austria;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Germany;Greece;Israel;Italy;Latvia;Lebanon;Morocco;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Turkey;
   Merck Serono S.A.- Geneva, an affiliate of Merck KGaA, Darmstadt, Germany
      2009   Phase 3   EUCTR2008-004954-34-FR   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Greece;Italy;Latvia;Poland;Portugal;Slovakia;Spain;
   Merck Serono S.A.-Geneva, an affiliate of Merck KGaA Darmstadt, Germany
      2006   Phase 3   EUCTR2006-002982-38-BE   Austria;Belgium;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Italy;Lithuania;Portugal;Slovakia;Spain;
   Merck Serono SA
      2007   -   EUCTR2006-003037-32-DE   Estonia;Germany;Italy;Lithuania;Spain;
   Merck Serono SA – Geneva
      2010   -   EUCTR2009-015502-19-GB   Belgium;Finland;Germany;Sweden;United Kingdom;
      2010   -   EUCTR2009-015502-19-DE   Belgium;Finland;Germany;Sweden;United Kingdom;
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-004505-32-IT   France;Germany;Italy;Spain;
   ROCHE
      2011   -   EUCTR2010-020337-99-IT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Czech Republic;Estonia;Finland;Germany;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Morocco;New Zealand;Peru;Poland;Portugal;Russian Federation;South Africa;Spain;Switzerland;Tunisia;Ukraine;United Kingdom;United States;
      2011   -   EUCTR2010-020315-36-IT   Argentina;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;Colombia;Croatia;Ireland;Italy;Mexico;Peru;Russian Federation;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
   Serono International SA
      2005   Phase 3   EUCTR2004-003799-13-ES   Denmark;Ireland;Lithuania;Spain;Sweden;United Kingdom;
      2004   -   EUCTR2004-000337-12-HU   Hungary;
   Teva Pharmaceutical Industries
      2004   Phase 4   NCT00202995   Canada;United States;
   The Multiple Sclerosis Research Group, Department of Clinical Neuroscience
      2009   -   EUCTR2008-008554-23-SE   Sweden;
   University of North Carolina, Chapel Hill
      2004   -   NCT00137176   United States;
   Universitätsklinikum Heidelberg
      2006   Phase 3   EUCTR2004-004403-37-DE   Germany;
   VU University Medical Center
      2011   -   EUCTR2011-003570-89-NL   Netherlands;
   sanofi-aventis Recherche & Dévelopment
      2009   -   EUCTR2008-006226-34-FR   Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
   sanofi-aventis recherche et development
      2009   Phase 3   EUCTR2008-006226-34-GR   Belgium;Czech Republic;France;Germany;Greece;Hungary;Italy;Spain;United Kingdom;
      2009   -   EUCTR2008-006226-34-BE   Belgium;Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
   sanofi-aventis recherche et developpement
      2010   -   EUCTR2008-006226-34-GB   Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Spain;Tunisia;United Kingdom;
      2009   -   EUCTR2008-006226-34-HU   Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Spain;Tunisia;United Kingdom;
      2009   -   EUCTR2008-006226-34-DE   Belgium;Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
      2009   -   EUCTR2008-006226-34-CZ   Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Spain;Tunisia;United Kingdom;
Rebif (IFN beta-1a subcutaneous three times per week)   
   Brigham and Women's Hospital
      2015   -   NCT02419638   United States;
Rebif (IFN ß-1a subcutaneous three times per week)   
   Brigham and Women's Hospital
      2015   -   NCT02419638   United States;
Rebif (Interferon beta-1a)   
   Merck KGaA
      2009   -   NCT01075880   Czech Republic;
   Merck KGaA, Darmstadt, Germany
      2016   -   NCT02921035   Algeria;Argentina;Bahrain;Bulgaria;Egypt;Germany;Hungary;Iran, Islamic Republic of;Korea, Republic of;Kuwait;Lebanon;Morocco;Poland;Saudi Arabia;Tunisia;United Arab Emirates;
Rebif (interferon beta 1a)   
   Biocad
      2014   Phase 2/Phase 3   NCT02727907   Russian Federation;
Rebif (interferon beta-1a), Merck Serono Europe Ltd   
   Bayer
      2016   -   NCT02749396   Finland;
Rebif 22   
   UCL Biomedicine R&D Unit
      2006   -   EUCTR2005-005751-18-GB   United Kingdom;
Rebif 22 micrograms   
   Biogen Portugal
      2016   Phase 4   EUCTR2016-000434-21-PT   Portugal;
Rebif 22 y 44 mcg   
   Merck, S.L.
      2006   -   EUCTR2006-000606-23-ES   Spain;
Rebif 22®   
   University Hospital Motol
      2011   Phase 4   EUCTR2011-001956-12-CZ   Czech Republic;
Rebif 44   
   The Walton Centre for Neurology and Neurosurgery
      2005   Phase 4   EUCTR2004-004903-39-GB   United Kingdom;
   UCL Biomedicine R&D Unit
      2006   -   EUCTR2005-005751-18-GB   United Kingdom;
Rebif 44 micrograms   
   Biogen Idec GmbH
      2005   -   EUCTR2004-004130-14-AT   Austria;
   Biogen Portugal
      2016   Phase 4   EUCTR2016-000434-21-PT   Portugal;
   Octapharma AG
      2015   Phase 3   EUCTR2012-005086-12-PL   Austria;Bulgaria;Germany;Hungary;Poland;Russian Federation;Serbia;Ukraine;
      2013   -   EUCTR2012-005086-12-HU   Austria;Bulgaria;Germany;Hungary;Poland;Russian Federation;
      2013   -   EUCTR2012-005086-12-DE   Austria;Bulgaria;Germany;Hungary;Poland;Russian Federation;
      2013   -   EUCTR2012-005086-12-BG   Austria;Bulgaria;Germany;Hungary;Poland;Russian Federation;
      2013   -   EUCTR2012-005086-12-AT   Austria;Bulgaria;Germany;Hungary;Poland;Russian Federation;
Rebif 44 micrograms solution for injection   
   Merck Serono International
      2010   -   EUCTR2008-003706-33-GR   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Greece;Italy;Norway;Portugal;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2008-003706-33-FR   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Greece;Italy;Norway;Portugal;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-003706-33-ES   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Greece;Italy;Norway;Portugal;Spain;Sweden;United Kingdom;
   Merck Serono S.A. - Geneva
      2009   Phase 3   EUCTR2008-003706-33-GB   Argentina;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Lebanon;Macedonia, the former Yugoslav Republic of;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2009   Phase 3   EUCTR2008-003706-33-BE   Argentina;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Lebanon;Macedonia, the former Yugoslav Republic of;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2009   -   EUCTR2008-003706-33-SE   Argentina;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Lebanon;Macedonia, the former Yugoslav Republic of;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2009   -   EUCTR2008-003706-33-NO   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Greece;Italy;Norway;Portugal;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-003706-33-DE   Argentina;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Lebanon;Macedonia, the former Yugoslav Republic of;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2009   -   EUCTR2008-003706-33-CZ   Argentina;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Lebanon;Macedonia, the former Yugoslav Republic of;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2009   -   EUCTR2008-003706-33-BG   Argentina;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Lebanon;Macedonia, the former Yugoslav Republic of;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2009   -   EUCTR2008-003706-33-AT   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Greece;Italy;Norway;Portugal;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2008-003706-33-FI   Argentina;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Lebanon;Macedonia, the former Yugoslav Republic of;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2008   -   EUCTR2008-003706-33-EE   Argentina;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;Finland;France;Georgia;Germany;Greece;India;Italy;Korea, Republic of;Lebanon;Macedonia, the former Yugoslav Republic of;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
   Merck Serono SA - Geneva
      2009   -   EUCTR2008-003706-33-PT   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Greece;Italy;Norway;Portugal;Spain;Sweden;United Kingdom;
Rebif 44 micrograms solution for injection in pre-filled syringe   
   Biogen Idec Limited
      2010   -   EUCTR2009-015556-15-NL   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
Rebif 44 µg   
   Serono GmbH
      2005   -   EUCTR2005-001026-89-DE   Germany;
Rebif 44®   
   University Hospital Motol
      2011   Phase 4   EUCTR2011-001956-12-CZ   Czech Republic;
Rebif 8,8 µg, Rebif 22µg   
   Serono GmbH
      2005   -   EUCTR2005-001026-89-DE   Germany;
Rebif 8.8 micrograms and 22 micrograms solution for injection in pre-filled syringe initiation pack   
   Biogen Idec Limited
      2010   -   EUCTR2009-015556-15-SI   Austria;Canada;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;United States;
      2010   -   EUCTR2009-015556-15-PT   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015556-15-NL   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015556-15-LV   Austria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Italy;Latvia;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;United States;
      2010   -   EUCTR2009-015556-15-HU   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015556-15-GR   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015556-15-GB   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015556-15-FI   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015556-15-ES   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015556-15-DK   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015556-15-DE   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015556-15-CZ   Austria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Italy;Latvia;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;United States;
      2010   -   EUCTR2009-015556-15-AT   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
Rebif 8.8 micrograms and 22 micrograms solution for injection in pre-filled syringe initiation pack.   
   Biogen Idec Limited
      2010   -   EUCTR2009-015556-15-SE   Austria;Canada;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;United States;
Rebif New Formulation + ibuprofen PRN   
   Merck KGaA
      2007   Phase 3   NCT00619307   France;Germany;
Rebif New Formulation + prophylactic Ibuprofen   
   Merck KGaA
      2007   Phase 3   NCT00619307   France;Germany;
Rebif New Formulation 44mcg multidose cartridge   
   Merck Serono International S.A.
      2008   -   EUCTR2008-000499-25-SE   Germany;Italy;Spain;Sweden;
      2008   -   EUCTR2008-000499-25-ES   Germany;Italy;Spain;Sweden;
      -   -   EUCTR2008-000499-25-DE   Germany;Italy;Spain;Sweden;
Rebif New Formulation Non Titrated   
   EMD Serono
      2007   Phase 3   NCT00472797   United States;
Rebif New Formulation Titrated   
   EMD Serono
      2007   Phase 3   NCT00472797   United States;
Rebif®   
   EMD Serono
      2014   Phase 4   NCT02117050   United States;
      2010   -   NCT01207648   Argentina;Canada;France;Italy;Russian Federation;Tunisia;United States;Venezuela;
      1999   Phase 3   NCT00292266   -
   Genzyme Corporation
      2008   -   EUCTR2007-001161-14-PL   Argentina;Australia;Brazil;Croatia;Czech Republic;France;Germany;Mexico;Poland;Russian Federation;Serbia;Sweden;Ukraine;United Kingdom;
      2008   -   EUCTR2007-001161-14-CZ   Argentina;Australia;Brazil;Croatia;Czech Republic;France;Germany;Mexico;Poland;Russian Federation;Serbia;Sweden;Ukraine;United Kingdom;
   Merck KGaA
      2013   Phase 4   NCT01791244   Germany;Sweden;
   Merck KGaA, Darmstadt, Germany
      2014   Phase 4   NCT02064816   Germany;
   PD Dr. Marcus Müller
      2015   Phase 1   NCT02364986   Germany;
   Queen Mary, University of London
      2009   -   EUCTR2008-000256-26-GB   United Kingdom;
   Sahlgrenska University Hospital
      2005   -   EUCTR2005-001008-37-SE   Sweden;
Rebif® (clone 484-39)   
   Merck KGaA
      2004   Phase 4   NCT00367484   -
Rebif® New Formulation   
   Merck KGaA
      2008   -   NCT01080027   Greece;
Rebif® New Formulation (IFN-beta-1a, RNF)   
   Merck KGaA
      2006   Phase 3   NCT00441103   Canada;Germany;Italy;Russian Federation;Spain;Switzerland;
Rebif® New Formulation (RNF) using RebiSmartTM   
   EMD Serono
      2008   Phase 3   NCT00735007   Canada;Germany;Italy;Spain;Sweden;United States;
Rebif® new formulation (RNF)   
   EMD Serono
      2008   Phase 3   NCT00725985   Argentina;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czechia;Estonia;Finland;France;Georgia;Germany;India;Italy;Korea, Republic of;Lebanon;Macedonia, The Former Yugoslav Republic of;Norway;Poland;Portugal;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
Recombinant Human Erythropoietin   
   Walton Centre for Neurology and Neurosurgery
      2008   -   EUCTR2008-005125-11-GB   United Kingdom;
Recombinant human IFN beta   
   Merck Serono International SA
      2007   -   EUCTR2006-005972-42-DE   France;Germany;
Recombinant human alpha B-crystallin   
   Delta Crystallon B.V.
      2012   -   EUCTR2011-004475-36-BG   Bulgaria;
   Delta Crystallon BV
      2012   Phase 2   NCT02442570   Bulgaria;
      2009   Phase 1   NCT02442557   Netherlands;
Recombinant human interferon beta   
   Serono International SA
      2004   -   EUCTR2004-000337-12-HU   Hungary;
Recombinant humanized anti-alpha 4 integrin antibody   
   BIOGEN IDEC LTD
      2007   -   EUCTR2005-004061-41-SE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2007   -   EUCTR2005-004061-41-AT   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Ireland;Italy;Spain;Sweden;United Kingdom;
      2006   Phase 3   EUCTR2005-004061-41-GB   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;New Zealand;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2006   Phase 3   EUCTR2005-004061-41-BE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2006   -   EUCTR2005-004061-41-IE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2006   -   EUCTR2005-004061-41-HU   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2006   -   EUCTR2005-004061-41-GR   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Ireland;Italy;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-004061-41-FI   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2006   -   EUCTR2005-004061-41-DK   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2006   -   EUCTR2005-004061-41-DE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2006   -   EUCTR2005-004061-41-CZ   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;
Recombinant interferon beta-1b   
   Bayer HealthCare AG
      2013   Phase 4   EUCTR2012-005262-35-GB   Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Portugal;Slovenia;Spain;Sweden;Switzerland;United Kingdom;
      2013   Phase 4   EUCTR2012-005262-35-ES   Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Portugal;Slovenia;Spain;Sweden;Switzerland;United Kingdom;
      2013   Phase 4   EUCTR2012-005262-35-CZ   Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Portugal;Slovenia;Spain;Sweden;Switzerland;United Kingdom;
      2013   -   EUCTR2012-005262-35-SI   Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Portugal;Slovenia;Spain;Sweden;Switzerland;United Kingdom;
      2013   -   EUCTR2012-005262-35-IT   Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Portugal;Slovenia;Spain;Sweden;Switzerland;United Kingdom;
      2013   -   EUCTR2012-005262-35-FI   Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Portugal;Slovenia;Spain;Sweden;Switzerland;United Kingdom;
      2013   -   EUCTR2012-005262-35-AT   Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Portugal;Slovenia;Spain;Sweden;Switzerland;United Kingdom;
Remibrutinib   
   Novartis Farmacéutica S.A.
      2022   Phase 3   EUCTR2020-005929-89-ES   Argentina;Brazil;Bulgaria;Canada;China;Croatia;Czechia;Estonia;France;Germany;Greece;Hungary;India;Italy;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;United Kingdom;United States;
      2022   Phase 3   EUCTR2020-005899-36-ES   Slovakia;Spain;
   Novartis Pharma AG
      2022   Phase 3   EUCTR2020-005929-89-SE   Argentina;Brazil;Bulgaria;Canada;China;Croatia;Czechia;Estonia;France;Germany;Greece;Hungary;India;Italy;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;United Kingdom;United States;
      2022   Phase 3   EUCTR2020-005899-36-SK   Argentina;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czechia;France;Germany;Guatemala;Hong Kong;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Netherlands;Poland;Russian Federation;Serbia;Slovakia;Spain;Switzerland;United Kingdom;United States;
   Novartis Pharmaceuticals
      2021   Phase 3   NCT05156281   United States;
      2021   Phase 3   NCT05147220   United States;
Repetitive transcranial magnetic stimulation (rTMS)   
   Shirley Ryan AbilityLab
      2017   -   NCT03723434   United States;
Repository Corticotropin Injection   
   Mallinckrodt
      2017   Phase 4   NCT03126760   United States;
Repository corticotropin injection   
   University at Buffalo
      2009   Phase 2   NCT00986960   United States;
Researchmanager program   
   Isala
      2021   -   NCT05242731   Netherlands;
Revaxis   
   University of Nottingham
      2010   Phase 2   EUCTR2007-001496-11-GB   United Kingdom;
RhEPO   
   Walton Centre for Neurology and Neurosurgery
      2008   -   EUCTR2008-005125-11-GB   United Kingdom;
RhIFN beta-1b   
   Nuron Biotech Inc.
      2011   Phase 3   NCT01464905   Belarus;Bulgaria;Croatia;Georgia;Hungary;India;Italy;Lebanon;Poland;Russian Federation;Serbia;Spain;Ukraine;
RhIGF-1 (CEP-151)   
   National Institute of Neurological Disorders and Stroke (NINDS)
      1997   Phase 2   NCT00001669   United States;
RhuMab 2H7   
   Hoffman La Roche Ltd
      2008   Phase 2   EUCTR2007-006338-32-FR   Belgium;Bulgaria;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Slovakia;Spain;United Kingdom;
      2008   Phase 2   EUCTR2007-006338-32-ES   Belgium;Bulgaria;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Slovakia;Spain;United Kingdom;
      2008   -   EUCTR2007-006338-32-NL   Belgium;Bulgaria;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;United Kingdom;
      2008   -   EUCTR2007-006338-32-FI   Belgium;Bulgaria;Czech Republic;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;United Kingdom;
RhumAb to IL-17A igG1-k-class   
   Novartis Pharma Services AG
      2012   -   EUCTR2011-001629-25-CZ   Czech Republic;Russian Federation;Ukraine;
RhumAb to Il-17A (IgG1-k-class)   
   Novartis Pharma Services AG
      2009   Phase 2   EUCTR2009-011626-34-SE   Czech Republic;Sweden;
      2009   -   EUCTR2009-011626-34-CZ   Czech Republic;Russian Federation;Serbia;Sweden;Ukraine;
Riboflavin   
   University of Iowa
      2010   Phase 1   NCT01381354   United States;
Rifampin   
   National Center for Research Resources (NCRR)
      2001   Phase 2   NCT00043264   United States;
Rilutek   
   UCL
      2014   Phase 2   EUCTR2012-005394-31-GB   United Kingdom;
Riluzole   
   S. Andrea Hospital
      2005   Phase 2   NCT00202397   Italy;
   UCL
      2014   Phase 2   EUCTR2012-005394-31-GB   United Kingdom;
   University College, London
      2014   Phase 2   NCT01910259   United Kingdom;
   University of California, San Francisco
      2006   Phase 2   NCT00501943   United States;
RimabotulinumtoxinB   
   Supernus Pharmaceuticals, Inc.
      2021   Phase 2/Phase 3   NCT04815967   -
Ritalin   
   Sheba Medical Center
      2003   Phase 1   NCT00220493   Israel;
Ritalin LA 20mg capsules   
   Medizinische Universität Wien
      2012   -   EUCTR2012-003418-15-AT   Austria;
Ritalin LA 30mg capsules   
   Medizinische Universität Wien
      2012   -   EUCTR2012-003418-15-AT   Austria;
Ritalin LA 40mg capsules   
   Medizinische Universität Wien
      2012   -   EUCTR2012-003418-15-AT   Austria;
Rituximab   
   AZIENDA OSPEDALIERA DI PADOVA
      -   Phase 1   EUCTR2008-005773-35-IT   Italy;
   Anders Svenningsson
      2016   Phase 3   NCT02746744   Sweden;
      2009   Phase 2   NCT01719159   Sweden;
   Centre Hospitalier de Pau
      2015   Phase 2   EUCTR2014-005493-11-FR   France;
   Claudio Gobbi
      2020   -   NCT04640818   Switzerland;
   Clinical Research Center, NHO Utano National Hospital
      2014   Phase 2,3   JPRN-UMIN000013453   Japan;
   Clinical Research Center, Utano National Hospital, National Hospital Organization
      2015   Phase 2,3   JPRN-UMIN000017217   Japan;
   Department of Pediatrics, Kobe Universtiy Graduate School of Medicine
      2012   -   JPRN-UMIN000009421   Japan;
   Genentech, Inc.
      2004   Phase 2/Phase 3   NCT00087529   Canada;United States;
      2004   Phase 2   NCT00097188   United States;
   Haukeland University Hospital
      2020   Phase 3   NCT04578639   Norway;
   Helse Bergen HF, Haukeland University Hospital
      2022   Phase 3   EUCTR2020-001205-23-SE   Sweden;
   Isfahan University of Medical Sciences
      2017   Phase 2/Phase 3   NCT03315923   Iran, Islamic Republic of;
      2015   Phase 2/Phase 3   NCT03002038   Iran, Islamic Republic of;
   Johns Hopkins University
      2014   Phase 1   NCT02253264   United States;
   Karolinska Institutet
      2018   Phase 3   NCT03979456   Sweden;
      2017   -   NCT03193866   Sweden;
   National Institute of Neurological Disorders and Stroke (NINDS)
      2010   Phase 1/Phase 2   NCT01212094   United States;
   Northwestern University
      2019   Phase 2/Phase 3   NCT03829566   United States;
   Oslo University Hospital
      2019   Phase 3   NCT04121403   Norway;
   Rigshospitalet, Denmark
      2021   Phase 3   NCT04688788   Denmark;
   Shandong University Qilu Hospital
      2021   Phase 4   ChiCTR2100043013   China;
   Tang-Du Hospital
      2014   Phase 4   NCT04256252   -
   The Ophthalmology Department of the Chinese Peoples Liberation Army Hospital
      2019   Phase 4   ChiCTR1900025744   China;
      2014   -   ChiCTR-ICR-15007177   China;
   University of California, San Francisco
      2004   Phase 1   NCT00501748   United States;
   University of Colorado, Denver
      2017   Phase 3   NCT02980042   United States;
      2012   Phase 2   NCT01569451   United States;
Rituximab IT   
   Centre Hospitalier de PAU
      2015   Phase 2   NCT02545959   France;
Rituximab IV   
   Centre Hospitalier de PAU
      2015   Phase 2   NCT02545959   France;
Rituximab Infusion   
   Wake Forest University Health Sciences
      2013   Phase 4   NCT02040116   United States;
Rituximab konsentrat til infusjonsvaeske oppløsning 10 mg/ml   
   Department of Neurology, Division of Clinical Neuroscience, Oslo University Hospital
      2019   Phase 3   EUCTR2019-001505-24-NO   Norway;
Rivastigmin   
   Novartis Pharma GmbH
      -   -   EUCTR2008-007015-32-DE   Germany;
Rivastigmine transdermal patch   
   Novartis Pharmaceuticals
      2009   Phase 4   NCT00881205   Germany;
Ro 496-4913/F03   
   F.Hoffmann-La Roche
      2011   Phase 3   EUCTR2010-020338-25-BG   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2010   -   EUCTR2010-020338-25-HU   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
Ro 496-4913/F07   
   F.Hoffmann-La Roche
      2013   Phase 3   EUCTR2010-020338-25-NL   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020338-25-PT   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020338-25-PL   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020338-25-GR   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020338-25-DE   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020338-25-CZ   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020338-25-BE   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-020338-25-AT   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020338-25-LT   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020338-25-GB   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2010-020338-25-FI   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;United States;
Rolipram   
   National Institute of Neurological Disorders and Stroke (NINDS)
      2001   Phase 2   NCT00011375   United States;
Ruxience   
   Danish Multiple Sclerosis Center, Rigshospitalet
      2020   Phase 3   EUCTR2020-002981-15-DK   Denmark;
SA237   
   Chugai Pharmaceutical Co. Ltd
      2015   Phase 3   EUCTR2013-003752-21-HU   France;Germany;Hungary;Italy;Japan;Poland;Spain;Taiwan;United Kingdom;United States;
      2015   -   EUCTR2013-003752-21-ES   France;Germany;Hungary;Italy;Japan;Poland;Spain;Taiwan;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-003752-21-IT   France;Germany;Hungary;Italy;Japan;Poland;Spain;Taiwan;United Kingdom;
   Chugai Pharmaceutical Co., Ltd.
      2019   -   JPRN-JapicCTI-205119   Japan;
      2014   Phase 3   JPRN-JapicCTI-132397   Japan, Asia except Japan, North America, Europe;
SAR339658   
   Genzyme Corporation
      2015   Phase 2   EUCTR2014-003265-19-PL   Canada;Czech Republic;Germany;Italy;Mexico;Poland;Russian Federation;Sweden;Switzerland;United States;
      2015   Phase 2   EUCTR2014-001643-20-SE   Canada;Czech Republic;Germany;Italy;Mexico;Poland;Russian Federation;Sweden;Switzerland;United States;
      2015   Phase 2   EUCTR2014-001643-20-PL   Canada;Czech Republic;Germany;Italy;Mexico;Poland;Russian Federation;Sweden;Switzerland;United States;
      2015   Phase 2   EUCTR2014-001643-20-DE   Canada;Czech Republic;Germany;Italy;Mexico;Poland;Russian Federation;Sweden;Switzerland;United States;
SAR441344   
   Sanofi-Aventis Recherche et Développement
      2021   Phase 2   EUCTR2020-004785-19-DE   Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Russian Federation;Spain;Turkey;United States;
      2021   Phase 2   EUCTR2020-004785-19-CZ   Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Russian Federation;Spain;Turkey;United States;
      2021   Phase 2   EUCTR2020-004785-19-BG   Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Russian Federation;Spain;Turkey;United States;
SAR441344 IV   
   Sanofi
      2021   Phase 2   NCT04879628   Bulgaria;Canada;Czechia;France;Germany;Spain;Turkey;Ukraine;United States;
SAR441344 SC   
   Sanofi
      2021   Phase 2   NCT04879628   Bulgaria;Canada;Czechia;France;Germany;Spain;Turkey;Ukraine;United States;
SAR442168   
   GENZYME CORPORATION
      2020   Phase 3   EUCTR2020-000647-30-IT   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lithuania;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000645-14-IT   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Latvia;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000637-41-IT   Austria;Belarus;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Hong Kong;Italy;Japan;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United States;
   Genzyme Corporation
      2021   Phase 3   EUCTR2020-000647-30-PT   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lithuania;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000645-14-PT   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Latvia;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000645-14-NL   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Latvia;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000645-14-HU   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Latvia;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000645-14-HR   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Latvia;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000645-14-DE   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Latvia;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000645-14-BE   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Latvia;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000644-55-DE   Argentina;Belgium;Brazil;Canada;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Latvia;Netherlands;Norway;Portugal;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-000637-41-AT   Austria;Belarus;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Hong Kong;Italy;Japan;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2020-000647-30-PL   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lithuania;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000647-30-NL   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lithuania;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000647-30-LT   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lithuania;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000647-30-GR   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lithuania;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000647-30-GB   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;China;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lithuania;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000647-30-FI   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lithuania;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000647-30-DK   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lithuania;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000647-30-DE   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lithuania;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000647-30-CZ   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lithuania;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000647-30-BG   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lithuania;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000645-14-GR   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Latvia;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000645-14-GB   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Latvia;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000645-14-FR   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Latvia;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000645-14-EE   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Latvia;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000645-14-DK   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Latvia;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000645-14-CZ   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Latvia;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000645-14-BG   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Japan;Latvia;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000644-55-SK   Argentina;Belgium;Brazil;Canada;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Latvia;Netherlands;Norway;Portugal;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000644-55-PT   Argentina;Belgium;Brazil;Canada;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Latvia;Netherlands;Norway;Portugal;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000644-55-NL   Argentina;Belgium;Brazil;Canada;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Latvia;Netherlands;Norway;Portugal;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000644-55-LV   Argentina;Belgium;Brazil;Canada;Chile;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Latvia;Netherlands;Norway;Portugal;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000644-55-HU   Argentina;Belgium;Brazil;Canada;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Latvia;Netherlands;Norway;Portugal;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000644-55-GR   Argentina;Belgium;Brazil;Canada;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Latvia;Netherlands;Norway;Portugal;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000644-55-GB   Argentina;Belgium;Brazil;Canada;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Latvia;Netherlands;Norway;Portugal;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000644-55-FR   Argentina;Belgium;Brazil;Canada;Chile;Croatia;Czech Republic;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Latvia;Netherlands;Norway;Portugal;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000644-55-CZ   Argentina;Belgium;Brazil;Canada;Chile;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Latvia;Netherlands;Norway;Portugal;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-000637-41-SE   Austria;Belarus;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Hong Kong;Italy;Japan;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2020-000637-41-PL   Austria;Belarus;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Hong Kong;Italy;Japan;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2020-000637-41-LT   Austria;Belarus;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Hong Kong;Italy;Japan;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2020-000637-41-FI   Austria;Belarus;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Hong Kong;Italy;Japan;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2020-000637-41-DK   Austria;Belarus;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Hong Kong;Italy;Japan;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2020-000637-41-DE   Austria;Belarus;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Hong Kong;Italy;Japan;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2020-000637-41-CZ   Austria;Belarus;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Hong Kong;Italy;Japan;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United States;
      2020   Phase 3   EUCTR2020-000637-41-BG   Austria;Belarus;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Hong Kong;Italy;Japan;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United States;
      2019   Phase 2   EUCTR2018-004731-76-SK   Canada;Czech Republic;Estonia;France;Netherlands;Russian Federation;Slovakia;Spain;Ukraine;United States;
      2019   Phase 2   EUCTR2018-004731-76-NL   Canada;Czech Republic;Czechia;Estonia;France;Netherlands;Russian Federation;Slovakia;Spain;Ukraine;United States;
      2019   Phase 2   EUCTR2018-004731-76-ES   Canada;Czech Republic;Estonia;France;Netherlands;Russian Federation;Slovakia;Spain;Ukraine;United States;
      2019   Phase 2   EUCTR2018-004731-76-EE   Canada;Czech Republic;Czechia;Estonia;France;Netherlands;Russian Federation;Slovakia;Spain;Ukraine;United States;
      2019   Phase 2   EUCTR2018-004731-76-CZ   Canada;Czech Republic;Estonia;France;Netherlands;Russian Federation;Slovakia;Spain;Ukraine;United States;
      2019   Phase 2   EUCTR2018-003927-12-SK   Canada;Czech Republic;Estonia;France;Netherlands;Norway;Russian Federation;Slovakia;Spain;Sweden;Ukraine;United States;
      2019   Phase 2   EUCTR2018-003927-12-SE   Canada;Czech Republic;Estonia;France;Netherlands;Norway;Russian Federation;Slovakia;Spain;Sweden;Ukraine;United States;
      2019   Phase 2   EUCTR2018-003927-12-NL   Canada;Czech Republic;Estonia;France;Netherlands;Norway;Russian Federation;Slovakia;Spain;Sweden;Ukraine;United States;
      2019   Phase 2   EUCTR2018-003927-12-ES   Canada;Czech Republic;Estonia;France;Netherlands;Norway;Russian Federation;Slovakia;Spain;Sweden;Ukraine;United States;
      2019   Phase 2   EUCTR2018-003927-12-EE   Canada;Czech Republic;Estonia;France;Netherlands;Norway;Russian Federation;Slovakia;Spain;Sweden;Ukraine;United States;
   Peking University Third Hospital
      2020   -   NCT04964791   China;
   Sanofi
      2019   Phase 2   NCT03889639   Canada;Czechia;Estonia;France;Netherlands;Russian Federation;Slovakia;Spain;Sweden;Ukraine;United States;
      2019   Phase 1   NCT04171310   United Kingdom;
SB-683699   
   GlaxoSmithKline Research & Development Ltd
      2007   Phase 2   EUCTR2006-007057-42-CZ   Belgium;Czech Republic;Denmark;Sweden;
      2007   -   EUCTR2006-007057-42-SE   Czech Republic;Denmark;Sweden;
      2007   -   EUCTR2006-007057-42-DK   Czech Republic;Denmark;Sweden;
      2007   -   EUCTR2006-007057-42-BE   Belgium;Czech Republic;Denmark;Sweden;
SB683699   
   GlaxoSmithKline
      2004   Phase 2   NCT00097331   Belgium;Canada;France;Germany;Italy;Poland;Romania;Russian Federation;Spain;United States;
   GlaxoSmithKline Research & Development Ltd
      2007   Phase 2   EUCTR2006-002633-20-GB   Austria;Finland;France;Germany;Italy;Lithuania;Netherlands;Spain;United Kingdom;
      2007   Phase 2   EUCTR2006-002633-20-FR   Austria;Finland;France;Germany;Italy;Lithuania;Netherlands;Spain;United Kingdom;
      2007   -   EUCTR2006-002633-20-LT   Austria;Finland;France;Germany;Italy;Lithuania;Netherlands;Spain;United Kingdom;
      2007   -   EUCTR2006-002633-20-IT   Austria;Finland;France;Germany;Italy;Lithuania;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2006-002633-20-NL   Austria;Finland;France;Germany;Italy;Lithuania;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2006-002633-20-FI   Austria;Finland;France;Germany;Italy;Lithuania;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2006-002633-20-DE   Austria;Finland;France;Germany;Italy;Lithuania;Netherlands;Spain;United Kingdom;
      2006   -   EUCTR2006-002633-20-AT   Austria;Finland;France;Germany;Italy;Lithuania;Netherlands;Spain;United Kingdom;
   GlaxoSmithKline S.A
      2006   Phase 2   EUCTR2006-002633-20-ES   Australia;Austria;Canada;Finland;France;Germany;Italy;Lithuania;Netherlands;New Zealand;Norway;Poland;Russian Federation;Spain;United Kingdom;
SC Peginterferon beta-1a   
   Biogen
      2017   -   NCT03347370   Germany;
SC interferon beta-1a   
   Biogen
      2017   -   NCT03347370   Germany;
SC interferon beta-1b   
   Biogen
      2017   -   NCT03347370   Germany;
SCLEROLYM   
   ImCyse S.A
      2014   Phase 1;Phase 2   EUCTR2014-001081-99-BE   Belgium;
SCM-010   
   Stem Cell Medicine Ltd.
      2019   Phase 1/Phase 2   NCT03696485   Israel;
SH U 555 C   
   C.H.U. de RENNES
      2008   -   EUCTR2007-005363-10-FR   France;
      2008   -   EUCTR2007-005362-12-FR   France;
   Max-Planck-Institute of Psychiatry
      2007   -   EUCTR2006-001337-17-DE   Germany;
SIPONIMOD FUMARIC ACID   
   NOVARTIS PHARMA SERVICES AG
      2021   Phase 3   EUCTR2020-002700-39-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Novartis Farmacéutica S.A.
      2021   Phase 3   EUCTR2020-002700-39-ES   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Novartis Pharma AG
      2021   Phase 3   EUCTR2020-002700-39-SK   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-002700-39-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-002700-39-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-002700-39-LV   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-002700-39-LT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-002700-39-HR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-002700-39-FR   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-002700-39-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-002700-39-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2020-002700-39-EE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2020-002700-39-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
SMderpept   
   Centrum Neurologii Krzysztof Selmaj
      2016   Phase 2   EUCTR2016-002180-33-PL   Poland;
SOLIRIS - 300 MG CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO 1 FLACONCINO (VETRO) 30 ML (10 MG/ML)   
   ALEXION PHARMACEUTICALS INCORPORATED
      2020   Phase 2;Phase 3   EUCTR2019-001829-26-IT   Canada;Germany;Italy;Japan;Korea, Republic of;Spain;United States;
SOLU MEDROL - 125 MG/2 ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONE A DOPPIA CAMERA DA 125 MG/2 ML   
   NOVARTIS PHARMA AG
      2018   Phase 2   EUCTR2017-004702-17-IT   Austria;Bulgaria;Czech Republic;Czechia;Estonia;Germany;Italy;Latvia;Lithuania;Poland;Russian Federation;Spain;United States;
SOLU-MODERIN 1 g   
   Servicio de Neurología
      2008   -   EUCTR2007-000888-15-ES   Spain;
SPARC0921   
   Sun Pharma Advanced Research Company Ltd.
      2016   Phase 3   EUCTR2016-001356-22-HU   Germany;Hungary;Russian Federation;Ukraine;United States;
SR-fampridine   
   University of Southern Denmark
      2014   Phase 4   NCT02143167   Denmark;
SUB0750MIG   
   St. Vincent's University Hospital
      2012   Phase 4   EUCTR2011-002561-38-IE   Ireland;
SUB175614   
   Celgene International II Sàrl (CIS II)
      2015   Phase 3   EUCTR2014-002320-27-PL   Austria;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Estonia;Georgia;Germany;Hungary;Latvia;Lithuania;Moldova, Republic of;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
SUB22282   
   Biogen Idec Limited
      2012   Phase 3   EUCTR2010-021978-11-IE   Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Ireland;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2012   -   EUCTR2010-021978-11-BE   Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Ireland;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-021978-11-GB   Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Ireland;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-021978-11-ES   Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Ireland;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-021978-11-DK   Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Ireland;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-021978-11-CZ   Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Ireland;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2010-021978-11-SE   Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Ireland;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2010-021978-11-PL   Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Ireland;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2010-021978-11-FI   Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Ireland;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2010-021978-11-DE   Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Iraq;Ireland;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
Saline   
   Haukeland University Hospital
      2021   Phase 1/Phase 2   NCT04749667   Norway;
   Innate Immunotherapeutics
      2014   Phase 2   NCT02228213   Australia;New Zealand;
   University at Buffalo
      2009   Phase 2   NCT00986960   United States;
Sativex   
   GW PHARMA LTD
      2008   -   EUCTR2006-005910-11-IT   Germany;Italy;Spain;United Kingdom;
   GW Pharma Ltd
      2020   Phase 3   EUCTR2019-002623-14-PL   Czech Republic;Czechia;Poland;Romania;United Kingdom;United States;
      2007   Phase 3   EUCTR2006-005910-11-CZ   Czech Republic;Germany;Italy;Spain;United Kingdom;
      2006   Phase 3   EUCTR2005-005265-11-GB   Czech Republic;France;United Kingdom;
      2006   Phase 3   EUCTR2005-005265-11-FR   Czech Republic;France;United Kingdom;
      2006   -   EUCTR2005-005265-11-CZ   Czech Republic;France;United Kingdom;
      2005   Phase 3   EUCTR2004-002509-63-GB   Czech Republic;United Kingdom;
      2005   -   EUCTR2004-002509-63-CZ   Czech Republic;United Kingdom;
   GW Pharma Ltd.
      2008   Phase 3   EUCTR2006-005910-11-GB   Czech Republic;Germany;Italy;Spain;United Kingdom;
      2008   -   EUCTR2006-005910-11-DE   Germany;Italy;Spain;United Kingdom;
      2007   -   EUCTR2007-002138-13-GB   United Kingdom;
   GW Pharmaceuticals Ltd.
      2012   Phase 4   NCT01964547   Czech Republic;
      2007   Phase 3   NCT00702468   United Kingdom;
      2006   Phase 3   NCT00391079   Canada;
      2005   Phase 3   NCT01599234   United Kingdom;
      2002   Phase 3   NCT01604265   United Kingdom;
   GW Research Ltd
      2013   Phase 3   NCT01868048   -
   IRCCS Centro Neurolesi Bonino-Pulejo
      2016   -   NCT03186664   Italy;
   S. Andrea Hospital
      2005   Phase 2   NCT00202423   Italy;
Sativex 2,7mg/2,5 mg Solucion para pulverizacion bucal   
   GW Pharma Limited
      2021   Phase 3   EUCTR2020-003271-18-ES   Australia;Belgium;Czech Republic;Czechia;Poland;Spain;Sweden;United Kingdom;
Sativex Oromucosal Spray   
   GW Pharma Limited
      2021   Phase 3   EUCTR2020-003271-18-CZ   Australia;Belgium;Czech Republic;Czechia;Poland;Spain;Sweden;United Kingdom;
      2021   Phase 3   EUCTR2019-002625-29-CZ   Czech Republic;Czechia;Poland;United Kingdom;
      2020   Phase 3   EUCTR2019-002625-29-PL   Czech Republic;Czechia;Poland;United Kingdom;
      2020   Phase 3   EUCTR2019-002625-29-GB   Poland;United Kingdom;
   GW Pharma Ltd.
      2011   -   EUCTR2011-000926-31-CZ   Czech Republic;
Sativex Oromucosal Spray (non-marketed)   
   GW Pharma Ltd
      2020   Phase 3   EUCTR2019-002623-14-CZ   Czech Republic;Czechia;Poland;Romania;United Kingdom;United States;
Sativex®   
   Almirall, S.A.
      2012   Phase 3   NCT01538225   Italy;
   GW Pharmaceuticals Ltd.
      2011   -   NCT02073474   -
      2008   Phase 3   NCT00681538   United Kingdom;
      2002   Phase 3   NCT00711646   United Kingdom;
      2002   Phase 3   NCT00678795   United Kingdom;
Satralizumab   
   Chugai Pharmaceutical Co., Ltd.
      2019   -   JPRN-JapicCTI-205119   Japan;
      2014   Phase 3   JPRN-JapicCTI-132397   Japan, Asia except Japan, North America, Europe;
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 3   EUCTR2021-001088-26-IT   Canada;France;Germany;India;Italy;Korea, Republic of;Turkey;United States;
   Hans-Christian von Buedingen
      2021   Phase 4   JPRN-jRCT2031200333   Bulgaria;Canada;Croatia;Georgia;Germany;Hungary;Italy;Japan;Korea;Malaysia;Poland;Romania;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Hoffmann-La Roche
      2022   Phase 3   NCT05199688   Argentina;Italy;Mexico;Ukraine;United States;
      2021   Phase 3   NCT04660539   Bulgaria;Canada;Croatia;Germany;Hungary;Italy;Japan;Korea, Republic of;Malaysia;Poland;Puerto Rico;Romania;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2014   Phase 3   NCT02073279   Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Georgia;Italy;Korea, Republic of;Malaysia;Philippines;Poland;Puerto Rico;Romania;Singapore;Taiwan;Turkey;Ukraine;United States;
      2014   Phase 3   NCT02028884   France;Germany;Hungary;Italy;Japan;Poland;Spain;Taiwan;Ukraine;United Kingdom;United States;
Satralizumab (120 mg/PFS with NSD)   
   F. Hoffmann-La Roche Ltd.
      2017   Phase 3   EUCTR2015-005431-41-PL   Bulgaria;Canada;Croatia;Georgia;Italy;Korea, Republic of;Malaysia;Poland;Romania;Russian Federation;Taiwan;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-005431-41-HR   Bulgaria;Canada;Croatia;Georgia;Italy;Korea, Republic of;Malaysia;Poland;Romania;Taiwan;Turkey;Ukraine;United States;
      2014   Phase 3   EUCTR2013-003752-21-PL   France;Germany;Hungary;Italy;Japan;Poland;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-003752-21-GB   France;Germany;Hungary;Italy;Japan;Poland;Spain;Taiwan;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-003752-21-DE   France;Germany;Hungary;Italy;Japan;Poland;Spain;Taiwan;United Kingdom;United States;
Satralizumab (120 mg/vial)   
   F. Hoffmann-La Roche Ltd.
      2017   Phase 3   EUCTR2015-005431-41-PL   Bulgaria;Canada;Croatia;Georgia;Italy;Korea, Republic of;Malaysia;Poland;Romania;Russian Federation;Taiwan;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-005431-41-HR   Bulgaria;Canada;Croatia;Georgia;Italy;Korea, Republic of;Malaysia;Poland;Romania;Taiwan;Turkey;Ukraine;United States;
      2014   Phase 3   EUCTR2013-003752-21-GB   France;Germany;Hungary;Italy;Japan;Poland;Spain;Taiwan;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-003752-21-DE   France;Germany;Hungary;Italy;Japan;Poland;Spain;Taiwan;United Kingdom;United States;
Satralizumab (120mg/vial)   
   F. Hoffmann-La Roche Ltd.
      2014   Phase 3   EUCTR2013-003752-21-PL   France;Germany;Hungary;Italy;Japan;Poland;Spain;Taiwan;Ukraine;United Kingdom;United States;
Satralizumab (RO5333787/Enspryng /SA237)   
   F. Hoffmann-La Roche Ltd.
      2014   Phase 3   EUCTR2013-003752-21-PL   France;Germany;Hungary;Italy;Japan;Poland;Spain;Taiwan;Ukraine;United Kingdom;United States;
Satralizumab (RO5333787/Enspryng/SA237)   
   F. Hoffmann-La Roche Ltd.
      2014   Phase 3   EUCTR2013-003752-21-GB   France;Germany;Hungary;Italy;Japan;Poland;Spain;Taiwan;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-003752-21-DE   France;Germany;Hungary;Italy;Japan;Poland;Spain;Taiwan;United Kingdom;United States;
Satralizumab (RO5333787/SA237)   
   F. Hoffmann-La Roche Ltd.
      2017   Phase 3   EUCTR2015-005431-41-PL   Bulgaria;Canada;Croatia;Georgia;Italy;Korea, Republic of;Malaysia;Poland;Romania;Russian Federation;Taiwan;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-005431-41-HR   Bulgaria;Canada;Croatia;Georgia;Italy;Korea, Republic of;Malaysia;Poland;Romania;Taiwan;Turkey;Ukraine;United States;
Satralizumab (r-INN)   
   F. Hoffmann-La Roche Ltd.
      2017   Phase 3   EUCTR2015-005431-41-PL   Bulgaria;Canada;Croatia;Georgia;Italy;Korea, Republic of;Malaysia;Poland;Romania;Russian Federation;Taiwan;Turkey;Ukraine;United States;
      2016   Phase 3   EUCTR2015-005431-41-HR   Bulgaria;Canada;Croatia;Georgia;Italy;Korea, Republic of;Malaysia;Poland;Romania;Taiwan;Turkey;Ukraine;United States;
      2014   Phase 3   EUCTR2013-003752-21-PL   France;Germany;Hungary;Italy;Japan;Poland;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-003752-21-GB   France;Germany;Hungary;Italy;Japan;Poland;Spain;Taiwan;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-003752-21-DE   France;Germany;Hungary;Italy;Japan;Poland;Spain;Taiwan;United Kingdom;United States;
Satrazlizumab (RO5333787/ Enspryng /SA237)   
   F. Hoffmann-La Roche Ltd.
      2014   Phase 3   EUCTR2013-003752-21-PL   France;Germany;Hungary;Italy;Japan;Poland;Spain;Taiwan;Ukraine;United Kingdom;United States;
Seasonal Quadrivalent influenza vaccine   
   Novartis Pharmaceuticals
      2018   Phase 3   NCT03650114   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
Seasonal influenza vaccine   
   Celgene
      2021   Phase 3   NCT05028634   Germany;United States;
   Novartis
      2010   Phase 3   NCT01199861   Austria;Belgium;Canada;Finland;France;Guatemala;Poland;Spain;Switzerland;United Kingdom;
Second-generation fumaric acid   
   Biogen Idec Inc.
      2004   -   EUCTR2004-000663-99-SE   Hungary;Sweden;
      2004   -   EUCTR2004-000663-99-HU   Hungary;Sweden;
      2004   -   EUCTR2004-000663-99-CZ   Czech Republic;Hungary;Sweden;
Secukinumab   
   NOVARTIS FARMA
      2013   -   EUCTR2012-004019-29-IT   Argentina;Canada;Colombia;Finland;Germany;Italy;Japan;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United States;
   Novartis Pharma AG
      2013   -   EUCTR2012-004019-29-SE   Argentina;Belgium;Canada;Colombia;Czech Republic;Finland;France;Germany;Italy;Japan;Poland;Portugal;Romania;Russian Federation;Spain;Sweden;Switzerland;Turkey;United States;
      2013   -   EUCTR2012-004019-29-PT   Argentina;Belgium;Canada;Colombia;Czech Republic;Finland;France;Germany;Italy;Japan;Poland;Portugal;Romania;Russian Federation;Spain;Sweden;Switzerland;Turkey;United States;
      2013   -   EUCTR2012-004019-29-PL   Argentina;Belgium;Canada;Colombia;Czech Republic;Finland;France;Germany;Italy;Japan;Poland;Portugal;Romania;Russian Federation;Spain;Sweden;Switzerland;Turkey;United States;
      2013   -   EUCTR2012-004019-29-FI   Argentina;Belgium;Canada;Colombia;Czech Republic;Finland;France;Germany;Italy;Japan;Poland;Portugal;Romania;Russian Federation;Spain;Sweden;Switzerland;Turkey;United States;
      2013   -   EUCTR2012-004019-29-DE   Argentina;Belgium;Canada;Colombia;Czech Republic;Finland;France;Germany;Italy;Japan;Poland;Portugal;Romania;Russian Federation;Spain;Sweden;Switzerland;Turkey;United States;
   Novartis Pharma K.K.
      2013   Phase 2   JPRN-JapicCTI-132178   -
   Novartis Pharma Services AG
      2012   -   EUCTR2011-001629-25-CZ   Czech Republic;Russian Federation;Ukraine;
See Intervention Description)   
   NorthShore University HealthSystem
      2016   Phase 4   NCT02670161   -
Sendoxan   
   Uppsala l?ns landsting
      2011   -   EUCTR2010-023560-40-SE   Brazil;Canada;Sweden;United States;
Sendoxane   
   Helse Bergen HF, Haukeland University Hospital
      2018   Phase 3   EUCTR2017-001362-25-DK   Denmark;Netherlands;
Serum Free Avonex   
   Biogen Idec
      2003   Phase 1   NCT00913250   -
Serum containing Avonex   
   Biogen Idec
      2003   Phase 1   NCT00913250   -
Sham Transcranial Direct Current Stimulation (tDCS)   
   University of Iowa
      2020   -   NCT04391023   United States;
Short-course Ocrelizumab   
   Johns Hopkins University
      2021   Phase 2   NCT04767698   United States;
Silodyx   
   Erasmus MC Dept. Urology
      2016   Phase 3   EUCTR2015-002820-20-NL   Netherlands;
Simethicone   
   Rocky Mountain MS Research Group, LLC
      2014   Phase 4   NCT02217982   United States;
SimvaHEXAL® 40 mg Filmtabletten   
   University College London Comprehensive Clinical Trials Unit
      2017   Phase 3   EUCTR2017-003328-56-GB   United Kingdom;
Simvastatin   
   Alabama Neurology Associates, PC
      2005   Phase 3   NCT00242268   United States;
   Anna Tsakiri
      2008   Phase 3   NCT00429442   Denmark;
   Biogen Idec
      2006   Phase 4   NCT00492765   Denmark;
   Glostrup Hospital, Dep. of Neurology
      2009   -   EUCTR2006-001827-21-DK   Denmark;
   Glostrup University Hospital, Copenhagen
      2006   Phase 3   NCT00261326   Denmark;
   Imperial College London
      2008   Phase 2   NCT00647348   United Kingdom;
   Tehran University of Medical Sciences
      2005   Phase 3   NCT00668343   Iran, Islamic Republic of;
   University College, London
      2019   Phase 2   NCT03896217   United Kingdom;
      2018   Phase 3   NCT03387670   Ireland;United Kingdom;
Simvastatin 40 mg film-coated tablets   
   University College London
      2020   Phase 2   EUCTR2017-003008-30-GB   United Kingdom;
   University College London Comprehensive Clinical Trials Unit
      2017   Phase 3   EUCTR2017-003328-56-GB   United Kingdom;
Simvastatin Alternova   
   Biogen Idec A/S
      2006   -   EUCTR2005-003930-16-SE   Finland;Sweden;
      2006   -   EUCTR2005-003930-16-FI   Finland;Sweden;
      2005   -   EUCTR2005-003930-16-DK   Denmark;Finland;Sweden;
Simvastatin in relapsing remitting multiple sclerosis   
   Assiut University
      2020   Phase 1   NCT04178980   -
Simvastatina Sandoz 40 mg comprimidos recubiertos con película EFG   
   University College London Comprehensive Clinical Trials Unit
      2017   Phase 3   EUCTR2017-003328-56-GB   United Kingdom;
Simvastatine   
   VUmc Neurology Department
      2020   Phase 2   EUCTR2019-003127-38-NL   Netherlands;
Simvastatine Sandoz 40 mg filmomhulde tabletten   
   University College London Comprehensive Clinical Trials Unit
      2017   Phase 3   EUCTR2017-003328-56-GB   United Kingdom;
Simvastatine Sandoz 40mg deelbare filmomhulde tabletten   
   University College London Comprehensive Clinical Trials Unit
      2017   Phase 3   EUCTR2017-003328-56-GB   United Kingdom;
Single-point cane (SPC)   
   Rowan University
      2014   -   NCT02227524   United States;
Single-pulse transcranial magnetic stimulation (spTMS)   
   Shirley Ryan AbilityLab
      2017   -   NCT03723434   United States;
Single-use autoinjector   
   Biogen Idec
      2005   Phase 3   NCT00915577   -
Single-use autoinjector with a prefilled liquid Avonex syringe   
   Biogen
      2009   Phase 3   NCT00828204   United States;
Sinvastatina Sandoz 40 mg comprimidos revestidos por película   
   University College London Comprehensive Clinical Trials Unit
      2017   Phase 3   EUCTR2017-003328-56-GB   United Kingdom;
Siponimob   
   NOVARTIS PHARMA SERVICES AG
      2021   Phase 3   EUCTR2020-002700-39-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Croatia;Czechia;Estonia;France;Germany;Guatemala;India;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Siponimod   
   NOVARTIS FARMA
      2012   -   EUCTR2012-003056-36-IT   Argentina;Australia;Austria;Bulgaria;Canada;Czech Republic;Egypt;Estonia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Poland;Portugal;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
   Novartis Pharma K.K.
      2014   Phase 3   JPRN-JapicCTI-142447   -
   Novartis Pharma Services AG
      2010   Phase 2   EUCTR2009-014392-51-PL   Canada;Finland;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Turkey;United States;
      2010   Phase 2   EUCTR2009-014392-51-HU   Canada;Finland;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Turkey;United States;
      2010   Phase 2   EUCTR2009-014392-51-FI   Canada;Finland;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Turkey;United States;
      2010   -   EUCTR2009-014392-51-DE   Canada;Finland;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Turkey;United States;
   Novartis Pharmaceuticals
      2021   Phase 3   NCT04926818   Australia;Austria;Belgium;France;Germany;India;Latvia;Mexico;Poland;Portugal;Russian Federation;Slovakia;Spain;Turkey;United States;
      2021   -   NCT04933552   United States;
      2021   -   NCT04895202   Switzerland;
      2021   -   NCT04540861   -
      2019   Phase 3   NCT03623243   Puerto Rico;United States;
Siponimod 0,   
   AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA
      2021   Phase 4   EUCTR2020-005947-22-IT   Italy;
Siponimod 0.25 mg tablet   
   Novartis Farmacéutica S.A
      2012   -   EUCTR2012-003056-36-ES   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
   Novartis Pharma Services AG
      2015   -   EUCTR2012-003056-36-FR   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003056-36-PL   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003056-36-IE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003056-36-GR   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003056-36-GB   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003056-36-BG   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003056-36-BE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-SK   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-SE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-PT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-LT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-HU   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-EE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-DE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-CZ   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-AT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   -   EUCTR2012-003056-36-LV   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      -   Phase 3   EUCTR2012-003056-36-NL   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
Siponimod 0.5 mg tablet   
   Novartis Farmacéutica S.A
      2012   -   EUCTR2012-003056-36-ES   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
   Novartis Pharma Services AG
      2015   -   EUCTR2012-003056-36-FR   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003056-36-PL   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003056-36-IE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003056-36-GR   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003056-36-GB   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003056-36-BG   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003056-36-BE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-SK   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-SE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-PT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-LT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-HU   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-EE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-DE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-CZ   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-AT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   -   EUCTR2012-003056-36-LV   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      -   Phase 3   EUCTR2012-003056-36-NL   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
Siponimod 1 mg tablet   
   Novartis Farmacéutica S.A
      2012   -   EUCTR2012-003056-36-ES   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
   Novartis Pharma Services AG
      2015   -   EUCTR2012-003056-36-FR   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003056-36-PL   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003056-36-IE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003056-36-GR   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003056-36-GB   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003056-36-BG   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003056-36-BE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-SK   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-SE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-PT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-LT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-HU   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-EE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-DE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-CZ   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-AT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   -   EUCTR2012-003056-36-LV   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      -   Phase 3   EUCTR2012-003056-36-NL   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
Siponimod 2 mg tablet   
   Novartis Farmacéutica S.A
      2012   -   EUCTR2012-003056-36-ES   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
   Novartis Pharma Services AG
      2015   -   EUCTR2012-003056-36-FR   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003056-36-PL   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003056-36-IE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003056-36-GR   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003056-36-GB   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003056-36-BG   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003056-36-BE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-SK   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-SE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-PT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-LT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-HU   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-EE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-DE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-CZ   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003056-36-AT   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2012   -   EUCTR2012-003056-36-LV   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      -   Phase 3   EUCTR2012-003056-36-NL   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Egypt;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
Sirolimus   
   National Institute of Allergy and Infectious Diseases (NIAID)
      2003   Phase 1/Phase 2   NCT00095329   United States;
Sivatin 40 mg film-coated tablets   
   University College London Comprehensive Clinical Trials Unit
      2017   Phase 3   EUCTR2017-003328-56-GB   United Kingdom;
Sivelestat   
   Tohoku University Hospital
      2013   Phase 1,2   JPRN-UMIN000010094   Japan;
Sleep assessment   
   Centre Hospitalier Universitaire de Saint Etienne
      2020   Phase 2   NCT03983720   France;
Smoked Cannabis   
   Center for Medicinal Cannabis Research
      2003   Phase 1/Phase 2   NCT00260741   United States;
      2001   Phase 1/Phase 2   NCT00248378   United States;
Sodium Chloride solution   
   Anders Svenningsson
      2016   Phase 3   NCT02746744   Sweden;
Sodium chlorid   
   Sykehuset Innlandet HF
      2009   -   NCT00764413   Norway;
Solifenacin Succinate   
   Astellas Pharma Inc
      2008   Phase 4   NCT00629642   Australia;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;
Soliris   
   Alexion Pharmaceuticals Inc.
      2020   Phase 2;Phase 3   EUCTR2019-001829-26-DE   Canada;Germany;Italy;Japan;Korea, Republic of;Spain;United States;
      2019   Phase 2;Phase 3   EUCTR2019-001829-26-ES   Canada;Germany;Italy;Japan;Korea, Republic of;Spain;United States;
SoluMedrol   
   University of Utah
      2014   -   NCT02296346   United States;
Solumedrol IM 125mg/2ml   
   NOVARTIS PHARMA AG
      2018   Phase 2   EUCTR2017-004702-17-IT   Austria;Bulgaria;Czech Republic;Czechia;Estonia;Germany;Italy;Latvia;Lithuania;Poland;Russian Federation;Spain;United States;
Somatorelin   
   UNIVERSITA' DEGLI STUDI DI NAPOLI FEDERICO II
      2009   -   EUCTR2008-007447-14-IT   Italy;
Spikevax   
   Novartis Pharma GmbH
      2021   Phase 4   EUCTR2020-005752-38-DE   Germany;
   Novartis Pharma Vertriebs GmbH
      2021   Phase 4   EUCTR2021-000307-20-DE   Germany;
Spiropent   
   Department of Neurology UMCG
      2006   -   EUCTR2006-004318-42-NL   Netherlands;
Ss-interferon   
   Sun Yat-sen University
      2006   -   NCT00818103   China;
Standard MS DMT   
   Novartis Pharmaceuticals
      2011   Phase 4   NCT01317004   Italy;
Standard MS DMTs   
   Novartis Pharmaceuticals
      2010   Phase 4   NCT01216072   Canada;Puerto Rico;United States;
Standard gadolinium contrast   
   National Center for Research Resources (NCRR)
      1999   -   NCT00006060   United States;
Standard interval dosing   
   VU University Medical Center
      2020   Phase 4   NCT04225312   Netherlands;
Standard treatment with a conventional drug   
   Northwestern University
      2005   Phase 2   NCT00273364   United States;
Standardized cannabis extract   
   Institut fur Klinische Forschung, Germany
      2006   Phase 3   NCT00552604   United Kingdom;
Statin   
   Università Popolare Homo & Natura
      2015   Phase 1   NCT02632591   Italy;
Stem Cell Transplantation   
   Stem Cells Arabia
      2016   Phase 1   NCT03069170   Jordan;
Steroid Cream   
   University of Nebraska
      2010   Phase 4   NCT00988988   United States;
Study Drug   
   Biogen
      2014   Phase 1   NCT02201849   United States;
Sublingual tizanidine   
   Teva GTC
      2008   Phase 1/Phase 2   NCT00464958   Israel;
Sunphenon EGCG   
   Friedemann Paul
      2009   Phase 2/Phase 3   NCT00799890   Germany;
Sunphenon EGCg   
   Charite Universitätsmedizin Berlin
      -   Phase 2;Phase 3   EUCTR2008-005213-22-DE   Germany;
Sunphenon EGCg TM   
   Charité-Universitätsmedizin Berlin
      2007   -   EUCTR2006-006323-39-DE   Germany;
Suspension media   
   University Hospital, Toulouse
      2015   Phase 1/Phase 2   NCT02403947   France;
Sustained-release oral dalfampridine   
   Sheba Medical Center
      2014   Phase 4   NCT02259361   Israel;
Suvorexant   
   Theodore R. Brown, MD MPH
      2017   Phase 4   NCT03110315   United States;
Syngeneic Bone Marrow Transplantation   
   Fred Hutchinson Cancer Research Center
      2008   Phase 2   NCT00716066   United States;
T cell vaccination   
   Hadassah Medical Organization
      2002   Phase 1/Phase 2   NCT01448252   Israel;
   Sheba Medical Center
      2002   Phase 3   NCT00228228   Israel;
T-Cell Vaccination   
   Sheba Medical Center
      1998   Phase 1/Phase 2   NCT00220428   Israel;
TACHIPIRINA - 500 MG COMPRESSE20 COMPRESSE   
   NOVARTIS PHARMA AG
      2018   Phase 2   EUCTR2017-004702-17-IT   Austria;Bulgaria;Czech Republic;Czechia;Estonia;Germany;Italy;Latvia;Lithuania;Poland;Russian Federation;Spain;United States;
TACI-Fc5   
   Merck Serono Geneva- an affiliate of Merck KGaA, Darmstadt Germany
      2008   -   EUCTR2007-003936-50-SE   Austria;Czech Republic;France;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
   Merck Serono International
      2009   Phase 2   EUCTR2008-005021-11-FR   Belgium;Czech Republic;France;Sweden;
      2009   Phase 2   EUCTR2008-005021-11-CZ   Belgium;Czech Republic;France;Sweden;
      2009   -   EUCTR2008-005021-11-SE   Belgium;Czech Republic;France;Sweden;
   Merck Serono International S.A.
      2008   Phase 2   EUCTR2007-003936-50-FR   Austria;Belgium;Czech Republic;France;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
      2008   Phase 2   EUCTR2007-003936-50-ES   Austria;Belgium;Czech Republic;France;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-003936-50-NL   Austria;Czech Republic;France;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
   Merck Serono S.A. - Geneva
      2008   -   EUCTR2007-003936-50-GB   Australia;Austria;Canada;Czech Republic;France;Lebanon;Lithuania;Netherlands;Russian Federation;Spain;Sweden;Ukraine;United Kingdom;United States;
      2008   -   EUCTR2007-003936-50-AT   Austria;Czech Republic;France;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
   Merck Serono SA - Geneva, An affiliate of Merck KGaA, Darmstadt, Germany
      2009   -   EUCTR2008-005021-11-BE   Belgium;Czech Republic;France;Sweden;
   Merck Serono SA - Geneva, an affiliate of Merck KGaA, Darmstadt, Germany
      2008   -   EUCTR2007-003936-50-CZ   Austria;Czech Republic;France;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-003936-50-BE   Austria;Belgium;Czech Republic;France;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
   Merck Serono SA-Geneva
      2008   -   EUCTR2007-003936-50-LT   Austria;Czech Republic;France;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
TCD after bosentan administration   
   Universitair Ziekenhuis Brussel
      2014   -   NCT02389426   Belgium;
TCD baseline   
   Universitair Ziekenhuis Brussel
      2014   -   NCT02389426   Belgium;
TECFIDERA   
   Biogen Idec Research Limited
      2019   Phase 3   EUCTR2018-000516-22-PT   Bulgaria;Colombia;Croatia;Estonia;Greece;Hungary;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Taiwan;Thailand;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-000516-22-HU   Bulgaria;Colombia;Croatia;Estonia;Greece;Hungary;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Taiwan;Thailand;Tunisia;Turkey;United States;
      2019   Phase 3   EUCTR2018-000516-22-EE   Bulgaria;Colombia;Croatia;Estonia;Greece;Hungary;Israel;Italy;Jordan;Korea, Republic of;Malaysia;Mexico;Portugal;Russian Federation;Saudi Arabia;Serbia;Taiwan;Thailand;Tunisia;Turkey;United States;
   CHU de Rennes
      2018   Phase 3   EUCTR2018-001292-21-FR   France;
TECFIDERA - 240 MG - CAPSULA RIGIDA GASTRORESISTENTE - USO ORALE - BLISTER (PVC/PE/PVDC-PVC ALLUMINIO) - 56 CAPSULE   
   FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
      2017   Phase 4   EUCTR2017-000559-26-IT   Israel;Italy;Switzerland;United States;
TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY]   
   Harvard Medical School
      2022   Phase 2   NCT04880577   -
TERIFLUNOMIDE HMR1726   
   Sanofi
      2019   Phase 4   NCT03856619   India;
TETRAHYDROCANNABINOL Botanical Drug Substance (THC BDS)   
   Almirall Hermal GmbH
      2016   Phase 4   EUCTR2015-004451-40-AT   Austria;Czech Republic;
TG-1101   
   TG Therapeutics
      2017   Phase 3   EUCTR2017-000639-15-HR   Belarus;Croatia;Georgia;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-000639-15-GB   Belarus;Croatia;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-000639-15-ES   Belarus;Croatia;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-000638-75-GB   Belarus;Georgia;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-000638-75-ES   Belarus;Georgia;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
   TG Therapeutics, Inc.
      2020   Phase 3   EUCTR2019-003625-16-HR   Belarus;Croatia;Georgia;Poland;Romania;Russian Federation;Serbia;Ukraine;United States;
      2017   Phase 3   EUCTR2017-000639-15-PL   Belarus;Croatia;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-000638-75-PL   Belarus;Georgia;Poland;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
THC   
   Aarhus Universitetshospital
      2018   Phase 2   EUCTR2018-002315-98-DK   Denmark;
TMP001   
   Dr. Frank Behrens
      2015   Phase 2   NCT02686788   Germany;
   Fraunhofer Gesellschaft for its Institute Fraunhofer Institute for Molecular Biology and Applied Ecology (IME)
      2015   Phase 2   EUCTR2014-004483-38-DE   Germany;
TORVAST*10CPR   
   DR DIMENSIONE RICERCA
      2005   -   EUCTR2005-001009-25-IT   Italy;
TSO   
   Charite Universitätsmedizin Berlin
      2011   Phase 2   EUCTR2009-015319-41-DE   Germany;
   Danish Multiple Sclerosis Research Center
      2009   Phase 2   EUCTR2008-007549-29-DK   Denmark;
TT Vaccine   
   Hoffmann-La Roche
      2015   Phase 3   NCT02545868   Canada;United States;
TV-5010   
   TEVA
      2004   -   EUCTR2004-000759-40-IT   Italy;
   TEVA ITALIA srl
      2004   -   EUCTR2004-000762-13-IT   Italy;
TV-5600   
   TEVA ITALIA srl
      2008   -   EUCTR2007-005450-23-IT   Bulgaria;Czech Republic;Estonia;Germany;Italy;Lithuania;Spain;
      2007   -   EUCTR2007-003226-19-IT   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;Sweden;United Kingdom;
   TEVA PHARMACEUTICALS INDUSTRIES LTD
      2013   Phase 3   EUCTR2012-003647-30-IT   Albania;Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Georgia;Germany;Greece;Hungary;Israel;Italy;Kazakhstan;Korea, Democratic People's Republic of;Korea, Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Puerto Rico;Russian Federation;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
   Teva Pharmaceutical Industries Ltd
      2013   Phase 3   EUCTR2012-003647-30-PL   Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Chile;Croatia;Czech Republic;Estonia;Georgia;Germany;Greece;Hungary;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Montenegro;Poland;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003647-30-HU   Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Chile;Croatia;Czech Republic;Estonia;Georgia;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Montenegro;Poland;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003647-30-ES   Albania;Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Georgia;Germany;Greece;Hungary;Israel;Italy;Kazakhstan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Montenegro;Poland;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003647-30-EE   Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Chile;Croatia;Czech Republic;Estonia;Georgia;Germany;Greece;Hungary;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Montenegro;Poland;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003647-30-CZ   Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Chile;Croatia;Czech Republic;Estonia;Georgia;Germany;Greece;Hungary;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Montenegro;Poland;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003647-30-BE   Albania;Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Georgia;Germany;Greece;Hungary;Israel;Italy;Kazakhstan;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Montenegro;Poland;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003647-30-AT   Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Montenegro;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003647-30-SK   Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Chile;Croatia;Czech Republic;Estonia;Georgia;Germany;Greece;Hungary;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Montenegro;Poland;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003647-30-LV   Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Chile;Croatia;Czech Republic;Estonia;Georgia;Germany;Greece;Hungary;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Montenegro;Poland;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003647-30-GR   Albania;Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Montenegro;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2012   Phase 3   EUCTR2012-003647-30-GB   Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Montenegro;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2009-015815-42-SK   Bulgaria;Czech Republic;Estonia;Germany;Italy;Lithuania;Poland;Slovakia;Spain;
      2010   Phase 3   EUCTR2009-015815-42-PL   Bulgaria;Czech Republic;Estonia;Georgia;Germany;Israel;Italy;Lithuania;Macedonia, the former Yugoslav Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;United States;
      2010   Phase 3   EUCTR2009-015815-42-LT   Bulgaria;Czech Republic;Estonia;Georgia;Germany;Israel;Italy;Lithuania;Macedonia, the former Yugoslav Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;United States;
      2010   Phase 3   EUCTR2009-015815-42-IT   Bulgaria;Czech Republic;Estonia;Germany;Italy;Lithuania;Poland;Slovakia;Spain;
      2010   Phase 3   EUCTR2009-015815-42-EE   Bulgaria;Czech Republic;Estonia;Georgia;Germany;Israel;Italy;Lithuania;Macedonia, the former Yugoslav Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;United States;
      2010   Phase 3   EUCTR2009-015815-42-CZ   Bulgaria;Czech Republic;Estonia;Georgia;Germany;Israel;Italy;Lithuania;Macedonia, the former Yugoslav Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;United States;
      2010   Phase 3   EUCTR2009-015815-42-BG   Bulgaria;Czech Republic;Estonia;Georgia;Germany;Israel;Italy;Lithuania;Macedonia, the former Yugoslav Republic of;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;United States;
      2010   Phase 3   EUCTR2009-012989-30-SE   Austria;Bulgaria;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2009-012989-30-FR   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
      2010   Phase 3   EUCTR2009-012989-30-BG   Austria;Bulgaria;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2010   Phase 3   EUCTR2009-012989-30-AT   Austria;Bulgaria;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2009   Phase 3   EUCTR2009-012989-30-NL   Austria;Bulgaria;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2009   Phase 3   EUCTR2009-012989-30-LT   Austria;Bulgaria;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2009   Phase 3   EUCTR2009-012989-30-HU   Austria;Bulgaria;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2009   Phase 3   EUCTR2009-012989-30-GB   Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2009   Phase 3   EUCTR2009-012989-30-ES   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2009-012989-30-EE   Austria;Bulgaria;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2009   Phase 3   EUCTR2009-012989-30-CZ   Austria;Bulgaria;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;United States;
      2009   -   EUCTR2009-011234-99-DE   Germany;
      2008   Phase 3   EUCTR2007-005450-23-SK   Bulgaria;Czech Republic;Estonia;Germany;Italy;Lithuania;Slovakia;Spain;
      2008   -   EUCTR2007-005450-23-LT   Bulgaria;Czech Republic;Estonia;Germany;Italy;Lithuania;Spain;
      2008   -   EUCTR2007-005450-23-ES   Bulgaria;Czech Republic;Estonia;Germany;Italy;Lithuania;Spain;
      2008   -   EUCTR2007-005450-23-EE   Bulgaria;Czech Republic;Estonia;Germany;Italy;Lithuania;Spain;
      2008   -   EUCTR2007-005450-23-DE   Bulgaria;Czech Republic;Estonia;Germany;Italy;Lithuania;Spain;
      2008   -   EUCTR2007-005450-23-CZ   Bulgaria;Czech Republic;Estonia;Germany;Italy;Lithuania;Spain;
      2008   -   EUCTR2007-005450-23-BG   Bulgaria;Czech Republic;Estonia;Germany;Italy;Lithuania;Spain;
      2008   -   EUCTR2007-003226-19-PT   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-003226-19-LT   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-003226-19-BG   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2007   Phase 3   EUCTR2007-003226-19-FR   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2007   Phase 3   EUCTR2007-003226-19-ES   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-003226-19-SE   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-003226-19-NL   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-003226-19-LV   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-003226-19-HU   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-003226-19-GB   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-003226-19-EE   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-003226-19-DE   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-003226-19-CZ   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2007   -   EUCTR2007-003226-19-AT   Austria;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;Sweden;United Kingdom;
      2006   Phase 2   EUCTR2005-004334-41-GB   Czech Republic;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Spain;United Kingdom;
      2006   Phase 2   EUCTR2005-004334-41-DE   Czech Republic;Germany;Hungary;Israel;Italy;Russian Federation;Spain;United Kingdom;
      2006   Phase 2   EUCTR2005-004334-41-CZ   Czech Republic;Germany;Hungary;Israel;Italy;Russian Federation;Spain;United Kingdom;
      2005   Phase 2   EUCTR2005-004334-41-HU   Czech Republic;Germany;Hungary;Israel;Italy;Russian Federation;Spain;United Kingdom;
   Teva Pharmaceutical Industries Ltd.
      2015   Phase 2   EUCTR2014-001579-30-DE   Canada;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2015   -   EUCTR2014-001579-30-NL   Canada;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-001579-30-IT   Canada;Germany;Italy;Netherlands;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-001579-30-GB   Canada;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-001579-30-ES   Canada;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
   Teva Pharmaceutical Industries, Ltd.
      2014   -   EUCTR2013-002082-19-NL   Belgium;Denmark;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Spain;Sweden;Switzerland;United Kingdom;
      2014   -   EUCTR2013-002082-19-ES   Denmark;Finland;Netherlands;Spain;Sweden;Switzerland;United Kingdom;
      2013   Phase 3   EUCTR2013-002082-19-GB   Belgium;Denmark;Finland;Netherlands;Spain;Sweden;Switzerland;United Kingdom;
      2013   Phase 3   EUCTR2013-002082-19-BE   Belgium;Denmark;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Spain;Sweden;Switzerland;United Kingdom;
      2013   -   EUCTR2013-002082-19-SE   Denmark;Finland;Netherlands;Spain;Sweden;Switzerland;United Kingdom;
      2013   -   EUCTR2013-002082-19-FI   Denmark;Finland;Netherlands;Spain;Sweden;Switzerland;United Kingdom;
      2013   -   EUCTR2013-002082-19-DK   Denmark;Finland;Netherlands;Spain;Sweden;Switzerland;United Kingdom;
TYSABRI 300 mg concentrado para solución para perfusión   
   Biogen Idec Limited
      2010   -   EUCTR2009-015556-15-ES   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
TYSABRI 300 mg concentrate for solution for infusion   
   BIOGEN IDEC LTD
      2006   Phase 3   EUCTR2005-004061-41-GB   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;New Zealand;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;
TYSABRI 300 mg solution à diluer pour perfusion   
   Hôpitaux Universitaires de Strasbourg
      2014   -   EUCTR2014-003209-14-FR   France;
TYSABRI and AVONEX   
   Biogen Idec
      2008   Phase 4   NCT00771043   United States;
TYSABRI*IV 1FL 300MG 15ML   
   BIOGEN IDEC LTD
      2011   -   EUCTR2010-024000-10-IT   Belgium;Germany;Italy;Spain;
      2011   -   EUCTR2010-021978-11-IT   Belgium;Canada;Czech Republic;Denmark;Finland;Germany;Ireland;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
TYSABRI®   
   BIOGEN IDEC LTD
      2007   -   EUCTR2005-004061-41-SE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2006   Phase 3   EUCTR2005-004061-41-BE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2006   -   EUCTR2005-004061-41-IE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2006   -   EUCTR2005-004061-41-HU   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2006   -   EUCTR2005-004061-41-GR   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Ireland;Italy;Spain;Sweden;United Kingdom;
      2006   -   EUCTR2005-004061-41-FI   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2006   -   EUCTR2005-004061-41-DK   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2006   -   EUCTR2005-004061-41-DE   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;
      2006   -   EUCTR2005-004061-41-CZ   Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;New Zealand;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;
Tachipirina CPR   
   NOVARTIS PHARMA AG
      2018   Phase 2   EUCTR2017-004702-17-IT   Austria;Bulgaria;Czech Republic;Czechia;Estonia;Germany;Italy;Latvia;Lithuania;Poland;Russian Federation;Spain;United States;
Tarenflurbil   
   Fraunhofer Gesellschaft for its Institute Fraunhofer Institute for Molecular Biology and Applied Ecology (IME)
      2015   Phase 2   EUCTR2014-004483-38-DE   Germany;
Targretin   
   Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge
      2015   Phase 2   EUCTR2014-003145-99-GB   United Kingdom;
Taurine   
   University of Iowa
      2010   Phase 1   NCT01381354   United States;
Tcelna   
   Opexa Therapeutics, Inc.
      2012   Phase 2   NCT01684761   Canada;United States;
Tecfidera   
   Banner Life Sciences LLC
      2019   Phase 1   NCT04022473   United States;
   Biogen GmbH
      2015   Phase 4   EUCTR2014-000395-26-DE   Germany;
   Biogen Idec Ltd.
      2009   Phase 3   EUCTR2008-004753-14-DE   Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Estonia;France;Germany;Greece;Guatemala;India;Ireland;Israel;Italy;Latvia;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Netherlands;New Zealand;Poland;Romania;Serbia;Slovakia;South Africa;Spain;Switzerland;Ukraine;United Kingdom;United States;
   Biogen Idec Norway
      2015   Phase 4   EUCTR2015-001197-18-NO   Norway;
   Biogen Idec Research Limited
      2014   Phase 4   EUCTR2013-001656-35-SK   Austria;Belgium;Canada;Czech Republic;France;Hungary;Italy;Portugal;Slovakia;Slovenia;Spain;
      2014   Phase 4   EUCTR2013-001656-35-SI   Austria;Belgium;Canada;Czech Republic;France;Hungary;Italy;Portugal;Slovakia;Slovenia;Spain;
      2014   Phase 4   EUCTR2013-001656-35-PT   Austria;Belgium;Canada;Czech Republic;France;Hungary;Italy;Portugal;Slovakia;Slovenia;Spain;
      2014   Phase 4   EUCTR2013-001656-35-IT   Austria;Belgium;Canada;Czech Republic;France;Hungary;Italy;Portugal;Slovakia;Slovenia;Spain;
      2014   Phase 4   EUCTR2013-001656-35-HU   Austria;Belgium;Canada;Czech Republic;France;Hungary;Italy;Portugal;Slovakia;Slovenia;Spain;
      2014   Phase 4   EUCTR2013-001656-35-FR   Austria;Belgium;Canada;Czech Republic;France;Hungary;Italy;Portugal;Slovakia;Slovenia;Spain;
      2014   Phase 4   EUCTR2013-001656-35-ES   Austria;Belgium;Canada;Czech Republic;France;Hungary;Italy;Portugal;Slovakia;Slovenia;Spain;
      2014   Phase 4   EUCTR2013-001656-35-CZ   Austria;Belgium;Canada;Czech Republic;France;Hungary;Italy;Portugal;Slovakia;Slovenia;Spain;
      2014   Phase 4   EUCTR2013-001656-35-BE   Austria;Belgium;Canada;Czech Republic;France;Hungary;Italy;Portugal;Slovakia;Slovenia;Spain;
      2014   Phase 4   EUCTR2013-001656-35-AT   Austria;Belgium;Canada;Czech Republic;France;Hungary;Italy;Portugal;Slovakia;Slovenia;Spain;
      2014   -   EUCTR2013-001895-40-IE   Ireland;United Kingdom;
      2014   -   EUCTR2013-001486-17-DE   Germany;
   Department of Clinical Sciences, Danderyd Hospital
      2015   Phase 3   EUCTR2015-004116-38-SE   Sweden;
   EMD Serono Research & Development Institute, Inc.
      2017   Phase 2   NCT02975349   Bulgaria;Czechia;Germany;Poland;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United States;
   Finn Sellebjerg
      2016   Phase 2   EUCTR2016-000283-41-DK   Denmark;
   IMS HEALTH GmbH & Co. OHG
      2016   -   NCT02823951   Canada;United States;
   Karolinska Institutet
      2017   Phase 4   EUCTR2017-002634-24-SE   Sweden;
      2017   Phase 4   EUCTR2016-003587-39-SE   Sweden;
   Merck KGaA
      2017   Phase 2   EUCTR2016-001448-21-SK   Bulgaria;Croatia;Czech Republic;Czechia;Poland;Russian Federation;Serbia;Slovakia;Spain;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-001448-21-PL   Bulgaria;Croatia;Czech Republic;Poland;Russian Federation;Serbia;Slovakia;Spain;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-001448-21-ES   Bulgaria;Croatia;Czech Republic;Poland;Russian Federation;Serbia;Slovakia;Spain;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-001448-21-CZ   Bulgaria;Croatia;Czech Republic;Poland;Russian Federation;Serbia;Slovakia;Spain;Turkey;Ukraine;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-001448-21-BG   Bulgaria;Croatia;Czech Republic;Poland;Russian Federation;Serbia;Slovakia;Spain;Turkey;Ukraine;United States;
   Northwestern University
      2013   Phase 2   EUCTR2012-004165-41-GB   United Kingdom;United States;
   University of Texas Southwestern Medical Center
      2016   Phase 4   NCT02739542   United States;
   Yale University
      2014   -   NCT02218879   United States;
Tecfidera (BG00012)   
   Biogen Idec Research Limited
      2015   Phase 4   EUCTR2013-001025-53-DK   Denmark;Finland;Netherlands;Norway;Spain;United Kingdom;
      2015   -   EUCTR2013-001025-53-ES   Denmark;Finland;Netherlands;Norway;Spain;United Kingdom;
Tecfidera (BG12)   
   Sheffield Teaching Hospitals NHS Foundation Trust
      2013   Phase 2/Phase 3   NCT03133403   United Kingdom;
Tecfidera®   
   Alkermes, Inc.
      2019   Phase 3   EUCTR2017-001294-16-DE   Germany;Poland;United States;
      2017   Phase 3   EUCTR2017-001294-16-PL   Germany;Poland;United States;
   Biogen Idec Italia S.r.l.
      2015   -   EUCTR2015-000303-21-IT   Italy;
   Biogen Idec Research Limited
      2015   Phase 3   EUCTR2014-004562-22-DE   Australia;Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Spain;United States;
Tecfidera® 120mg magensaftresistente Hartkapseln   
   Universitätsklinikum Münster
      2015   Phase 4   EUCTR2014-003481-25-DE   Germany;
Tecfidera® 240mg magensaftresistente Hartkapseln   
   Universitätsklinikum Münster
      2015   Phase 4   EUCTR2014-003481-25-DE   Germany;
Tecifdera (dimethyl fumarate)   
   Brigham and Women's Hospital
      2015   -   NCT02419638   United States;
Temelimab   
   GeNeuro Innovation SAS
      2021   Phase 2   NCT05049161   Sweden;
      2020   Phase 2   NCT04480307   Sweden;
      2020   Phase 2   EUCTR2019-004822-15-SE   Sweden;
Temsirolimus Tablets   
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development
      2005   -   EUCTR2005-000171-18-FI   Finland;
Teriflunomide   
   Actelion
      2015   Phase 3   NCT02425644   Argentina;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czech Republic;Czechia;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
   Aventis Pharmaceuticals Inc.
      2006   -   EUCTR2004-000555-42-PT   Czech Republic;Denmark;Estonia;Italy;Norway;Portugal;Sweden;United Kingdom;
   Biocad
      2019   Phase 2   NCT04056897   Russian Federation;
   Centre Hospitalier Universitaire de Nice
      2015   Phase 3   NCT02587195   France;
   Centre hospitalier de l'Université de Montréal (CHUM)
      2015   -   NCT02490982   Canada;
   Genzyme, a Sanofi Company
      2014   Phase 3   NCT02201108   Australia;Belgium;Bulgaria;Canada;China;Estonia;France;Greece;Israel;Lebanon;Lithuania;Macedonia, The Former Yugoslav Republic of;Morocco;Netherlands;North Macedonia;Poland;Portugal;Russian Federation;Serbia;Slovenia;Spain;Tunisia;Turkey;Ukraine;United Kingdom;United States;
   Hoffmann-La Roche
      2021   Phase 3   NCT04586023   Austria;Brazil;Bulgaria;Canada;Denmark;France;Greece;Guatemala;India;Italy;Korea, Republic of;Mexico;Poland;Russian Federation;Turkey;United Kingdom;United States;
      2021   Phase 3   NCT04586010   Argentina;China;Finland;Germany;Hong Kong;Hungary;Italy;Netherlands;Peru;Portugal;Russian Federation;Spain;Switzerland;Taiwan;Ukraine;United States;
   Jan Lycke
      2019   Phase 4   NCT04129736   Sweden;
   McGill University
      2016   -   NCT03561402   Canada;
   Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
      2020   Phase 3   NCT04338061   Belarus;Brazil;Bulgaria;Canada;France;Germany;Greece;India;Italy;Latvia;Lithuania;Malaysia;Moldova, Republic of;Norway;Philippines;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;Turkey;Ukraine;United States;
      2020   Phase 3   NCT04338022   Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Colombia;Croatia;Czechia;Estonia;Finland;France;Georgia;Germany;Hong Kong;Hungary;India;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
   NOVARTIS PHARMA SERVICES AG
      2017   Phase 3   EUCTR2015-005419-33-IT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Czech Republic;Egypt;Finland;France;Germany;Hungary;India;Italy;Latvia;Lebanon;Lithuania;Mexico;Peru;Portugal;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Arab Emirates;United Kingdom;United States;
      2017   Phase 3   EUCTR2015-005418-31-IT   Argentina;Australia;Belgium;Bulgaria;Canada;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
   Novartis Farmacéutica S.A.
      2022   Phase 3   EUCTR2020-005929-89-ES   Argentina;Brazil;Bulgaria;Canada;China;Croatia;Czechia;Estonia;France;Germany;Greece;Hungary;India;Italy;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;United Kingdom;United States;
      2022   Phase 3   EUCTR2020-005899-36-ES   Slovakia;Spain;
   Novartis Pharma AG
      2022   Phase 3   EUCTR2020-005929-89-SE   Argentina;Brazil;Bulgaria;Canada;China;Croatia;Czechia;Estonia;France;Germany;Greece;Hungary;India;Italy;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Turkey;United Kingdom;United States;
      2022   Phase 3   EUCTR2020-005899-36-SK   Argentina;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czechia;France;Germany;Guatemala;Hong Kong;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Netherlands;Poland;Russian Federation;Serbia;Slovakia;Spain;Switzerland;United Kingdom;United States;
   Novartis Pharmaceuticals
      2021   Phase 3   NCT05156281   United States;
      2021   Phase 3   NCT05147220   United States;
   Providence Health & Services
      2013   Phase 4   NCT01970410   United States;
   Sanofi
      2013   Phase 4   NCT01895335   Austria;Belgium;Canada;Chile;Finland;France;Germany;Greece;Italy;Norway;Spain;Sweden;United Kingdom;United States;
      2011   Phase 3   NCT01252355   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Colombia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Netherlands;Norway;Portugal;Russian Federation;Slovakia;Spain;Sweden;Tunisia;Turkey;United Kingdom;United States;
      2011   Phase 2   NCT01403376   Austria;Canada;Germany;Russian Federation;Ukraine;
      2009   Phase 3   NCT00883337   Belgium;Canada;Czech Republic;France;Germany;Greece;Hungary;Italy;Poland;Spain;Switzerland;Tunisia;United Kingdom;
      2008   Phase 3   NCT00751881   Australia;Austria;Belarus;Belgium;Canada;Chile;China;Czech Republic;Estonia;France;Germany;Greece;Mexico;Netherlands;Philippines;Poland;Romania;Slovakia;South Africa;Spain;Sweden;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2008   Phase 3   NCT00622700   Australia;Austria;Brazil;Bulgaria;Canada;Chile;Czech Republic;Denmark;Estonia;Finland;France;Germany;Hungary;Italy;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;Turkey;Ukraine;United Kingdom;United States;
      2007   Phase 2   NCT00811395   Austria;Canada;Germany;Italy;Spain;United Kingdom;United States;
      2007   Phase 2   NCT00489489   Canada;Germany;Italy;Poland;Spain;United States;
      2007   Phase 2   NCT00475865   Austria;Canada;Germany;Italy;United Kingdom;United States;
      2004   Phase 3   NCT00134563   Austria;Canada;Chile;Czech Republic;Denmark;Estonia;Finland;France;Germany;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2001   Phase 2   NCT01487096   Canada;France;
   Sanofi-Aventis US, Inc.
      2004   -   EUCTR2004-000555-42-AT   Austria;Czech Republic;Denmark;Estonia;Italy;Norway;Portugal;Sweden;United Kingdom;
   Sanofi-Aventis recherche & de'veloppement
      2008   -   EUCTR2007-003997-24-IT   Austria;Italy;Spain;United Kingdom;
   Sanofi-Aventis recherche & développement
      2008   -   EUCTR2007-003997-24-GB   Austria;Italy;Spain;United Kingdom;
      2007   -   EUCTR2007-003997-24-ES   Austria;Italy;Spain;United Kingdom;
      2007   -   EUCTR2007-003997-24-AT   Austria;Italy;Spain;United Kingdom;
   Sanofi-aventis U.S. Inc
      2007   -   EUCTR2006-003134-14-IT   Germany;Italy;Spain;
      2007   -   EUCTR2004-000555-42-EE   Czech Republic;Denmark;Estonia;Italy;Norway;Portugal;Sweden;United Kingdom;
   Sanofi-aventis U.S. Inc.
      2007   Phase 2   EUCTR2006-004893-29-GB   Austria;Germany;Italy;United Kingdom;
      2007   Phase 2   EUCTR2006-003134-14-ES   Germany;Italy;Spain;
      2007   -   EUCTR2006-004893-29-IT   Austria;Germany;Italy;United Kingdom;
      2007   -   EUCTR2006-004893-29-AT   Austria;Germany;Italy;United Kingdom;
      2007   -   EUCTR2006-003134-14-DE   Germany;Italy;Spain;
      -   -   EUCTR2006-004893-29-DE   Austria;Germany;Italy;United Kingdom;
   Sanofi-aventis US, Inc
      2008   Phase 3   EUCTR2004-000555-42-GB   Austria;Czech Republic;Denmark;Estonia;Italy;Norway;Portugal;Sweden;United Kingdom;
      2005   -   EUCTR2004-000555-42-DK   Czech Republic;Denmark;Estonia;Italy;Norway;Portugal;Sweden;United Kingdom;
      2004   -   EUCTR2004-000555-42-SE   Czech Republic;Denmark;Estonia;Italy;Norway;Portugal;Sweden;United Kingdom;
      2004   -   EUCTR2004-000555-42-NO   Czech Republic;Denmark;Estonia;Italy;Norway;Portugal;Sweden;United Kingdom;
   Sanofi-aventis recherche & développement
      2010   -   EUCTR2007-004452-36-SK   Austria;Belgium;Czech Republic;Estonia;France;Germany;Greece;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2007-004452-36-SE   Austria;Belgium;Czech Republic;Estonia;France;Germany;Greece;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2007-004452-36-GR   Austria;Belgium;Czech Republic;Estonia;France;Germany;Greece;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2007-004452-36-GB   Australia;Austria;Belarus;Belgium;Canada;Chile;China;Czech Republic;Estonia;France;Germany;Greece;Mexico;Netherlands;Philippines;Poland;Romania;Slovakia;Spain;Sweden;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2008   Phase 3   EUCTR2006-001152-12-FR   Austria;Bulgaria;Czech Republic;Denmark;Estonia;Finland;France;Germany;Hungary;Lithuania;Slovakia;United Kingdom;
      2008   -   EUCTR2007-004452-36-FR   Austria;Belgium;Czech Republic;Estonia;France;Germany;Greece;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-004452-36-ES   Austria;Belgium;Czech Republic;Estonia;France;Germany;Greece;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-004452-36-EE   Austria;Belgium;Czech Republic;Estonia;France;Germany;Greece;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-004452-36-DE   Austria;Belgium;Czech Republic;Estonia;France;Germany;Greece;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2006-001152-12-SK   Austria;Bulgaria;Czech Republic;Denmark;Estonia;Finland;France;Germany;Hungary;Lithuania;Slovakia;United Kingdom;
   TG Therapeutics, Inc.
      2017   Phase 3   NCT03277261   United States;
      2017   Phase 3   NCT03277248   United States;
   Tanaka Tomoyuki
      2021   Phase 3   JPRN-jRCT2021200035   Belarus;Bulgaria;Canada;China;Czechia;Denmark;Estonia;Finland;Germany;Italy;Japan;Lithuania;Poland;Romania;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United States;
   Turku University Hospital
      2017   Phase 4   EUCTR2016-003622-16-FI   Finland;
   UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI
      2016   Phase 4   EUCTR2016-001515-20-IT   Italy;
   University at Buffalo
      2018   -   NCT03526224   United States;
   University of Michigan
      2018   -   NCT03464448   United States;
   sanofi-aventis Recherche & Dévelopment
      2009   -   EUCTR2008-006226-34-FR   Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
   sanofi-aventis U.S Inc
      2007   -   EUCTR2004-000555-42-CZ   Czech Republic;Denmark;Estonia;Italy;Norway;Portugal;Sweden;United Kingdom;
   sanofi-aventis group
      2011   -   EUCTR2010-023172-12-GR   Austria;Belgium;Denmark;Estonia;Finland;Germany;Greece;Hungary;Italy;Lithuania;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;
   sanofi-aventis recherche de veloppement
      2007   -   EUCTR2006-003361-14-IT   Austria;Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Netherlands;Portugal;Sweden;United Kingdom;
   sanofi-aventis recherche & developpement
      2011   -   EUCTR2011-001160-21-DE   Austria;Canada;Germany;Russian Federation;Ukraine;
      2011   -   EUCTR2011-001160-21-AT   Austria;Canada;Germany;Russian Federation;Ukraine;
   sanofi-aventis recherche & développement
      2009   -   EUCTR2007-004452-36-AT   Australia;Austria;Belarus;Belgium;Canada;Chile;China;Czech Republic;Estonia;France;Germany;Greece;Mexico;Netherlands;Philippines;Poland;Romania;Slovakia;Spain;Sweden;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2009   -   EUCTR2006-003361-14-EE   Austria;Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Netherlands;Portugal;Sweden;United Kingdom;
      2009   -   EUCTR2006-003361-14-CZ   Austria;Canada;Chile;Czech Republic;Denmark;Estonia;Finland;France;Germany;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2009   -   EUCTR2006-001152-12-LT   Australia;Austria;Belarus;Bulgaria;Canada;Chile;Czech Republic;Denmark;Estonia;Finland;France;Germany;Hungary;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;Turkey;Ukraine;United Kingdom;United States;
      2009   -   EUCTR2006-001152-12-DE   Austria;Bulgaria;Czech Republic;Denmark;Estonia;Finland;France;Germany;Hungary;Lithuania;Slovakia;United Kingdom;
      2008   Phase 3   EUCTR2007-004452-36-BE   Australia;Austria;Belarus;Belgium;Canada;Chile;China;Czech Republic;Estonia;France;Germany;Greece;Mexico;Netherlands;Philippines;Poland;Romania;Slovakia;Spain;Sweden;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2008   Phase 3   EUCTR2006-003361-14-PT   Austria;Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Netherlands;Portugal;Sweden;United Kingdom;
      2008   Phase 3   EUCTR2006-001152-12-BG   Austria;Bulgaria;Czech Republic;Denmark;Estonia;Finland;France;Germany;Hungary;Lithuania;Slovakia;United Kingdom;
      2008   -   EUCTR2007-004452-36-NL   Australia;Austria;Belarus;Belgium;Canada;Chile;China;Czech Republic;Estonia;France;Germany;Greece;Mexico;Netherlands;Philippines;Poland;Romania;Slovakia;Spain;Sweden;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2008   -   EUCTR2007-004452-36-CZ   Australia;Austria;Belarus;Belgium;Canada;Chile;China;Czech Republic;Estonia;France;Germany;Greece;Mexico;Netherlands;Philippines;Poland;Romania;Slovakia;Spain;Sweden;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States;
      2008   -   EUCTR2006-003361-14-NL   Austria;Canada;Chile;Czech Republic;Denmark;Estonia;Finland;France;Germany;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2008   -   EUCTR2006-003361-14-DK   Austria;Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Netherlands;Portugal;Sweden;United Kingdom;
      2008   -   EUCTR2006-001152-12-HU   Australia;Austria;Belarus;Bulgaria;Canada;Chile;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Hungary;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;Turkey;Ukraine;United Kingdom;United States;
      2008   -   EUCTR2006-001152-12-EE   Australia;Austria;Belarus;Bulgaria;Canada;Chile;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Hungary;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;Turkey;Ukraine;United Kingdom;United States;
      2007   Phase 3   EUCTR2006-003361-14-SE   Austria;Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Netherlands;Portugal;Sweden;United Kingdom;
      2007   Phase 3   EUCTR2006-003361-14-GB   Austria;Canada;Czech Republic;Denmark;Estonia;Finland;France;Germany;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2007   Phase 3   EUCTR2006-001152-12-GB   Australia;Austria;Belarus;Bulgaria;Canada;Chile;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Hungary;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;Turkey;Ukraine;United Kingdom;United States;
      2007   Phase 3   EUCTR2006-001152-12-FI   Austria;Bulgaria;Czech Republic;Denmark;Estonia;Finland;France;Germany;Hungary;Lithuania;Slovakia;United Kingdom;
      2007   Phase 3   EUCTR2006-001152-12-CZ   Australia;Austria;Belarus;Bulgaria;Canada;Chile;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Hungary;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;Turkey;Ukraine;United Kingdom;United States;
      2007   -   EUCTR2006-003361-14-DE   Austria;Canada;Chile;Czech Republic;Denmark;Estonia;Finland;France;Germany;Italy;Netherlands;Poland;Portugal;Russian Federation;Sweden;Switzerland;Ukraine;United Kingdom;United States;
      2007   -   EUCTR2006-001152-12-DK   Australia;Austria;Belarus;Bulgaria;Canada;Chile;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Hungary;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;Turkey;Ukraine;United Kingdom;United States;
      2007   -   EUCTR2006-001152-12-AT   Austria;Bulgaria;Czech Republic;Denmark;Estonia;Finland;France;Germany;Hungary;Lithuania;Slovakia;United Kingdom;
      2006   Phase 3   EUCTR2006-003361-14-FI   Austria;Czech Republic;Denmark;Estonia;Finland;Germany;Italy;Netherlands;Portugal;Sweden;United Kingdom;
      2006   -   EUCTR2006-003361-14-AT   Austria;Canada;Chile;Czech Republic;Denmark;Estonia;Finland;France;Germany;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
   sanofi-aventis recherche et development
      2012   -   EUCTR2010-023172-12-LT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Italy;Korea, Republic of;Lithuania;Netherlands;Norway;Portugal;Russian Federation;Slovakia;Spain;Sweden;Tunisia;Turkey;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-023172-12-SK   Austria;Belgium;Denmark;Estonia;Finland;Germany;Greece;Hungary;Italy;Lithuania;Netherlands;Norway;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2011   Phase 3   EUCTR2010-023172-12-HU   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Italy;Korea, Republic of;Lithuania;Netherlands;Norway;Portugal;Russian Federation;Slovakia;Spain;Sweden;Tunisia;Turkey;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-023172-12-BE   Austria;Belgium;Denmark;Estonia;Finland;Germany;Greece;Hungary;Italy;Lithuania;Netherlands;Norway;Portugal;Slovakia;Spain;Sweden;United Kingdom;
      2011   -   EUCTR2010-023172-12-SE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Italy;Korea, Republic of;Lithuania;Netherlands;Norway;Portugal;Russian Federation;Slovakia;Spain;Sweden;Tunisia;Turkey;United Kingdom;United States;
      2011   -   EUCTR2010-023172-12-PT   Austria;Belgium;Denmark;Estonia;Finland;Germany;Greece;Hungary;Italy;Lithuania;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;
      2011   -   EUCTR2010-023172-12-NO   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Italy;Korea, Republic of;Lithuania;Netherlands;Norway;Portugal;Russian Federation;Slovakia;Spain;Sweden;Tunisia;Turkey;United Kingdom;United States;
      2011   -   EUCTR2010-023172-12-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Italy;Korea, Republic of;Lithuania;Netherlands;Norway;Portugal;Russian Federation;Slovakia;Spain;Sweden;Tunisia;Turkey;United Kingdom;United States;
      2011   -   EUCTR2010-023172-12-IT   Austria;Belgium;Denmark;Estonia;Finland;Germany;Greece;Hungary;Italy;Lithuania;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;
      2011   -   EUCTR2010-023172-12-GB   Austria;Belgium;Denmark;Estonia;Finland;Germany;Greece;Hungary;Italy;Lithuania;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;
      2011   -   EUCTR2010-023172-12-FI   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Italy;Korea, Republic of;Lithuania;Netherlands;Norway;Portugal;Russian Federation;Slovakia;Spain;Sweden;Tunisia;Turkey;United Kingdom;United States;
      2011   -   EUCTR2010-023172-12-ES   Austria;Belgium;Denmark;Estonia;Finland;Germany;Greece;Hungary;Italy;Lithuania;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;
      2011   -   EUCTR2010-023172-12-EE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Italy;Korea, Republic of;Lithuania;Netherlands;Norway;Portugal;Russian Federation;Slovakia;Spain;Sweden;Tunisia;Turkey;United Kingdom;United States;
      2011   -   EUCTR2010-023172-12-DK   Austria;Belgium;Denmark;Estonia;Finland;Germany;Greece;Hungary;Italy;Lithuania;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;
      2011   -   EUCTR2010-023172-12-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;Estonia;Finland;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Netherlands;Norway;Portugal;Russian Federation;Slovakia;Spain;Sweden;Tunisia;Turkey;United Kingdom;United States;
      2011   -   EUCTR2010-023172-12-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Guatemala;Hungary;Italy;Korea, Republic of;Lithuania;Netherlands;Norway;Portugal;Russian Federation;Slovakia;Spain;Sweden;Tunisia;Turkey;United Kingdom;United States;
      2009   Phase 3   EUCTR2008-006226-34-GR   Belgium;Czech Republic;France;Germany;Greece;Hungary;Italy;Spain;United Kingdom;
      2009   -   EUCTR2008-006226-34-IT   Belgium;Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
      2009   -   EUCTR2008-006226-34-ES   Belgium;Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
      2009   -   EUCTR2008-006226-34-BE   Belgium;Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
   sanofi-aventis recherche et developpement
      2010   -   EUCTR2008-006226-34-GB   Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Spain;Tunisia;United Kingdom;
      2009   -   EUCTR2008-006226-34-HU   Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Spain;Tunisia;United Kingdom;
      2009   -   EUCTR2008-006226-34-DE   Belgium;Czech Republic;France;Germany;Hungary;Italy;Spain;United Kingdom;
      2009   -   EUCTR2008-006226-34-CZ   Belgium;Canada;Czech Republic;France;Germany;Hungary;Italy;Spain;Tunisia;United Kingdom;
Teriflunomide (HMR1726)   
   Sanofi
      2013   -   NCT03198351   Canada;United States;
      2006   Phase 3   NCT00803049   Austria;Canada;Chile;Czech Republic;Denmark;Estonia;Finland;France;Germany;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2002   Phase 2   NCT00228163   Canada;France;
Teriflunomide 14 MG Oral Tablet [Aubagio]   
   Centre Hospitalier Universitaire de Nice
      2017   Phase 3   NCT03122652   France;Germany;Martinique;Sweden;Switzerland;Turkey;United Kingdom;
Teriflunomide HMR1726   
   Sanofi
      2020   Phase 3   NCT04410991   Argentina;Belgium;Brazil;Canada;Chile;Croatia;Czechia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Latvia;Netherlands;Norway;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   NCT04410978   Austria;Belarus;Bulgaria;Canada;China;Czechia;Denmark;Estonia;Finland;Germany;Italy;Japan;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United States;
      2014   Phase 1   NCT02046629   China;
      2013   Phase 3   NCT01863888   Belgium;Germany;Netherlands;
Teriflunomide capsule   
   Novartis Pharmaceuticals
      2016   Phase 3   NCT02792231   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czechia;Finland;France;Germany;Hungary;India;Italy;Latvia;Lithuania;Mexico;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2016   Phase 3   NCT02792218   Argentina;Australia;Belgium;Bulgaria;Canada;Croatia;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Puerto Rico;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;
Testosterone   
   University of California, Los Angeles
      2014   Phase 2   NCT02317263   -
Testosterone undecanoate   
   Health Sciences Centre, Winnipeg, Manitoba
      2012   Phase 2   NCT01516554   Canada;
Tetanus diphtheria toxoid vaccine (Td)   
   Biogen
      2008   Phase 4   NCT00536120   United States;
Tetanus diphtheria toxoids vaccine   
   Biogen
      2015   Phase 2   NCT02097849   United States;
Tetanus toxoid (TT) containing vaccine (Td, Tdap)   
   Novartis Pharmaceuticals
      2018   Phase 3   NCT03650114   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Japan;Latvia;Lithuania;Mexico;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
Tetanus toxoid vaccine   
   Novartis
      2010   Phase 3   NCT01199861   Austria;Belgium;Canada;Finland;France;Guatemala;Poland;Spain;Switzerland;United Kingdom;
Tetanus, diphtheria, and acellular pertussis vaccine   
   Celgene
      2021   Phase 3   NCT05028634   Germany;United States;
Tetracycline   
   Università Popolare Homo & Natura
      2015   Phase 1   NCT02632591   Italy;
Tetracycline - Statin - Antimycotic   
   Università Popolare Homo & Natura
      2015   Phase 0   NCT02606929   Italy;
Tetrahydrocannabinol (THC)   
   Tiffany J. Braley, MD, MS
      2022   Phase 2   NCT05269628   United States;
Tetrahydrocannabinol Botanical Drug Substance (THC BDS)   
   GW Pharma Limited
      2022   Phase 3   EUCTR2020-004306-58-LT   Bulgaria;Canada;Hungary;Italy;Lithuania;Spain;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003271-18-ES   Australia;Belgium;Czech Republic;Czechia;Poland;Spain;Sweden;United Kingdom;
      2021   Phase 3   EUCTR2020-003271-18-CZ   Australia;Belgium;Czech Republic;Czechia;Poland;Spain;Sweden;United Kingdom;
      2021   Phase 3   EUCTR2019-002625-29-CZ   Czech Republic;Czechia;Poland;United Kingdom;
      2020   Phase 3   EUCTR2019-002625-29-PL   Czech Republic;Czechia;Poland;United Kingdom;
      2020   Phase 3   EUCTR2019-002625-29-GB   Poland;United Kingdom;
   GW Pharma Ltd
      2020   Phase 3   EUCTR2019-002623-14-PL   Czech Republic;Czechia;Poland;Romania;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002623-14-GB   Czech Republic;Poland;Romania;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002623-14-CZ   Czech Republic;Czechia;Poland;Romania;United Kingdom;United States;
Thiamine   
   University of Iowa
      2010   Phase 1   NCT01381354   United States;
Thiotepa   
   OSPEDALE S. RAFFAELE
      2007   Phase 2   EUCTR2007-000586-38-IT   Italy;
Thymoglobuline   
   Sheffield Teaching Hospitals
      2020   Phase 3   EUCTR2019-001549-42-GB   United Kingdom;
   Uppsala l?ns landsting
      2011   -   EUCTR2010-023560-40-SE   Brazil;Canada;Sweden;United States;
Thymoglobuline®   
   Helse Bergen HF, Haukeland University Hospital
      2019   Phase 3   EUCTR2017-001362-25-NL   Denmark;Netherlands;
      2018   Phase 3   EUCTR2017-001362-25-DK   Denmark;Netherlands;
Thymol   
   Department of Neurology and Neurological Science, Tokyo Medical and Dental University
      2021   -   JPRN-UMIN000043910   Japan;
Tissue Selective Estrogen Complex   
   University of California, San Francisco
      2016   Phase 2   NCT02710214   United States;
Tizanidine (sublingual or oral)   
   Teva GTC
      2006   Phase 1/Phase 2   NCT00358293   Israel;
Tizanidine hydrochloride capsule   
   Elan Pharmaceuticals
      2002   Phase 3   NCT00047580   United States;
Tocilizumab   
   Department of Immunology, National Institute of Neuroscience, NCNP
      2014   -   JPRN-UMIN000012705   Japan;
      2012   -   JPRN-UMIN000007866   Japan;
      2011   -   JPRN-UMIN000005889   Japan;
   Department of Neurology, Shimane University Hospital
      2016   -   JPRN-UMIN000022201   Japan;
   Fu-Dong Shi
      2017   Phase 1/Phase 2   NCT03062579   China;
   Yamamura Takashi
      2013   -   JPRN-jRCTs031180346   Japan;
      2012   -   JPRN-jRCTs031180152   Japan;
Tocilizumab Injection   
   Tianjin Medical University General Hospital
      2017   Phase 2/Phase 3   NCT03350633   China;
Tolebrutinib   
   National Institute of Neurological Disorders and Stroke (NINDS)
      2021   Phase 2   NCT04742400   United States;
   Sanofi
      2020   Phase 3   NCT04458051   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Latvia;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   NCT04411641   Argentina;Australia;Austria;Belarus;Belgium;Bulgaria;Canada;China;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lithuania;Netherlands;Norway;Poland;Portugal;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   NCT04410991   Argentina;Belgium;Brazil;Canada;Chile;Croatia;Czechia;France;Germany;Greece;Hungary;India;Israel;Korea, Republic of;Latvia;Netherlands;Norway;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   NCT04410978   Austria;Belarus;Bulgaria;Canada;China;Czechia;Denmark;Estonia;Finland;Germany;Italy;Japan;Lithuania;Mexico;Poland;Romania;Russian Federation;Spain;Sweden;Taiwan;Turkey;Ukraine;United States;
      2019   Phase 2   NCT03996291   Canada;Czechia;Estonia;France;Netherlands;Russian Federation;Spain;Ukraine;United States;
Tolerogenic Dendritic cells loaded with myelin peptides   
   Sara Varea
      2015   Phase 1   NCT02283671   Spain;
Tolerogenic Fibroblasts   
   FibroBiologics
      2020   Early Phase 1   NCT05080270   Mexico;
Tolerogenic dendritic cells (tolDC)   
   University Hospital, Antwerp
      2017   Phase 1   NCT02618902   Belgium;
Tolperisone HC1   
   Avigen Inc
      2007   Phase 2   EUCTR2007-001031-63-CZ   Czech Republic;Germany;
      2007   -   EUCTR2007-001031-63-DE   Germany;
Tolperisone HCl   
   Avigen
      2007   Phase 2   NCT00532532   Czech Republic;Former Serbia and Montenegro;Germany;Russian Federation;Serbia;Ukraine;
Tolpersan   
   Avigen Inc
      2007   Phase 2   EUCTR2007-001031-63-CZ   Czech Republic;Germany;
      2007   -   EUCTR2007-001031-63-DE   Germany;
Tolposan   
   Avigen Inc
      2007   Phase 2   EUCTR2007-001031-63-CZ   Czech Republic;Germany;
      2007   -   EUCTR2007-001031-63-DE   Germany;
Topical Preparation H arm   
   New York University School of Medicine
      2015   Phase 4   NCT02665221   United States;
Tovaxin   
   Opexa Therapeutics, Inc.
      2007   Phase 2   NCT00595920   United States;
Tovaxin Autologous T Cell Vaccine   
   Opexa Therapeutics, Inc.
      2002   Phase 1/Phase 2   NCT00587691   United States;
Tovaxin Autologous T cell vaccine   
   Opexa Therapeutics, Inc.
      2006   Phase 2   NCT00245622   United States;
Tracleer   
   UZ Brussel
      2017   Phase 2   EUCTR2017-001253-13-BE   Belgium;
Trancopal Dolo   
   Charité-Universitätsmedizin Berlin
      2007   Phase 2   EUCTR2006-005262-39-DE   Germany;
Transcranial Magnetic Stimulation (TMS)   
   Maimónides Biomedical Research Institute of Córdoba
      2019   Phase 1/Phase 2   NCT04062331   -
Trekking pole (TP).   
   Rowan University
      2014   -   NCT02227524   United States;
Trichuris suis Ova   
   Danish Multiple Sclerosis Research Center
      2009   Phase 2   EUCTR2008-007549-29-DK   Denmark;
Trichuris suis eggs   
   Danish Multiple Sclerosis Research Center
      2009   Phase 2   EUCTR2008-007549-29-DK   Denmark;
Trichuris suis ova   
   Charite University, Berlin, Germany
      2012   Phase 2   NCT01413243   Germany;
   Rigshospitalet, Denmark
      2010   Phase 2   NCT01006941   Denmark;
Trichuris suis ova (eggs), embryonated, viable   
   Charite Universitätsmedizin Berlin
      2011   Phase 2   EUCTR2009-015319-41-DE   Germany;
Trileptal   
   Queen Mary University London
      2014   Phase 2   EUCTR2013-002419-87-GB   United Kingdom;
Triomar™ (omega-3 fatty acids)   
   Haukeland University Hospital
      2004   Phase 2/Phase 3   NCT00360906   Norway;
Trivalent seasonal influenza vaccine   
   Biogen
      2010   Phase 2   NCT01051349   Czech Republic;Czechia;Germany;Hungary;India;Poland;Russian Federation;Ukraine;United Kingdom;
Trulicity 0,75 mg injekcný roztok naplnený v injekcnom pere.   
   Lekárska fakulta UK Bratislava
      2019   Phase 2   EUCTR2019-003001-94-SK   Slovakia;
Tylenol Pill   
   Holy Name Medical Center, Inc.
      2017   Phase 4   NCT03424733   United States;
Tysabri   
   Amsterdam University Medical Center
      2019   Phase 4   EUCTR2019-002566-13-NL   Netherlands;
   BIOGEN IDEC LTD
      2006   -   EUCTR2005-004061-41-IT   Australia;Austria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;New Zealand;Spain;Sweden;Switzerland;Turkey;United Kingdom;
   Biogen
      2018   -   NCT03399981   United States;
   Biogen Idec
      2014   Phase 4   EUCTR2014-003669-97-BE   Belgium;
   Biogen Idec International GmbH
      2010   Phase 4   EUCTR2009-009503-19-BE   Belgium;
   Biogen Idec Limited
      2012   Phase 3   EUCTR2010-021978-11-IE   Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Ireland;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2012   -   EUCTR2010-021978-11-BE   Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Ireland;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-021978-11-GB   Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Ireland;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-021978-11-ES   Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Ireland;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-021978-11-DK   Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Ireland;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-021978-11-CZ   Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Ireland;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2010-021978-11-SE   Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Ireland;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2010-021978-11-PL   Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Ireland;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2010-021978-11-FI   Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Ireland;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2011   -   EUCTR2010-021978-11-DE   Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Iraq;Ireland;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2010   -   EUCTR2009-015556-15-SI   Austria;Canada;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;United States;
      2010   -   EUCTR2009-015556-15-SE   Austria;Canada;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;United States;
      2010   -   EUCTR2009-015556-15-PT   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015556-15-NL   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015556-15-LV   Austria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Italy;Latvia;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;United States;
      2010   -   EUCTR2009-015556-15-HU   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015556-15-GR   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015556-15-GB   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015556-15-FI   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015556-15-DK   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015556-15-DE   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2009-015556-15-CZ   Austria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Italy;Latvia;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;United States;
      2010   -   EUCTR2009-015556-15-AT   Austria;Denmark;Finland;Germany;Greece;Hungary;Italy;Netherlands;Portugal;Slovenia;Spain;Sweden;United Kingdom;
   BiogenIdec A/S
      2009   -   EUCTR2008-008065-35-SE   Sweden;
   CHU de Toulouse
      2009   -   EUCTR2008-005906-38-FR   France;
   Dansk Multipel Sclerose Center
      2010   Phase 2   EUCTR2009-016703-35-DK   Denmark;
   Imperial College London
      2008   Phase 4   EUCTR2007-007394-22-GB   United Kingdom;
   Karolinska Institutet
      2017   Phase 4   EUCTR2017-002634-24-SE   Sweden;
      2017   Phase 4   EUCTR2016-003587-39-SE   Sweden;
   Kessler Foundation
      2021   -   NCT04565431   United States;
   Northwestern University
      2013   Phase 2   EUCTR2012-004165-41-GB   United Kingdom;United States;
   Novartis Pharma Services AG
      2012   -   EUCTR2011-001437-16-DE   Australia;Austria;Canada;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
   Polpharma Biologics S.A.
      2019   Phase 3   EUCTR2018-004751-20-PL   Belarus;Croatia;Georgia;Moldova, Republic of;Poland;Serbia;Ukraine;
      2019   Phase 3   EUCTR2018-004751-20-HR   Belarus;Croatia;Georgia;Moldova, Republic of;Poland;Serbia;Ukraine;
   Turku University Hospital
      2013   Phase 4   EUCTR2013-004626-28-FI   Finland;
   University at Buffalo
      2007   -   NCT00937677   United States;
   University of Chicago
      2010   -   NCT01071512   United States;
   Universitätsklinikum Münster
      2014   -   EUCTR2013-004616-21-DE   Germany;
   Uppsala l?ns landsting
      2011   -   EUCTR2010-023560-40-SE   Brazil;Canada;Sweden;United States;
   VU medical center
      2016   Phase 4   EUCTR2016-000345-31-NL   Netherlands;
Tysabri ® (Natalizumab)   
   University of South Florida
      2011   -   NCT01455220   United States;
Tysabri®   
   Biogen Idec Research Limited
      2015   Phase 4   EUCTR2013-004622-29-DK   Australia;Czech Republic;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
      2015   Phase 4   EUCTR2013-004622-29-DE   Australia;Czech Republic;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
      2015   -   EUCTR2013-005586-39-DE   Germany;Italy;United States;
      2014   Phase 4   EUCTR2013-004622-29-SE   Australia;Czech Republic;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
      2014   Phase 4   EUCTR2013-004622-29-GB   Australia;Czech Republic;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
      2014   Phase 4   EUCTR2013-004622-29-ES   Australia;Canada;Czech Republic;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
      2014   Phase 4   EUCTR2013-004622-29-CZ   Australia;Czech Republic;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
      2014   -   EUCTR2013-004622-29-IT   Australia;Canada;Czech Republic;Denmark;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
   Sheffield Teaching Hospitals NHS Foundation Trust
      2013   Phase 2/Phase 3   NCT03133403   United Kingdom;
Tysabri® (natalizumab)   
   Biogen
      2010   -   NCT01070823   United States;
UK: Sativex Oromucosal Spray   
   GW Pharma Ltd
      2020   Phase 3   EUCTR2019-002623-14-GB   Czech Republic;Poland;Romania;United Kingdom;United States;
UNDIFFERENTIATED AUTOLOGOUS MESENCHYMAL STEM CELLS   
   SALK - Gemeinnützige Salzburger Landeskliniken Betriebsges. m.b.H., Christian-Doppler-Klinik, UK für Neurologie der PMU
      -   -   EUCTR2015-000137-78-AT   Austria;
URBASON 40 mg comprimidos   
   Servicio de Neurología
      2008   -   EUCTR2007-000888-15-ES   Spain;
UVEDOSE 100 000 UI, solution buvable en ampoule   
   MERCK SERONO s.a.s
      2009   -   EUCTR2009-013695-46-FR   France;
Ublituximab   
   Johns Hopkins University
      2016   Phase 1   NCT02276963   United States;
   TG Therapeutics, Inc.
      2019   Phase 3   NCT04130997   Belarus;Croatia;Georgia;Poland;Russian Federation;Serbia;Ukraine;United States;
      2017   Phase 3   NCT03277261   United States;
      2017   Phase 3   NCT03277248   United States;
      2017   Phase 2   NCT03381170   United States;
      2016   Phase 2   NCT02738775   United States;
Ubltuximab   
   TG Therapeutics
      2017   Phase 3   EUCTR2017-000639-15-GB   Belarus;Croatia;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
Ucb L059   
   Søren H. Sindrup, Department of Neurology, Odense University Hospital
      2006   -   EUCTR2006-000397-71-DK   Denmark;
Ultomiris   
   Alexion Pharmaceuticals, Inc.
      2020   Phase 3   EUCTR2019-003352-37-PL   Australia;Austria;Canada;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-003352-37-NL   Australia;Austria;Canada;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-003352-37-ES   Australia;Austria;Canada;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-003352-37-DK   Australia;Austria;Canada;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-003352-37-DE   Australia;Austria;Canada;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-003352-37-AT   Australia;Austria;Canada;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
Ultra small particles of iron oxide (USPIO)   
   Max-Planck-Institute of Psychiatry
      2007   -   EUCTR2006-001337-17-DE   Germany;
Ultrasmall particles of iron oxide   
   Max-Planck-Institute of Psychiatry
      2007   -   EUCTR2006-001337-17-DE   Germany;
Ultromiris   
   ALEXION PHARMACEUTICALS INCORPORATED
      2020   Phase 3   EUCTR2019-003352-37-IT   Australia;Austria;Canada;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States;
Umbilical cord derived Mesenchymal Stem Cells   
   University of Jordan
      2017   Phase 1/Phase 2   NCT03326505   Jordan;
Umbilical cord mesenchymal stem cells   
   Translational Biosciences
      2014   Phase 1/Phase 2   NCT02034188   Panama;
Untreated to atorvastatin treatment   
   Charite University, Berlin, Germany
      2003   Phase 2   NCT00616187   -
Urbason   
   Servicio de Neurología, HU. Germans Trias i Pujol
      2012   Phase 4   EUCTR2012-001965-34-ES   Spain;
Urbason solubile forte   
   IFSgGmbH, Institute for clinical research
      2006   -   EUCTR2005-005592-14-DE   Germany;
Urbason® solubile forte   
   University Medical Center Hamburg Eppendorf
      2013   Phase 2   EUCTR2012-004807-10-DE   Germany;
Urine samples   
   Centre Hospitalier Universitaire de Nimes
      2013   Phase 3   NCT01817166   France;
V08CA02   
   Universitätsklinikum Erlangen
      2010   -   EUCTR2009-014857-34-DE   Germany;
V08CA09   
   Universitätsklinikum Erlangen
      2010   -   EUCTR2009-014857-34-DE   Germany;
VARDENAFILO HIDROCLORURO   
   Unidad de Neuroinmunología
      2005   Phase 4   EUCTR2004-003761-33-ES   Spain;
VAY736   
   Novartis Pharma Services AG
      2014   Phase 2   EUCTR2013-002324-16-PL   Czech Republic;Poland;Russian Federation;Ukraine;United States;
      2014   Phase 2   EUCTR2013-002324-16-CZ   Czech Republic;Poland;Russian Federation;Ukraine;United States;
   Novartis Pharmaceuticals
      2013   Phase 2   NCT02038049   Czech Republic;Czechia;Germany;Poland;Russian Federation;Ukraine;United States;
VB13S1   
   The Immune Response Corporation
      2007   Phase 2   EUCTR2006-003384-30-SK   Slovakia;
VB5S2   
   The Immune Response Corporation
      2007   Phase 2   EUCTR2006-003384-30-SK   Slovakia;
VB6S5   
   The Immune Response Corporation
      2007   Phase 2   EUCTR2006-003384-30-SK   Slovakia;
VENLAFAXINE HYDROCHLORIDE   
   Novartis Pharma GmbH
      -   -   EUCTR2011-001692-39-DE   Germany;
VESIcare 10Mg Tablet   
   Brigitte Schürch
      2021   Phase 4   NCT04819360   Switzerland;
VIGANTOL OIL   
   MERCK SERONO SA
      2011   -   EUCTR2010-020328-23-IT   Austria;Belgium;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;Netherlands;Portugal;
VITAMINA D3 KERN PHARMA SOLUCIÓN OLEOSA   
   Javier Olascoaga Urtaza
      2013   Phase 2   EUCTR2012-004602-97-ES   Spain;
VSN16R   
   Canbex Therapeutics Ltd
      2015   Phase 2   NCT02542787   United Kingdom;
      2015   Phase 2   EUCTR2014-004412-11-GB   United Kingdom;
VX15/2503   
   Vaccinex Inc.
      2012   Phase 1   NCT01764737   United States;
Vaginal estriol   
   Texas Tech University Health Sciences Center
      2019   Phase 2/Phase 3   NCT03774407   United States;
Vardenafil (hidrocloride)   
   Unidad de Neuroinmunología
      2005   Phase 4   EUCTR2004-003761-33-ES   Spain;
Vatelizumab   
   Genzyme Corporation
      2015   Phase 2   EUCTR2014-003265-19-PL   Canada;Czech Republic;Germany;Italy;Mexico;Poland;Russian Federation;Sweden;Switzerland;United States;
      2015   Phase 2   EUCTR2014-001643-20-SE   Canada;Czech Republic;Germany;Italy;Mexico;Poland;Russian Federation;Sweden;Switzerland;United States;
      2015   Phase 2   EUCTR2014-001643-20-PL   Canada;Czech Republic;Germany;Italy;Mexico;Poland;Russian Federation;Sweden;Switzerland;United States;
      2015   Phase 2   EUCTR2014-001643-20-DE   Canada;Czech Republic;Germany;Italy;Mexico;Poland;Russian Federation;Sweden;Switzerland;United States;
   Genzyme, a Sanofi Company
      2015   Phase 2   NCT02306811   Canada;Poland;Russian Federation;United States;
      2014   Phase 2   NCT02222948   Canada;Poland;Russian Federation;Sweden;United States;
Vehicle Gel   
   Biogen
      2016   Phase 4   NCT02568111   -
Venlafaxin Hexal   
   Novartis Pharma GmbH
      -   -   EUCTR2011-001692-39-DE   Germany;
Venlafaxine   
   Novartis Pharmaceuticals
      2011   Phase 4   NCT01436643   Germany;
Verum arm receiving Gilenya®   
   Charite University, Berlin, Germany
      2013   Phase 2/Phase 3   NCT01647880   Germany;
Verum arm receiving Vitamin D oil   
   Charite University, Berlin, Germany
      2011   Phase 2   NCT01440062   Germany;
Video calling program Better-close   
   Isala
      2021   -   NCT05242731   Netherlands;
Video game therapy   
   University Hospital of Ferrara
      2017   -   NCT03353974   Italy;
Vidofludimus calcium   
   Immunic AG
      2022   Phase 3   EUCTR2021-000028-36-BG   Albania;Belarus;Bulgaria;Colombia;Georgia;Greece;India;Lithuania;Mexico;Moldova, Republic of;North Macedonia;Poland;Russian Federation;Ukraine;United States;
      2022   Phase 2   EUCTR2021-000048-23-NL   Bulgaria;Canada;Czechia;Finland;Germany;Hungary;Moldova, Republic of;Netherlands;North Macedonia;Poland;Romania;Russian Federation;Serbia;Ukraine;United States;
      2022   Phase 2   EUCTR2021-000048-23-DE   Bulgaria;Canada;Czechia;Finland;Germany;Hungary;Moldova, Republic of;Netherlands;North Macedonia;Poland;Romania;Russian Federation;Serbia;Ukraine;United States;
      2021   Phase 2   EUCTR2021-000048-23-BG   Bulgaria;Czechia;Finland;Germany;Hungary;Moldova, Republic of;Netherlands;North Macedonia;Poland;Romania;Russian Federation;Serbia;Ukraine;
VigantOL oil plus interferon beta-1a (Rebif)   
   Merck KGaA
      2011   Phase 2   NCT01285401   Austria;Belgium;Denmark;Estonia;Finland;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Portugal;Switzerland;
Vigantol   
   University College Dublin
      2012   Phase 2   EUCTR2012-000635-68-IE   Ireland;
Vigantol Oel   
   Merck Serono
      2011   -   EUCTR2010-020328-23-LV   Austria;Belgium;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;Netherlands;Norway;Portugal;Switzerland;
      2011   -   EUCTR2010-020328-23-EE   Austria;Belgium;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;Netherlands;Norway;Portugal;Switzerland;
      2011   -   EUCTR2010-020328-23-DE   Austria;Belgium;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;Netherlands;Norway;Portugal;Switzerland;
      2010   Phase 2   EUCTR2010-020328-23-DK   Austria;Belgium;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;Netherlands;Norway;Portugal;Switzerland;
      2010   -   EUCTR2010-020328-23-FI   Austria;Belgium;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;Netherlands;Norway;Portugal;Switzerland;
   Merck Serono SA - Geneva, an affiliate of Merck KGaA
      2012   Phase 2   EUCTR2010-020328-23-PT   Austria;Belgium;Denmark;Estonia;Finland;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Portugal;Switzerland;
      2011   -   EUCTR2010-020328-23-AT   Austria;Belgium;Denmark;Estonia;Finland;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Portugal;Switzerland;
   Merck Serono SA-Geneva an affiliate of Merck KgaA, Darmstadt
      2011   -   EUCTR2010-020328-23-BE   Austria;Belgium;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;Netherlands;Portugal;
   Merck Serono The Netherlands - a division of Merck B.V.
      2011   -   EUCTR2010-020328-23-NL   Austria;Belgium;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;Netherlands;Portugal;
Vigantol Oil   
   Merck Serono
      2011   -   EUCTR2010-020328-23-LV   Austria;Belgium;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;Netherlands;Norway;Portugal;Switzerland;
      2011   -   EUCTR2010-020328-23-LT   Austria;Belgium;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;Netherlands;Norway;Portugal;Switzerland;
      2011   -   EUCTR2010-020328-23-EE   Austria;Belgium;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;Netherlands;Norway;Portugal;Switzerland;
      2011   -   EUCTR2010-020328-23-DE   Austria;Belgium;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;Netherlands;Norway;Portugal;Switzerland;
      2010   Phase 2   EUCTR2010-020328-23-DK   Austria;Belgium;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;Netherlands;Norway;Portugal;Switzerland;
      2010   -   EUCTR2010-020328-23-FI   Austria;Belgium;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;Netherlands;Norway;Portugal;Switzerland;
   Merck Serono SA - Geneva, an affiliate of Merck KGaA
      2012   Phase 2   EUCTR2010-020328-23-PT   Austria;Belgium;Denmark;Estonia;Finland;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Portugal;Switzerland;
      2011   -   EUCTR2010-020328-23-AT   Austria;Belgium;Denmark;Estonia;Finland;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Portugal;Switzerland;
   Merck Serono SA-Geneva an affiliate of Merck KgaA, Darmstadt
      2011   -   EUCTR2010-020328-23-BE   Austria;Belgium;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;Netherlands;Portugal;
   Merck Serono The Netherlands - a division of Merck B.V.
      2011   -   EUCTR2010-020328-23-NL   Austria;Belgium;Denmark;Estonia;Finland;Germany;Italy;Latvia;Lithuania;Netherlands;Portugal;
Vigantol® Oil   
   Academic MS Center Limburg
      -   Phase 2   EUCTR2014-000728-97-NL   Netherlands;
Vigantol® Öl 20.000 I.E./ml   
   Charité - Universitätsmedizin Berlin
      2011   Phase 2   EUCTR2011-002785-20-DE   Germany;
Vitamin A   
   Tehran University of Medical Sciences
      2011   Phase 4   NCT01407211   Iran, Islamic Republic of;
      2010   Phase 4   NCT01417273   Iran, Islamic Republic of;
      2009   Phase 4   NCT01225289   Iran, Islamic Republic of;
Vitamin D   
   Centre Hospitalier Universitaire de Nimes
      2013   Phase 3   NCT01817166   France;
   Mazandaran University of Medical Sciences
      2013   Phase 3   NCT01768039   Iran, Islamic Republic of;
   University Medical Centre Maribor
      2017   Phase 4   NCT03385356   Slovenia;
Vitamin D3   
   AlJohara M AlQuaiz, M.D.
      2013   Phase 2   NCT01753375   Saudi Arabia;
   American University of Beirut Medical Center
      2018   -   NCT03610139   Lebanon;
   Carmel Medical Center
      2010   Phase 4   NCT01005095   Israel;
   Isfahan University of Medical Sciences
      2015   -   NCT02696590   Iran, Islamic Republic of;
   Johns Hopkins University
      2012   Phase 3   NCT01490502   United States;
      2010   -   NCT01667796   United States;
   Maastricht University Medical Center
      2009   -   NCT00940719   Netherlands;
   University of Toronto
      2006   Phase 1/Phase 2   NCT00644904   Canada;
Vitamin E/Selenium   
   National Center for Complementary and Integrative Health (NCCIH)
      1999   Phase 1/Phase 2   NCT00010842   United States;
Vitamin K   
   Biogen
      2017   Phase 4   NCT03091569   Italy;
      2011   Phase 3   NCT01462318   Czech Republic;Hungary;Poland;Russian Federation;United States;
WAY-130799   
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development
      2005   -   EUCTR2005-000171-18-FI   Finland;
Warm compress prior to injection of glatiramer acetate   
   Teva Neuroscience, Inc.
      2005   Phase 4   NCT00239993   United States;
Water   
   Department of Neurology and Neurological Science, Tokyo Medical and Dental University
      2021   -   JPRN-UMIN000043910   Japan;
   Ohio State University
      2017   -   NCT03244696   United States;
Wristband physical activity monitor   
   Oakland University
      2015   -   NCT02335450   United States;
XBD173   
   Imperial College London
      2018   -   NCT03850301   United Kingdom;
XCEL-MC-ALPHA   
   Banc de Sang i Teixits
      2015   Phase 1/Phase 2   NCT02495766   Spain;
      2014   -   EUCTR2012-000734-19-ES   Spain;
XYOSTED 75 milligram (mg) in 0.5 ML Auto-Injector   
   Tulane University
      2021   Phase 4   NCT04601233   United States;
Xeomin   
   OSPEDALE S. RAFFAELE
      2008   -   EUCTR2007-006268-32-IT   Italy;
ZK 157046   
   Bayer AB, Bayer Health Care, Bayer Schering Pharma
      2007   -   EUCTR2006-005270-47-SE   Austria;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
   Bayer Schering Pharma
      2007   -   EUCTR2006-005270-47-SI   Austria;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
      2007   -   EUCTR2006-005270-47-HU   Austria;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
      -   -   EUCTR2006-005270-47-DE   Austria;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
   Bayer Schering Pharma AG
      2007   -   EUCTR2006-005270-47-LV   Austria;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
      2007   -   EUCTR2006-005270-47-GR   Austria;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
      2007   -   EUCTR2006-005270-47-BE   Austria;Belgium;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
   SCHERING
      2007   -   EUCTR2006-005270-47-IT   Austria;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
   Schering AG
      2007   Phase 3   EUCTR2006-005270-47-FR   Austria;Belgium;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
      2007   Phase 3   EUCTR2006-005270-47-FI   Austria;Belgium;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
      2007   Phase 3   EUCTR2006-005270-47-ES   Austria;Belgium;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
      2007   -   EUCTR2006-005270-47-NL   Austria;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
      2007   -   EUCTR2006-005270-47-IE   Austria;Belgium;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
      2007   -   EUCTR2006-005270-47-AT   Austria;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Latvia;Netherlands;Slovenia;Spain;Sweden;
ZOL446H   
   North Bristol Trust
      2009   -   EUCTR2008-005304-93-GB   United Kingdom;
   Novartis Pharma GmbH
      2010   -   EUCTR2009-011888-37-DE   Germany;
ZOLEDRONIC ACID MONOHYDRATE   
   Novartis Pharma GmbH
      2010   -   EUCTR2009-011888-37-DE   Germany;
Zenapax   
   National Institute of Neurological Disorders and Stroke (NINDS)
      1999   Phase 2   NCT00001934   United States;
Zeposia   
   Kessler Foundation
      2021   -   NCT04885894   United States;
Zinbryta   
   BIOGEN IDEC RESEARCH LIMITED
      2017   Phase 3   EUCTR2016-002820-10-IT   Canada;Denmark;France;Germany;Italy;United Kingdom;United States;
   Biogen Idec Research Limited
      2017   Phase 3   EUCTR2016-002820-10-GB   Canada;Denmark;France;Germany;Italy;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002820-10-DE   Canada;Germany;Italy;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-003176-39-CZ   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Finland;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;United States;
[123I]CLINDE   
   Institute for Neurodegenerative Disorders
      2008   Phase 1   NCT00612872   United States;
[18F] PBR06   
   Institute for Neurodegenerative Disorders
      2009   Phase 1   NCT01028209   United States;
[18F]-FEPPA   
   Institute for Neurodegenerative Disorders
      2009   Phase 1   NCT00970333   United States;
[18F]Florbetapir PET imaging   
   Institute for Neurodegenerative Disorders
      2012   Phase 4   NCT01767493   United States;
[C-11]Methylreboxetine   
   Brigham and Women's Hospital
      2020   Phase 1/Phase 2   NCT04144257   United States;
      2017   Phase 1/Phase 2   NCT03207464   United States;
[C-11]PBR28   
   Brigham and Women's Hospital
      2016   Phase 1/Phase 2   NCT02649985   United States;
[C11]PK-1195 PET scan   
   Weill Medical College of Cornell University
      2014   -   NCT02207075   United States;
[F-18]PBR06   
   Brigham and Women's Hospital
      2020   Phase 3   NCT04510220   United States;
      2020   Phase 1/Phase 2   NCT04144257   United States;
      2019   Phase 1/Phase 2   NCT03983252   United States;
      2016   Phase 1/Phase 2   NCT02649985   United States;
[F-18]SDM-8   
   Brigham and Women's Hospital
      2021   Early Phase 1   NCT04634994   United States;
[Zr-89]Oxine-labeled leukocytes PET/MR   
   University of Alabama at Birmingham
      2021   Phase 1   NCT03807973   -
fampridine-SR (4-aminopyridine, 4-AP)   
   Acorda Therapeutics
      2003   Phase 2   NCT00053417   Canada;United States;
glatiramer acetate   
   Teva Pharmaceutical Industries, Ltd.
      2006   Phase 3   EUCTR2006-002037-20-FI   Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2006   Phase 3   EUCTR2006-002037-20-ES   Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2006   -   EUCTR2006-002037-20-HU   Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2006   -   EUCTR2006-002037-20-GB   Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2006   -   EUCTR2006-002037-20-DE   Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2006   -   EUCTR2006-002037-20-CZ   Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Spain;United Kingdom;
      2006   -   EUCTR2006-002037-20-BE   Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Spain;United Kingdom;
of MitoQ   
   VA Office of Research and Development
      2020   Phase 1/Phase 2   NCT04267926   United States;